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Abstract 
A study of the intrapulmonary pharmacology and immunology of 
tuberculosis therapy 
Andrew Duncan McCallum  
 
Background: Shorter, more efficacious, treatments for pulmonary tuberculosis (TB) are required. 
Knowledge of the contributions of drug therapy and the immune system to TB cure will inform 
efforts to optimise treatment. 
This study investigates whether antibiotic exposure at the site of infection determines the rate of 
bacterial clearance and clinical treatment response; and whether impaired alveolar macrophage 
function in HIV-infection limits the ability of the immune system to eradicate TB. 
Methods: Malawian adults with microbiologically-confirmed pulmonary TB were recruited to a 
longitudinal cohort study. Participants received standard first-line therapy, and supplied serial 
sputum samples to assess TB bacillary elimination in the sputum.  Two-month sputum culture status 
was recorded, and rates of failure or relapse to one-year post-treatment. 
Plasma and intrapulmonary samples were collected at 8 and 16 weeks into treatment, and drug 
concentrations measured. Population PK modelling generated estimates of drug exposure in plasma, 
epithelial lining fluid (ELF), and alveolar cells.  
Alveolar macrophage function was assessed using quantitative flow cytometry-based reporter bead 
assays, and ELF cytokine levels measured by ELISA. 
Results: 157 participants were recruited. Despite weight-based dosing, peak plasma concentrations 
of first-line drugs were low relative to therapeutic drug monitoring targets. All 4 drugs achieved 
higher concentrations in ELF and alveolar cells, with isoniazid and pyrazinamide 20 and 50-fold 
higher in ELF than plasma respectively. Ethambutol concentrations were highest in alveolar cells. 
Rifampicin and isoniazid AUC/Cmax in plasma and ELF were related to treatment response across 
several endpoints. Peak concentrations of both drugs in plasma were associated with a shorter time 
to sputum culture negativity, and more favourable final outcomes. AUC/Cmax in ELF were associated 
with more rapid bacillary elimination, shorter time to sputum culture negativity, and for rifampicin 
Cmax in plasma, more favourable late outcomes.  
HIV infection modulated alveolar macrophage innate immune functions in pulmonary TB. Interferon-
γ concentrations in ELF remained high out to 4-months of treatment in HIV-infected participants, 
with corresponding high superoxidative burst activity and blunted phagocytosis. Initiation of 
antiretroviral therapy in new HIV diagnoses, with a degree of immune reconstitution, may contribute 
to ongoing pulmonary inflammation in co-infected patients.  
Conclusions: Higher plasma and ELF rifampicin and isoniazid drug concentrations in pulmonary TB 
are associated with improved treatment response. Combining agents with good intra- and extra-
cellular drug penetration may be important when designing new regimens for TB. 
TB/HIV co-infection is associated with alterations in the innate immune environment within the 
lungs that may reflect impaired control of TB infection. Ongoing efforts to expand test-and-treat and 
target hard to reach groups may reduce the number of late presenters with TB/HIV co-infection. 
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1 General introduction 
1.1 Tuberculosis: the global picture 
 
“The remedies are in our own backyards” 
Selman Waksman, 1949 
 
Tuberculosis is an ancient disease. Given its geographic distribution, the genus Mycobacterium may 
be over 150 million years old [1]. One member, Mycobacterium ulcerans, typically exists in tropical 
and subtropical wetlands, habitats that were last in contiguity during the Jurassic period. In East 
Africa, members of the Mycobacterium tuberculosis complex, the agents responsible for tuberculosis 
(TB) disease, emerged from a broader progenitor species up to 3 million years old, contemporaneous 
with early hominids, and co-evolving with their human host [2]. Modern strains of Mycobacterium 
tuberculosis (Mtb) are likely the clonal progeny of a single common ancestor originating 20 – 35,000 
years ago [2].   
TB has claimed its’ victims throughout known history and much of prehistory. It was a disease of the 
ancient world, being found in the mummies of Egypt and Peru, and likely entering the biblical record 
as the wasting disease schachepheth; it was a disease of the classical world, known to Hippocrates 
and the classical Greeks as phthisus; and it was a disease of the medieval period known as scrofula, 
treated by the ‘royal touch’ as late as the reign of Queen Anne [3, 4].   
By the late 18th Century, a tuberculosis epidemic was sweeping across Western Europe. The 
Industrial Revolution brought immense social and economic upheaval as huge numbers of individuals 
moved from country to towns for work. The cramped and polluted cities provided perfect conditions 
for the spread of TB, such that mortality rates leapt to 1,121 / 100,000 by 1771-1780 [5]. Before 
1730, nearly 15% of all deaths in London were due to TB [5]; by 1810, deaths rates from TB were to 
reach a peak of 25% before declining as standards of living improved [6]. As the epidemic spread, 
efforts to characterise and understand the disease were redoubled. René Laennac, best known for 
the invention of the stethoscope, was to classify and describe the pathogenesis of pulmonary and 
extrapulmonary TB in detail in D’Auscultation Mediate in 1819, only to succumb to TB himself at the 
age of 45 (the diagnosis aided by one of his own stethoscopes) [3]. 
In 1882, our understanding of tuberculosis, and indeed infectious diseases, leapt forward with 
Robert Koch’s presentation of Die Aetiologie der Tuberculose to the Berlin Physiological Society. For 
the first time, the tubercle bacillus was recognised, and he provided convincing evidence of the 
communicable nature of the disease. He later went on to demonstrate that Mtb met all of his 
famous postulates for establishing a causative relationship between microbe and disease [3]. With 
this knowledge, TB was registered as a notifiable disease, and patients were encouraged to enter 
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sanitoria for rest, nutrition, and clean air, while their bodies fought the infection. While sanitoria 
may have had some benefit for those with minimal disease [7], perhaps unsurprisingly, the efficacy 
of clean air and rest in treatment of TB was limited. A large study in 1923 found that the mortality of 
untreated smear-positive patients was 61% in sanatoria, comparted with 81% of those cared for at 
home [8].  
The middle of the 20th century saw a revolution in the treatment of TB, infectious diseases, and even 
in clinical trial design. In 1943, Albert Schatz, a graduate student in soil microbiology, identified a 
compound from the bacteria Streptomyces griseus that stopped the growth of Mtb [9]. The 
compound he named streptomycin; the era of chemotherapy for TB was born. The efficacy of 
streptomycin in the treatment of pulmonary TB was demonstrated in 1948 in a pioneering 
randomised controlled trial [10], followed by the development of “triple therapy” with the addition 
of isoniazid and para-aminosalicylic acid in 1955 [11]. By the 1980’s, rifampicin-containing regimens 
had shortened treatment to 6 months with a relapse rate of less than 3% by 36 months, with the 
British Thoracic Society recommending the use of the standard first-line regimen still in use today 
[12-15]. With fully oral, efficacious, affordable short-course therapy available, tuberculosis seemed 
destined to be a disease of the past. 
The latter half of the 20th century witnessed a resurgence in TB, with the World Health Assembly 
declaring a Global Health Emergency in 1993 [16]. The HIV pandemic drove an upsurge in TB 
incidence, peaking in 2005-6, and now only gradually declining. By 2016, 1.6 million lives were lost to 
the disease, and TB overtook HIV as the leading cause of death worldwide [17]. In this one year 
alone, 10.4 million individuals were estimated to have fallen ill with TB, and nearly half a million 
cases of multi-drug resistant TB (MDR-TB) cases occurred [17, 18]. As has been the status quo for 
many years, the WHO African Region remained burdened with the highest incidence of both diseases 
worldwide [17-19]. Although containing only 13% of the global population, the African Region had 
25% of the world’s TB cases, and nearly double the average burden of disease: 254 cases per 
100,000 compared with 140 per 100,000 globally.   
With the Millennium Development Goals (MDG) behind us, 2015 saw us looking forward to 2035 and 
the vision of ‘a world free of TB’. The End TB Strategy rests on 3 pillars: integrated, patient-centred 
care and prevention; bold policies and supportive systems; and intensified research and innovation 
[20]. By 2020, more than 90% of all notified TB cases should be successfully treated, and by 2035, TB 
deaths should have reduced to 95% of 2015 levels. This will not be achieved on the current trajectory 
- an annual decline in incidence of 1.5% [17] – and safer, easier, and shorter treatment regimens for 
active TB will be required. Efforts to optimise TB treatment must be informed by knowledge of the 
contributions of drug therapy and the immune system to successful treatment, and form the basis of 
this thesis.   
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1.2 Tuberculosis: The African perspective 
 
Africa, in particular sub-Saharan Africa (SSA), was hit hardest by the TB epidemic. Of the 30 TB/HIV 
high burden countries (HBCs) accounting for 97% of the estimated global number of HIV-infected TB 
cases, 22 are in Africa [21]. Malawi, despite having a relatively small population, was comfortably 
included in the top 20 lists by both absolute numbers and rates. With an incidence of 159 / 100,000 
population, TB added further strain to an already overstretched health service [17, 18].  
2015 saw the end of the MDGs. While the MDG target of reducing TB incidence rates was reached 
globally, the target of reducing TB prevalence and mortality by 50% compared with 1990 was not 
met in Africa (Figure 1.1) [18]. TB prevalence reduced by 42% globally since 1990, with the African, 
Eastern Mediterranean, and European Regions falling short of target. While Europe was experiencing 
a rapid reduction in TB mortality after a peak in the late 1990s, mortality reduction in the African 
Region was slow and trending towards a plateau (Figure 1.2). An overwhelming 90% of total TB 
deaths, and 80% of HIV-uninfected TB deaths, occurred in the African and South-East Asian Regions 
in 2014. Malawi, with 42 deaths per 100,000 population (HIV-infected cases), exceeded the global 
average of 21 per 100,000 at the end of the MDG period.   
 
 
Figure 1.1: Global trends in estimated rates of TB incidence (1990-2014), and prevalence and mortality rates 
(1990-2015)  
The panel on the left shows estimated TB incidence rates including HIV-infected TB (green line), and estimated 
incidence rate of HIV-infected TB (red line).  The centre and right panels show the trends in global prevalence 
and mortality rates from 1990 to 2015.  The dashed lines represent the Stop TB Partnership targets of a 50% 
reduction by 2015.  Shaded areas represent uncertainty bands.  Mortality excludes TB deaths among HIV-
infected people.  [18] 
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Figure 1.2: Estimated TB mortality rates 1990-2015 by WHO region 
Estimated TB mortality excludes deaths among HIV-infected people.  Shaded areas represent uncertainty bands.  
The dashed lines represent the Stop TB Partnership targets of a 50% reduction by 2015 compared to 1990.  [18] 
 
1.3 TB and HIV: the “cursed duet” 
 
The risk of developing TB disease in people living with HIV (PLHIV) is estimated to be 26 times that of 
those who are not infected with HIV [18]. HIV co-infection exists in nearly a third of all TB cases in 
the African Region, accounting for as many as 74% of incident TB cases among PLHIV worldwide [17, 
18]. The combined epidemics of TB and HIV in SSA significantly contributed to the region’s failure to 
achieve the MDG targets on mortality reduction. 
HIV infection impairs the cellular immunity key to TB control, such that co-infected individuals are 
more likely to activate latent disease [22], or to experience more rapid clinical progression of TB 
disease after infection with Mtb [23, 24]. Indeed, co-infected individuals are estimated to have a 10% 
annual risk of developing TB disease [22, 25, 26], compared with a 10-20% lifetime risk in HIV-
uninfected individuals [27, 28]. Furthermore, those with HIV are more likely to have TB relapse or 
reinfection after previous TB treatment [29-36]. Genetic analysis suggests that exogenous re-
infection rather than endogenous reactivation accounts for more cases of recurrent TB in HIV-
infected individuals, suggesting that these individuals are more predisposed to developing TB disease 
on exposure to Mtb [30, 33].   
The presentation of TB disease differs in HIV-infected individuals, and is closely related to CD4 count 
[37]. At lower CD4 counts, symptoms may be minor [38], or even absent [39, 40]. Non-specific 
clinical features can make diagnosis challenging, with smear-negative, extra-pulmonary and 
disseminated disease seen more commonly in PLHIV [41, 42]. A meta-analysis of post-mortem 
studies in adult HIV-infected patients dying in hospitals in sub-Saharan Africa identified that 43.2% 
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(pooled estimate; 95% CI: 38.0-48.3) of patients had evidence of TB at post-mortem [43]. TB was 
disseminated in 87.9% (82.2-93.7) of cases, and undiagnosed at time of death in nearly half of adult 
HIV/AIDS-related deaths.  
WHO advocates a 4-part symptom screen as part of intensified TB case-finding in PLHIV: any of 
current cough, fever, night sweats, or weight loss. With an overall sensitivity of 78.9% (95% CI: 58.3–
90.0), specificity of 49.6% (95% CI: 29.2-70.1), and negative predictive value of 97.7% (95% CI :97.4-
98.0) at 5% prevalence of TB among PLHIV, use of this algorithm will identify a proportion of 
individuals needing further diagnostic evaluation for TB, and is of particular use in resource-limited 
settings [44]. Evaluation of symptom screening in PLHIV suggests that this may still miss a sizeable 
fraction of TB cases, particularly in HIV-infected pregnant women, indicating that further adjuvant 
diagnostic tools will be needed to help identify TB in PLHIV [45, 46]. 
Despite poorer treatment outcomes, TB treatment remains the same regardless of the patient’s HIV 
status. With increasing availability of anti-retroviral therapy (ART), important decisions regarding the 
‘when’ and ‘what’ of HIV therapy need to be made. Subgroup analysis of three major trials have 
shown a consistent benefit of early ART – within 2 weeks of TB treatment – in those with CD4 counts 
of less than 50 cells/mm3 [47-49]. The optimal timing of ART at higher CD4 counts remains uncertain. 
A meta-analysis has shown that starting ART before or during TB therapy will reduce the risk of death 
by nearly three-fifths [50]. Furthermore, consideration must be given as to the choice of ART 
regimen: important drug-drug interactions (DDIs) between TB and HIV medications exist that may 
reduce drug efficacy or increase the risk of toxicity. Rifampicin is the most potent inducer of 
cytochrome P450 enzymes, and may reduce patient exposure to ART, particularly nevirapine and 
protease inhibitors, to sub-therapeutic levels, risking virological failure [51].  This is particularly 
challenging in resource-limited settings such as Malawi, where options for second-line ART are 
limited. 
 
1.4 TB treatment targets: research priorities 
1.4.1 Global targets 
 
Although considerable progress has been made in TB control since the 1990s,  the WHO End TB 
Strategy goal of ‘a world free of TB’ by 2035 [20] will not be achieved without further improvements 
to the routinely used antibiotic regimens for both drug susceptible and resistant disease. Alongside a 
95% reduction in mortality compared to 2015 levels, End TB seeks to achieve a 90% reduction in TB 
incidence, and complete prevention of catastrophic costs due to TB for TB-affected families by 2035 
[20]. Goal 3 of the United Nations Sustainable Development Goals (SDGs) aims to end the TB 
epidemic by 2030 [52]. 
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In response to these challenges, the last 20 years have witnessed considerable activity in TB 
therapeutics, with repurposing of existing antibiotics, and development of entirely new 
pharmaceutical compounds. However, selection of appropriate doses of many agents, and 
construction of the most efficacious combination regimens present ongoing questions. Clinical 
pharmacokinetic (PK) and pharmacodynamic (PD) studies may help resolve these, and will be 
discussed further in the following sections.  
 
1.4.2 Shorter treatment for TB 
 
Patients infected with Mtb without any evidence of antibiotic resistance require 6 months of 
multidrug therapy to treat uncomplicated drug-sensitive disease (DS-TB) [53]. Adherence of every 
patient to 6 months of chemotherapy has proved impossible for public health services to support 
[54], and is exacerbated by significant toxicity and problematic DDIs when combined with ART [51]. 
Poor adherence and complex polypharmacy lead to unfavourable outcomes and it has become 
apparent that shorter TB treatment is needed [53]. Mathematical modelling suggests that shortening 
effective chemotherapy to 2 months would reduce TB incidence by up to 20%, and mortality by up to 
25%. More modest gains could be achieved by treatment abbreviation to 4 months [55-57].  
To date, attempts to shorten treatment for DS-TB have been unsuccessful. Pre-clinical data, and 
studies of time-to-culture conversion suggested that fluoroquinolone-containing regimens have 
treatment-shortening potential [58], yet relapse rates were in the region of 20% when tested in 
clinical trials [59-61]. A trial of shorter treatment for patients with non-cavitatory disease on baseline 
chest X-rays and negative sputum cultures at 2 months had to be stopped due to an increased risk of 
relapse [62]. 
Linked to failures in DS-TB therapy, a marked increase has been observed in the incidence of MDR-
TB, caused by Mtb bacteria which are resistant to both rifampicin and isoniazid. The estimated 
number of MDR-TB cases worldwide rose from 250,000 in 2009 to 480,000 in 2015 [63]. Extensively 
drug resistant (XDR-) TB, with super-added resistance to injectable second line drugs and 
fluoroquinolones comprises 10% of MDR-TB cases. MDR-TB typically requires treatment 
prolongation to 18-20 months, although the WHO has approved the use of a 9-12-month regimen in 
some circumstances [64, 65]. The second line drugs used for MDR-TB carry additional toxicities so 
the need for faster, cleaner therapy is even stronger than in drug susceptible disease. Ultimately, 
detailed interrogation of antibiotic exposure-response relationships may accelerate development of 
shorter, less toxic therapy for all forms of TB. 
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1.4.3 Addressing TB treatment failure 
 
In contrast to many other infectious diseases, failure to culture TB at the end of treatment does not 
necessarily indicate cure [66]. After 2 months of treatment, most patients do not have culturable TB 
in their sputum, yet require a further 4 months of therapy to prevent relapse [67]. The early British 
Medical Research Council (BMRC) studies identified that recurrent TB after treatment completion 
was a significant problem necessitating prolonged follow-up [15]; and as such, the composite 
outcome of failure at end of treatment and relapse after treatment completion became the gold 
standard endpoint for clinical trials of tuberculosis therapy [15, 66]. In contrast to the good 
treatment outcomes seen in the original clinical trials, TB cure rates in high-burden countries are 
sub-optimal [18, 47, 68]; and rates of recurrence after treatment completion are high in those with 
TB-HIV co-infection [31, 36, 69, 70]. Alongside shorter therapies, research must optimise existing TB 
treatment to reduce the unfavourable outcomes of relapse, acquired drug resistance, and death.   
Understanding why patients relapse after a full course of treatment is essential to reducing the 
morbidity and mortality of recurrent TB disease, and the considerable personal and economic costs 
of retreatment and MDR regimens. There are multiple explanations for poor treatment outcomes, 
from programmatic (treatment delivery, adherence), to clinical (toxicity, drug-drug interactions, 
extent of disease), to pre-clinical and bench science (PK, PD, drug resistance, immunology). 
Understanding host factors, drug exposure at the site of infection, and mycobacteriological factors 
driving treatment response will form the basis of the remainder of this thesis. 
 
1.5 Capturing TB treatment response 
1.5.1 Recording programmatic outcomes 
 
Collection of TB data forms part of a country’s health information system, and is reported to both 
national TB control programmes (NTPs) and the WHO. As such, standardised outcome definitions are 
required to allow data to be compared within and between NTPs and enable monitoring of 
programme performance [71]. These definitions are discussed further in Chapter 2, but ultimately 
programmatic outcomes will differ from those required in clinical trials evaluating different 
regimens. The WHO treatment outcomes above do not consider the possibility of post-treatment 
relapse, nor do they distinguish between death due to TB or other causes. As such, alternative 
endpoints must be used when evaluating TB treatment response in clinical trials.  
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1.5.2 Late treatment outcomes: the gold standard 
 
The early BMRC studies and subsequent clinical experience have shown TB relapse after treatment 
completion to be a significant problem [15] necessitating adoption of relapse-free cure 18-24 
months after treatment initiation as the gold standard endpoint for definitive Phase III trials of new 
therapies [15, 66]. However trials of this duration, or longer for MDR-TB, are complicated and 
expensive to complete [65]. In highly endemic settings, particularly with high rates of HIV co-
infection, TB re-infection risks contaminating this endpoint unless careful molecular fingerprinting 
can be undertaken to distinguish between true relapse and re-infection [30, 33].  
 
1.5.3 Early treatment outcomes: choice of surrogates 
 
Despite the urgent need for ‘ultra-short’ TB treatment and the availability of new compounds to 
evaluate, efficient conduct of clinical trials remains difficult. As such, clinical PK-PD analyses based on 
earlier efficacy outcomes in Phase II trials may help to compare novel combinations of drugs and 
dosages using fewer patients over a shorter timeframe so that only candidate regimens with the 
greatest efficacy and treatment shortening potential advance to Phase III evaluation. For this to 
work, these early outcomes should reliably predict relapse. A selection of treatment efficacy 
outcomes is described in Table 1.1.   
Traditionally, for DS-TB patients with pulmonary TB, sputum culture conversion (SCC) from ‘positive’ 
to ‘negative’ at two months is used to represent treatment efficacy [72-74].  However, this simple 
biomarker shows only modest correlation with late outcomes [66, 75, 76]. In recent years, attention 
has shifted towards weekly sputum sampling to more accurately record the ‘time to culture 
conversion’ and provide more information on the anti-bacterial effect of therapy over the entire 
study period than binary measurement at a single time-point [77-79]. Modern studies have also seen 
a gradual move from microbiological treatment monitoring on solid (e.g. Lowenstein-Jensen [LJ]) 
media to liquid culture (e.g. the Mycobacterial Growth Indicator Tube [MGIT] system) because liquid 
Mtb culture is easier, provides faster results and converts to ‘negative’ later during therapy [80-82]. 
It is generally believed that TB relapse is driven by drug-tolerant bacteria which survive despite 
antibiotic therapy [53]. Therefore, whilst the pharmacodynamics of distinct bacterial phenotypes in 
different media are incompletely understood [83], it seems intuitive that liquid culture systems 
which revive ‘persister’ organisms for longer will provide better surrogates of final outcomes [84, 
85]. However, liquid culture will still fail to capture a significant proportion of these persister bacilli. 
The use of exogenous culture filtrate or resuscitation-promoting factors has shown that 
expectorated sputum may contain many drug-tolerant, differentially-culturable TB bacilli, that will 
still not be detected using standard liquid culture techniques [86, 87]. 
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Timing of outcome 
measurement 
Outcome 
measurement 
Strengths Weaknesses 
Late  
(typically the end of post-
treatment follow-up) 
Treatment failure or 
post-treatment 
relapse 
1. Clinically relevant 
 
2. Gold standard endpoint 
for stable cure in Phase III 
clinical trials 
1. Studies are very long and 
expensive to conduct 
 
2. Unless careful molecular tests 
can be undertaken the endpoint of 
relapse may be contaminated by 
TB re-infection in highly endemic 
settings, especially with high rates 
of HIV co-infection 
Early 
(typically 2 months for DS-
TB, may be 24 weeks for 
MDR-TB) 
Sputum culture 
conversion (SCC) * at 
a defined endpoint 
1. Results are simple to 
understand and interpret 
 
2. Only requires sputum 
sampling at 2 time-points 
1. Only modest correlation with 
late outcomes 
 
2. Binary data do not use all 
possible information (e.g. 2-month 
results cannot discriminate 
between patients who are culture 
negative at 8 weeks, even if one 
culture converted at 2 weeks and 
the other at 6 weeks) 
Time to SCC * 1. Results are simple to 
understand and interpret 
 
2. Provides more 
discriminatory data than 
SCC  
1. Correlation with late outcomes 
has not been well validated 
 
2. Frequent sputum sampling 
required; wider sampling windows 
reduce the accuracy of the 
measurement 
Statistical modelling 
of bacterial 
elimination rates 
from serial 
quantitative 
bacteriology data †  
1. Provides information on 
antimicrobial efficacy 
across the whole sampling 
time, even on patients 
who do not convert to 
negative 
 
2. Allows multi-phase 
patterns of bacterial 
clearance to be assessed 
1. Correlation of estimated 
summary parameters from mixed 
effects modelling with late 
outcomes has not been well 
validated 
 
2. Data analysis is computationally 
complex to perform 
 
3. Results are not always simple to 
understand and interpret  
Table 1.1: Treatment efficacy outcomes used in clinical PK-PD studies and clinical trials for tuberculosis 
 * SSC or ‘time to SCC’ data can be generated using solid or liquid culture media; culture conversion is often later 
in liquid culture systems. † Quantitative bacteriology data can be generated from log10CFU/ml counts on solid 
media or time to positivity results in liquid culture systems 
 
Newer methods to monitor TB treatment response and set early outcome measures for PK-PD 
studies involve use of serial quantitative bacteriology to chart the decline in Mtb bacillary load. In 
solid media, incubation of homogenised sputum onto on selective agar plates (e.g. Middlebrook 
7H10 or 7H11) allows the number of colony forming units (usually expressed in log10CFU/ml) in each 
expectorated patient sample to be counted [88-90]. For liquid culture, the time to positivity (TTP) 
after inoculation of processed sputum into MGIT tubes provides an inverse measure of bacillary load 
(usually expressed in hours or days) because shorter delay until detection of growth represents 
higher bacterial burden [89, 91-93]. Early bactericidal activity (EBA) studies lasting up to 14 days 
directly report changes from baseline in log10CFU/ml counts or TTP [84, 94-96], whilst studies 
extending out for 8-12 weeks may deploy statistical modelling techniques to summarise evolving 
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patterns of bacillary clearance over a longer period [58, 89, 97]. Separate elimination rates can be 
reported for distinct ‘early bactericidal’ and ‘sterilising’ phases of treatment [72, 74, 77] and 
correlation has been described between sterilisation phase rate coefficients and long-term DS-TB 
outcomes (Figure 1.3) [89]. More data are required to validate those relationships.  
 
 
Figure 1.3: Modelling bacillary elimination from sputum 
A: Biphasic bacillary elimination from sputum.  Serial counts of viable bacillary load over TB treatment reveals a 
biphasic response suggesting the existence of at least 2 subpopulations. Initially, multiplying extracellular 
bacteria in log phase growth are killed rapidly by the ‘early bactericidal activity’ (EBA) of anti-TB drugs – the α-
slope; thereafter, surviving bacteria in varying states of non-replicating persistence are eliminated more slowly 
by the ‘sterilising activity’ of the regimen – the β-slope.  The slow sterilisation phase is one of the main 
determinants of the length of treatment.  Adapted from [65]. 
B: Sterilising activity of a regimen determines the duration of treatment.  The sterilising activity reflects the 
effectiveness of a regimen to eliminate non-replicating persister organisms.  Different rates of bacillary 
elimination (β-slope) mean that for some, 6 months of therapy will be more than needed to completely eradicate 
Mtb, whereas for others this would be insufficient.  For all 3 regimens in this example, all subjects are below the 
limit of detection of Mtb into the continuation phase.  
C: Binary endpoints (2-month culture conversion) will not capture the dynamics of bacillary elimination.  
Regimens with good EBA and poor SA may achieve culture conversion by 2 months, but the poor activity against 
persister organisms risks later relapse.  Those with poor EBA, but good SA may still be culture positive at 2 
months, but the rate of bacillary elimination during the later stages of treatment completely eradicates the Mtb.  
Adapted from [77].  
D: Baseline bacillary load determines treatment outcome.  For the 2 examples with lower baseline bacillary 
loads (green and yellow), both patients achieve negative cultures at month 2, but the poorer SA in the yellow 
regimen leads to late failure.  In the 2 patients with higher baseline bacillary loads (orange and red), neither are 
culture negative by month 2.  The orange patient appears to have had a successful outcome at end of treatment 
(below the limit of detection) but has an early relapse; whereas the red patient is still culture positive at end of 
treatment.  Adapted from [77]. 
EBA: early bactericidal activity; SA: sterilising activity; RHZE: intensive phase therapy (rifampicin, isoniazid, 
pyrazinamide, ethambutol); RH: continuation phase therapy (rifampicin, isoniazid) 
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Presently, no early TB outcome measure convincingly predicts long-term relapse and there is no 
consensus on which to use. This is demonstrated by the recent failure of thee multi-centre phase III 
trials to shorten drug-susceptible TB treatment from 6 to 4 months by inclusion of a fluoroquinolone 
[59-61] despite promising results from Phase II clinical studies which used end-points of 2-month SCC 
[81, 98, 99], time to culture conversion [99] and bacillary elimination rate [58]. Therefore, PK-PD 
studies relating antibiotic exposure to early outcomes must be aware of the potential limitations to 
their findings. Future clinical PK-PD analyses may be crucial to development of better treatment 
response biomarkers.  
 
1.6 Drug therapy for TB 
1.6.1 First-line anti-tuberculosis therapy for DS-TB 
 
Standard “short course” TB treatment for new patients comprises an intensive phase of 2 months 
with 4 drugs daily (RHZE: R – rifampicin, H – isoniazid, Z – pyrazinamide, E – ethambutol) followed by 
a continuation phase of 4 months with 2 drugs (RH). These drugs are typically supplied in fixed-dose 
combinations (FDCs), allowing for ease of prescription, and reducing the risk of drug resistance due 
to episodes of monotherapy when drugs are supplied individually [100]. FDCs of anti-TB drugs 
appear in the WHO Model List of Essential Medicines at the doses recommended in Table 1.2 below. 
A complete 6-month course from the Global TB Drug Facility costs around $40 per person [63]. 
 
Drug Recommended daily dose 
Dose and range 
(mg/kg body weight) 
Maximum  
(mg) 
Rifampicin (R) 10 (8-12) 600 
Isoniazid (H) 5 (4-6) 300 
Pyrazinamide (Z) 25 (20-30) - 
Ethambutol (E) 15 (15-20) - 
Streptomycin (S) * 15 (12-18) - 
Table 1.2: Recommended doses of first-line anti-tuberculosis drugs for adults 
* Patients aged over 60 years or weighing less than 50 kg may not be able to tolerate more than 500–750 mg 
daily. From [100]. 
 
The standard first-line regimen is recommended for all new TB patients (no prior history of TB 
treatment, or previously received less than one month of treatment) with a few exceptions where 
the risk of drug resistance requires a different choice of regimen [100]. New patients in areas with a 
high prevalence of isoniazid resistance in new patients may have ethambutol added to rifampicin 
and isoniazid in the continuation phase, and new patients with active TB after contact with a patient 
with drug-resistant TB should be prescribed a regimen based on the drug susceptibility test (DST) of 
the source case while their own DST results are awaited.  
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The standard regimen applies to patients with extrapulmonary TB, with the exceptions of TB of the 
central nervous system, bone or joint, for which some expert groups recommend treatment 
prolongation to 9 or 12 months [101, 102]. In TB meningitis, ethambutol is replaced by streptomycin 
during the intensive phase [100]. In addition, adjunctive corticosteroids may reduce the risk of death 
in TB meningitis and pericarditis [103-105]. Where previous guidelines indicated that ethambutol 
could be omitted in HIV-uninfected patients with non-cavitatory, smear-negative pulmonary or 
extrapulmonary TB, this recommendation has been removed [100].  
Standard regimens for those previously treated for TB depend on the likelihood of MDR-TB, given 
that previous TB treatment is a strong determinant of drug resistance [106]. Retreatment regimens 
are chosen at a country level by NTPs based on rates of MDR-TB, the routine and timely availability 
of DST, and whether retreatment is for treatment failure (higher risk of MDR-TB) rather than relapse 
or default [100]. In Malawi, rates of drug resistance are low [107]. In new cases, rates of MDR or 
rifampicin resistance was estimated at 0.75% (0-1.6), and 6.4% (3.8-8.9%) in previously treated cases 
[63]. Xpert MTB/RIF is recommended to screen for MDR-TB in cases of recurrent TB, and where 
unavailable, empiric MDR-TB treatment advised for those whose previous treatment has failed [105]. 
At the time of the study, those with recurrent TB after relapse or default were prescribed a 
retreatment regimen of 3 months of RHZE with the addition of the injectable streptomycin for the 
first 2 months, followed by 5 months of RHE if no resistance identified. While this regimen is shorter 
and less toxic than standard MDR-TB regimens, the requirement for 2 months of inpatient stay for 
patient and guardian is associated with catastrophic household costs [108].     
 
1.6.2 Development of first-line anti-tuberculosis therapy 
 
The work of the Tuberculosis Research Unit of the BMRC, and its collaborators, were instrumental in 
the development of shorter regimens for TB in the period 1946-1986. Through the introduction of 
randomised clinical trials to the development of regimens, treatment was abbreviated from 18 
months or more to 6 months, and made available in even the poorest of countries [15]. This work 
has been comprehensively summarised in detail by Fox et al [15], but some of the key steps in 
building todays regimen are detailed below. 
Until the middle of the 20th century, treatment options for tuberculosis were limited to surgery, 
nutrition, and environmental measures. In 1944, both para-aminosalicylic acid and streptomycin 
were shown to have anti-mycobacterial activity, and were subsequently included in the first 
combination therapy for tuberculosis [9, 109, 110]. Isoniazid, a nicotinamide analogue, followed in 
1952, and remains in the first line regimen in use today [111]. The combination of streptomycin, 
isoniazid, and para-aminosalicylic acid for 1-2 years was the first “curative” regimen for TB, with 
relapse rates as low as 4% [15], and remained the standard treatment for TB for nearly 15 years 
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[112]. Combination therapy as a strategy to reduce the emergence of drug-resistance was identified 
early in the development of antituberculosis chemotherapy [113, 114], and by the 1960s, a two 
phase model of therapy was proposed [115]. An “intensive phase” of three or more drugs would 
rapidly reduce the bacillary burden without the emergence of resistance, followed by a prolonged 
“continuation phase” where one or more drugs killed any quiescent, residual organisms. 
Animal studies had suggested that rifampicin and pyrazinamide had high sterilising activity, and 
potential for rapid sputum conversion [15]. In 1970, trials in East and Central Africa added rifampicin 
or pyrazinamide to 6-month regimens with SH, achieving relapse rates of 3% and 8% respectively by 
2 years of follow up compared to 29% with SH alone, and comparable to existing regimens using 2 
months of SH and thioacetazone (T), followed by 16 months of ST [116-118]. Follow on studies 
looked to shorten the duration of the expensive drugs rifampicin and pyrazinamide, and found that 
an initial phase containing 2 months of rifampicin and pyrazinamide achieved favourable culture 
conversion and relapse rates [119-121]. Continuation of pyrazinamide beyond the first two months 
of therapy did not reduce the rate of relapse, suggesting it was only active in the first months of 
treatment [14, 122].  
By the 1990s, the US Public Health Service had shown that 6 months of RH, with 2 months of 
pyrazinamide was as effective as 9 months of RH [123]. In the UK, the British Thoracic Society 
demonstrated that 6 months of RH supplemented with ZE during the intensive phase was as 
effective as regimens containing streptomycin and pyrazinamide [124], with the added benefit of 
offering completely oral-based therapy without the toxicity of streptomycin. In 2004, the efficacy of 
daily 2RHZE/4RH was demonstrated in a multicentre randomised trial [125], and remains the 
standard first-line regimen recommended by the WHO [100].  
 
1.6.3 Pharmacology of first-line anti-tuberculosis drugs 
 
1.6.3.1 Rifampicin 
Rifampicin, a rifamycin, is a first-line bactericidal drug that inhibits bacterial DNA-dependent RNA 
polymerase [126]. By binding to the beta subunit of RNA polymerase essential for DNA transcription, 
rifampicin interferes with protein synthesis required for survival of the bacterium [127].  
The rifamycins were discovered in the late 1950s; a new class of molecules with antibiotic activity in 
the secretions of the soil bacteria Streptomyces mediterranei [128]. Chemical modification of the 
natural metabolite rifamycin B led to the discovery of rifamycin SV, initially used for the intravenous 
or topical treatment of some gram-positive or biliary infections [129]. Further modification yielded 
rifampicin, an orally available analogue with antimycobaterial properties in vitro [129, 130]. By 1970, 
rifampicin was added to streptomycin and isoniazid in the BMRC East and Central Africa trials, 
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demonstrating considerable treatment shortening properties [117]. Omission of rifampicin from the 
continuation phase led to relapse rates above 30% [13, 14]. 
The pharmacokinetics of rifampicin are highly variable, with up to 10-fold inter-individual variability 
in maximum plasma concentration (Cmax) and half-life (T1/2) [131, 132]. Most PK studies measure 
total drug concentration, assuming equilibrium between protein-bound and protein-unbound 
fractions. As it is the protein-unbound fraction that exerts pharmacological effect at the site of action 
[133], the extent of protein binding will have a bearing on concentration-response relationships 
[134]. Rifampicin may be up to 80% protein-bound [135], mainly to albumin, however there may be 
considerable variation in the degree of protein binding in states of undernutrition, and ultimately the 
extent of drug exposure [134]. Agents with high plasma protein binding may experience clinical 
failure when total drug concentration monitored rather than the unbound fraction [136]. 
Rifampicin is readily absorbed and distributes well throughout body tissues and fluids [126, 135]. 
Absorption is affected by administration with food, taking longer to reach maximal plasma 
concentration, but the extent of absorption is not affected [137-139]. Variable absorption has been 
described, with subgroups with short or long absorption lag phases [131, 140]. After a single dose, 
rifampicin has 90-95% bioavailability [126], dropping to around 68% after 3 weeks of treatment 
[141], indicating autoinduction of first pass effect [142]. As a potent enzyme inducer, rifampicin 
induces its’ own metabolism, such that the plasma half-life drops from 2.3-5 hours at treatment 
outset to 2-3 hours with repeated administration [126]. This is associated with increased elimination 
of rifampicin and its’ metabolite 25-desacetylrifampicin into the bile over time on treatment [143]. 
Biliary excretion of rifampicin occurs after hepatocellular uptake, primarily mediated by organic 
anion-transporting polypeptide 1B1 (OATP1B1) coded for by the gene SLCO1B1 [144, 145]. Recent 
reports from South Africa and Uganda suggest that SLCO1B1 single nucleotide polymorphisms (SNPs) 
are more common in African patients and associated with reduced rifampicin exposure [146, 147]. 
However, recent reports from Malawi and South India have been unable to show a PK effect, and 
may be due to the relative rarity of the SNPs in these populations [148, 149].  
Alongside OATP1B1, rifampicin is a substrate for the drug transporter, P-glycoprotein (P-gp) [150]. By 
binding to and activating the pregnane X receptor, rifampicin induces multiple phase I (including 
cytochrome P450, particularly CYP3A4) and phase II drug metabolising enzymes, and drug 
transporters such as P-gp [135, 150]. Consequently, plasma rifampicin concentrations reduce on 
treatment from a combination of induction of drug transporters and enzyme induction.  
   
  
Drug Chemical class, mechanism of action, 
role in TB treatment 
Mechanism of 
resistance 
Pharmacokinetic profile [126, 151] Key plasma pharmacokinetic 
indices  
RIFAMPICIN 
 
 
RIFAMYCIN 
Inhibits DNA-dependent RNA 
polymerase preventing protein 
synthesis [126, 127] 
Early bactericidal and sterilising activity 
[94] 
Mutation in RNA 
polymerase subunit 
beta (rpoB): 
conformational change 
and defective 
rifampicin binding 
[152] 
ABSORPTION: Rapid absorption; 90-95% bioavailability (single dose); ~65% 
bioavailability (multiple doses) [141] 
DISTRIBUTION: Extensive distribution (discolours body fluids); 80-90% 
protein bound 
METABOLISM: Undergoes enterohepatic circulation; desacetylation into 
active form; CYP450 inducer 
EXCRETION: 30% urine; 65% faeces                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
10 mg/kg 
Cmax: 4-6 µg/ml 
Tmax: 2-3 hours 
T1/2: 2-5 hours  
(↓ after repeated doses) 
AUC0-24: 20-40 mg.h/l [131, 153-
155] 
MIC: 0.03-0.5 µg/ml [156] 
ISONIAZID 
 
 
NICOTINAMIDE DERIVATIVE 
Interferes with cell wall synthesis 
Bactericidal in high doses 
Mutation in 
mycobacterial 
catalase-peroxidase 
KatG [157] 
ABSORPTION: Rapid absorption; 40-80% bioavailability (lower in fast 
acetylators due to a higher first pass effect) 
DISTRIBUTION: Extensive distribution; negligible protein binding 
METABOLISM: Acetylation (genetically determined); fast acetylators – rapid 
metabolism; slow acetylators – slow metabolism  
EXCRETION: 75-95% in urine 
5 mg/kg 
Cmax: 3-6 µg/ml 
Tmax: 0.75-2 hours 
T1/2: 1.5 hours fast acetylators;  
4 hours slow acetylators 
AUC0-∞: 15-30 mg.h/l [154, 155, 
158, 159] 
MIC: 0.03-0.25 µg/ml [156] 
PYRAZINAMIDE 
 
 
NICOTINAMIDE DERIVATIVE 
Unknown mechanism 
Active at acidic pH [160] 
De-energises Mtb cell membrane 
potential [161] 
Interferes with fatty acid synthesis [162] 
Inhibits trans-translation in non-
replicating organisms [163] 
Mutations in 
pyramidinase gene 
(pncA) [161] 
ABSORPTION: Well absorbed; 73% bioavailability 
DISTRIBUTION: Widely distributed (including cerebrospinal fluid); 5% 
protein-bound 
METABOLISM: Hydrolysed and hydroxylated to 5-hydroxy-pyrazinoic acid 
(active form) 
EXCRETION: Metabolites renally excreted; 3% excreted unchanged 
25-35 mg/kg 
Cmax: 30-50 µg/ml 
Tmax: 1-3 hours 
T1/2: 9 hours  
AUC0-∞: 250-500 mg.h/l [154, 
155, 158, 164] 
MIC: 6-50 µg/ml (at pH 5.5) 
ETHAMBUTOL 
 
 
ETHYLENEDIAMINE 
Inhibits cell wall synthesis [165] 
Bacteriostatic 
Mutations in embCAB 
operon encoding 
arabinosyl-
transferases [166] 
ABSORPTION: Well absorbed; 80% bioavailability 
DISTRIBUTION: Well distributed (except cerebrospinal fluid); 10-40% 
protein-bound 
METABOLISM: 15% metabolised to aldehyde and dicarboxylic metabolites  
EXCRETION: Unchanged in urine 
25 mg/kg 
Cmax: 2-5 µg/ml 
Tmax: 2-3 hours 
T1/2: Biphasic: 2-4, then 12-14 
AUC0-∞: 20-30 mg.h/l [154, 155, 
158, 167] 
MIC: 0.5-8 µg/ml [156] 
Table 1.3: Pharmacology of first-line anti-tuberculosis drugs  
Summary of the mechanisms of action and resistance, PK profile and key PK indices. Estimated PK indices from TB patients at steady state where available. Wild-type MIC distributions shown. 
Adapted from [126, 151, 168], additional references in table.     
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Rifampicin is metabolised by B-esterases in liver microsomes into 25-desacetylrifampicin, an active 
metabolite with up to 50% of the activity of rifampicin against clinical isolates [169-171]. Human 
arylacetamide deacetylase (AADAC) is responsible for this transformation, and while pre-clinical 
studies have implicated SNPs in the AADAC gene in significantly reduced rifampicin clearance [172], 
clinical PK studies from Malawi were unable to identify a pharmacogenetic effect of this 
polymorphism [148]. Plasma concentrations of 25-desacetylrifampicin may only be around 10% of 
rifampicin concentrations, but may vary considerably between patients [173, 174]. Rifampicin is 
progressively metabolised to 25-desacetylrifampicin though enterohepatic cycling, and excreted in 
the faeces [151]. 
Rifampicin is one of the most potent enzyme inducers known to man, and is responsible for 
numerous clinically-significant DDIs due to increased drug metabolism or transport [175]. Full 
enzyme induction after starting rifampicin is reached after 1 week, and baseline activity restored 2 
weeks after discontinuing rifampicin [175]. Rifampicin co-administration may significantly reduce 
concentrations of multiple drug classes, including oral contraceptives, warfarin, calcium-channel 
blockers, statins, glucocorticoids, and opiates, necessitating dose adjustments [150, 175, 176]. DDIs 
are particularly problematic when rifampicin is co-administered with ART [51]. Rifampicin may 
reduce nevirapine concentrations by up to 55% [177-179], and co-administration of rifampicin and 
nevirapine has been associated with greater risk of virological failure and death compared to 
efavirenz-containing regimens [180]. Rifampicin has not been consistently shown to reduce efavirenz 
concentrations, and is the current non-nucleoside reverse transcriptase inhibitor recommended in 
TB-HIV co-infection [181].  
Perhaps more challenging are DDIs between rifampicin and protease inhibitors in second-line ART 
[181]. Rifampicin-protease inhibitor co-administration may reduce plasma protease inhibitor 
concentrations by up to 95% [51, 182], and be associated with unacceptable toxicity [51, 183, 184]. 
Switching to alternative rifamycins, such as rifabutin or rifapentine, may be associated with fewer 
DDIs than rifampicin, but are less available in resource-limited settings [51, 100]. Alternatives to 
protease inhibitors with minimal drug interactions are in development [185], and may become major 
alternatives to existing ART [186]. In the meantime, a strategy of double-dose boosted lopinavir for 
patients on TB treatment requiring second-line ART may be a suitable regimen to limit the effect of 
DDIs in these settings [187].  
Rifampicin is generally well tolerated at therapeutic doses, but is associated with gastrointestinal 
upset (nausea, vomiting, abdominal pain), pruritis, and (benign) discoloration of body fluids [102]. 
Administration in those with chronic liver disease, poor nutrition, alcoholism, or advanced age, may 
be associated with hepatoxicity [126], whereas moderate rises in transaminases are common and 
without clinical significance [100, 188].   
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1.6.3.2 Isoniazid 
Isoniazid (isonicotinic acid hydrazide) is a nicotinamide derivative first tested in humans in 1952 
[189-191]. Isoniazid is a prodrug which requires activation by the Mtb catalase-peroxidase enzyme 
KatG [192]. The activated isoniazid causes irreversible inhibition of the enoyl reductase carrier 
protein (inhA), essential to produce mycolic acids required for the mycobacterial cell wall [192, 193]. 
As such, isoniazid is bactericidal against rapidly dividing organisms, but bacteriostatic against slowly 
dividing organisms [126]. Nitric oxide generated by KatG oxidation of the hydrazine nitrogens further 
contributes to the antimycobacterial role of isoniazid [194].  Mutations in the katG gene of Mtb 
confer resistance to isoniazid though reduction or loss of activity of the catalase-peroxidase [157]. 
Rapid emergence of isoniazid resistance during monotherapy was identified in the earliest trials of 
isoniazid treatment [191], and prompted the use of triple-drug therapy (2SHT/16HT) to reduce the 
risk of acquisition of resistance [15, 195, 196]. 
The pharmacokinetics of isoniazid are also highly variable [159]. Mutations in the enzyme system 
required for its’ elimination results in trimodal elimination (fast, intermediate, slow) [197], with 
differences in acetylisoniazid excretion noted as early as 1953 [198]. Isoniazid clearance is driven by 
N-acetyltransferase 2 in the liver and small intestine, regulated by the polymorphic NAT2 gene [199, 
200]. SNPs in several NAT2 alleles confer acetylation phenotype [200, 201]. Low drug exposure in 
fast acetylators may be associated with increased risk of treatment failure, relapse or acquired drug 
resistance, whereas high exposure in slow acetylators may be associated with toxicity [201]. 
Currently, assignment of NAT2 phenotype is complex and must be inferred by genotyping for 
multiple SNPs and performing haplotype analyses. However, studies in European bladder cancer 
patients have identified a single common tag-SNP (rs1495741), which could predict the overall 
phenotype [202]. Recent work from Malawi suggest that the rs1495741 tag-SNP may be 
conveniently deployed for to simplify NAT2 phenotype assignation when interpreting data on 
isoniazid containing regimens in clinical trials [Sloan et al, unpublished data]. 
After an oral dose, isoniazid is rapidly absorbed, and achieves peak plasma concentrations within 1-2 
hours [126, 169]. Administration with food may reduce the bioavailability of isoniazid, reduce the 
Cmax, and increase the Tmax [137, 203]. Isoniazid undergoes first pass metabolism in the 
gastrointestinal tract and liver, reducing bioavailability though presystemic elimination [204]. This 
effect is greater in fast acetylator patients [205], such that slow acetylators may achieve higher Cmax 
concentrations [140]. Acetylator status alters the half-life of isoniazid, with rapid acetylators having 
an elimination half-life of approximately 50% of slow acetylators [126, 155, 197].  
Isoniazid is minimally protein bound and distributes well into tissues [126, 206], with a peripheral 
volume of distribution as high as 1730 l [159]. Isoniazid appears to achieve concentrations in 
cerebrospinal fluid comparable to plasma [207], and in lung epithelial lining fluid and alveolar cells 
[208, 209]. As a small polar molecule, isoniazid appears to achieve homogenous distribution across 
the caseum, interstitium, and cavity of lung lesions in explant samples from TB patients [210]. 
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Isoniazid achieves rapid reductions in the bacillary load (EBA) in the first few days of treatment [90, 
211], and this may in part be due to the extensive tissue distribution. After 3 days of treatment, 
isoniazid activity decreases due to the development of katG mutations and the production of 
mycobacterial efflux pumps [212].     
Adverse events attributed to isoniazid may occur in up to 5.4% of patients, with risk of toxicity 
associated with acetylator status [126]. Peripheral neuropathy is more common in slow acetylators 
[126, 213], and can be prevented by supplemental vitamin B6 (pyridoxine) [214, 215]. Isoniazid 
competitively inhibits activation of pyridoxine into coenzymes required for protein metabolism and 
production of some neurotransmitters [214]. Optic neuritis, psychosis, and convulsions, are rarer 
complications of isoniazid treatment, and may necessitate withdrawal [100].  
Hepatotoxicity occurs in up to 3% of patients aged over 50 years, and risk was increased with regular 
alcohol consumption [216]. Hepatotoxicity has been related to acetylator status [217], and the 
production of toxic metabolites [218]. Isoniazid is more likely to be associated with hepatotoxicity 
than rifampicin, but the risks were increased when prescribed together [219]. Enzyme induction by 
rifampicin may increase the generation of toxic metabolites [220]. 
 
1.6.3.3 Pyrazinamide 
Pyrazinamide is an unusual drug used exclusively in combination therapy for tuberculosis. First 
synthesized in 1936, it was not until 1952 that its’ anti-tuberculous activity was noted in mouse 
models [161, 221, 222]. Testing in humans followed immediately, and was found to be effective 
against TB [223]. Hepatotoxicity in the early human studies prevented its’ inclusion in the early trials 
of combination therapy, partly due to the high initial doses chosen (3 g per day) [224-226]. In the 
1970s, pyrazinamide was reappraised in the trials of potential short-course regimens due to the 
limited evidence from earlier studies suggesting accelerated sputum culture conversion, and good 
sterilising activity in animal models [15]. Inclusion of pyrazinamide to 6-month SH-based regimens, 
with or without rifampicin, achieved relapse rates of 4-8%, and sputum culture conversion rate of up 
to 83% [15, 118, 121]. Further trials explored the minimum duration of pyrazinamide required for 
relapse-free cure, identifying that there was no treatment benefit in extending pyrazinamide therapy 
beyond the first 2 months of therapy [13, 14, 122]. 
Despite its’ central role in reducing treatment duration from 9-12 months to 6 months, 
pyrazinamide’s mechanism of action is incompletely understood. It has no anti-TB activity under 
normal culture conditions at near-neutral pH [227], no activity in guinea pig models of TB [223], and 
minimal early bactericidal activity in TB patients [90]. Its’ ability to shorten treatment suggests it 
works primarily as a sterilising agent, mainly between 15 and 56 days of therapy [84, 228].  
Pyrazinamide is preferentially active against semi-dormant, non-growing Mtb [161]. It is a prodrug, 
and requires conversion to pyrazinoic acid (POA) by bacterial nicotinamidase/pyrazinamidase [161, 
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229]. It appears to be active against TB only at acidic pH, which may occur during active 
inflammation early in treatment [160, 161]. Cytoplasmic POA has no antimycobacterial activity, is 
excreted, and in acidic conditions converted to the uncharged protonated POA (HPOA) [161]. HPOA 
permeates the cell and accumulates in the cytoplasm. The protons brought in with HPOA acidify the 
cytoplasm and inhibit key enzyme pathways, de-energise the cell membrane potential and affect 
membrane transport functions, ultimately killing the mycobacterium [161]. This mechanism of action 
explains the greater activity of pyrazinamide against non-replicating Mtb. Acid-facilitated uptake of a 
weak acid is non-specific, but Mtb is unable to counteract the effect of influx due to a deficient POA 
efflux mechanism [161]. This efflux system is downregulated in dormant bacilli, with consequent 
accumulation of HPOA in the cytoplasm [161]. Alternative mechanisms of action include inhibition of 
fatty acid synthase [162], or though inhibition of trans-translation in non-replicating organisms [163]. 
Resistance is linked to highly diverse mutations in the pyrazinamidase gene (pncA) required for 
conversion of pyrazinamide to POA [161, 229]. 
The pharmacokinetics of pyrazinamide appear to be less variable than for the other first-line drugs 
[155]. The drug is rapidly absorbed, with Tmax increasing from 1 to 3 hours with co-administration 
with a high-fat meal [126, 230, 231]. Studies in South Africa have suggested a bimodal distribution in 
absorption rate [164]. It is metabolized mainly in the liver and excreted in the urine [100]. 
Pyrazinamide has a plasma half-life of approximately 10 hours making it suitable for once-daily 
dosing [232]. The drug is widely distributed (volume of distribution 29 l [164]), achieving near-plasma 
concentrations in the CSF [207] and alveolar cells [233]; and seemingly concentrating in lung lining 
fluid [233]. Systemic exposure to the metabolite POA is approximately 20% of that of pyrazinamide 
[232]. Pyrazinamide has a pH-dependent MIC against Mtb [161], limiting the usefulness of 
pharmacokinetic indices using MIC as a measure of drug sensitivity.  
Polyarthalgia is one of the commonest side effects of pyrazinamide therapy, secondary to inhibition 
of renal tubular secretion of uric acid, and may require treatment with allopurinol [100]. Dose should 
be reduced in patients with renal failure, typically to thrice-weekly administration [100]. 
Hepatotoxicity discouraged pyrazinamide use after the earliest studies in humans, but is less 
common when used at 25-35 mg/kg for only the first 2 months of treatment [126]. 
 
1.6.3.4 Ethambutol 
Ethambutol, an ethylenediamine, was developed in response to increasing resistance to first-line 
drugs [234]. Ethambutol was discovered in 1961 when screening synthetic compounds in mice for 
protection against the H37Rv strain of Mtb [235]. Trials in humans soon followed, but “toxic 
amblyopia” was noted at doses of 60-100 mg/kg in nearly half of patients [236]. MRC trials using 
ethambutol at doses as low as 6 mg/kg followed, and found ethambutol to be as effective as para-
aminosalicylic acid when combined with isoniazid, and better tolerated [237, 238]. Further work 
demonstrated that ethambutol could replace intramuscular streptomycin [124, 239, 240]. 
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Combination therapy with rifampicin and isoniazid enabled treatment shortening to 9 months [241]. 
Ethambutol features as an intensive phase medication in the WHO-approved first-line regimen [100], 
primarily for the protection it offers companion drugs (particularly rifampicin) against the 
development of resistance where undiagnosed mono-resistance is present [242]. Ethambutol is 
bacteriostatic rather than bactericidal, and works by inhibiting transfer of mycolic acids into the 
bacterial cell wall [165]. Mutations in the embCAB operon encoding arabinosyltransferases confers 
ethambutol resistance [166]. 
Ethambutol is well-absorbed after oral administration, but takes between 2 and 3 hours to achieve 
maximal plasma concentrations [243-245]. Co-administration with food delays absorption and 
reduces the Cmax [243]. Oral bioavailability is around 80% [244, 246], and the drug is 10-40% bound 
to plasma proteins [169, 246]. Over 75% of ethambutol is excreted unchanged in the urine, making it 
a useful anti-tuberculosis medication in liver disease [126, 169, 246, 247]. Renal clearance of 
ethambutol is up to 5 times higher than creatinine, indicating the role of active renal tubular 
secretion in ethambutol elimination [246]. Consequently, ethambutol dosing should be adjusted in 
renal disease [100, 242]. 
Population-PK studies have shown that ethambutol distributes well, with a central and peripheral 
volume of distribution of 82 l and 623 l respectively [167]. A notable exception is cerebrospinal fluid: 
ethambutol penetrates inflamed meninges, but does not have demonstrated efficacy in TB 
meningitis [248-250]. The WHO recommends that streptomycin replace ethambutol in TB meningitis 
[100]. In the lung lining fluid, ethambutol appears to equilibrate with plasma, and concentrate within 
the alveolar cells [251]. 
Adverse events are rare with ethambutol treatment at standard doses [100]. The risk is development 
of retrobulbar neuritis, with reduced visual acuity or loss of red-green colour discrimination [100, 
102]. This effect is dose-related, and ocular assessment is recommended before and during 
treatment [100, 252]. The difficulty of assessing ocular toxicity in children previously discouraged the 
use of ethambutol in children under 5 years of age, but was reassessed due to toxicity concerns with 
thiacetazone [253]. Extensive experience of ethambutol in children does not suggest an increased 
risk of ocular adverse events [254, 255], and paediatric dosing was recently revised upwards (to 15-
25 mg/kg) to achieve concentrations similar to adult targets, though still falling short [256, 257]. 
 
1.7 PK-PD studies in optimising TB therapy 
 
The clinical trial sequence that resulted in current short course chemotherapy for DS-TB was 
completed by 1985, and moved directly from Phase I studies of restricted scope to pivotal Phase III 
trials [258]. Modern PK-PD tools and population pharmacokinetic analysis had not yet been 
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established [53].  Consequently, correlation between drug concentration and therapeutic effect was 
incompletely evaluated. 
Subsequent pre-clinical experiments have derived summary PK measures, including the maximum 
drug concentration (Cmax) or area under the concentration-time curve (AUC), from murine or hollow 
fibre system (HFS) models of TB disease [259-265]. These parameters may be expressed relative to 
the minimum inhibitory concentration (MIC) of each antibiotic for the infecting Mtb isolate, and 
related to the rate of bacterial clearance from the model. Results suggest that the efficacy of 
rifampicin, isoniazid, pyrazinamide and ethambutol are driven by AUC/MIC [261, 263-265]. For 
rifampicin, isoniazid and ethambutol there is also a relationship between efficacy and Cmax/MIC [263-
265]. Data from retrospective meta-analyses contend that the PK-PD indices associated with efficacy 
in HFS studies are also relevant to clinical disease [266]. 
Alongside this thought-provoking pre-clinical PK-PD work sits a growing body of population PK 
literature revealing up to 10-fold inter-individual variability in plasma PK indices for first-line anti-
tuberculous drugs [131, 159, 164, 167], with PK variability accounting for a proportion of 
unfavourable outcomes even amongst patients who do not miss doses of medication [267]. Studies 
comparing drug concentrations (particularly the Cmax of rifampicin) to a pre-defined reference range 
invariably show antibiotic exposure to be unpredictable and lower than expected [155, 268], giving 
rise to the argument that more detailed clinical PK-PD studies are needed to delineate the 
contribution of inadequate antibiotic exposure to unfavourable outcomes. Two potential benefits 
are cited for this approach; 1) improved knowledge of the PK-PD drivers of treatment success may 
enable early phase clinical trials to predict whether doses escalation of key agents could facilitate 
treatment shortening in new standardised regimens; and 2) greater understanding of early PK-PD 
targets linked to long-term cure may permit therapeutic drug monitoring (TDM) and intensification 
of therapy for patients at high risk of unfavourable outcomes. 
 
1.7.1 Clinical PK-PD study design 
 
A generic design to provide an overview of clinical PK-PD studies in TB is outlined in Figure 1.4. For 
illustration, only the current 6-month treatment regimen for DS-TB is shown but timescales and 
regimens may be adapted for MDR-TB. PK-PD studies nested within early phase clinical trials may 
compare multiple drugs and dose combinations.  
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Figure 1.4: Generic study design for clinical PK-PD studies in tuberculosis  
Procedures to generate PK parameters are shown in green. Procedures to generate PD parameters and study 
outcome measures are shown in red.  PK-PD parameters which may be related to study outcome measures are 
shown in yellow.  PTB: pulmonary tuberculosis, R: rifampicin, H: isoniazid, Z: pyrazinamide, E: ethambutol. 
Number before drug combinations denotes intended duration of therapy in months. Other abbreviations are as 
described in the main text. a TB cultures to determine early efficacy measures may be set up in solid or liquid 
culture. b Treatment failure is normally defined as persistently positive sputum cultures until the end of TB 
therapy. c Relapse is normally defined as cure (negative sputum culture) at the end of TB therapy but reversion to 
positive cultures with the same Mtb strain as the baseline isolate during post-treatment follow-up. From [269]. 
 
Blood sampling for plasma or serum PK assays are generally drawn after daily medications have 
reached a steady state concentration cycle, typically after at least 14 days of therapy. Intensive PK 
sampling to establish the AUC for the 24 hours after dosing (AUC0-24) is costly and labour intensive 
because a minimum of six or seven blood samples must be collected at carefully recorded time-
points. All specimens should be promptly centrifuged so that plasma or serum can be harvested and 
frozen at -80oC, prior to batched analysis by high performance liquid chromatography (HPLC) and 
mass spectrometry. For studies in TB endemic, resource-poor countries bioanalysis often requires 
cold shipment to distant laboratories. Novel approaches to measuring drug exposure or activity in 
resource-limited settings include the use of dried blood spot methods to store and transport samples 
[270], urine colorimetry to detect low rifampicin exposure [271], or even co-culturing patient’s Mtb 
isolate with their plasma on treatment in liquid culture to give an indication of the relative activity of 
the treatment regimen [272]. For some anti-tuberculous drugs (e.g. amikacin [273], kanamycin [273], 
moxifloxacin [274] and linezolid [275] in MDR-TB) limited sampling strategies have sought to 
determine which single time-point measurements best represent more complex PK indices. For 
other antibiotics (e.g. rifampicin) Bayesian statistical techniques have been deployed to calculate 
AUCs from sparse sampling strategies (often 2-3 blood draws) [276]. Potential drawbacks to the 
Bayesian approach are the need for prior intensive PK data from the same population and reliance 
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on sophisticated computer software [168]. There is also a lack of consensus on optimum sparse 
sampling time-points for some drugs [277, 278].      
As with pre-clinical studies, it is recognised that antibiotic PK parameters such as AUC and Cmax 
should be related to the MIC of each drug for the infecting Mtb isolate. In fact, lack of detailed 
epidemiological data on MIC distributions for Mtb from most high-incidence TB settings [156, 279, 
280] makes calculation of AUC/MIC and Cmax/MIC more important for clinical pharmacology studies 
than for murine or HFS models. Mtb MIC assay plates covering most first and second line anti-
tuberculous drugs are available which may expand access to PK-PD testing for TB patients [281-283]. 
Selection of appropriate outcome measures after establishing PK-PD parameters of interest remains 
challenging, as discussed above.  
 
1.7.2 Existing clinical PK-PD data 
 
Table 1.4 describes published studies which have adopted a PK-PD approach to relate plasma or 
serum antibiotic exposure to DS-TB treatment efficacy in adults. The collective results are difficult to 
interpret; some studies report an association between PK variability and treatment response [284-
291] whilst others do not [292-296]. No PK-PD markers consistently emerge as potential predictors 
of efficacy in Phase II clinical trials, or targets to inform TDM strategies in clinical practice.  
 
Author, year and 
site  
N= PK sampling  PK 
parameters 
MICs  Outcome measures Results 
Narita, 2001, 
USA [293] 
69 RH 
2, 6 h 
Cmax No Late: TB recurrence 
(presumed relapse) 
after completion of 
therapy 
No effect of R or H PK on 
treatment outcome 
Weiner, 2003, 
USA [285] 
133 Rp, H 
1, 2, 5, 24 h 
Cmax 
AUC0-12h 
No Late: Composite 
outcome of treatment 
failure and relapse 
Lower Rp and H AUC0-12h 
associated with poor 
outcome 
Weiner, 2003, 
USA [284] 
102 Rp, H 
1, 2, 3, 6, 24 
h 
 
Cmax 
AUC0-12h 
AUC0-24h 
No Late: Composite 
outcome of treatment 
failure and relapse 
Development of 
rifamycin resistance 
Lower Rb AUC0-24h associated 
with poor outcome and 
development of 
antimicrobial resistance 
Lower H AUC0-12h associated 
with poor outcome and 
development of rifamycin 
resistance  
Ribera, 2007, 
Spain [296] 
22 RH 
0.5, 1.5, 2, 
3, 4, 6, 8, 12 
h 
Cmax 
AUC0-24h 
No Late: Composite 
outcome of treatment 
failure and relapse 
No effect of R or H PK on 
outcome 
Chang, 2008, 
Hong Kong [292] 
72 R only 
2, 4 h 
Cmax No Early: 2-month SCC No effect of R PK on 2-
month SCC 
Chideya, 2009, 
Botswana [286] 
225 RHZE 
1, 2, 6 h 
Cmax 
AUC0-6h 
No Late: Composite 
outcome of treatment 
failure or death 
during therapy 
Low Cmax for Z (<35 mg/l) 
associated with poor 
outcome 
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Burhan, 2013, 
Indonesia [287] 
167 RHZE 
2 h * 
 
C2h No Early: 2-month SCC 
Additional post-hoc of 
≥ 1 positive sputum 
culture at 4, 8 or 24 
weeks 
No effect of R, H or E PK on 
2-month SCC 
Low C2h for Z (<35 mg/l) 
associated with ≥ 1 positive 
sputum culture at 4, 8 or 24 
weeks 
Pasipanodya, 
2013, South 
Africa [288] 
142 RHZ 
0.5, 1, 1.5, 
2, 2.5, 3, 4, 
6, 8 h 
Cmax 
AUC0-24h 
No Early: 2-month SCC 
Late: Composite 
outcome of treatment 
failure, death and 
relapse  
Low Cmax for Z (<58.3 mg/l) 
most strongly associated 
with reduced 2-month SCC  
Low AUC0-24h for R (<13 
mg.h/l), H (<52 mg.h/l) and Z 
(<363 mg.h/l) associated 
with poor long-term 
outcomes 
Chigutsa, 2014, 
South Africa 
[289] 
154 RHZE 
4-8 samples 
over 7 h 
Cmax 
AUC0-24h 
Yes Early: 8-week sputum 
bacterial elimination 
rates †  
Low Cmax for R (<8.2 mg/l) 
and low AUC0-24h/MIC (<11.3 
mg.h/l) associated with 
slower bacterial elimination 
Prahl, 2014, 
Denmark [290] 
32 RHZE 
2 h 
C2h No Late: Treatment 
failure 
Treatment failure more 
common with low C2h of 
both R (<8 mg/l) and H (<3 
mg/l) 
Requena-
Méndez, 2014, 
Peru [295] 
113 H 
2, 6 h 
C2h No Late: Composite 
outcome of treatment 
failure and relapse 
No effect of H PK on 
outcome 
Sloan, 2014, 
Malawi [89] 
133 RHZE 
2, 6 h 
Cmax 
AUC0-6h 
No Early: 2-month SCC 
Early: 8-week sputum 
bacterial elimination 
rates ‡  
Late: Composite 
outcome of treatment 
failure and relapse 
Lower AUC0-6h for H and Z 
associated with reduced 2-
month SCC 
Low AUC0-6h for H (<15 
mg.h/l) associated with 
slower bacillary elimination 
Lower AUC0-6h for H 
associated with poor long-
term outcomes 
Mah, 2015, 
Canada [291] 
134 RH 
1-2, 6 h 
Cmax No Early: 2-month SCC Low Cmax of H (<3 mg/l) 
associated with reduced 2-
month SCC 
Park, 2015, South 
Korea [294] 
413 RHZE 
2 h 
C2h No Early: 2-month SCC 
Late: Composite 
outcome of treatment 
failure and relapse 
No effect of R, H or E PK on 
2-month SCC or late 
outcome 
Table 1.4: Summary of PK-PD studies to evaluate antibiotic exposure-treatment efficacy relationships in 
adults with DS-TB 
* Full PK profile done on a subset of 9 patients  
† Bacterial elimination rates based on time to event modelling from liquid culture data [297] 
‡ Bacterial elimination rates based on mixed effects modelling from solid and liquid culture data [89] 
Rp: rifapentine, H: isoniazid, Rb: rifabutin, Z: pyrazinamide, E: ethambutol. Other abbreviations are as described 
in the main text. 
 
There are several potential explanations for these mixed results. Pharmacological variability is one of 
many factors influencing TB treatment [168] and may have varying impact in different settings. The 
published studies suffer from considerable heterogeneity in design and execution. Most reported 
antibiotic concentrations at one or two time-points only, reducing the accuracy of Cmax and AUC 
calculations. Only one related PK indices to MICs from infecting Mtb isolates [289]. A wide range of 
early and late treatment outcomes measures were used. Treatment failure and relapse are relatively 
rare events so small cohorts may have been insufficiently powered to demonstrate the effect of 
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antibiotic exposure on unfavourable outcome rates; and in general, few studies are powered with 
PK-PD analyses as the primary outcome. Finally, the majority were single-arm observational studies 
which may have diminished their ability to detect relationships with treatment efficacy; for example, 
most of inter-individual variability in rifampicin concentrations in African settings was at the lower 
end of the likely exposure-response curve [155, 268], making it difficult to demonstrate the 
incremental benefit of higher concentrations on steeper sections of the curve. Standardisation of 
clinical PK-PD study design may provide clarification and facilitate meta-analysis of data from 
different sites [298, 299].   
While modern PK-PD methods may improve TB treatment, more work is required to translate PK-PD 
data into practically useful information for researchers and clinicians. The next sections will provide 
specific examples of ongoing work where PK-PD studies are proving beneficial. 
 
1.7.3 Ongoing PK-PD work in DS-TB 
 
DS-TB compromises 95% of TB cases worldwide, with a public health approach required to manage 
large numbers of patients in low resource settings. Therefore, the main utility of PK-PD work in DS-
TB will likely be for development of new, dose-optimised, standard regimens rather than individual 
patient TDM. 
The clearest example of an antibiotic for which dose and exposure-response relationships require re-
analysis is rifampicin, a key sterilising mycobacterial RNA synthesis inhibitor which is critical for 
achieving relapse-free cure with current DS-TB regimens [15, 125]. 
The current rifampicin dose (10 mg/kg once daily) was selected in the 1960s to facilitate 6-month 
treatment whilst minimising expense [300]. Even when costs dropped, toxicity concerns discouraged 
dose escalation. However, pre-clinical experiments now suggest that increased rifampicin doses (up 
to 160 mg/kg/day) may be tolerable and could shorten treatment [260, 264, 301, 302]. Monotherapy 
studies in humans have demonstrated a steeper fall in bacterial load over 2-14 days with modest 
dose increases [84, 303], and a systematic review of trials including rifampicin doses up to 20 mg/kg 
showed an association between higher doses and faster SCC [300]. In 2015, a maximum tolerated 
dose study from Cape Town reported rifampicin dosing up to 35mg/kg without any limiting toxicity 
so further work, beginning at 50mg/kg is planned [304]. Data from Bolivia, Nepal and Uganda 
corroborate the absence of rifampicin toxicity to 20mg/kg [305]. The accumulative evidence 
illustrates a need for new clinical PK-PD studies of high dose rifampicin use.   
Intensive PK sampling and analysis from the Cape Town study showed that increased rifampicin 
doses caused “super-proportional” increases in plasma antibiotic exposure; doubling the dose from 
10 to 20 mg/kg was associated with a more than four-fold increase in AUC0-24h, the average AUC0-24h 
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at 35 mg/kg was almost 10-fold higher than with standard dosing and the lowest recorded AUC0-24h 
and Cmax increased with almost every dose step [304].  Although not powered to detect differences 
in microbiological efficacy, there was a trend towards faster day 14 sputum bacterial clearance rates 
on solid and liquid media at 35 mg/kg than at lower doses and the AUC0-24h of rifampicin at day 14 
was a better predictor of 14-day bactericidal activity than the dose administered (either in ‘mg’ or 
weight-adjusted as ‘mg/kg’) [304].  
A further Multi Arm Multi Stage randomised Phase II trial of several novel treatments for DS-TB 
(including high dose rifampicin, moxifloxacin and the experimental compound SQ109) in South Africa 
and Tanzania has since shown reduced time to sputum culture conversion on liquid media at 
rifampicin 35 mg/kg across a period of 12 weeks. A 20 patient PK sub-study from that cohort 
confirmed that rifampicin dose escalation has a “super-proportional” plasma drug exposure effect 
[306]. Emerging evidence suggests that these higher doses are associated with more rapid sputum 
sterilisation [307, 308]. Additional PK-PD insights may be gleaned from further Phase II trials on the 
efficacy of high dose rifampicin (www.clinicaltrials.gov NCT00760149 in Tanzania). 
Whilst these data are encouraging, caution is required. Most high dose rifampicin studies excluded 
HIV co-infected patients or selectively recruited ART-naïve individuals with high CD4 counts. Severely 
immunocompromised HIV patients may be at higher risk of poor drug absorption or adverse events 
and, as rifampicin is a potent inducer of cytochrome P450 enzymes, higher doses may present an 
increased challenge in the management of drug-drug interactions. Future clinical PK-PD studies 
should investigate exposure-response on TB outcomes in this vulnerable population [51]. 
Furthermore, the notorious unreliability of early PD markers at predicting relapse precludes 
confidence that rifampicin dose escalation will permit treatment shortening until completion of 
definitive trials. One Phase III study, (RIFASHORT, NCT02581527) has recently started recruiting with 
experimental regimens containing 1200 mg and 1800 mg of rifampicin (20-30 mg/kg for 60 kg 
adults). Whilst these data will be valuable it remains to be seen whether this level of dose escalation 
is enough, particularly as current PK-PD and toxicity data suggests scope to go higher. 
PK-PD and dose escalation studies have been undertaken on other rifamycins. Rifapentine produces 
higher serum concentrations than rifampicin after 10 mg/kg oral dosing and has a longer half-life (15 
hours, compared to 2-3 hours for rifampicin) [168]. Dose increases to 20 mg/kg have been tolerated 
by healthy volunteers, although the rises in plasma AUC0-24h associated with higher doses were not 
super-proportional [309]. Clinical trials including rifapentine are ongoing (TBTC Study 31, 
NCT02410772). Rifabutin is sometimes substituted for rifampicin in patients with high DDI risk 
because it is less potent inducer of cytochrome P450 enzymes [80, 310]. Its absorption is variable in 
HIV patients [311] and toxicities (including leucopenia and uveitis) are concentration dependent. 
TDM is highly recommended and dose increases may be problematic. 
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Alongside the rifamycins, administration of pyrazinamide for the first 2 months of treatment is key to 
the sterilising efficacy of 6-month first line regimens for DS-TB [15, 122, 161]. Pyrazinamide primarily 
exerts anti-tuberculous activity in acidic conditions.  Whilst EBA studies with pyrazinamide 
demonstrated poor independent bactericidal activity over 14 days, it enhanced the activity of other 
drugs [84] and some clinical PK-PD studies have shown that reduced exposure is associated with 
poor late outcomes [286-288]. The population PK profile of pyrazinamide is more stable than 
rifampicin or isoniazid so predictable plasma concentrations are usually achieved [164, 268, 312]. 
The currently recommended dose is 20-30 mg/kg. Concerns about side-effects of arthralgia and 
dangerous hepatotoxicity have stifled calls for dose escalation. However, pre-clinical data suggest 
that doses up to 60 mg/kg could improve efficacy [261]. A meta-analysis of dose-toxicity 
relationships in clinical studies reported that, although arthralgia is dose-related, higher dose 
pyrazinamide did not significantly increase hepatotoxicity and some adverse liver events may be 
idiosyncratic [313]. Computer simulations suggest that modest pyrazinamide dose increases (up to 
40 mg/kg) alongside higher dose rifampicin may accelerate 2-month SCC. Clinical trials with nested 
PK-PD analyses and toxicity monitoring are planned to test this proposition.  
Pharmacological lessons on optimal dosing and drug-drug interactions may yet emerge from the 
Phase III fluoroquinolone trials which failed to shorten DS-TB therapy [59-61]. A PK sub-study of the 
OFLOTUB trial [59] identified that gatifloxacin exposure decreased with rifampicin, isoniazid, and 
pyrazinamide co-administration; and that double-dose gatifloxacin may optimise the bactericidal 
effect and reduce the probability of resistance [314]. Similarly, drug-drug interactions between 
rifampicin and isoniazid and moxifloxacin reduce moxifloxacin Cmax and AUC by 32% and 31% 
respectively [315]. Refinement of fluoroquinolone dosing though PK-PD studies may improve 
outcomes in future trials.   
 
1.7.4 Intra-individual PK variability and special populations 
 
Rather than poor adherence, pre-clinical and mathematical models predict that inter-individual PK 
variability accounts for a large proportion of therapeutic failures [267, 316].  In experimental hollow 
fibre systems modelling plasma PK with poor adherence, therapy failure was only encountered when 
non-adherence was ≥60% [267].  Even with perfect adherence, 1% of patients would develop MDR-
TB due to PK variability alone. Wide inter-individual variability in the plasma exposure of some anti-
tuberculous antibiotics partly underpins the rationale for clinical PK-PD studies [131, 159, 164, 167]. 
Co-morbidities, concomitant medications, dietary intake and genetic factors regulating drug 
metabolism all contribute. Greater understanding of the role played by genotype may identify 
patients at high risk of low exposure, potentially focussing TDM and earlier intervention to improve 
outcomes. Patient genotypes for drug metabolising enzymes and transporters may explain up to 30% 
of PK variability for all drugs [317, 318].   
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Isoniazid clearance is driven by N-acetyltransferase 2 enzymes in the liver and small intestine, 
regulated by the polymorphic NAT2 gene [200]. Low isoniazid exposure in fast acetylators may be 
associated with increased risk of unfavourable outcomes and acquired drug resistance; while high 
exposure in slow acetylators may be associated with toxicity [201]. Given the dominant effect of 
NAT2 genotype on isoniazid exposure, practicing clinicians and researchers should consider 
categorising patients by acetylator status. 
Genotypic drivers of rifampicin variability are less clear. Recent reports from South Africa and 
Uganda suggest that SNPs in SLCO1B1 are more common in African patients and associated with up 
to 28% reduction in rifampicin AUC0-24h in homozygotes [146, 319]. However, given extensive 
population diversity in SLCO1B1 polymorphism carriage [320], these findings have not been 
replicated in India, Tanzania, or Malawi [149, 321]. 
Some PK variability is associated with physiologically distinct, but previously neglected populations 
where a strong case exists for separate PK-PD studies and clinical trials. Foremost amongst these are 
children.  Previously, paediatric dosing and duration of first-line TB therapy were extrapolated on a 
mg/kg basis from adult studies, but this resulted in lower plasma concentrations than the adult 
population.  In 2010, the WHO recommended increased doses of all 4 first line TB drugs [256]. Few 
PK studies have been performed to assess the impact of these adjustments. Emerging data from 
South Africa and Malawi indicate that rifampicin exposures remain low [257, 322]. A cohort 
evaluation of 161 Indian children aged 1-15 has suggested that a low Cmax for rifampicin (<3.01 mg/l) 
or pyrazinamide (<38.01 mg/l) predicted late outcomes of treatment failure or death [323]. There is 
almost no clinical PK-PD information on second-line drugs for MDR-TB in paediatric populations. 
Although the evidence is debateable, patients with HIV co-infection [155, 324] diabetes mellitus 
[325] and pregnant women [326] may also have unusual PK-PD profiles, necessitating detailed sub-
studies to clarify the role of TDM and altered antibiotic dosing. Systematic use of early TDM with 
dose correction in diabetic patients has shown potential to shorten time to sputum culture 
conversion [327]. 
 
1.7.5 PK-PD at the site of disease 
 
All the PK-PD data described hitherto report antibiotic exposure in peripheral blood, but TB is not 
primarily a bloodstream infection. In pulmonary TB, Mtb exists within discrete microenvironments: 
intracellular organisms within granuloma macrophages; free extracellular organisms in caseum, 
cavities and airways; and in apparently ‘normal’ interstitial lung tissue (Figure 1.5) [328]. It is 
improbable that unbound drug passively equilibrates between blood and all tissue compartments so 
investigation of relationships between peripheral blood and lesion PK-PD is important. Advantages 
and disadvantages of clinically focussed methods for this are outlined in Table 1.5. 
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Sampling site Advantages Disadvantages 
Plasma/serum Ease of repeat sampling 
Multiple / rich PK sampling possible 
Most existing data for comparison is from these 
samples 
 
Far from site of infection 
Unclear relationship with outcome 
Wide inter-individual variability  
Bronchoalveolar 
lavage 
‘Near infection’ samples - alveolar macrophages 
and epithelial lining fluid 
Can be paired with rich plasma/serum sampling 
Models of intrapulmonary exposure can be 
developed using population modelling techniques 
Invasive procedure 
Single time point sampling 
Sample from alveoli and bronchioles rather than 
within granuloma 
Drug loss due to efflux when sampling 
Differential penetration depending on inflamed / 
non-inflamed lung / different lobes 
Sampling retrieves mixture of macrophages, T-
lymphocytes and epithelial cells 
Lung explant 
studies (see 
1.7.5.2) 
Can assess spatial drug penetration 
Can combine with spatial data on drug 
susceptibility profile and MIC  
Only possible in patients requiring lung resection 
(either severe disease or a sub-set of MDR-TB 
patients) 
Single time point drug concentrations 
Cerebrospinal 
fluid 
(for TB 
meningitis) 
Accessible 
Can be paired with rich plasma sampling 
Models of CSF drug exposure can be developed 
using population modelling techniques 
Invasive procedure 
Single time point sampling 
Traumatic tap will contaminate samples 
Table 1.5: Pharmacokinetic sampling sites 
 
1.7.5.1 Intrapulmonary PK-PD 
The simple premise that the unbound drug will passively equilibrate between plasma and lesion is 
unlikely to hold true when we consider the complexity of TB pathology. The presence of a blood-
alveolar barrier impedes the free diffusion of antimicrobials into the lung in a similar, though 
presumably less robust, manner to the blood-brain barrier [329, 330]. Tight junctions between 
alveolar epithelial cells prevent the passive diffusion of antimicrobials down a concentration gradient 
and these molecules must use the transcellular route [329]. Influx and efflux transporters acting 
across this barrier will either facilitate or impede the passage of drugs into the pulmonary secretions 
[331, 332]. Infection and inflammation may further modulate the distribution of drugs into the 
alveolar space by disrupting this barrier: previous infections and fibrous scarring can reduce the 
diffusion of antimicrobials, whereas the increased permeability seen in active inflammation may 
facilitate the passage of both free and protein-bound antimicrobials [333, 334].  
The physicochemical properties of the antimicrobial will also affect its’ distribution.  The blood-
alveolar barrier will favour the diffusion of small and lipophilic molecules by the transcellular route 
[335]. Pyrazinamide, as a small polar molecule, will preferentially accumulate within the acellular 
caseum rather than in inflammatory cells [328]. The degree of protein-binding will determine the 
extent of pulmonary penetration.  In vivo, antimicrobials exist in both free and protein-bound forms, 
with only the unbound antimicrobial fraction at the target site responsible for its’ therapeutic effect 
[331]. Protein binding is often reversible, and typically the free fraction of antimicrobial will 
dissociate from the protein beforehand to cross the blood-alveolar barrier [330]. As a result, there 
may be a lag in pulmonary penetration of highly protein-bound antimicrobials [331]. Albumin 
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concentrations in the epithelial lining fluid (ELF; approximately 3.7 mg/ml) are considerably lower 
than those in plasma (approximately 40 mg/ml), with potential impact on protein-bound 
antimicrobials such as rifampicin [329, 336]. 
Following administration, antimicrobials are subject to biotransformation by all organs and tissues of 
the body - in the gut lumen, in plasma, within membranes, on first pass though the liver – and thus 
some degree of metabolism may already have occurred before the drug is distributed to the 
pulmonary compartment [53]. Metabolism by Clara cells in the lung may affect local concentrations, 
with these cells containing a large proportion of the pulmonary complement of CYP450 enzymes 
[337, 338].   
Alveolar macrophages (AMs) represent more than 95% of the cells retrieved in BAL, and are the 
major host cell niche for intracellular Mtb [339]. Understanding antimicrobial penetration into these 
cells is crucial to explaining how antituberculosis treatment (ATT) works at the site of infection. 
Activation of AMs due to inflammation may further modulate intracellular drug concentrations 
through active transport and efflux systems [53, 330].  Intracellular accumulation at the site of 
infection supports the argument that peripheral measures of drug concentration may not 
adequately explain drug exposure-response relationships in pulmonary TB. 
 
1.7.5.2 Measuring intrapulmonary drug concentrations 
One novel approach is to generate spatial drug penetration information by performing matrix-
assisted laser desorption/ionization (MALDI) mass spectrometry on dissected tissue from patients 
undergoing lung resection surgery for antibiotic-refractory disease [53, 340]. Early results suggest 
excellent rifampicin and pyrazinamide penetration into the central necrotic caseum of TB 
granulomas but peripheral intracellular accumulation of moxifloxacin [210].  These data may explain 
why rifampicin and pyrazinamide are critical DS-TB sterilising agents but treatment shortening trials 
with moxifloxacin were unsuccessful [60, 61]. An alternative approach using microdialysis on ex vivo 
pulmonary cavities from patients with MDR-TB shows excellent penetration of levofloxacin into 
cavity walls, and a good correlation between serum and cavitatory concentrations [341]. From a PD 
perspective, lung resection studies have shown differing drug susceptibility patterns in Mtb isolates 
from different pulmonary cavities of the same patient [342, 343] and mathematical models suggest 
that bacilli in compartments with low antibiotic penetration develop higher MICs. Overall, this 
advanced PK-PD work on resected lung tissue is beginning to generate very detailed information on 
the extent and consequences of antibiotic exposure at the site of infection. A disadvantage of these 
experiments is that they are only possible on a small sub-set of unusual and highly selected patients 
with very severe TB and particularly distorted lung anatomy.   
An alternative means of ‘near infection’ PK sampling is the use of bronchoalveolar (BAL) lavage to 
sample ELF and AMs. Given the invasive nature of this procedure, all previous BAL studies were 
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conducted on small numbers of healthy volunteers with single time-point sampling (Table 1.6). 
Single dosing will not capture the PK at steady state, and single time-points will not fully capture 
drug exposure – AUC or Cmax. Results show extensive variability in the pulmonary penetration of first-
line drugs. In ELF, isoniazid concentrations appeared low in relation to likely MICs for clinical Mtb 
isolates and projected rifampicin AUC/MIC measurements appeared insufficient to suppress 
resistance in a high proportion of subjects [208, 233, 251, 344, 345]. AM/ELF concentration ratios 
ranged from 0.1 to >20, with rifampicin, ethambutol, and fluoroquinolones concentrating most 
effectively within cells suggesting considerable antimicrobial activity will reside within the 
macrophage [53, 251, 346]. Difficulties for BAL-based studies are the potential clinical hazard and 
infection control risks associated with performing bronchoscopies on sick patients and the need to 
collect luminal specimens rather than those directly from granulomas.   
Measurement of intrapulmonary drug concentrations using BAL is technically challenging, and there 
are several important limitations to consider. To account for dilution of ELF by saline, the urea 
dilution measurement is typically used to calculate the volume of ELF obtained. Urea concentration 
in the ELF can be compared to that in plasma, enabling a dilution factor to be estimated and thus the 
volume of ELF obtained by sampling [347]. It is assumed that in conditions of equilibrium, plasma 
and BAL concentrations of urea should be approximately equal [330]. Given that BAL fluid must 
dwell in the lungs for a period to gather the distal alveolar lining [330], urea diffusion from blood and 
interstitium to BAL will potentially lead to a 100-300% increase in the estimate of ELF volume after 
only 1 minute of stagnation [348]. Shorter dwell times and pooling of BAL aliquots may minimise this 
effect.  
Drug efflux adds further variability to antimicrobial measurements in ELF and AM, reducing the 
measured concentrations in macrophages and increasing the extracellular free concentrations. Due 
to dilution of ELF with saline during the lavage process, the extracellular antimicrobial concentration 
may fall by 100-fold, and rapid effusion of antimicrobial from the AM follows [349]. Drug efflux and 
cell lysis may be minimised by rapid centrifugation and placing the sample on ice after collection 
[349, 350]. After centrifugation, AM from the pellet suspension can be counted in a haemocytometer 
for use in the calculation of intracellular drug concentrations.  
One of the major limitations of the previous studies of intrapulmonary PK for TB drugs (Table 1.6) 
has been the use of single time-point sampling, preventing estimation of AUC and Cmax. Sparse 
intrapulmonary PK data from individual samples taken at different time-points in different 
individuals can be pooled with rich plasma sampling to enable development of a population PK 
model using Bayesian methods. 
 
  
Drug Author, year 
and site  
N= Dosage regimen  Plasma PK 
sampling time 
(hours post 
dose) 
Plasma 
concentration 
(µg/ml, mean ± 
SD)  
BAL PK 
sampling time 
(hours post 
dose) 
ELF 
concentration 
(µg/ml, mean ± 
SD) 
ELF/plasma 
penetration 
ratio (mean ± 
SD) 
AM concentration 
(µg/ml, mean ± 
SD) 
AM/plasma 
penetration 
ratio (mean ± 
SD) 
R
IF
 
Ziglam, 2002, 
UK [346] * 
12 600 mg OD x 1 dose 2-5 15.5 ± 1.41 (SE) 2-5 5.3 ± 0.67 (SE) 
 
0.34 251.8 ± 65.92 16.26 
Conte, 2004, 
USA [345] † 
10 M HIV – 
10 F HIV – 
10 M HIV + 
10 F HIV + 
600 mg OD x 5 doses 
600 mg OD x 5 doses 
600 mg OD x 5 doses 
600 mg OD x 5 doses 
4 
4 
4 
4 
9.6 ± 7.5 
10.9 ± 4.4 
6.5 ± 2.4 
9.6 ± 6.4 
4 
4 
4 
4 
1.9 ± 2.2 
1.8 ± 1.3 
1.4 ± 1.0 
3.0 ± 1.6 
0.2 ± 0.2 
0.2 ± 0.2 
0.2 ± 0.2 
0.2 ± 0.2 
6.8 ± 5.4 
13.5 ± 7.1 
6.4 ± 2.4 
14.4 ± 6.6 
0.9 ± 0.5 
1.5 ± 1.0  
0.9 ± 0.5 
1.5 ± 1.0 
Katiyar, 2008, 
India [209] ‡ 
6 
6 
500 mg OD x 1 dose 
30 mg OD INH x 1 dose 
NR 
NR 
6.96 
0.45 
NR 
NR 
31.29 
2585.2 
NR 
NR 
1.04 (µg/106 AM) 
117.55 
NR 
NR 
IN
H
 
Conte, 2002, 
USA [208] † 
10 M HIV – FA  
10 F HIV - FA 
10 M HIV + FA 
11 F HIV + FA 
10 M HIV - SA 
10 F HIV - SA 
10 M HIV + SA 
9 F HIV + SA 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
300 mg OD x 5 doses 
4 
4 
4 
4 
4 
4 
4 
4 
0.17 ± 0.21 
0.59 ± 0.69 
0.47 ± 0.38 
0.71 ± 0.8 
0.87 ± 0.81 
1.03 ± 0.73 
1.08 ± 0.81 
1.43 ± 1.0 
4 
4 
4 
4 
4 
4 
4 
4 
1.0 ± 1.55 
1.21 ± 1.72 
0.82 ± 0.79 
1.78 ± 1.7 
3.28 ± 4.68 
5.86 ± 6.92 
2.15 ± 1.90 
1.96 ± 1.7 
1.2 ± 1.9 
1.2 ± 1.9 
1.2 ± 1.9 
1.2 ± 1.9 
3.2 ± 8.1 
3.2 ± 8.1 
3.2 ± 8.1 
3.2 ± 8.1 
1.1 ± 2.73 
7.92 ± 6.72 
3.08 ± 4.55 
1.05 ± 1.6 
3.83 ± 8.94 
1.93 ± 3.68 
0.95 ± 1.70 
1.06 ± 2.0 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
Katiyar, 2008, 
India [209] ‡ 
6 
6 
250 mg OD x 1 dose 
15 mg OD INH x 1 dose 
NR 
NR 
3.75 
0.25 
NR 
NR 
7.25 
1601 
NR 
NR 
0.95 
90.88 
NR 
NR 
O’Brien, 1998, 
USA [351] § 
6 300 mg OD x ≥ 5 doses 2 4.9 ± 0.8 2 0.44 ± 0.24 NR NR NR 
P
ZA
 
Conte, 1999, 
USA [233] † 
10 M HIV - 
10 F HIV - 
10 M HIV + 
10 F HIV + 
1000 mg OD x 5 doses 
1000 mg OD x 5 doses 
1000 mg OD x 5 doses 
1000 mg OD x 5 doses 
4 
4 
4 
4 
20.1 ± 6.2 
23 ± 5.8 
16.4 ± 5.42 
25 ± 7.1 
4 
4 
4 
4 
443 ± 180 
535 ± 297 
406 ± 198 
340 ± 167 
22 ± 11.8 
22 ± 11.8 
22 ± 11.8 
22 ± 11.8 
21.8 ± 18.6 
22.3 ± 21 
12.2 ± 10.2 
12.2 ± 17 
0.83 ± 0.7 
0.83 ± 0.7 
0.83 ± 0.7 
0.83 ± 0.7 
Katiyar, 2008, 
India [209] ‡ 
6 
6 
1250 mg OD x 1 dose 
75 mg OD INH x 1 dose 
NR 
NR 
111.4 
1.46 
NR 
NR 
1240 
18381 
NR 
NR 
34.32 
1010.67 
NR 
NR 
ET
H
 
Conte, 2001, 
USA [251] † 
10 M HIV - 
10 F HIV - 
10 M HIV + 
10 F HIV + 
15 mg/kg OD x 5 doses 
15 mg/kg OD x 5 doses 
15 mg/kg OD x 5 doses 
15 mg/kg OD x 5 doses 
4 
4 
4 
4 
2.3 ± 0.7 
1.9 ± 0.6 
2.4 ± 1.0 
1.7 ± 0.7 
4 
4 
4 
4 
2.6 ± 1.7 
1.9 ± 0.6 
2.2 ± 1.0 
1.9 ± 0.5 
 44.7 ± 14.2 
44.5 ± 15.6 
46.0 ± 17.0 
82.0 ± 39.4 
 
Table 1.6: Summary of intrapulmonary PK studies to evaluate antibiotic exposure in adults 
* patients undergoing diagnostic bronchoscopy. † volunteers with or without AIDS. ‡ healthy volunteers. § patients with pulmonary TB.  SD: standard deviation, SE: standard error, OD: once daily, 
NR: not recorded, INH: inhaled, FA: fast acetylators, SA: slow acetylators 
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1.7.5.3 Extrapulmonary PK-PD 
15-20% of TB cases are extra-pulmonary. Penetration of antibiotics to other infection sites may differ 
from the lungs. Specific PK-PD studies have been completed in TB meningitis, where treatment 
regimens derived from data on pulmonary TB do not account for the extent of drug penetration 
across the blood-brain barrier. Isoniazid, pyrazinamide, and the fluoroquinolones reach 
cerebrospinal fluid (CSF) in high concentrations, whereas streptomycin does not [249].  Interestingly, 
for fluoroquinolones both “low” and “high” CSF drug exposures are associated with poorer 
outcomes, and intermediate exposures are associated with less death and disability [352]. It is 
possible that more extensive breakdown of the blood-brain barrier with severe disease explains the 
link between higher drug exposure and poorer outcomes.  
CSF rifampicin exposure is lower than plasma  [207] and Phase II clinical trial of rifampicin (13 mg/kg) 
intravenously alongside moxifloxacin, isoniazid, pyrazinamide and corticosteroids in Indonesia 
identified a survival benefit from higher CSF rifampicin concentrations, with substantially lower 6-
month mortality in patients receiving the higher dose [353, 354].  Conversely, a Phase II trial in 
Vietnam, using oral rifampicin (15 mg/kg) and levofloxacin (20 mg/kg) did not improve survival [355].  
More studies are needed to determine whether rifampicin dose escalation, perhaps allied to 
intravenous administration, does improve outcomes [304, 356].  
 
1.8 Host pulmonary immune function and successful TB control 
 
No discussion of response to TB treatment would be complete without consideration of the host 
response to infection. The last section of this general introduction discusses the central role of the 
alveolar macrophage in the natural history of TB disease and immune response to infection, and the 
interplay between drug treatment and host response. 
 
1.8.1 Alveolar macrophage function 
 
Phagocytosis, literally “eating-cell process”, emerged as a means of acquiring nutrients in single-
celled organisms [357]. On encountering a target particle, protists engulf the particle to create an 
intracellular phagosome. Digestive enzyme-containing lysosomes fuse with the phagosome, creating 
a phagolysosome in which the particle was broken down to release nutrients for metabolic processes 
within the cell. In multicellular organisms, this process evolved further as a mechanism to remove 
cell debris, kill pathogenic microorganisms, and generate antigens to present to the adaptive 
immune system [357]. Through these additional capabilities, professional phagocytes represent one 
of the first lines of defence in the innate immune system. 
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AMs are specialised phagocytes residing in the pulmonary alveolus; a major interface between the 
body and the outside world. The lungs are constantly exposed to inhaled particulates, including 
microbes, and thus the AM must be able to phagocytose and kill bacteria, and where unable to do 
this completely, recruit an immune response [358]. The AM differs from inflammatory macrophages 
adapted for antimicrobial host defence; its responsiveness must be tightly regulated to minimise 
damage to the delicate gas exchanging alveolar structures though immune mediator release [339]. 
The AM has a key role in the natural history of TB infection as the first effector cell of the innate 
immune system encountered by inhaled Mtb. 
 
1.8.1.1 Phagocytic capacity 
Phagocytosis is an essential step in microbial host defence. Pattern recognition receptors (PRR) on 
the plasma membrane of AMs are the first receptors to encounter, recognise, and facilitate 
internalisation of pathogens [359]. Pathogens are identified though conserved molecular patterns in 
microorganisms (pathogen-associated molecular patterns), and on internalisation, initiate 
inflammatory signalling and antimicrobial pathways [359, 360]. Furthermore, pathogen identification 
activates pathways that boost antigen presentation to lymphocytes, enhancing the adaptive immune 
response [357, 360]. Cytokine feedback from activated lymphocytes further promote intracellular 
antimicrobial activity within the phagosome and ability to stimulate T cells [357]. The majority of 
inhaled pathogens will be recognised, ingested, and degraded by this first-line innate immune 
defence without development of signs or symptoms of disease [359]. 
Considerable heterogeneity exists within macrophage populations. In contrast to ‘classically 
activated’ inflammatory macrophages, ‘alternatively activated’ macrophages such as the AM have 
high levels of IL-10 expression and possess anti-inflammatory and immunoregulatory roles [358, 
361]. These cells do not produce large amounts of potentially-damaging oxidants, and instead 
secrete some anti-inflammatory cytokines [339]. AMs are specially-adapted for their environment 
with a large surface area, and a range of cell-surface receptors to enable ingestion of a diverse range 
of particles. They possess a generous complement of secondary lysosomes for the enzymatic 
digestion of phagocytosed particles, further demonstrating their key phagocytic role [358]. 
Impairment of AM phagocytic function may be associated with disease. Exposure to cigarette smoke 
is associated with reduced macrophage phagocytic capacity, and has been linked to increased risk of 
respiratory infections and progression of chronic respiratory disease [362, 363]. In diabetes, reduced 
expression of CD14 and macrophage receptor with collagenous structure (MARCO) impaired sentinel 
activity and phagocytosis of Mtb resulting in poor TB control in animal models [364]. HIV infection 
preferentially infects small alveolar macrophages, and has been associated with reduced phagocytic 
capacity [365]. 
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1.8.1.2 The superoxide burst 
The superoxide burst is one of the key antimicrobial weapons in the macrophage’s armamentarium. 
On phagocytosis of pathogens, the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase is activated, starting a chain of reactions leading to the production of reactive intermediates 
with potent antimicrobial activity [357, 366]. NADPH reduces oxygen to superoxide, superoxide 
dismutase converts superoxide to hydrogen peroxide, and superoxide may further bind to iron and 
nitric oxide intermediates, releasing hypervalent iron and peroxynitrite [357, 367]. Generation of the 
phagolysosomal superoxide burst causes oxidative cytoplasmic injury, DNA damage, and potentially 
disrupts the outer membrane allowing the permeation of degradative enzymes [368, 369]. In vitro 
experiments using beads coated with oxidation-sensitive fluorochromes has shown the oxidative 
burst in macrophages to be short-lived, with maximum activity 25-30 minutes following phagocytosis 
[370]. Furthermore, macrophages activated by exposure to lipopolysaccharide (LPS) or interferon-γ 
(IFN-γ) had increased rate and extent of oxidation, indicating that immune-modulation can enhance 
the phagosomal antimicrobial activity of macrophages [370, 371]. Infection of macrophages with 
Mtb may be associated with enhanced generation of the oxidative burst [372]. 
Patients suffering from Chronic Granulomatous Disease are deficient in components of the NADPH 
oxidase pathway and are susceptible to recurrent pyogenic infections, particularly with 
Staphylococcus aureus, demonstrating the importance of this pathway in host defence [373]. 
Alveolar macrophages exposed to carbon particulates in biomass smoke leads to particulate loading 
of the macrophage, with dose-dependent impairment of phagocytosis and reduced oxidative burst 
capacity [374]. Individuals exposed to household smoke have a higher incidence of pneumonia and 
TB, and may be partly explained by these defects in the innate immune defence against infection 
[374].  
HIV is associated with increased risk of respiratory infection [375]. Alveolar macrophages can be 
subdivided into small and large populations based on size, and exhibit differential function [365]. HIV 
preferentially infects small alveolar macrophages, and may be associated with impaired 
phagocytosis, whereas large alveolar macrophages in HIV-infected individuals have impaired 
superoxide burst. Furthermore, given that HIV RNA may be isolated from alveolar macrophages of 
patients on suppressive ART, functional impairment may persist even on treatment [376]. Taken 
together, these data suggest that the superoxide burst is an essential defence against 
intrapulmonary pathogens.   
 
1.8.1.3 Bulk proteolysis 
Alongside the superoxide burst, hydrolysis of ingested materials serves to degrade biological 
materials, and generate epitopes from internalised pathogens for presentation to T cells [357]. On 
activating the adaptive immune response, cytokine release from activated lymphocytes feedback on 
macrophages, further improving their ability to stimulate T cells and kill pathogens [357, 371].  
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Interestingly, macrophages activated with IFN-γ demonstrate a marked reduction in proteolytic 
activity within the early phagosome, whereas late phagolysosomes retain degradative capacity [377]. 
Limited proteolysis has been implicated in optimal antigen presentation [378], and this suggests that 
under stimulation with IFN-γ, the macrophage optimises functions required for the adaptive immune 
response. Indeed, dendritic cells represent specialised antigen-presenting cells, and show reduced 
resting proteolytic function compared to macrophages, supporting the argument that reduced 
proteolysis favours epitope generation [357]. In contrast, resting macrophages may have increased 
proteolytic activity, as they are required to be highly degradative, but are not required to be 
generate an immune response. While optimising antigen presentation by downregulating 
proteolysis, activated macrophages ensure microbial kill by enhancing the magnitude of the 
superoxide burst [357, 370]. 
Previous work in Malawi demonstrated that HIV infection may impair proteolytic function in both 
small and large macrophages, and was not restricted to HIV-infected macrophages [365]. This may 
reflect high levels of IFN-γ in the lungs of asymptomatic HIV-infected individuals [379]. 
 
1.8.2 The site of infection: Mtb survival within the macrophage 
 
The alveolar macrophage can efficiently remove routinely encountered microbes, but may fail to do 
so for host-adapted intracellular organisms [339]. The role of the macrophage in the natural history 
of TB infection is therefore twofold and contradictory: contain and kill the TB, but also act as the 
growth niche for its’ survival [380].  
Upon inhalation, Mtb enters and survives within the macrophage by circumventing the cellular 
immune response though several pathways. Firstly, Mtb interacts with PRRs on the surface of 
alveolar macrophages, initiating signalling cascades that facilitate its phagocytosis [381]. 
Complement and mannose receptors on the surface of the macrophage bind to opsonised Mtb or 
surface mannosylated liparabinomannan respectively, with more virulent Mtb strains showing 
greater receptor affinity [382]. Once internalised, Mtb can induce peroxisome proliferator-activated 
receptor gamma (PPAR-γ), a negative regulator of macrophage activation [383]. Through increasing 
expression of lymphocyte-function antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1), 
infected cells increase adhesion and limit trafficking to sentinel lymph nodes, delaying priming of the 
adaptive immune response [384]. Furthermore, by decreasing expression of complement receptors 
CR3 and CR4, further phagocytosis is reduced, potentially maintaining the intracellular niche for 
longer [384].  
Secondly, internalised Mtb secretes macromolecules that interfere with phagolysosomal fusion [385-
388]. Secreted tyrosine phosphatases, such as protein tyrosine phosphatase (PtpA), bind to 
macrophage vacuolar-H+-ATPase (V-ATPase) and exclude it from the phagosome [389]. Delivery of V-
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ATPase to the phagosome is essential for the rapid acidification of the phagosome, and by blocking 
this step, Mtb can evade some of the antimicrobial pathways described above, including superoxide 
burst, and proteolytic destruction [389, 390]. Some Mtb may even translocate from phagosome to 
cytosol [391]. By avoiding phagosomal maturation, Mtb escapes destruction, but also prevents 
efficient epitope generation and antigen presentation by the macrophage.   
Thirdly, Mtb appears to be able to inhibit assembly of NADPH oxidase, required for generation of the 
superoxide burst. Nucleoside diphosphate kinase (Ndk) produced by Mtb can inhibit NADPH oxidase 
assembly, reducing the generation of reactive oxygen species and microbial kill [392]. In addition, 
Ndk may reduce the apoptotic response to Mtb, an important step in priming the adaptive immune 
response [393]. Ndk knockdown significantly reduces Mtb survival in vitro and in vivo [392]. 
Fourthly, by attenuating macrophage antigen presentation functions, infected macrophages can 
evade host immune surveillance. Typically, epitopes created by limited proteolysis would be loaded 
onto cell surface MHC II for presentation to T helper cells [390]. T cell activation results in generation 
of cytokines optimising macrophage antimicrobial activities, and recruitment of effector T cells with 
cytolytic activity [390]. Mtb-infected macrophages can down modulate the steps required for 
antigen presentation though inhibition of MHC II gene expression [394], impairment of MHC II 
trafficking and maturation [390, 395], and reduced autophagy and antigen presentation [390]. 
Finally, Mtb-infected macrophages may be able to escape clearance though apoptosis. Apoptosis is a 
tightly regulated form of cell death, whereby infected cells are broken down into membrane-bound 
apoptotic bodies, that would be recognised and removed by professional phagocytes by 
efferocytosis [390]. When the burden of intracellular bacilli overwhelms the AM’s capacity for 
phagolysosomal killing, induction of controlled cell death though apoptosis may aid killing of 
intracellular bacteria [396, 397]. Virulent strains of Mtb can reduce the extent of macrophage 
apoptosis, escaping this mechanism of control [398]. Furthermore, Mtb seems able to tip the 
macrophage into a necrotic death pathway, enabling infection of neighbouring cells where apoptosis 
would not [399]. Mtb-infection appears to alter the normal function of the alveolar macrophage to 
preserve its’ growth niche. Through its interaction with macrophage PRRs, virulent Mtb enters its 
intracellular niche, and activates cellular pathways that allow for its replication and survival before 
protective immune responses are completely activated. 
 
1.8.3 The site of infection: Mtb survival within the lung 
 
TB survives within complex lesions in the lung, with the pathological hallmark being the granuloma: 
the outcome of the local interplay between the bacterium and the host response (Figure 1.5). The 
granuloma is the interface between the innate and acquired responses, and is essential in containing 
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the growth of intracellular Mtb and limiting dissemination [339]. However, the view that granuloma 
formation walls off and limits bacillary spread is likely an oversimplification.  
Infected AMs secrete TNF-α, IL-12, and chemokines, encouraging cellular influx and developing the 
early granuloma [400, 401]. In spite of this cellular influx, Mtb disseminates outside the lung early in 
infection, but rarely causes signs of disease in this early phase, except in infants and those with HIV 
co-infection [402]. The development of the acquired immune response is preceded by the presence 
of Mtb in the draining lymph nodes, and expression of Mtb antigens in the lymph nodes [403, 404]. 
Early infection is a dynamic process, with accumulation of inflammatory cells, but also migration of 
host cells into and out of the developing granuloma [402]. Heavily-infected dendritic cells appear to 
form the earliest link with the draining lymph node, and express MHC II [403, 405]. These cells 
present bacterial antigen to T cells for the priming and expansion of antigen-specific T cells [406]. 
However, Mtb appears to subvert this process, promoting expansion of regulatory T cells in the 
lymph node, a suppressive population that limits effector T cell priming [407]. As a result, generation 
of the adaptive immune response to Mtb infection is delayed, occurring 7-9 days after initial 
infection [402]. On arrival, the high bacterial burden and complex mix of pro-inflammatory and anti-
inflammatory cytokines, conspire to impair T cell functionality and further reduce the host’s ability to 
eradicate the infection [408]. Consequently, Mtb has time to develop an established lung lesion 
before T cells arrive in sufficient numbers to limit bacterial growth [403, 404]. 
The migration of effector T cells to the infected lung results in the development of an organised 
granuloma of macrophages, lymphocytes, and fibroblasts [406]. Central to Mtb control are the CD4+ 
T (TH1) cells, the importance of which is underscored by the effect of HIV-induced CD4+ T cell 
depletion. Close proximity and signalling between CD4+ T cells and infected AMs is a necessary 
component of the acquired immune response, and has been highlighted using mouse models. In 
chimeric mouse models in which some phagocytes express MHC II and others do not, the Mtb 
intracellular bacillary load was significantly higher in macrophages unable to express MHC II [409]. 
MHC II signals the presence of intracellular pathogen to CD4+ T cells though the display of pathogen-
derived peptides, leading to IFN-γ release from the T cells.  IFN-γ activates the macrophage, 
improves its’ antimicrobial activity, and thus inhibits Mtb intracellular replication [339, 410].  For this 
to occur, direct contact between infected macrophage and Mtb-specific CD4+ T cell in the granuloma 
is required. Alongside IFN-γ, CD4+ cells release cytokines such as IL-17 to mediate the recruitment of 
TH1 cells to the lungs on Mtb challenge [411, 412]. They also seem to help determine the 
architecture of the developing granuloma: HIV-infected individuals have disorganised granulomas, 
associated with loss of Mtb containment [413]. 
Within the granuloma, CD4+ and CD8+ T cells are found in abundance in the granulomatous-fibrotic 
layer and in lymphoid aggregates within the granuloma, in close association with macrophages and 
multinucleate giant cells [414]. In contrast, these T cells are notably absent from the necrotic zone of 
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non-cavitating lesions and the luminal surface of open cavitating lesions, where cell-associated Mtb 
is seen in large numbers [414]. In the former, the close association between macrophage and T cells 
results in an efficient immune response, with control of Mtb replication. In the latter, macrophages 
and T cells do not co-localise, with the likelihood that luminal phagocytes remain permissive for 
bacillary growth [414].  
 
Figure 1.5: The pulmonary site of TB infection  
Inhaled Mtb in airborne droplets initially infects alveolar macrophages. Infected cells migrate into the 
interstitium, interact with tissue macrophages and circulating monocytes, initiate activation of the immune 
system, and begin formation of a cellular granuloma. While initially vascular, over time a central avascular 
caseum develops, surrounded by a mantle of macrophages, lymphocytes, and an external fibrous cuff. The 
amorphous core of caseous debris contributes to the destruction of the vasculature, and eventually liquefies and 
necroses. Cavities are created where lesions with necrotic centres open into airways.  Containment of the Mtb 
infection is lost with the rupture of the granuloma; viable, infectious MTB spill into the airways and multiply 
rapidly in the extracellular environment out with effective immune control. Figure from [328]. 
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In contrast to CD4+ cells, the place of CD8+ (cytotoxic) cells in Mtb defence is less well resolved.  
CD8+ cells identify and kill cells they recognise as ‘foreign’ by several mechanisms: production of 
proteins that result in lysis or apoptosis of target cells, mediating death signalling though the FAS 
ligand, or generation of TNF [406]. The result of these pathways is apoptosis of the infected cell, 
reducing Mtb viability. In support of this, knockout mice lacking β2-microglobulin are unable to 
generate CD8+ T cells, and succumb rapidly to Mtb following infection [415]. This may be partly 
explained by their role in cytolysis of infected macrophages, and direct killing of Mtb [416].   
The architecture of the gas exchanging tissues in the lungs is at risk of damage from an over-zealous 
inflammatory response to infection, and must therefore be kept in careful balance. Tight control of 
the pro-inflammatory response may be at the expense of loss of sterilising immunity. An excessive 
neutrophilic response to infection results in tissue damage though release of granule contents, and is 
kept in check by IFN-γ and the acquired immune response [406]. IFN-γ inhibits CD4+ production of 
the cytokine IL-17, limiting neutrophilic infiltration [417]. Regulatory T cells (CD4+CD25+) at the site 
of infection produce IL-10 and transforming growth factor-β, immunosuppressive cytokines that 
further limit the extent of inflammation [418]. Ultimately, for most individuals, the arrival of the cell-
mediated response does not result in resolution of TB infection, or sterilisation of the lesions. 
Instead, bacillary growth stabilises, the bacteria adopt a quiescent, non-replicating state, and a 
period of stalemate between immune activity and bacillary load develops [386].     
The outcome of the primary infection is largely determined by cell-mediated immunity: in 90-95% of 
those infected, successful granuloma formation and T cell-dependent activation of macrophages 
controls Mtb multiplication and a period of latency follows.  For a minority, immune activity results 
in successful sterilisation of the infection and mineralisation of the lesion [386].  For others, the 
natural history of pulmonary TB takes a different course, with localised caseation, necrosis, and 
rupture of the granuloma releasing viable bacteria into the airways: active TB disease [386].   
The host immune response to TB infection described above is complex, but does not consider the 
additional modulating effect of drug therapy on immune control of infection. Few data exist 
describing the interplay between the immune microenvironment in the lung and TB therapy. By 
debulking the disease, drug therapy may reduce the pro-inflammatory environment in the lung, and 
improve alveolar macrophage clearance of infection. Furthermore, immune reconstitution in HIV-
infected patients starting ART can be expected to alter the immune microenvironment in the lung 
through CD4+ T cell reconstitution. The last section of this thesis will explore these key AM functions 
after initiation of treatment, and the interplay with HIV co-infection and ART. 
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1.9 Hypotheses 
 
The development of shorter, more effective, regimens for the treatment of tuberculosis represents a 
priority for research. Characterising the compartmental pharmacology and local immunology in the 
lungs of patients receiving treatment for pulmonary TB may inform the selection of drugs or 
optimisation of doses for new therapies, and provide key insights into the causes of poor treatment 
outcomes on standard therapy. 
Our hypotheses are: 
1. Predictive PK-PD science:  Antibiotic exposure at the site of infection may determine the 
rate of bacterial clearance and clinical treatment response in TB patients. 
2. Immunological dysfunction: HIV and/or Mtb impair alveolar macrophage function, despite 
therapy, and impair the ability of the immune system to eradicate Mtb.  
The remainder of this thesis will describe a clinical study describing firstly the intrapulmonary 
pharmacokinetics of anti-TB therapy and associated pharmacodynamic response, and secondly, the 
function of the alveolar macrophage in TB infection and its’ contribution to TB control in a cohort of 
Malawian adults receiving treatment for pulmonary TB.  
 
1.10 Research questions 
 
This study aimed to address the hypotheses above by answering the following research questions: 
1. What is the relationship between the plasma and intrapulmonary pharmacokinetics of anti-
TB therapy? 
2. What is the relationship between intrapulmonary pharmacokinetics and TB treatment 
response? 
3. How does alveolar macrophage function change over time on anti-TB therapy; and how is 
this related to TB treatment response? 
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2 Clinical study design 
2.1 Overall design 
 
The SPITT Study (Studying the intrapulmonary Pharmacology and Immunology of Tuberculosis 
Therapy) was a prospective cohort study of 160 adult patients on standard first-line therapy for 
pulmonary TB. Fifty subjects participated in a bronchoscopy sub-study in which intrapulmonary anti-
TB drug pharmacokinetics and cellular immunology were assessed in detail. Patients were recruited 
and managed by a study team based at Queen Elizabeth Central Hospital (QECH), the Malawi-
Liverpool-Wellcome Trust Clinical Research Programme (MLW), and the University of Malawi College 
of Medicine (CoM).  
The study was performed in urban Blantyre, Malawi; a country with a high TB/HIV burden in South-
Central Africa [63]. Recruitment and follow-up occurred between January 2016 and October 2018. 
Adult patients with microbiologically-confirmed pulmonary TB (PTB) were referred to the study by 
the TB Officers of the Malawi National Tuberculosis Control Programme (NTP) for screening and 
enrolment. TB drug prescribing and standard programmatic management continued under the NTP 
throughout the study period. 
Potential participants were profiled at baseline, and returned for 4 visits during the intensive phase 
of TB therapy to submit sputum samples. The last of these visits coincided with a research 
bronchoscopy and rich plasma PK sampling for the participants in the Intrapulmonary Arm, repeated 
2 months later in the middle of the continuation phase of therapy. The remaining participants 
followed the same sampling schedule, but simply returned for sparse plasma PK sampling. Two-
month sputum culture conversion was recorded as a binary outcome at the end of the intensive 
phase of treatment. Participants were followed up for one year after treatment completion, with 
WHO treatment outcome and rates of bacteriologically- or clinically-defined failure or relapse 
recorded. A schematic of the study design is shown in Figure 2.1. 
  
 
 
 
 
Figure 2.1: Study schematic 
R: rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol.
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2.2 Description of study site 
2.2.1 Socioeconomic and health indicators in Malawi 
 
Malawi is a small country in South-Central Africa, bordered by Mozambique, Zambia, and Tanzania 
(Figure 2.2). It had a total population of 17,215,000 in 2015, and ranks amongst the world’s most 
densely populated and least developed countries [419, 420]. By 2008, population density was 
estimated at 139 persons per square kilometre, with further increases projected due to a high total 
fertility rate of 4.4, and low contraceptive prevalence rate of 59.2% in married women [420, 421]. 
Almost 48% of the population are younger than 15 years old [422]. 84.8% of the population live in a 
rural setting, with as many as 85% of the population involved in agricultural activities, predominantly 
low productivity subsistence farming [422]. 
 
 
Figure 2.2: Location of Malawi within Africa, and location of Blantyre within Malawi 
The panel on the left shows Malawi, blue, within south-central Africa. The panel on the right shows the 28 
administrative districts of Malawi, with the location of Blantyre City highlighted. From [423] 
  
Poverty remains a major problem for Malawi, with 50.7% of the population at the national poverty 
line and 25% defined as ‘ultra-poor’ [424]. The economy has been heavily dependent on aid from 
external funders. In 2009, donor funding was frozen due to corruption concerns and economic 
mismanagement, with Malawi’s development budget dropping by nearly 80% [424]. By 2016, Gross 
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Domestic Product was increasing at 2.7% per year, a marked reduction from the 8% growth seen in 
2007-2008, and inflation was running at 23.5%  [419, 424]. Gross National Income per capita was 
only $320 in 2013 [424]. Malawi ranks at 170 out of 187 countries on the Human Development Index 
(0.481); a composite statistic of life expectancy, education, and per capita income indicators. 
Life expectancy at birth is low - 60 years for females, 57 for males – but increased by 14 years 
between 2000 and 2012 [420, 424]. Under-five mortality remains high at 64 deaths per 1,000 live 
births, but considerable gains have been made from 245 deaths per 1,000 live births in 1990 [420, 
424]. Maternal mortality too has fallen, from 957 deaths per 100,000 live births in 1990 to 634 in 
2015 [420, 424]. By 2014, the Government of Malawi was allocating 11.4% of their budget to health, 
falling short of the 15% target from the Abuja Declaration [420, 424]. Significant improvements in 
health had been made by 2015, with Malawi achieving half of the MDGs, including those targets for 
reducing child mortality, and combatting HIV, AIDS, malaria, and other diseases [424].  
 
2.2.2 HIV and TB control in Malawi 
 
Malawi is burdened with a high HIV prevalence, with 10.6% of 15-49 year olds testing positive for 
HIV [420]. HIV incidence per 100,000 population fell from 956 in 2000 to 211 by 2013, mainly due to 
the natural evolution of the epidemic and successful implementation of prevention measures [420]. 
HIV/AIDS remains the leading cause of death however, killing over 40,000 people in 2012 [424]. HIV 
prevalence and density is high in the Southern Region of Malawi, and particularly in the urban 
districts of Blantyre, Zomba, and Lilongwe [425]. 
The Malawian National AIDS Commission (NAC) has achieved considerable success in reducing AIDS-
related deaths, largely through the rapid expansion of the ART programme, and earlier provision of 
ART [425]. By the end of 2014, 67% of those eligible for ART were on treatment, with 69% of those 
ever initiated on ART retained alive on treatment [425]. While this falls short of the UNAIDS 90-90-90 
targets (90% of people living with HIV know their status; 90% of people diagnosed on ART; and 90% 
of those on ART virally suppressed, by 2020), ongoing progress in provision of HIV testing and 
counselling and renewed focus on key populations can be expected to improve Malawi’s 
performance against these indicators [420, 425]. The progress to date has been achieved in part 
through rolling out ART services to peripheral health centres, and task-shifting from clinicians to 
nurses, counsellors, and HIV diagnostic assistants: a new cadre of health worker [425]. 
In 2013, first-line ART was switched to tenofovir, lamivudine, and efavirenz (Regimen 5A) [425]. This 
addressed concerns of toxicity with the previous regimen (stavudine, lamivudine, nevirapine), and 
enabled safe co-administration with TB therapy. 93% of those on ART were taking Regimen 5A by 
2014, with nearly 91% of those classified as having > 95% adherence based on pill counts and self-
reported missed doses [425].   
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Accompanying the HIV epidemic, Malawi was hit hard by the resurgent TB epidemic in the region 
[63]. Total TB incidence was estimated at 193 cases per 100,000 population in 2015, with 104 cases 
per 100,000 population TB/HIV co-infected (54%) (Figure 2.3) [63]. 93% of TB cases knew their HIV 
status. Mortality was estimated at 13 deaths per 100,000 population, rising to 38 per 100,000 
population in the TB/HIV co-infected population [63]. As of 2016, only 10% of the TB budget was 
funded domestically [63]. 
TB diagnosis and management in Malawi is managed by the NTP of the Ministry of Health. The NTP 
recommends that all TB suspects submit sputum for smear microscopy, especially among HIV-
infected individuals having TB symptoms of any duration, or HIV-uninfected suspects with a cough 
lasting 2 weeks or more [105]. Rapid molecular testing (Xpert MTB/RIF) has been introduced to some 
hospitals and larger health centres, and was prioritised in smear-negative TB suspects, hospitalised 
TB suspects, and confirmed retreatment cases or MDR-TB suspects for rapid identification of genetic 
rifampicin resistance [105]. A single sputum sample with only one bacilli detected (acid fast or 
fluorescent) in a TB suspect is sufficient for classification as a smear-positive case, and an indication 
for treatment [105]. In 2015, 75% of notified new and relapse cases were pulmonary, of whom, 58% 
were bacteriologically-confirmed [63]. 
Only 0.75% of new TB cases were found to have rifampicin-resistant or multidrug-resistant TB, and 
6.4% of previously treated cases [63]. Low rates of primary resistance to first line TB drugs was a 
prerequisite for this study to prevent confounding of clinical endpoints and rates of bacillary 
elimination by unidentified MDR-TB cases, and for safety of staff performing research bronchoscopy 
in these patients. 
Treatment of TB at the community level is coordinated by specialised health surveillance assistants, 
the TB officers (TBOs). TBOs register patients in the district TB register, and provide drugs (Table 
2.7). New TB cases are generally managed on an outpatient basis from the local health centre. Since 
1984, Malawi has implemented a directly observed treatment, short-course (DOTS) approach to TB 
management [426]. A treatment supervisor is assigned to each patient - either a health worker, 
volunteer, guardian, or trained member of the community – who watches the patient swallow the 
tablets through the whole course of treatment and monitors progress by marking administration on 
the patient’s TB treatment card [105]. Decentralisation of TB diagnosis and care and early adoption 
of DOTS have been instrumental in achieving success rates of 85% in new and relapse cases [63].  
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Figure 2.3: TB incidence and treatment success in Malawi, 2016 
The panel on the left shows the trends in TB incidence in the whole population, and the incidence of TB/HIV co-
infection. The panel on the right shows TB treatment success rates from 2000-2015. MDR/RR-TB: multidrug-
resistant/rifampicin-resistant TB; XDR-TB: extremely drug-resistant TB (not shown). From [63] 
 
By 2014, 90% of TB/HIV co-infected patients were receiving both TB treatment and ART, with 
approximately two-thirds already on ART by the time of TB diagnosis [425]. Provision of integrated 
TB/HIV care required close collaboration between the NTP and the National AIDS Commission, but 
has successfully enabled the creation of ‘one-stop shops’ for HIV and TB care [105, 425]. As such, 
TBOs are expected to provide HIV testing and counselling to all TB patients, initiate ART early in TB 
patients (within 2 weeks), and provide anti-TB drugs and ART in the same room, by the same person 
[105]. In HIV clinics, healthcare workers are trained to screen for TB in their HIV-infected patients 
[425]. 
 
2.2.3 Blantyre demographics 
 
Blantyre is the second largest city in Malawi, located in the Southern Region of the country. It had an 
estimated population of 850,000 in 2014, with as many as 65% living in informal urban settlements 
characterised by poor living conditions [427]. Ndirande, the most populous unplanned area, had a 
population of approximately 118,000 individuals [427]. In the Integrated Household Survey 2010-
2011, 7.4% of the Blantyre City population reportedly suffered from TB and/or HIV [422]. Uneven 
distribution of health facilities in the city results in residents in the informal settlements having the 
greatest difficulty accessing proper and affordable healthcare [427]. 
Poverty in Blantyre City stands at 24% [427]; with as many as 24% of the urban population reporting 
inadequate food, 20.7% inadequate housing, 34.9% inadequate clothing, and 32.3% inadequate 
health care [422]. Unemployment in Blantyre runs at 8%, and 36% of the economically-active 
population are self-employed and predominantly work in the informal sector [423, 427]. 
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2.2.4 Queen Elizabeth Central Hospital (QECH) and referral health centres 
 
QECH is the largest hospital in Malawi, based in central Blantyre. QECH houses the main TB Registry 
for the district, and a large TB ward with space for approximately 80 patients. TB suspects attending 
or inpatient in QECH have sputum smear microscopy or Xpert MTB/RIF testing performed in the 
main QECH laboratory, and are sent with their results to the TB Registry. Ambulant TB patients are 
typically referred to their local health centres for registration and treatment, while the QECH site 
registers and manages unwell patients and those on TB re-treatment regimens. The main study 
office was housed on the TB Ward by the TB Registry. 
Blantyre District (urban) had 6 health centres with TBOs providing TB registration and treatment - 
Bangwe, Chilomoni, Limbe, Ndirande, South Lunzu, and Zingwangwa - as well as the private / non-
governmental hospitals at Blantyre Adventist, Chitawira, Mlambe, and Mwaiwathu. A number of 
these facilities, including Ndirande, Bangwe, and Zingwangwa, were equipped with facilities to 
perform sputum smear-microscopy on site. Close liaison with the TBOs at these sites was required 
for referral of potential participants for screening. 
 
2.2.5 Participating laboratories 
 
2.2.5.1 MLW Immunology Laboratory 
The MLW Clinical Research Programme formed in 1995 as a partnership between the University of 
Malawi College of Medicine (CoM), the Liverpool School of Tropical Medicine (LSTM), the University 
of Liverpool (UoL), and the Wellcome Trust as the major funder. The main facilities are based on the 
QECH campus, a 5-minute walk from the TB Ward and study office. 
The main laboratories were renovated in 2016. All BAL processing and immunology work took place 
in the Immunology Laboratory. The laboratory was equipped with 3 Class 2 Biological Safety Cabinets 
(BSC), 2 flow cytometers, and equipment for tissue culture. A biosafety level-3 (BSL-3) laboratory 
was built during the 2016 refurbishment enabling cell infection experiments and manipulation of 
Mtb cultures, and a cell-sorter installed in 2017. 
 
2.2.5.2 MLW/CoM Hit TB Hard Laboratory 
All TB mycobacteriology (smears, Xpert MTB/RIF, MIC, MGIT culture) was performed at the “Hit TB 
Hard” laboratory. The laboratory is housed at the CoM, University of Malawi, and contains 2 Class 2 
BSCs in a dedicated mycobacteriology room. Sputum decontamination, smears, MGIT inoculation, 
isolate identification, and storage took place in this facility. In 2016, a modular BSL-3 laboratory was 
constructed at the same site. This housed the Becton Dickinson BACTEC MGIT 960 System, and was 
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where all manipulation of TB cultures occurred. The Hit TB Hard Laboratory participates in quality 
control through the UK National External Quality Assessment Programme. 
The Hit TB Hard Laboratory was a 15-minute walk from the study office. The laboratory messengers 
transported samples from the study office in a biohazard container daily. Samples were logged on 
arrival, placed in a fridge, and processed within 24 hours of collection. 
  
2.2.5.3 University of Liverpool Bioanalytical Facility 
RHZE PK assays were developed and performed at the Bioanalytical Facility (BAF), UoL. The facility 
houses 6 quadropole mass spectrometers, currently unavailable in Malawi, for precise measurement 
of drug concentrations.  
The BAF is managed by the Institute of Translational Medicine, in collaboration with LSTM, and 
receives infrastructural support for bioanalysis from the Liverpool Biomedical Research Centre 
funded by Liverpool Health Partners. The BAF is GCLP accredited.  
 
2.2.5.4 MLW Core Laboratory 
The MLW Core Laboratory was responsible for processing blood samples for full blood counts, CD4 
counts, urea and creatinine, and liver function tests. Samples were taken from the study office in a 
cooler box and transported to Specimen Reception at the back of the QECH site. Samples were 
processed on the same day and results uploaded onto the password-protected Laboratory 
Information Management Service. The Biochemistry and Haematology Laboratories participate in 
quality control through the UK National External Quality Assessment Programme. 
The Core Laboratory stored baseline plasma and serum samples at -80oC, and managed the archiving 
of clinical specimens obtained by the study. The Core Laboratory team also facilitated the shipment 
of samples to the UK for PK processing. 
 
2.3 Description of study team and collaborators 
 
The Principal Investigator (PI) was responsible for overall design, planning, and conduct of the study. 
The study involved the coordinated effort of a large team of individuals, summarised in Table 2.1. 
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Study Site Main Tasks 
Study Office, QECH 
Irene Sheha *, SPITT Research Nurse, 2016-2018 
Madalitso Chasweka *, SPITT/PERSIST† Research Nurse, 
2016-2017 
Alex Chitani *, SPITT Clinical Officer, 2016-2017 
Timothy Joseph *, Laboratory Messenger, 2016-2017 
Monica Matola *, Laboratory Messenger, 2016-2017 
Ken Kaswaswa, Fieldworker, 2017-2018 
• Screening and recruitment of study participants 
• Coordinating follow-up 
• Coordinating sampling days (plasma and 
bronchoscopy) 
• Clinical review of adverse events / unplanned 
visits 
• Sample delivery to participating laboratories 
• Tracing of patients 
MLW Immunology Laboratory, MLW 
Aaron Chirambo *, SPITT Laboratory Technician, 2016-
2018 
Leonard Mvaya *, SPITT/PERSIST† Research Assistant, 
2016-2017 
Dr David Cox *, MSc Student, 2017 
• Processing plasma, BAL, and exhaled breath 
condensate samples for PK assays 
• Running flow cytometry based reporter bead 
assays and cytokine ELISAs 
• Storage of plasma, BAL, and exhaled breath 
condensate samples  
• Running multiplex PCR on respiratory samples 
Hit TB Hard Laboratory, MLW/CoM 
Aaron Chirambo *, SPITT Laboratory Technician, 2016-
2018 
Doris Shani, Laboratory Manager, and team 
Mercy Kamdolozi, Laboratory Technician, 2017 
• Performing sputum smears and MGIT cultures 
• Performing sputum Xpert MTB/RIF 
• Sputum MIC for rifampicin, isoniazid, ethambutol 
• Storage of sputum samples 
Bioanalytical Facility, UoL 
Dr Laura Else, Facility Manager, 2015-2018 
Sujan Dilly-Penchala, Assay Development Lead, 2015-2018 
Dr Lisa Stone, Research Associate, 2015-2016 
• RHZE assay development – plasma, epithelial 
lining fluid, alveolar macrophages, and exhaled 
breath condensate 
• Performing PK assays 
Core Laboratory, MLW 
Brigitte Denis, Laboratory Manager, and team, 2016-2018 
Mavis Menyere, Senior Laboratory Technician, 2017 
Moses Saidi, Laboratory Technician, 2017 
Mazuba Masina, Laboratory Technician, 2017 
• Performing routine blood tests 
• Storage of plasma and serum samples 
• Assistance with sample shipment 
• Assistance with multiplex PCR 
Clinical Investigation Unit, QECH 
Sr Rose Malamba, CIU Manager, and team, 2016-2017 
• Assisting with research bronchoscopies 
Blantyre Health Centres 
Blantyre District Health Office and TB Officers, 2016-2017 
Srs Nyembezi Chinkhombe and Ruth Mbweza, TB Ward 
Managers QECH, and team 2016-2018 
• Identification and referral of TB patients meeting 
screening criteria 
• Assisting in locating patients lost to follow up 
Radiology Department, QECH 
George Mubisa, Head of Department, and team, 2016-
2017 
• Performing baseline chest X-rays 
Table 2.1: SPITT Study Team and collaborators 
* indicates personnel under direct supervision of the PI. † Some study members were shared with the PERSIST 
study, running at the same time in the CIU and Immunology Laboratory 
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2.4 Study timeline 
 
Laboratory work to optimise processing of BAL samples for LC-MS took place in Liverpool between 
April and June 2015. Further work to optimise and adapt the RHZE assay for plasma, epithelial lining 
fluid, and alveolar macrophages continued with the BAF between June 2015 and June 2017. 
Study design, protocol development, and ethics applications took place between January and 
September 2015. The PI received formal training in bronchoscopy from the Royal Liverpool and 
Aintree University Hospitals, and the Countess of Chester Hospital, in the 6 months prior to 
departure for Malawi. Development of standard operating procedures (SOPs), recruitment and 
training of study staff occurred between September 2015 and January 2016.  
Recruitment ran from January 2016 to April 2017. Patient follow-up concludes in October 2018. 
 
2.5 Patient flow 
2.5.1 Screening and enrolment 
 
Patients were identified and referred by TBOs at QECH and referral health centres in urban Blantyre. 
TBOs referred adult patients newly diagnosed with pulmonary TB (smear- or Xpert MTB/RIF-positive) 
to the study office at QECH for screening and enrolment.  
The study aimed to recruit 3 patients per week to ensure a manageable laboratory workload. Close 
collaboration with TBOs was required to meet this target, and monthly meetings with all the TBOs 
were used to review referral success. The study was initially going to recruit all patients from QECH 
at the point of treatment initiation, but it soon became apparent that successful decentralisation of 
TB diagnosis and care to local health centres meant that most ambulant pulmonary TB patients on 
first line treatment were managed outside QECH. While the aim was to recruit patients as close to 
the start of TB treatment as possible for the purposes of baseline sputum bacillary load and 
radiology, the study accepted screening visits up to 4 days after treatment initiation to allow patients 
from referral health centres time to attend.  
It was possible to obtain pre-treatment sputum smear, culture (MGIT), and time-to-positivity data 
for several enrolled participants through collaboration with Professor Liz Corbett and the Hit TB Hard 
study. Sputum samples are routinely collected from patients attending health centres around 
Blantyre to accompany their diagnostic sample, and processed at the MLW/CoM Hit TB Hard 
Laboratory for monitoring and evaluation purposes.  
Patients attending for screening were assessed using a questionnaire based on the inclusion and 
exclusion criteria below. Those meeting the inclusion criteria were provided with a patient 
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information sheet in English or Chichewa (the major language in Southern and Central Malawi) 
according to personal preference, and had the study protocol verbally described to them in detail by 
a study nurse. Those willing to participate were then asked to sign an informed consent form (ICF; 
Appendix A: Informed consent form), asking for general consent for data collection and sampling, 
and specific consent to ship samples overseas for PK measurement. Illiterate participants indicated 
their consent by a witnessed thumb print. Those not wishing to participate were referred to the NTP 
for ongoing clinical care. On signing the ICF, participants were allocated with a unique screening 
identifier and asked to provide a spot sputum sample for smear microscopy, Xpert MTB/RIF, and 
MGIT culture. Screening blood samples were taken to assess full blood count, urea, creatinine, 
bilirubin, ALT, and baseline CD4 count. A urinary pregnancy test (β-HCG) was performed on all 
female participants. The study sampling schedule is summarised in Figure 2.4 opposite.  
HIV testing is part of standard care for new TB patients, and Malawian NTP Guidelines advise that 
TB/HIV co-infected patients be started on ART within the first 2 weeks of TB treatment [105]. 
Counselling and offering HIV testing as a requirement for study participation was not a deviation 
from routine practice, and existing care pathways at QECH were used for care of those with TB/HIV. 
HIV testing was repeated by the TB Counsellor attached to the ward in those that did not have a 
documented negative test result taken in the preceding 3 months. HIV-infected individuals who were 
not yet on ART were referred for initiation of ART according to national guidelines, provided via the 
NTP.   
Potential participants were invited to return after 48-72 hours for the Baseline Visit and enrolment. 
The results of screening bloods and sputum smear and Xpert MTB/RIF testing were reviewed against 
the inclusion and exclusion criteria. Those eligible for recruitment were allocated a unique 
participant identifier, and went on to complete the Baseline Visit questionnaire, detailed below. 
Ongoing consent to participate was assessed at each visit and recorded in the electronic case report 
file (CRF). 
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Figure 2.4: Sampling schedule schematic 
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2.5.1.1 Inclusion criteria 
Patients were enrolled in the study based on a single sputum smear-positive result. This was 
performed by the NTP, and repeated by the study team at screening. Where sputum smear 
microscopy was not being performed by the NTP (due to intermittent staffing or power issues), Xpert 
MTB/RIF-positive results from the QECH Laboratory were accepted for inclusion. All participants had 
at least one sputum sample confirmed as Mtb-positive by either culture or molecular testing (Xpert 
MTB/RIF).  
Sputum smears were graded according to international guidelines [105, 428]. The grading scheme is 
included in Table 2.2 below. The full inclusion criteria are detailed in Table 2.3. 
 
Grading Interpretation 
‘0’ or ‘negative’ No bacilli seen in 100 fields * 
‘scanty’ or actual number counted 1 to 9 bacilli seen (either acid-fast or fluorescent) in 100 fields † 
‘1+’ 10 to 99 bacilli seen (either acid-fast or fluorescent) in 100 fields 
‘2+’ 1 to 10 bacilli seen (either acid-fast or fluorescent) per 1 field, check 50 fields 
‘3+’ > 10 bacilli seen (either acid-fast or fluorescent) per 1 field, check 20 fields 
Table 2.2: Grading of sputum smear microscopy results  
(IUALTD and NTP Guidelines [105, 428]) 
* At least 5 minutes should be taken to read 100 fields before reporting the slide as negative.  
† A finding of 3 or fewer bacilli in 100 fields does not correlate well with culture positivity. 
 
Inclusion criteria 
• Newly diagnosed pulmonary tuberculosis 
o Sputum smear-positive for acid-fast bacilli OR sputum Xpert MTB/RIF positive 
o Ultimately confirmed by culture and/or Xpert MTB/RIF 
• Commencing first-line standard anti-TB therapy 
• Age >18 years 
• Willing and able to give informed consent 
• Consent to, or written result of, HIV test 
• Negative serum pregnancy test (women of childbearing potential) 
• Ambulant 
Table 2.3: Inclusion criteria 
 
2.5.1.2 Exclusion criteria 
Given the exploratory nature of the study, and the requirement for bronchoscopy in some 
participants, stringent exclusion criteria were applied to safeguard the wellbeing of participants 
(Table 2.4). Published guidelines for bronchoscopy conduct were followed to ensure participant 
safety [429, 430].   
Microbiological-confirmation of TB was a requirement to participate in the study. Given the time for 
culture results to become available, patients would be enrolled and subsequently excluded should 
cultures fail to isolate Mtb, or no positive Xpert MTB/RIF samples available. 
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Exclusion criteria 
o Microbiologically-unconfirmed TB (no positive culture or Xpert MTB/RIF samples) 
o Significant anaemia (Hb <8 g/dl) 
o Significant renal dysfunction (serum creatinine >177 µmol/l (2 mg/dl)) 
o Significant hepatic dysfunction (total bilirubin >51 µmol/l (3 mg/dl), alanine transaminase > 200 IU/l) 
o Very poor clinical performance status suggestive of imminent mortality (WHO Performance Score 4) 
o Contraindication to bronchoscopy [430] 
o Absolute:  
▪ Unstable cervical spine 
▪ Unresponsive hypoxia 
▪ Unstable angina 
▪ Bleeding diathesis 
▪ Malignant cardiac arrhythmia 
o Relative: 
▪ Poorly cooperative patient 
▪ Any significant and uncontrolled general medical condition (excluding TB / HIV) 
o On ‘re-treatment’ regimen for TB or prior treatment for MDR-TB 
o Anticipated obvious difficulties with follow up 
Table 2.4: Exclusion criteria 
 
2.5.1.3 Withdrawal criteria 
Withdrawal criteria 
o Participant request 
o Participant lost to follow-up and untraceable by study staff 
o Participant transferred out of Blantyre and unable to attend follow-up 
o All cultures negative for Mtb 
o Baseline drug resistance to rifampicin identified by Xpert MTB/RIF 
o Adverse drug reactions requiring interruption of treatment 
o Poor adherence to therapy 
o Complications arising from TB (e.g. requiring steroids or surgery) 
o Death attributable to causes other than active TB 
o Pregnancy 
o Serious adverse event directly attributable to the research 
Table 2.5: Withdrawal criteria 
 
2.5.2 Study visits 
 
2.5.2.1 Baseline visit (BL) 
The Baseline Visit occurred immediately after enrolment, typically 3 days after the Screening Visit. 
Participants were administered a short questionnaire comprising a clinical history of the current TB 
episode, with details of their past medical history, HIV status and ART regimen, co-administered 
medications and socio-economic status. Participants graded their own health using a Likert-type 
scale (responses including “excellent”, “good”, “fair”, and “poor”), while the study nurses assessed 
the participant’s functional ability by their WHO Performance Status (Table 2.6). 
Participants received their TB prescription from the NTP, and the number of tablets prescribed was 
documented on the CRF. The NTP issues daily, fixed-dose combination (FDC) tablets containing 150 
mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol, according to the 
WHO-approved weight-adjusted treatment regimen for the initial 2 months of intensive therapy 
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(Table 2.7) [105].  Participants were advised to take their anti-TB therapy regularly at the same time 
each morning.  
 
Grade Performance status 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature, e.g. light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 
50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5  Dead 
Table 2.6: WHO Performance Status  
Assessment of global clinical functional status was done according to the scale above [431]. 
 
 
 
Body weight (kg) 
Intensive Phase 
2 months 
[RHZE] 
[R150/H75/Z400/E275] 
Number of tablets 
Continuation Phase 
4 months 
[RH] 
[R150/H75] 
Number of tablets 
30-37 2 2 
38-54 3 3 
55-74 4 4 
75 and over 5 5 
Table 2.7: Weight-adjusted TB treatment regimen 
FDC tablets were prescribed by the NTP. 
 
Vital signs (pulse, respiratory rate, temperature, blood pressure, oxygen saturations), weight and 
height were recorded. Patients were then examined clinically by the PI or study clinical officer. 
Before completing the visit, contact details were recorded, and participants issued with a 100 ml 
wide mouth sputum collection pot and biohazard bag. Participants were given the date of their next 
sampling visit and advised to collect an overnight sputum sample beforehand, detailed below. 
Participants were sent for a posteroanterior chest X-ray to record baseline radiological extent of 
disease prior to departure. 
Participants were sequentially allocated to the Intrapulmonary Arm such that a maximum of 3 
research bronchoscopies were booked per week to accommodate the timetable of the Clinical 
Investigation Unit. If more than 3 subjects were enrolled in a week, these additional patients would 
enter the Plasma Arm. Once fifty patients had been allocated to the Intrapulmonary Arm, 
recruitment continued to meet the target sample size of 100 in the Plasma Arm. Participants were 
also allocated to a sampling block (Block 1 or 2) based on their participant identifier number. This 
determined the schedule for their Sputum Sampling Visits and PK sampling times. 
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2.5.2.2 Sputum sampling visits (S1-S4) 
Participants with odd-numbered participant identifiers (Block 1) returned on weeks 1, 3, 5, and 7 for 
Sputum Sampling Visits, whereas those with even-numbered participant identifiers (Block 2) 
returned on weeks 2, 4, 6, and 8 of therapy.  Creation of 2 staggered but balanced blocks avoided an 
unmanageable volume of laboratory work, whilst maximising the spread of sampling times. The last 
sample taken (week 7 or 8) was used for the 2-month culture endpoint.  
At the preceding visits, participants were issued with a sputum pot and biohazard bag. They were 
advised to rinse their mouth after their evening meal and before commencement of overnight 
sampling, and instructed on optimal cough technique. Participants were asked to collect an 
overnight sample between 6 pm the evening before the Sputum Sampling Visit and 6 am the 
following morning, or production of first morning sample (whichever was later). Samples were to be 
kept out of direct sunlight, and brought to the study office by 8 am. On receipt, samples were taken 
to the Hit TB Hard Laboratory where they were processed immediately for liquid culture (MGIT). 
During this visit, participants had a brief clinical review, and details of any change in therapy, HIV 
status, or ART regimen collected. The last of these visits (between weeks 7-8) coincided with a 
research bronchoscopy for those in the Intrapulmonary Arm, and sparse plasma PK sampling for 
those in the Plasma Arm (see below). 
 
2.5.2.3 Bronchoscopy visits (IPPK1 / IPPK2) 
Participants in the Intrapulmonary Arm were invited to return to QECH for 2 bronchoscopy sampling 
days, separated by 8 weeks. The first visit occurred between weeks 7-8 of the intensive phase 
(coinciding with Sputum Sampling Visit S4) for reasons of subject tolerability, operator safety, and to 
ensure the drugs had achieved steady state. The second visit occurred around weeks 15-16 of 
treatment. 
Participants were asked to attend the study office by 7 am, having fasted from midnight. Participants 
were asked to sign a specific bronchoscopy ICF (Appendix B: Bronchoscopy informed consent form), 
or indicate consent by witnessed thumb print. Vital signs were recorded – blood pressure, pulse, 
respiratory rate, oxygen saturation, and temperature. They were assessed for any contraindications 
to bronchoscopy by the PI, and the procedure only performed if safe to do so. 
 
2.5.2.3.1 Plasma sampling 
Rich plasma PK sampling occurred alongside BAL sampling. Participants were allocated by block to 
one of two plasma sampling sub-designs as below: 
Block 1:   0 0.5  1 3 5 (hours post-dose) 
Block 2:  0 2 4 6 8 (hours post-dose) 
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The first blood sample was taken at 7:30 am (time 0, pre-dose), at which point participants were 
observed to take their anti-TB therapy with a small volume of water. An intravenous cannula was 
inserted and flushed with heparin saline to avoid the need for repeated venepuncture. At each time 
point, blood was collected in 6 ml lithium heparin tubes, protected from light, and immediately 
transported on ice to the MLW Immunology Laboratory. Plasma was separated by centrifugation 
(1000 x g, 10 minutes) and stored at -80oC. Participants were not allowed to eat or drink until after 
their bronchoscopy. 
In addition to PK sampling, participants had blood taken at the time of bronchoscopy for 
measurement of plasma urea. This was compared to the urea concentration in BAL supernatant by 
the urea dilution method, described further in 5.2.2, enabling calculation of the volume of epithelial 
lining fluid [432]. 
 
2.5.2.3.2 Bronchoscopy sampling 
Participants were able to have a bronchoscopy 2 hours after taking their anti-TB drugs [429], the 
exact timing of which varied according to a pre-determined matrix based on an optimal design 
calculation. Participants either had an early (2 hours post-dose), middle (4 hours post-dose), or late 
(6 hours post-dose) bronchoscopy. This produced a composite profile matrix of BAL drug exposure, 
and aimed to capture the peak drug concentration (Cmax) for the components of anti-TB therapy in 
BAL.   
Bronchoscopy and BAL sampling occurred in the Clinical Investigation Unit (CIU) at QECH. The CIU is 
jointly managed through MLW and the Departments of Medicine and Surgery, QECH, and provides 
bronchoscopy, gastrointestinal endoscopy, spirometry, and induced sputum sampling for both 
research and clinical service. The CIU has safely performed over 2,500 research bronchoscopies in 
both healthy volunteers and in patients with a diagnosis of sputum smear-negative TB, while the 
LSTM Respiratory Infection Group has performed over 1,000 research bronchoscopies to date in the 
UK and Malawi [430]. The PI performed the bronchoscopies for the study. 
The CIU is well ventilated with 4 extractor fans to ensure continuous flow of air through the unit.  
Bronchoscopy staff used personal protective equipment during bronchoscopy (N95 masks, gowns, 
gloves, eye protection) and followed standard infection control procedures and CDC 
recommendations [433, 434]. From previous experience of bronchoscopy and induced sputum 
procedures on TB suspects, institutional infection control procedures are stringent. 
Bronchoscopy and BAL sampling were performed as previously described [430]. In brief, topical 
lidocaine was applied to the nasal and pharyngeal mucosa in semi-recumbent participants. A fibre-
optic bronchoscope (BF-1T260 EVIS Video Bronchoscope, Olympus, UK) was passed through the nose 
or mouth to the level of a sub-segmental bronchus of the right middle lobe. Mucosal anaesthesia 
using 2 ml aliquots of 2% lidocaine was applied at the larynx, trachea, right main bronchus, and right 
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middle lobe. Four aliquots of warmed sterile saline – 40 ml, 60 ml, 60 ml, and 40 ml – were instilled 
into the right middle lobe and aspirated with gentle hand suction. The dwell time was less than 10 
seconds. Samples were expelled into 50 ml Falcon Tubes held on melting ice, and transported to the 
laboratory for immediate processing after the last aliquot collected. Where appropriate and 
requested, intravenous midazolam was available for sedation. Participant’s oxygen saturation was 
monitored by pulse oximetry throughout the procedure, and participants were transferred to the 
recovery suite for further monitoring for 2 hours after the procedure. Participants could eat and 
drink an hour after the procedure providing their swallow had been assessed as safe, and were 
followed up by telephone call 48-72 hours after the bronchoscopy. 
 
2.5.2.4 Plasma pharmacokinetic visits (SPPK1 / SPPK2) 
As for participants in the Intrapulmonary Arm, participants in the Plasma Arm were invited to return 
to QECH for 2 plasma sampling days, separated by 8 weeks. The first visit occurred between weeks 7-
8 of treatment, the second during weeks 15-16. Participants were asked to arrive fasted, and were 
observed to take their anti-TB medications with a small volume of water. Those in Block 1 had blood 
samples taken 1 and 3 hours after their medications; those in Block 2 at 2 and 4 hours. Blood was 
collected in 6 ml lithium heparin tubes, protected from light, and immediately transported on ice to 
the MLW Immunology Laboratory. Sparse sampling from the Plasma Arm was undertaken for 
incorporation into the population PK model from the Intrapulmonary Arm, and used to predict the 
intrapulmonary concentrations for all cohort participants whether they had a bronchoscopy or not 
(Chapters 4 and 5).   
 
2.5.2.5 End of treatment visit (EOT) 
Participants attended at the end of 6 months of tuberculosis therapy for a short clinical review. 
Details of any change in therapy, HIV status, or ART regimen were collected, and a spot sputum 
sample submitted for smear-microscopy and liquid culture if expectorating. If smear or culture 
positive, the participant was referred back to the NTP for re-registration and re-treatment [105]. 
Blood was collected for end of treatment CD4 count. 
 
2.5.2.6 Follow up visits (FUP1 / FUP2 / FUP3 / EOS) 
Follow-up was arranged with the QECH study team 3, 6, 9, and 12 months after completion of 
therapy. Telephone follow up was offered to those unable to attend, or for whom it was impractical 
to do so, provided they remained clinically well. The 12-month follow-up visit was the end of study 
visit (EOS), following which subjects were released from the study. 
Participants were assessed for recurrent TB symptoms and asked to submit a sputum sample to test 
for TB relapse if they had a productive cough. These samples were processed by smear-microscopy 
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as for the EOT samples. Participants with recurrent infection were referred to the TB Registry for re-
treatment according to NTP guidelines [105]. 
 
2.5.2.7 Unplanned visits and adverse events 
Participants were encouraged to contact the study team directly in the event of any intercurrent 
illnesses, treatment complications, or drug side-effects over the course of treatment and follow-up. 
The PI or study clinical officer assessed subjects attending for unplanned visits in case any 
intervention was required. Details of adverse events and unplanned visits were logged in an 
electronic CRF and followed up to resolution. Where appropriate, initial investigations were 
requested and patients were referred to the relevant clinic for ongoing management. 
 
2.5.2.8 Loss to follow-up 
Minimising loss to follow-up over 18 months and multiple visits was a major challenge for this study. 
While the primary endpoint was at 2 months (see below), capturing rates of TB relapse in the year 
following treatment required active management of the cohort to minimise loss to follow-up. 
Understandably, several patients forgot to attend appointments, were too unwell to travel, or 
moved out of urban Blantyre to convalesce elsewhere. At enrolment, the study team recorded a 
written description of where the participant lived, along with a basic map. Mobile telephone 
numbers for the participant and next of kin were recorded where possible. These details were stored 
in a locked cupboard in the study office. 
Approximate appointment dates were generated at enrolment and logged in the study diary. A 
password-protected electronic ‘dashboard’ displayed all the study visits, with a separate row for 
each participant, and flagged as ‘overdue’ when the visit date was passed without an electronic CRF 
being submitted. This enabled ready identification of missed visits, reviewed at a weekly team 
meeting. Attempts were made to contact participants or their next of kin by telephone to rearrange 
appointments. Where a week had passed with no attendance or contact, a fieldworker would visit 
the participant at home to identify the reason for non-attendance and facilitate the visit if willing. If 
they no longer wished to attend, participants were withdrawn from the study. The fieldworker 
would be dressed in plain clothes to maintain confidentiality. Participants were specifically asked to 
consent for a fieldworker visit at enrolment.   
 
2.5.2.9 SPITT-LAT transfer 
The Life After pulmonary TB (LAT) Study was a prospective cohort study of 400 adult patients 
completing treatment for pulmonary TB in urban Blantyre, running at the same time as the SPITT 
study. This study focussed on the nature and impact of residual lung scarring in the year following 
treatment, using non-invasive investigations such as CXR / CT imaging, spirometry, and exercise 
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capacity assessment, alongside completion of quality of life and health economic questionnaires, to 
measure respiratory health and functional capacity. Given that these studies shared a similar patient 
population, and both aimed to improve the care provided to TB patients in Malawi, there were 
significant efficiency and scientific benefits if patients could participate in both studies sequentially. 
In August 2016, ethical approval was granted for participants in the SPITT study to be sequentially 
recruited into the LAT Study. TB patients nearing the end of treatment, including SPITT participants, 
were referred to the LAT team by the TB Officers. This would typically occur after the second 
bronchoscopy or sparse plasma sampling visit, and before the EOT visit. Patients were provided with 
a patient information leaflet explaining the process of sequential recruitment and transfer from 
SPITT to LAT, emphasising that transfer to the LAT study was entirely voluntary. Transfer into the LAT 
study had no impact on the total duration of follow-up required, which remained 1-year following TB 
treatment completion. Those patients transferring would have more intensive follow up 
appointments at 6 and 12-months after TB treatment completion, and completion of additional 
respiratory investigations including chest imaging, spirometry, exercise testing, and questionnaire 
completion.  
SPITT participants consenting to transfer were asked to complete the existing approved LAT Study 
consent form (COMREC P.10/15/1813, LSTM 15.040RS), as well as a new consent form specifically 
designed to address issues of sequential recruitment. All follow-up would then occur under the LAT 
team, with the data required from the EOT, follow-up visits (FUP1 / FUP2 / FUP3) and EOS visits 
being collected by the LAT team at their routine appointments. These data were uploaded to the LAT 
study database, and only data that would have been routinely collected in the SPITT study follow-up 
and end-of-study visits was shared with the SPITT study team. An automated procedure for the 
routine extraction of these data facilitated this. End of treatment sputum samples and CD4 counts 
were collected by the LAT team. Patient flow is illustrated in Figure 2.5. 
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Figure 2.5: SPITT-LAT sequential recruitment schematic 
The top panel illustrates patient flow in the SPITT study, with intensive sampling during the 6 months of TB 
treatment, followed by 1 year of minimal follow up to capture rates of TB relapse. The middle panel illustrates 
patient flow in the LAT study, with participants recruited at the end of TB treatment and followed up over 1 year. 
The bottom panel illustrates patient flow for SPITT patients sequentially recruited to the LAT study. After the first 
6 months of intensive sampling, participants would join the LAT study for ongoing follow up.  
 
2.6 Defining study outcomes 
2.6.1 WHO treatment outcome 
 
TB treatment outcome was recorded using NTP and WHO definitions (Table 2.8) [71, 105]. The final 
EOT sputum sample was used to determine whether the patient was determined to be 
microbiologically-cured. Outcomes recorded by the NTP were captured and reviewed. 
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Outcome Definition [100, 105] 
Cure A pulmonary TB patient with bacteriologically confirmed TB at the beginning of 
treatment who was smear- or culture-negative in the last month of treatment and 
on at least one previous occasion. 
Treatment completion A TB patient who completed treatment without evidence of failure BUT with no 
record to show that sputum smear or culture results in the last month of treatment 
and on at least one previous occasion were negative, either because tests were not 
done or because results are unavailable. 
Treatment failure A TB patient whose sputum smear or culture is positive at month 5 or later during 
treatment. 
Died *  A TB patient who dies for any reason before starting or during the course of 
treatment. 
Lost to follow-up A TB patient who did not start treatment or whose treatment was interrupted for 2 
consecutive months or more. 
Not evaluated A TB patient for whom no treatment outcome is assigned.  This includes cases 
“transferred out” to another treatment unit as well as cases for whom the 
treatment outcome is unknown to the reporting unit. 
Treatment success The sum of cured and treatment completed. 
Table 2.8: Treatment outcome definitions  
* Decisions on the attributable cause of death were made by the PI in consultation with a physician from QECH 
independent from the study team.  Death was further classified as “definitely or probably attributable to active 
TB” or “attributable to causes other than active TB”. 
 
2.6.2 Final study outcome 
 
As the WHO treatment outcomes above do not consider the possibility of post-treatment relapse, 
nor do they distinguish between death due to TB or other causes, the final treatment outcomes at 18 
months were grouped as below (Table 2.9).  
 
Final Outcome Definition 
Cure A pulmonary TB patient with bacteriologically confirmed TB at the beginning of 
treatment, who was smear- or culture-negative in the last month of treatment and 
on at least one previous occasion, AND showed no clinical or bacteriological 
evidence of relapse during 1 year of post-treatment follow-up. 
Treatment 
completion 
A TB patient who completed treatment without evidence of failure BUT with no 
record to show that sputum smear or culture results in the last month of 
treatment and on at least one previous occasion were negative (either because 
tests were not done or because results are unavailable), AND showed no clinical or 
bacteriological evidence of relapse during 1 year of post-treatment follow-up. 
Treatment failure A TB patient who had any of the following: (i) 2 positive TB sputum tests (smear, 
culture, or molecular method) at EOT; (ii) 1 positive TB sputum test (smear, 
culture, or molecular method) at EOT, and clinical features indicating a need for re-
treatment; (iii) clinical features indicating a need for re-treatment in the absence 
of supporting bacteriology; (iv) death during treatment definitely or probably 
attributable to active TB. 
Relapse During 1 year of post-treatment follow up. Criteria as for treatment failure, but 
patient had been classified as cured or completed treatment at EOT. 
Other This includes all patients withdrawn from the study according to the criteria 
described above. 
Table 2.9. Final study outcomes 
 
Cure or treatment completion were grouped as ‘favourable outcomes’, treatment failure or relapse 
as ‘unfavourable outcomes’. Those meeting the withdrawal criteria (Table 2.5) were grouped as 
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‘other’, with the reason for withdrawal specified on the CRF. This included patients dying of causes 
unrelated to TB, those that defaulted therapy, or those transferring out of Blantyre with unknown 
outcomes.    
Where treatment failure, death, or relapse had to be determined on clinical grounds, this decision 
was made by the PI in consultation with a physician from QECH independent from the study team. 
Death was further classified as ‘definitely or probably attributable to active TB’ or ‘attributable to 
causes other than active TB’. Only deaths attributable to TB were included as unfavourable 
outcomes.  
Those participants whose sputum smear or culture was positive at 5 months or later whilst on anti-
TB therapy were classified as treatment failure. Included in this definition were those patients found 
to have MDR-TB at any point during treatment.  
Recurrent TB in the year following treatment is more likely to be relapse than re-infection. Those 
participants who were diagnosed with TB bacteriologically (smear, culture, or molecular method) 
after previous TB treatment with a successful outcome (‘cure’ or ‘treatment completion’) were 
classified as relapse at the end of study, as were those with a clinical decision to treat TB after 
previous TB treatment with a successful outcome. Spoligotyping to differentiate relapse from re-
infection was not performed, but isolates have been stored that may enable this at a later date.  
 
2.7 Endpoints 
2.7.1 Primary endpoints 
 
1. Predicted intrapulmonary AUC/MIC for anti-TB therapy  
2. Two-month sputum culture conversion  
 
2.7.2 Secondary endpoints 
 
1. Bacillary elimination rate (BER) 
a. Rate of change in sputum time-to-positivity in liquid culture  
2. Alveolar macrophage function on anti-TB therapy 
a. Change in Activity Index – superoxide burst and bulk proteolysis 
b. Change in phagocytic activity 
3. Clinical endpoints 
a. WHO treatment outcome for TB patients 
b. Bacteriologically- or clinically-defined failure or relapse at 12 months 
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2.7.3 Justification 
 
TB treatment response was assessed using surrogate endpoints. The endpoint of post-treatment 
relapse requires a large sample size and follow-up, and was outside the scope of this work. Current 
chemotherapy regimens were chosen based on 2MCC endpoints, which have a statistically 
significant relationship to clinical endpoints [66]. Time-to-positivity of baseline cultures is linked to 
rates of 2MCC and treatment failure / relapse [93, 435, 436], and by recording the BER we have a 
continuous pharmacodynamic measure of response to treatment [89]. 
 
 
2.8 Sample size calculation 
2.8.1 Plasma Arm 
 
The primary endpoint compares the AUC/MIC between 2-month sputum converters and non-
converters. Using a two-sided significance level of 0.05, power of 80%, and effect size of 0.6 (Cohen’s 
d), 45 subjects per group would be required if the groups (converters / non-converters) were of 
equal size (power calculation for t-tests of means, ‘pwr’ package in R (version 3.1.2). Presuming that 
75% of participants would sputum culture convert by 2 months, the sample size was calculated using 
the formula: 
1
𝑛1
+
1
𝑛2
=
2
𝑛𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡
 
With 𝑛𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡 = 45, the total sample size was 120, of whom 90 are sputum converters (𝑛1), and 
30 are non-converters (𝑛2). A power table for different sample sizes is shown below.  
Sample Size (n) Power (%) 
40 36.0 
60 50.8 
80 63.1 
100 73.0 
120 80.6 
140 86.3 
160 90.4 
Table 2.10: Power table for sample sizes 
 
Recruiting 150 participants into the Plasma Arm, allowing for 20% loss to follow-up, would give 80% 
power to detect an effect size of 0.6. Given the time taken for sputum culture results to become 
available, and the need for culture-confirmation for inclusion, the study aimed to recruit a slightly 
larger sample of 160 patients to account for those participants that were ultimately culture negative 
and excluded. 
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2.8.2 Intrapulmonary Arm 
 
Sample size and optimal study design were based on estimated precision of the PK indices (clearance 
and volume of distribution). Models with coefficients of variation (%CV) of less than 25% are 
generally deemed to have precise parameter estimates [437]. Using (i) previous plasma population 
pharmacokinetics from Malawi [322], (ii) estimates for the between-compartment transfer rate 
constants and volume of distribution of the pulmonary compartment [344, 432], and (iii) the 
software PopDes, a number of sub-designs were trialed.  
 
Estimating the precision of the intrapulmonary estimates is made difficult by the limited prior data 
on pulmonary penetration of anti-TB therapy. A previous PK model using data from a rabbit model of 
pulmonary penetration, and single time point bronchoalveolar lavage samples (4 hours post-dose) 
from previous small studies achieved a %CV of 10% for epithelial lining fluid and 9% for alveolar 
macrophages [340, 345, 438]. Given the constraints of a single bronchoscopy per sampling day, and 
the practicalities of the CIU hours of operation, the optimal design for the SPITT Study was based on 
1 bronchoscopy (variably-timed: early/middle/late), with 5 plasma samples. Attempts to predict 
precision resulted in a 1 log drop in estimated %CV when 3 bronchoscopy time points are used (15 
participants per time point, n=45). By recruiting 50 participants, we allowed for 10% unsatisfactory 
bronchoalveolar lavage returns, failure to tolerate the procedure, and loss to follow-up. Local 
experience indicates that retention in research bronchoscopy studies is >90%, suggesting that there 
was sufficient contingency in the study design.   
 
2.9 Ethical approval 
 
Ethical approval for the study was granted by the University of Malawi College of Medicine Research 
Ethics Committee (P.09/15/1800) and the Liverpool School of Tropical Medicine Research Ethics 
Committee (15.033). Ethics approval letters are included in Appendix C: COMREC approval 
certificate and Appendix D: LSTM REC approval letter.  
 
2.10 Data management 
 
SOPs were developed and followed for correct and confidential management of data in accordance 
with best practice. Study participants were assigned a unique identifier at enrolment under which all 
data were captured. Paper documents were identified with a participant barcode, and a secure 
folder linking identifiable patient data (names, addresses, etc.) to study identifier was stored in 
locked filing cabinet in the research office, only accessible to the study team. 
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Data were collected by study team members on electronic CRFs using handheld data capture devices 
running Open Data Kit. Skip patterns, restrictions, and checks were included to minimise data entry 
errors. Questions were prepared in both English and Chichewa, and interviews conducted in the 
language of the participant’s choosing. Study team members were trained on interview conduct and 
electronic data collection before study start to ensure standardised data input.  
Laboratory data were automatically stored within the MLW Laboratory Information Management 
System and routinely pulled into the study database. Experimental data were held in different tables 
within the master database. All electronic data were stored in a password protected database to 
which only the PI and data managers had access to. A web based ‘dashboard’ collated data from the 
database to keep track of recruitment and missed appointments. Data were backed up on the secure 
LSTM server, and two password protected hard drives.  
Data were exported to the statistical software R [439] and pharmacometric software NONMEM© 
(version 7.4.0, ICON Development Solutions, Ellicott City, MD, United States of America) for analysis. 
Details of the analytical techniques used are included in Chapters 3-7. Statistical significance was 
reported at the level of p<0.05, unless stated otherwise. 
Anonymised data will be held for a minimum of 10 years following project completion. Subsequently 
data will be disposed of appropriately and in accordance with University of Malawi / LSTM protocols.  
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3 Clinical study description 
3.1 Introduction 
 
This chapter describes study recruitment and follow-up success, response to TB treatment by two-
month culture conversion (2MCC), and favourable or unfavourable final treatment outcomes in the 
cohort. The clinical, socioeconomic, and radiological characteristics of the cohort are described with 
their relationship to treatment response.  
As the leading driver of the TB epidemic in sub-Saharan Africa [17], HIV co-infection, extent of 
immunosuppression, and uptake of antiretroviral therapy (ART) are a focus of this chapter. More 
than half of notified TB cases in SSA are coinfected with HIV [17], and at greater risk of death or 
recurrent disease after treatment completion [440, 441]. Given the role of early ART in both the 
prevention of TB disease in people living with HIV [442], and in decreasing mortality in co-infected 
patients [47], ART administration in the cohort is examined. In the past decade, a hugely successful 
programme of ART rollout has put more than 12 million patients in sub-Saharan Africa onto regular 
treatment [443]. In Malawi, ART scale-up between 2005 and 2015 achieved an impressive 43% 
reduction in TB incidence in HIV-infected patients at a population level [444].  
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set the ambitious 90-90-90 
targets for 2020: 90% of people living with HIV should know their status; 90% with HIV should be on 
ART; and 90% of those on ART should have viral suppression. Malawi has committed to meeting 
these targets [445]. By the start of study recruitment, Malawi had adopted the policy of universal 
ART eligibility regardless of CD4 count [445]. It remains to be seen what impact this will have on TB 
incidence. 
Tuberculosis has historically been, and continues to be, strongly associated with poverty. Poverty is 
an important risk factor for development of TB disease [446], partly through overcrowding, poor 
nutrition, and reduced access to healthcare [447-449]; whereas TB is an important risk factor for 
increasing poverty through dissaving, lost income, and catastrophic costs [450]. Furthermore, both 
poverty and catastrophic costs may be associated with adverse treatment outcomes [451]. In 
recognition of this relationship, the WHO has targeted elimination of catastrophic costs due to 
tuberculosis by 2020 [452]. Given the central importance of poverty on risk of disease and response 
to treatment, measures of socioeconomic status in the cohort are described. Household biomass 
exposure, through burning wood and charcoal, is common in Malawi and linked to poverty [453]. 
Biomass exposure is associated with risk of altered innate immune function [374] and risk of 
infections such as TB [454], and is captured in the baseline questionnaires. 
Finally, clinical and radiological predictors of treatment response are considered. Severity of illness 
at baseline, comorbidities, body mass index, and pre-treatment health-seeking behaviour are 
Chapter 3  Clinical study description 
 
 
Page 70 
described and related to 2MCC and final outcome. Few of these clinical factors have been 
consistently related to treatment response. In contrast, baseline chest X-ray (CXR) provides useful 
information on disease extent and severity, and is related to response. Cavitatory disease is 
associated with higher baseline bacillary load [455], lower likelihood of 2MCC [456], and greater risk 
of recurrent disease after treatment completion [14, 241, 457]. However, CXR scoring can be 
subjective and prone to high inter-reader variability [458]. A simple CXR scoring system predictive of 
2MCC and baseline smear grade [459], developed in Papua Province, Indonesia, and later used in 
cohorts from Malawi [89], and South Africa [460, 461], was used as a predictor in this cohort. 
2MCC was chosen as an early marker of treatment response. Culture conversion has been widely 
used as a surrogate endpoint of final treatment response in clinical trials, given its early availability 
and simple interpretation [15, 66]. However, it is an imperfect surrogate marker of relapse-free cure, 
performing well in the early trials in Hong Kong, but inferior to three-month culture conversion in 
the East African trials [66]. Given these limitations, alternative markers of treatment response (time 
to culture conversion, bacillary elimination rate) are explored in subsequent chapters. 
The gold standard endpoint in Phase III trials remains the composite outcome of treatment failure or 
post-treatment relapse to 18-24 months of follow-up [15]. Study participants were followed-up to 18 
months post-treatment initiation to capture this final outcome. Data collection to this endpoint will 
continue until the end of 2018, and thus this thesis will assess this endpoint for the first 138 patients 
completing the study.  
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3.2 Methods 
 
Conduct of the cohort study is described in detail in Chapter 2. The methods for determining CXR 
score and 2MCC outcomes are detailed below. 
 
3.2.1 Chest radiography 
 
Participants underwent a baseline postero-anterior CXR in the Department of Radiology, QECH. For 
the first 125 participants, a digital CXR was performed, electronically-labelled with the participant ID, 
and reviewed on MicroDicom version 0.9.1. Due to a technical fault with the digital radiography 
machine, the remaining 34 participants had printed full-size CXR films. One participant did not 
attend radiology for a CXR, and withdrew from the study before this could be arranged. 
CXRs were reviewed independently by both the PI and an external radiologist. Scoring was 
performed using the method developed by Ralph et al [459]. The total amount of affected lung in 
each zone was estimated, and the total percentage of each lung affected by any pathology 
calculated (0-100). The presence of nodules (small or large), consolidation (patchy or confluent), 
effusions (0, < 25% hemithorax, ≥ 25% hemithorax), lymphadenopathy (0, unilateral, bilateral), 
fibrosis, cavitation (0, < 4 cm, ≥ 4 cm) or miliary disease was captured and entered onto an electronic 
CRF. A final weighted score was calculated using the equation below: 
𝐶𝑋𝑅 𝑠𝑐𝑜𝑟𝑒 = 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑙𝑢𝑛𝑔 𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 (%) + 40 𝑖𝑓 𝑐𝑎𝑣𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 
Prior to scoring study CXRs, the PI and radiologist reviewed a training set of PTB CXRs to familiarise 
themselves with the method. Concordance between each element of assessment was reviewed and 
only factors with significant agreement used for analysis. The top 5% most discrepant films were re-
read by both the PI and radiologist, and scored by consensus. For continuous variables, the average 
of the radiologist and PI score was used. For categorical variables with discrepant results, the 
outcome reported by the radiologist was chosen as the final result.  
 
3.2.2 Determination of two-month culture conversion 
 
6 sputum samples were collected from each participant: 1 screening, 4 during the intensive phase of 
treatment (S1-S4), and 1 at the end of TB treatment. The methods for sputum decontamination and 
liquid MGIT culture are described in detail in Chapter 6. 
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The result of sputum culture was recorded as a binary positive / negative outcome from the liquid 
MGIT results as per Table 3.1. For a positive result to be recorded, Mtb growth had to be confirmed, 
with or without contaminating organisms. 
2MCC was defined as Mtb culture positivity at the start of treatment, with subsequent negative 
cultures for Mtb, without reversion to culture positivity (stable culture conversion). The 2-month 
sputum sample was collected at the S4 sputum sampling visit, occurring at the end of the intensive 
phase of treatment. Those participants with only Xpert MTB/RIF positivity did not have a 2MCC 
outcome recorded. 
 
Liquid MGIT culture result Definition Interpretation for 2MCC 
Positive, Mtb Tube positive on BACTEC MGIT 960 (< 42 days) 
AFB identified on ZN smear of pellet 
AND 
Cording identified on ZN microscopy 
AND 
MPT64 antigen test positive 
AND  
No growth on blood agar * 
Positive 
Positive, MOTT Tube positive on BACTEC MGIT 960 (< 42 days) 
AFB identified on ZN smear of pellet 
AND 
(No cording identified on ZN microscopy 
OR 
MPT64 antigen test negative) 
AND 
Growth on LJ slopes at 25oC / 45oC / 37oC with PNB † 
Negative 
Initial contamination Tube positive on BACTEC MGIT 960 (< 42 days) 
AFB not identified on ZN smear of pellet 
Sample returned to incubator and re-read at 2 weeks 
Mtb now confirmed by ZN, cording, and MPT64 antigen test 
Positive 
Mixed contamination Tube positive on BACTEC MGIT 960 (< 42 days) 
AFB identified on ZN smear of pellet 
AND 
Cording identified on ZN microscopy 
AND 
MPT64 antigen test positive 
AND  
Growth on blood agar * 
Positive 
Final contamination Tube positive on BACTEC MGIT 960 (< 42 days) 
AFB not identified on ZN smear of pellet 
Sample returned to incubator and re-read at 2 weeks 
AFB not identified on ZN smear of pellet 
No positive result on re-culture of pellet 
Negative ‡ 
Negative No growth after 42 days in liquid MGIT culture § Negative 
Table 3.1: Interpretation of MGIT culture results 
6 different outcomes of MGIT culture were recorded. * Positive samples were plated on blood agar. Mtb will not 
grow on blood agar, whereas other contaminating organisms will. † Mtb will grow on LJ slopes at 37oC, but not 
at 25oC, 45oC, or 37oC with PNB – used to distinguish between Mtb and MOTT. ‡ Final contamination was classed 
as negative for the determination of 2MCC outcomes. It is possible that these samples still contain small 
numbers of Mtb, but have been masked by the rapid growth of contaminating organisms. § Samples were 
cultured for 42 days (6 weeks) before a negative result could be recorded. AFB: acid-fast bacilli; LJ: Lowenstein-
Jensen; MOTT: mycobacteria other than tuberculosis; PNB: paranitrophenol benzoic acid; ZN: Ziehl-Neelsen 
stain. 
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3.2.3 Statistical analysis 
 
All statistical analysis was performed in the statistical software R (version 3.5.0) [439]. Summary 
statistics were used to describe the characteristics of study participants, using the ‘psych’ and 
‘tableone’ packages. Normally distributed continuous variables were assessed by one-way analysis of 
variance, and non-normally distributed data by Kruskal-Wallis test. Categorical variables were 
assessed by chi-squared test or Fisher’s exact tests where the number of participants in any category 
was less than 5. Statistical significance was reported at the level of p<0.05 unless stated otherwise. 
Linear regression was used to explore variables associated with CXR score, and logistic regression for 
factors associated with cavitation on CXR, 2MCC, and final treatment outcome. Continuous variables 
were normalised for regression analysis.  
CXR inter-reader agreement was tested using the concordance coefficients, ρc for continuous 
variables and the kappa statistic for categorical variables. Prevalence-adjusted, bias-adjusted kappa 
values were calculated according to the method described by Byrt [462], and Landis and Koch 
guidelines used to interpret kappa values for dichotomous variables [463] (kappa ≤ 0.00, poor; 0.00-
0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; 0.81-1.00, almost perfect). 
Only those with ‘substantial’ or greater agreement were analysed further. 
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3.3 Results: recruitment, follow-up success, and outcomes 
3.3.1 Recruitment and follow-up success 
 
3.3.1.1 Recruitment 
Recruitment and follow-up are summarised in the CONSORT diagram opposite (Figure 3.1). 248 TB 
patients were referred by the TB Officers, with 55 ineligible on the screening questionnaire. 193 
patients had screening bloods and sputum collected, and 160 eligible participants were enrolled in 
the study. 3 participants were excluded post-recruitment as their TB diagnosis was not 
microbiologically-confirmed (by culture or Xpert MTB/RIF). 
Study recruitment originally focussed on the TB Registry at QECH. Because of decentralisation of TB 
diagnosis and care to referral health centres in Blantyre, it was necessary to apply for an amendment 
to expand the study sites to 6 health centres registering patients for TB treatment in urban Blantyre 
(Table 3.2). Patients were referred to the study office at QECH based on a new diagnosis of 
pulmonary TB (sputum smear- or Xpert MTB/RIF-positive) for screening. QECH remained the main 
recruitment location, followed closely by Limbe and Ndirande Health Centres. Participants continued 
to receive their TB treatment from their local health centre, but attended QECH for all study visits. 
 
Recruitment site n (%) 
QECH 40 (25.5) 
Limbe 36 (22.9) 
Ndirande 31 (19.7) 
Bangwe 24 (15.3) 
Zingwangwa 16 (10.2) 
Chilomoni 9 (5.6) 
Mpemba  1 (0.6) 
Table 3.2: Recruitment sites in urban Blantyre 
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Figure 3.1: Study CONSORT diagram 
New TB patients were identified by Blantyre TB Officers and referred to the study team for screening and 
enrolment. Patients were excluded post-recruitment if none of the sputum samples were positive for Mtb on 
culture or Xpert MTB/RIF. Participants were allocated to the Intrapulmonary or Plasma Arms sequentially based 
on the availability of bronchoscopy slots in the Clinical Investigation Unit. Participants entering the LAT study 
had all follow-up visits with the LAT study and the data collected from their database. * 19 participants were still 
in follow-up by July 2018, and are expected to complete the study by October. These participants were all in the 
Plasma Arm. Final outcome data was unavailable for these participants. † died during TB re-treatment for 
treatment failure. Counted as death attributable to TB. LTFU: lost to follow-up. 
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90/157 (57.3%) eligible patients were referred based on a positive smear result taken by the NTP, 
and 67/157 (42.7%) with a positive Xpert MTB/RIF result. Table 3.3 summarises the results of the 
baseline smear grade (NTP or screening) for all study participants. 
 
Diagnostic sputum result n (%) Mean TTP in MGIT (days) 
Xpert MTB/RIF only 27 (17.2) 17.8 
Smear scanty 10 (6.4) 17.0 
1+ 25 (15.9) 11.6 
2+ 32 (20.4) 10.1 
3+ 63 (40.1) 8.0 
Table 3.3: Baseline sputum smear grade 
Some participants were referred based on Xpert MTB/RIF positivity, with a negative screening smear collected by 
the study. MGIT: Mycobacteria Growth Indicator Tube; TTP: time-to-positivity – an inverse measure of bacillary 
load. 
 
The commonest reason for screen failure was being unable or unwilling to attend follow-up (n=46). 
While 51/202 (25.2%) of those willing to join the study were female, a significantly higher proportion 
of those declining involvement were female (24/46, 52.2%; p=0.001). 18 screened patients did not 
attend for enrolment, but there were no significant differences in the age and sex distribution of 
attenders and non-attenders. 
15 patients met study exclusion criteria. 10 patients were excluded due to severe anaemia 
(haemoglobin < 8 g/dl), 3 due to kidney injury (creatinine > 2 mg/dl), and 2 due to raised bilirubin (> 
3 mg/dl). Ineligible patients were reviewed by the study clinician and referred to clinic or for 
admission as required. 
Enrolled participants were sequentially allocated to the 2 arms of the study based on the availability 
of bronchoscopy slots in the CIU. 3 participants per week were provisionally allocated to the 
Intrapulmonary Arm, but only remained in this group if they successfully underwent the procedure 
at weeks 7-8 of TB treatment. 51 participants entered the Intrapulmonary Arm of the study. 
 
3.3.1.2 Follow-up 
A total of 1651 study visits were completed by July 2018. The fourth sputum sampling visit (S4) 
coincided with the end of the intensive phase of treatment, and involved collection of the overnight 
sputum sample required to determine 2MCC: the primary endpoint of the study. 137/157 (87.3%) 
participants provided this sample. 130/157 (82.8%) remained in follow-up to completion of 6 months 
of treatment; and 110/157 (70.1%) to 1-year post-treatment. A further 19 participants are expected 
to complete the study by October 2018. 68/157 (43.3%) completed this follow-up in the LAT study. 
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3.3.2 Withdrawals and adverse events 
 
3.3.2.1 Withdrawals 
31/157 (19.7%) participants did not complete the full 18-months of follow-up. 24 participants 
withdrew from the study after enrolment, and 7 died of TB and were included as unfavourable 
outcomes in the final analysis. Of the 24 withdrawing from the study, 10 had sufficient data to assess 
2MCC. The commonest reason for withdrawal was participants declining further follow-up, followed 
closely by those lost to follow-up (LTFU) and untraceable. HIV-uninfected participants were more 
likely to be LTFU than HIV-infected participants (Table 3.4).  
 
Withdrawal reason HIV-uninfected, n=9  HIV-infected, n=22 p value † 
Participant lost to follow-up and untraceable 
by study staff (n, %) 
6 (66.7) 2 (9.1) 0.003 
Participant request (n, %) 1 (11.1) 6 (27.3) 0.639 
Participant transferred out of Blantyre (n, %) 1 (11.1) 5 (22.7) 0.642 
Death – not attributable to TB (n, %) * 1 (11.1) 2 (9.1) 1.000 
Death – attributable to TB (n, %) * - 7 (31.8) - 
Table 3.4: Study withdrawals by HIV status 
* Decisions on the attributable cause of death were made by the PI in consultation with a physician from QECH 
independent from the study team.  Death was classified as “definitely or probably attributable to active TB” or 
“attributable to causes other than active TB”. † compared by chi-squared or Fisher’s exact test. Death 
attributable to TB was classed as an “unfavourable” final outcome rather than a reason for withdrawal. 
 
10 participants died during the study; 8 during TB treatment, 2 during follow-up. Most died (7/10, 
70%) due to TB disease, all of whom were HIV-infected, with death occurring a median 27 days [IQR 
14-46] into treatment. Non-TB causes of death included severe gastroenteritis, fever, and shock in 
the context of immune reconstitution inflammatory syndrome in a 43-year-old man with a new 
diagnosis of HIV, CD4 count 23 cells/mm3. Another patient, a 25-year-old HIV-uninfected man died at 
home after a short vomiting illness during the continuation phase of treatment. His neighbours 
reported he had been drinking heavily shortly prior to death. The third patient died of suspected 
meningitis 3 months after TB treatment completion. He presented with confusion and headache in 
the context of probable ART failure, and died before he could be reviewed by a senior clinician. 
These patients were removed from analysis of final outcomes. 
While 24 participants withdrew after enrolment, only 8 of these were truly lost to follow-up and 
untraceable. 25% of participants had no telephone and were challenging to follow-up in the event of 
missed appointments. Halfway through recruitment a fieldworker was appointed to locate missing 
participants at home and ascertain if they were willing to continue in the study. By so doing, it was 
possible to improve rates of retention. 6 participants moved away from urban Blantyre during the 
study, and were no longer able to attend study visits. Participants would often return to their home 
village during illness, and their TB care would be transferred to their local NTP TB Officer. 
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As participants only remained in the Intrapulmonary Arm if they completed the procedure, the 
number of withdrawals during the intensive phase of treatment was greater in the Plasma Arm. This 
requirement to remain in follow-up to 7 weeks of treatment meant that early study attrition due to 
early mortality or withdrawal was missed in the Intrapulmonary Arm, but was essential to ensure 
safety of participants. The effects of this are discussed below. No participants allocated to the 
Intrapulmonary Arm declined to have the first bronchoscopy. 
 
3.3.2.2 Adverse events 
Side-effects attributed to TB drugs were common, occurring in 54/157 (34.4%) participants (Table 
3.5). The commonest reported side-effect was joint or muscle pains in 43/157 (27.4%) participants, 
typically attributed to pyrazinamide use. HIV-infected individuals were significantly more likely to 
report nausea or vomiting than HIV-uninfected individuals. 
 
Complication or toxicity HIV-uninfected (n=66) HIV-infected (n=91) p value * 
Any complication or toxicity (n, %) 20 (30.3) 34 (37.4) 0.454 
Skin rash (n, %) 1 (1.5) 3 (3.3) 0.639 
Nausea or vomiting (n, %) 0 (0.0) 14 (15.4) <0.001 
Jaundice (n, %) 0 (0.0) 1 (1.1) 1.000 
Joint or muscle pains (n, %) 17 (25.8) 26 (28.6) 0.834 
Paraesthesia or numbness (n, %) 6 (9.1) 10 (11.0) 0.793 
Visual disturbance (n, %) 1 (1.5) 0 (0.0) 0.420 
Table 3.5: Drug side-effects, stratified by HIV status 
* compared by chi-squared or Fisher’s exact test. 
 
16/157 (10.2%) participants were reviewed for adverse events or intercurrent illnesses occurring 
during TB treatment (Table 3.6). HIV-infected patients were more likely to experience an 
intercurrent illness (p=0.015), with gastroenteritis and oro-oesophageal candidiasis most common.  
 
 Intercurrent illness HIV-uninfected (n=66) HIV-infected (n=91) p value  
Sepsis (n, %) 1 (1.5) 2 (2.2) 
 
Bacterial meningitis (n, %) 0 (0) 2 (2.2) 
Community acquired pneumonia (n, %) 0 (0) 2 (2.2) 
Gastroenteritis (n, %) 0 (0) 3 (3.3) 
Pneumocystis jirovecii pneumonia (n, %) 0 (0) 1 (1.1) 
Oro-oesophageal candidiasis (n, %) 0 (0) 3 (3.3) 
Orchitis (n, %) 0 (0) 1 (1.1) 
Pleurisy (n, %) 1 (1.5) 0 (0) 
Total (n, %) 2 (3.0) 14 (15.4) 0.015 * 
Table 3.6: Intercurrent illnesses during TB treatment, stratified by HIV status  
* compared by Fisher’s exact test. 
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92 research bronchoscopies were completed with one adverse event. The patient was a 38-year-old 
man recently started on ART. He was well on arrival, and the procedure was uncomplicated. On 
extubation, he complained of dizziness, blurred vision, and nausea. Supplementary oxygen was 
administered with a bolus of IV dextrose. The event was classed as an idiosyncratic reaction to the 
mucosal lignocaine used in the procedure: a recognised side effect of lignocaine [429, 430]. He was 
admitted overnight for observation, and discharged home in the morning with no sequelae. 3 further 
patients had minor nosebleeds on extubation that resolved spontaneously.  
 
3.3.3 Treatment outcomes 
 
129/157 participants (82.2%) were culture-positive for Mtb on their screening sample, and a further 
7 participants had positive MGIT cultures collected by the Hit TB Hard Study for monitoring and 
evaluation. 126/157 (80.3%) participants had sufficient results to assess 2MCC. By two months of TB 
treatment, 62.7% had culture-converted, whilst 37.3% remained culture-positive. This was strongly 
related to baseline smear grade: those 2+/3+ positive for AFB were significantly less likely to culture 
convert by 2 months as compared to those with negative, scanty, or 1+ diagnostic samples 
(p=0.001). Baseline drug sensitivity was assessed using Xpert MTB/RIF: no patients had rifampicin 
resistance. Baseline MICs to rifampicin, isoniazid, and ethambutol are discussed in Chapter 6. 
Final treatment outcome (favourable / unfavourable) was recorded 1 year after completion of 
treatment. Follow-up of the cohort is still ongoing, and is anticipated to finish in late 2018. For this 
thesis, analysis of final outcomes is restricted to the first 138 participants that had completed 
treatment and follow-up by July 2018. By this point, 100/114 (87.7%) of those with final outcome 
data had a favourable treatment outcome recorded.  
14 unfavourable final outcomes were recorded: 9 treatment failures, of which 6 were deaths due to 
TB, and 5 diagnoses of recurrent TB (Table 3.7). There was no significant difference in final outcomes 
between the 2 arms of the study (p=0.076). Details of the unfavourable outcomes are included in 
Table 3.8. All failures and relapses were referred to the NTP for further management, and sputum 
samples were stored where possible. 
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Final outcome Intrapulmonary Arm 
(favourable: n=42 
unfavourable: n=2 
other: n=7 *) 
Plasma Arm 
(favourable: n=58 
unfavourable: n=12 
other: n=17 *) 
Cohort 
(favourable: n=100 
unfavourable: n=14 
other: n=24 *) 
Favourable 
 
Cure 
Treatment completion 
42 (95.5) 
 
18 (40.9) 
24 (54.5) 
58 (82.9) 
 
35 (50.0) 
23 (32.9) 
100 (87.7) 
 
53 (46.5) 
47 (41.2) 
Unfavourable 
 
Treatment failure † 
Relapse 
2 (4.5) 
 
2 (4.5) 
0 (0.0) 
12 (17.1) 
 
7 (10.0) 
5 (7.1) 
14 (12.3) 
 
9 (7.9) 
5 (4.4) 
Table 3.7: Final outcomes 
Percentages of those with a final favourable / unfavourable outcome recorded. * withdrawn from the study, 
including deaths due to causes other than TB – not included in final outcome assessment. † Includes death due to 
TB. Decisions on the attributable cause of death were made by the PI in consultation with a physician from QECH 
independent from the study team.  Death was classified as “definitely or probably attributable to active TB” or 
“attributable to causes other than active TB”. Only deaths attributable to TB were included as unfavourable 
outcomes.  
 
ID Age  Sex HIV and ART 
status 
Baseline 
CD4 count 
(cells/mm3) 
2MCC EOT smear 
/ culture 
status 
Details 
Treatment failure 
13 34 Male HIV-infected, on 
ART > 4 years 
350 Non-
converted 
Smear-
positive 
EOT smear-positive 
27 45 Male HIV-infected, 
new diagnosis 
65 Insufficient 
data 
Not 
available 
Died during treatment, 
attributed to TB 
41 35 Male HIV-uninfected 330 Non-
converted 
Smear-
positive 
(NTP) 
EOT smear-positive (NTP) 
44 56 Male HIV-infected, 
new diagnosis 
65 Converted Not 
available 
Died during treatment, 
attributed to TB 
82 37 Male HIV-infected, on 
ART > 4 years 
17 Converted Not 
available 
Died during treatment, 
attributed to TB 
92 41 Male HIV-infected, on 
ART < 1 year 
331 Insufficient 
data 
Not 
available 
Died during treatment, 
attributed to TB 
96 38 Female HIV-infected, 
new diagnosis 
262 Converted Not 
available 
Died during treatment, 
attributed to TB 
154 35 Female HIV-infected, on 
ART ≤ 4 years 
854 Converted Culture-
positive 
EOT culture-positive 
157 62 Male HIV-infected, 
new diagnosis 
205 Insufficient 
data 
Not 
available 
Died during treatment, 
attributed to TB 
TB relapse  
70 40 Male HIV-infected, 
new diagnosis 
10 Converted Negative Persistent symptoms post-
treatment. 
Hepatosplenomegaly and 
lymphadenopathy. Lymph 
node aspirate MTB 
detected on Xpert MTB/RIF 
75 23 Male HIV-uninfected 425 Converted Negative Persistent dyspnoea post-
treatment. Radiological 
diagnosis of recurrent 
disease 
106 32 Female HIV-infected, 
new diagnosis 
323 Non-
converted 
Negative Ongoing symptoms post-
treatment. CXR suggested 
active TB, Xpert MTB/RIF 
positive. Died while on 
retreatment 
138 18 Male HIV-uninfected 1180 Insufficient 
data 
Negative Smear-positive post-
treatment 
150 32 Female HIV-infected, 
new diagnosis 
188 Converted Negative Smear-positive post-
treatment 
Table 3.8: Description of participants with unfavourable outcomes  
2MCC: 2-month culture conversion; EOT: end-of-treatment; NTP: National Tuberculosis Control Programme. 
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3.4 Results: description of clinical cohort 
3.4.1 Comparison of Plasma and Intrapulmonary Arms 
 
Participants were not randomised to Plasma or Intrapulmonary Arms, but rather allocated 
sequentially based on availability of bronchoscopy slots. As 8 participants withdrew or died before 
they had a bronchoscopy, the two arms were compared for any significant differences between the 
groups (Table 3.9). 4 participants failed to attend their bronchoscopy slot, 3 participants died 
(attributable to TB), and 1 transferred out of Blantyre. 
Participants in the Intrapulmonary Arm were younger (median age 32 vs. 34 years; p=0.026), had a 
lower BMI (median 17.9 vs. 18.7 kg/m2; p=0.023), and were less likely to be HIV-infected (45.1 vs. 
64.2%; p=0.036). Those participants originally allocated to the Intrapulmonary Arm (n=8) were 
compared to those that underwent bronchoscopy (n=51). These participants were more likely to be 
tachypnoeic at enrolment (mean 25 vs. 20 breaths per minute; p=0.031), hypoxic (oxygen 
saturations 92 vs. 97%; p<0.001), and have a higher white cell count at baseline (7.4 vs. 6.9 x103/µl; 
p=0.043), suggesting that these participants were more unwell. When these participants are grouped 
with those that underwent bronchoscopy, this did not alter the age or BMI differences, but removed 
the significant difference in HIV status between the groups (47.5% Intrapulmonary Arm vs. 64.3% 
Plasma Arm; p=0.057). The overall cohort was sex imbalanced, with 120/157 (76.4%) of the cohort 
male.  
 
Characteristic Total (n=157) Intrapulmonary Arm 
(n=51) 
Plasma Arm (n=106) p value * 
Age  
(median [IQR]) 
34 [28, 39] 32 [26, 36] 34 [28, 41] 0.026 
Male sex  
(n, %) 
120 (76.4) 44 (86.3) 76 (71.7) 0.070 
Weight in kg  
(median [IQR]) 
51.1 [46.9, 55.6] 50.0 [47.3, 53.8] 52.0 [46.6, 56.5] 0.237 
Change in weight in kg 
(median [IQR]) † 
4.9 [2.3, 7.7] 3.6 [1.3, 6.7] 5.0 [2.9, 8.4] 0.175 
Height in cm  
(median [IQR]) 
167 [161, 172] 168 [162, 173] 166 [160, 172] 0.243 
BMI in kg/m2  
(median [IQR]) 
18.4 [17.0, 19.8] 17.9 [16.8, 18.9] 18.7 [17.1, 20.1] 0.023 
HIV-infected 
(n, %) 
91 (58.0) 23 (45.1) 68 (64.2) 0.036 
CD4 count  
(median [IQR]) 
301 [154, 481] 348 [181, 513] 285 [147, 463] 0.266 
Diagnostic smear (n, %) 
- Negative 
- Scanty 
- 1+ 
- 2+ 
- 3+ 
 
- 27 (17.2) 
- 10 (6.4) 
- 25 (15.9) 
- 32 (20.4) 
- 63 (40.1) 
 
- 7 (13.7) 
- 7 (13.7) 
- 4 (7.8) 
- 12 (23.5) 
- 21 (41.2) 
 
- 20 (18.9) 
- 3 (2.8) 
- 21 (19.8) 
- 20 (18.9) 
- 42 (39.6) 
0.034 
Table 3.9: Comparison of baseline characteristics of participants by study arm 
* compared by chi-squared or Fisher’s exact test. † Change in weight between the start and end of TB treatment. 
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3.4.2 HIV parameters 
 
89/157 (56.7%) of the cohort were HIV-infected at enrolment, 66/157 (42.0%) HIV-uninfected. 2 
further participants were diagnosed with HIV during the study, both due to provider-initiated testing 
(PITC) between the baseline and first sputum sampling visit. They were classed as HIV-infected for 
subsequent analysis. 39/91 (42.9%) of TB/HIV co-infected participants knew their status and were 
established on ART prior to the diagnosis of TB. 52/91 (57.1%) learned they were HIV-infected whilst 
care-seeking with TB symptoms, and had either just started ART or were about to do so. Of those on 
ART, all were receiving combination therapy with tenofovir, lamivudine, and efavirenz, bar one 
female participant using nevirapine as the core agent and subsequently switched to efavirenz.  
Table 3.10 compares HIV-infected and HIV-uninfected participants. The median CD4 count at 
baseline was 178 cells/mm3 in HIV-infected individuals, and 464 cells/mm3 in uninfected individuals 
(p<0.001). Both groups had a similar median increase in CD4 counts over the 6 months of TB 
treatment: 61 and 69 cells/mm3 respectively. 5/66 (7.6%) of HIV-uninfected participants had 
significant CD4 depression at baseline with counts between 50 and 199 cells/mm3 (mean 171.6 
cells/mm3, increasing by 177 cells/mm3 by end of treatment). These participants were not diagnosed 
with HIV during the study, but were noted to be significantly underweight (mean BMI 17.3 kg/m2). 
Previous work has identified severe CD4+ T-lymphopenia in HIV-uninfected individuals [464], and 
associations between marked CD4 depression and low BMI [465]. HIV-uninfected participants had a 
higher grade of smear positivity on their diagnostic smear sample (p=0.048).  
Characteristic HIV-uninfected participants 
(n=66) 
HIV-infected participants 
(n=91) 
p value * 
Age in years (median [IQR]) 30 [25, 35] 35 [32, 42] <0.001 
Male sex (n, %) 56 (84.8) 64 (70.3) 0.054 
Previous HIV test (n, %) 64 (97.0) 90 (98.9) 0.778 
Baseline CD4 count in cells/mm3 
(median [IQR]) 
464 [373, 637] 178 [80, 285] <0.001 
End of treatment CD4 count in 
cells/mm3 (median [IQR]) 
622 [412, 749] 242 [159, 374] <0.001 
Change in CD4 count in cells/mm3 
(median [IQR]) 
69 [-18, 203] 61 [4, 116] 0.648 
Baseline CD4 count in cells/mm3, 
stratified (n, %) 
- <50 
- 50-199 
- 200-349 
- >350 
 
 
- 0 (0.0) 
- 5 (7.6) 
- 9 (13.6) 
- 52 (78.8) 
 
 
- 15 (16.5) 
- 39 (43.0) 
- 22 (24.2) 
- 15 (16.5) 
<0.001 
Weight in kg (median [IQR]) 52.40 [48.1, 56.9] 50.00 [45.0, 54.2] 0.016 
Change in weight in kg (median [IQR]) 4.0 [2.0, 6.9] 5.3 [2.6, 8.7] 0.163 
BMI in kg/m2 (median [IQR]) 18.6 [17.4, 20.2] 18.3 [16.8, 19.5] 0.126 
Diagnostic smear (n, %) 
- Negative 
- Scanty 
- 1+ 
- 2+ 
- 3+ 
 
- 5 (7.6) 
- 4 (6.1) 
- 9 (13.6) 
- 15 (22.7) 
- 33 (50.0) 
 
- 22 (24.2) 
- 6 (6.6) 
- 16 (17.6) 
- 17 (18.7) 
- 30 (33.0) 
0.048 
Table 3.10: Comparison of HIV-infected and HIV-uninfected participants at baseline 
* compared by chi-squared or Fisher’s exact test. 
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Further comparison of HIV parameters in TB/HIV co-infected participants by sex identified some 
important differences (Table 3.11). Female participants were more likely than male participants to 
already know their HIV status at TB diagnosis (63 vs. 34.4%; p=0.022) and already be taking ART 
(p=0.040). Despite this, median and stratified CD4 counts were similar between male and female 
participants. Though more female than male participants had been established on ART for more than 
4 years, they had low CD4 counts (median 128 cells/mm3 [IQR 94.5-193]) suggesting ART treatment 
failure. 
 
Characteristic Total (n=91) Female participants 
(n=27) 
Male participants 
(n=64) 
p value * 
Established HIV diagnosis  
(n, %) 
39 (42.9) 17 (63.0) 22 (34.4) 0.022 
ART duration at baseline (n%) 
- Not yet on ART 
- ART < 1 year 
- ART ≤ 4 years 
- ART > 4 years 
 
- 52 (57.1) 
- 13 (14.3) 
- 12 (13.2) 
- 14 (15.4) 
 
- 10 (37.0) 
- 5 (18.5) 
- 4 (14.8) 
- 8 (29.6) 
 
- 42 (65.6) 
- 8 (12.5) 
- 8 (12.5) 
- 6 (9.4) 
0.040 
Started ART during study (n, %) 51 (56.0) 10 (37.0) 41 (64.1) 0.032 
Baseline CD4 count in 
cells/mm3, stratified (n, %) 
- <50 
- 50-199 
- 200-349 
- >350 
 
 
- 15 (16.5) 
- 39 (42.9) 
- 22 (24.2) 
- 15 (16.5) 
 
 
- 1 (3.7) 
- 15 (55.6) 
- 5 (18.5) 
- 6 (22.2) 
 
 
- 14 (21.9) 
- 24 (37.5) 
- 17 (26.6) 
- 9 (14.1) 
0.089 
Baseline CD4 count in 
cells/mm3 (median [IQR]) 
178 [80, 285] 172 [134, 309] 178 [65, 280] 0.217 
End of treatment CD4 count in 
cells/mm3 (median [IQR]) 
242 [159, 374] 259 [169, 364] 242 [152, 379] 0.603 
Change in CD4 count in 
cells/mm3 (median [IQR]) 
61 [4, 116] 36 [-29, 98] 70 [18, 114] 0.118 
Table 3.11: Comparison of HIV parameters by sex in TB/HIV co-infected participants 
* compared by chi-squared or Fisher’s exact test. 
 
While the Intrapulmonary Arm contained more HIV-uninfected participants than the Plasma Arm, 
there were no significant differences in ART status or CD4 distribution between the arms in TB/HIV 
co-infected participants. 
51 participants started ART during TB treatment, with 88% (45/51) of new starts receiving ART within 
the first 2 weeks of TB treatment. The remaining TB/HIV co-infected patients were all on ART by the 
completion of TB treatment. Figure 3.2 shows CD4 counts by ART status. HIV-uninfected participants 
had significantly higher CD4 counts at baseline, even when compared to those on ART for more than 
4 years. 
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Figure 3.2: Mean baseline CD4 count stratified by HIV and ART status  
Error bars show standard errors. 
 
3.4.3 Socio-economic status 
 
The socioeconomic status of participants was compared to data from the Malawi Demographic and 
Health Survey 2015-16 [421] and the Integrated Household Survey 2010-11 [422]. Comparisons to 
urban data were made where possible. Table 3.12 describes household level data, and Table 3.13 
describes individual level data stratified by sex. 
Compared to urban households, the households of study participants were more likely to be headed 
by a male, cook inside, and use charcoal as their main cooking fuel. Exposure to biomass fuel smoke 
in the home may be an important risk factor for the development of active tuberculosis [466, 467]. 
Study participants were also less likely to own a bicycle or car. 
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Characteristic Study cohort (n=157) Urban Malawian 
households (n=4,042) 
[421] 
p value * 
Household size (mean (SD)) 4.2 (2.1) 4.3 - 
Male household head (n, %) 130 (82.9) 3,064 (75.8) 0.046 
Household members receiving a regular 
salary (mean (SD)) 
1.2 (0.5) -  - 
Usual place for cooking (n, %) 
- In a separate building 
- Outdoors 
- In the house  
 
- 14 (8.9) 
- 64 (40.8) 
- 79 (50.3) 
 
- 918 (22.7) 
- 1997 (49.4) 
- 1123 (27.8) 
<0.001 
Usual cooking fuel (n, %) 
- Electricity 
- Kerosene 
- Coal or lignite 
- Charcoal  
- Wood 
- No foods cooked 
 
- 8 (5.1) 
- 0 (0) 
- 0 (0) 
- 139 (88.5) 
- 10 (6.4) 
- 0 (0) 
 
- 481 (11.9) 
- 81 (0.2) 
- 40 (0.1) 
- 2603 (64.4) 
- 930 (23) 
- 81 (0.2) 
<0.001 
 
Electricity at home (n, %) 80 (51.0) 1968 (48.7) 0.577 
Shared toilet facility (n, %) 102 (65.0)  2061 (51) <0.001 
Car owned by household (n, %) 5 (3.2) 525 (13) <0.001 
Motorbike owned by household (n, %) 2 (1.3)  117 (2.9) 0.326 
Bicycle owned by household (n, %) 29 (18.5) 1196 (29.6) 0.003 
Table 3.12: Household characteristics of study cohort compared to urban Malawian households 
* compared by chi-squared or Fisher’s exact test. 
 
Study participants attained lower levels of education compared to urban Malawian adults (p<0.001), 
and were more likely to be currently unemployed (p<0.001). Most male participants were usually 
employed in unskilled manual work, and female participants in domestic service. Literacy rates were 
higher in male than in female participants, with more men able to read a newspaper (112/120, 
93.3% vs. 32/37, 86.5%; p<0.001). Food insecurity was relatively common in the cohort, with 18/37 
(48.6%) female participants reporting skipped meals in the preceding 2 weeks for there to be enough 
food for their children, compared to 26/120 (21.7%; p<0.001) in males. A history of ever smoking 
was also commoner in the study cohort than the general population, with 66/120 (55%) of men 
giving a history of smoking. 
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Characteristic Study cohort Urban Malawian adults  p value * 
Male  n=120 n=1,340 [421, 422]  
Literacy (n, %) 
- not at all literate 
- part sentence literacy 
- whole sentence literacy 
- secondary school or higher literacy 
 
- 4 (3.3) 
- 7 (5.8) 
- 67 (55.8) 
- 42 (35.0) 
 
- 52 (3.9) 
- 75 (5.6) 
- 977 (72.9) 
- 236 (17.6) 
<0.001 
 
Able to read a newspaper (n, %) 112 (93.3) - - 
Highest level of education (n, %) 
- never attended school 
- standards 1 to 4 
- standards 5 to 8 
- forms 1 or 2 
- forms 3 or 4 
- university or higher 
 
- 2 (1.7) 
- 12 (10.0) 
- 31 (25.8) 
- 26 (21.7) 
- 43 (35.8) 
- 6 (5.0) 
 
- 28 (2.1) 
- 284 (21.2) 
- 91 (6.8) 
- 395 (29.5) 
- 307 (22.9) 
- 236 (17.6) 
<0.001 
Current employment status (n, %) 
- currently employed 
- not currently employed 
- not employed in the 12 months  
preceding the survey 
 
- 65 (54.2) 
- 53 (44.2) 
- 2 (1.7) 
 
- 976 (72.8) 
- 60 (4.5) 
- 306 (22.8) 
<0.001 
 
Usual occupation (n, %) 
- agriculture work 
- clerical work 
- sales and services work 
- professional or technical 
or managerial work 
- skilled manual work 
- unskilled manual work 
- domestic service 
 
- 0 (0.0) 
- 2 (1.7) 
- 15 (12.5) 
- 19 (15.8) 
 
- 16 (13.3) 
- 60 (50.0) 
- 8 (6.7) 
 
- 67 (6.5) 
- 61 (5.9) 
- 155 (15) 
- 214 (20.7) 
 
- 321 (31) 
- 179 (17.3) 
- 36 (3.5) 
<0.001 
Ever smokes tobacco (n, %) 66 (55.0) 159 (11.9) <0.001 
Ever drinks alcohol (n, %) 85 (70.8) - - 
Married (n, %) 64 (53.3) 3,742 (52.5) † 0.856 
Female  n=37 n=4,496 [421, 422]  
Literacy (n, %) 
- not at all literate 
- part sentence literacy 
- whole sentence literacy 
- secondary school or higher literacy 
 
- 5 (13.5) 
- 4 (10.8) 
- 21 (56.8) 
- 7 (18.9) 
 
- 432 (9.6) 
- 261 (5.8) 
- 3,251 (72.3) 
- 553 (12.3) 
0.120 
 
Able to read a newspaper (n, %) 32 (86.5) - - 
Highest level of education (n, %) 
- never attended school 
- standards 1 to 4 
- standards 5 to 8 
- forms 1 or 2 
- forms 3 or 4 
- university or higher 
 
- 3 (8.1) 
- 4 (10.8) 
- 17 (45.9) 
- 6 (16.2) 
- 7 (18.9) 
- 0 (0.0) 
 
- 153 (3.4) 
- 1,232 (27.4) 
- 441 (9.8) 
- 1,272 (28.3) 
- 850 (18.9) 
- 553 (12.3) 
<0.001 
Current employment status (n, %) 
- currently employed 
- not currently employed 
- not employed in the 12 months  
preceding the survey 
 
- 13 (35.1) 
- 22 (59.5) 
- 2 (5.4) 
 
- 2,405 (53.5) 
- 243 (5.4) 
- 1,852 (41.2) 
<0.001 
Usual occupation (n, %) 
- agriculture work 
- clerical work 
- sales and services work 
- professional or technical 
or managerial work 
- skilled manual work 
- unskilled manual work 
- domestic service 
 
- 0 (0.0) 
- 1 (2.7) 
- 3 (8.1) 
- 3 (8.1) 
 
- 0 (0.0) 
- 10 (27.0) 
- 20 (54.1) 
 
- 235 (8.9) 
- 156 (5.9) 
- 680 (25.7) 
- 696 (26.3) 
 
- 98 (3.7) 
- 550 (20.8) 
- 230 (8.7) 
<0.001 
Ever smokes tobacco (n, %) 2 (5.4) 4 (0.1) <0.001 
Ever drinks alcohol (n, %) 6 (16.2) - - 
Married (n, %) 22 (59.5) 15,155 (61.7) ‡ 0.912 
Table 3.13: Individual participant socio-economic characteristics compared to urban Malawian adults 
* compared by chi-squared or Fisher’s exact test. † denominator 7,128 men. ‡ denominator 24,562 women. 
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Relative wealth was assessed using a simplified socioeconomic / poverty score based on data from 
the 1998 Integrated Health Survey [468]. While slightly dated, this provides a helpful indication of 
relative wealth, and allows the construction of wealth quintiles. Using 8 variables (household owns a 
fridge, number of household residents, household size squared, age of household head, education 
level of the household head, number of salaried household members, household owns a car or 
motorbike, household gets lighting from electricity or gas, household owns a bed, and an indicator 
for Blantyre city), relative wealth can be calculated. The histogram in Figure 3.3 shows the 
distribution of relative wealth quintiles, and their modest correlation with participants self-reported 
wealth. Participants graded their wealth levels relative to their neighbours using a simple Likert-type 
scale. 
 
  
Figure 3.3. Relative wealth 
A: Histogram of participants relative wealth score; B: Boxplot of self-reported wealth versus relative wealth 
score. Diamonds represent mean, bar median. 
 
In summary, the study population was poorer, less educated, and more likely to be unemployed than 
the general urban Malawian population. They were more likely to be exposed to biomass fuel smoke 
at home, and reported higher rates of ever smoking. 
 
3.4.4 Clinical description 
 
At the baseline visit, study participants underwent a comprehensive clinical review. Details of the 
current illness and past medical history were captured, and participants were examined by a study 
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clinician. Observations were recorded, and blood samples processed for baseline full blood count, 
renal and liver function tests. These results are summarised in Table 3.14, stratified by HIV status. 
 
Characteristic HIV-uninfected 
participants (n=66) 
HIV-infected 
participants (n=91) 
p value * 
Clinical history 
Cough (n, %) 65 (98.5) 91 (100) 0.871 
Fever (n, %) 35 (53.0) 54 (59.3) 0.532 
Weight loss (n, %) 58 (87.9) 84 (92.3) 0.511 
Night sweats (n, %) 42 (63.6) 67 (73.6) 0.244 
Duration of illness in weeks (median [IQR]) 4 [3, 8] 4 [3, 8] 0.736 
Haemoptysis (n, %) 14 (21.5) 10 (11.0) 0.115 
Lymphadenopathy (n, %) 1 (1.5) 3 (3.3) 0.852 
Prior antibiotic treatment (n, %) 35 (53.0) 53 (58.2) 0.627 
Visited traditional healer (n, %) 9 (13.6) 8 (8.8) 0.481 
Hospitalised for this illness (n, %) 6 (9.1) 11 (12.1) 0.737 
Vital signs at baseline 
Pulse in beats per minute (mean (SD)) 97 (21) 108 (19) 0.001 
Respiratory rate in breaths per minute  
(median [IQR]) 
21 [18, 23] 21 [17, 24] 0.360 
Temperature in oC (median [IQR]) 36.2 [36.2, 36.3] 36.2 [36.1, 36.4] 0.688 
Oxygen saturations in % (median [IQR]) 98 [96, 98] 98 [97, 99] 0.261 
Systolic blood pressure in mmHg  
(median [IQR]) 
113 [100, 125] 106 [96, 116] 0.025 
Clinically septic at baseline (n, %) † 9 (13.6) 10 (11.0) 0.799 
WHO Performance Status (n, %) 
- 0: fully active 
- 1: able to perform light work 
- 2: self-caring, but no work 
- 3: limited self-care 
 
- 62 (93.9) 
- 4 (6.1) 
- 0 (0) 
- 0 (0) 
 
- 78 (85.7) 
- 10 (11.0) 
- 2 (2.2) 
- 1 (1.1) 
0.257 
Laboratory investigations at baseline 
Haemoglobin in g/dl (median [IQR]) 12.1 [10.6, 13.6] 10.6 [9.6, 12.1] <0.001 
White cell count x 103/µl (median [IQR]) 6.9 [5.9, 8.6] 6.5 [4.9, 8.5] 0.213 
Platelet count x 103/µl (median [IQR]) 445 [309, 575] 430 [276, 560] 0.943 
Monocyte-lymphocyte ratio (median [IQR]) 0.2 [0.1, 0.4] 0.4 [0.2, 0.6] 0.001 
Creatinine clearance in ml/min (median [IQR]) 114.7 [93.3, 138.4] 101.1 [83.6, 121.7] 0.008 
Bilirubin in µmol/l (median [IQR]) 10 [7, 14] 7 [6, 11] 0.002 
ALT in IU/l (median [IQR]) 18 [13, 26] 24 [16, 36] 0.02 
Table 3.14: Baseline clinical description of study participants 
* compared by chi-squared or Fisher’s exact test. † Based on source of infection, and 2 or more of: temperature 
<36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 breaths per minute, white cell count <4 or >12 x 
103/µl. 
 
The median duration of illness was 4 weeks, and was similar in both HIV-infected and uninfected 
participants. Over half of the participants had received prior antibiotic therapy during the diagnostic 
pathway. Six participants reported co-existing illnesses (other than HIV): 3 were on treatment for 
asthma, 1 for hypertension, 1 for peripheral neuropathy, and 1 on phenobarbitone for epilepsy. 
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At baseline review, HIV-infected participants were more tachycardic (mean pulse 108 vs. 97 bpm; 
p=0.001), and had a lower systolic blood pressure (median 106 vs. 113 mmHg; p=0.025). 19/157 
(12.1%) participants were clinically septic at baseline, based on the 1992 Consensus Conference 
definitions [469]. The definition of sepsis changed in 2016 to include the Sequential Organ Failure 
Assessment (SOFA) score [470], but as some of these variables were not captured in this study, 
sepsis is defined by the earlier guidelines.  
Baseline laboratory investigations showed that HIV-infected participants were more anaemic 
(median haemoglobin 10.6 vs. 12.1 g/dl; p<0.001), had poorer renal function (median creatinine 
clearance 101.1 vs 114.7 ml/min; p=0.008), and had a higher ALT (median 24 vs. 18 IU/l; p=0.002). 
Anaemia is a common feature of both HIV infection [471] and HIV-associated TB [472], and was more 
severe in the HIV-infected participants. A baseline haemoglobin less than 8 g/dl (severe anaemia) 
was an exclusion criterion for the study, and resulted in 10 patients being excluded from the study.  
The peripheral blood monocyte-lymphocyte ratio (ML ratio) has been postulated as a biomarker of 
immunity to TB disease and response to treatment, with an increased ML ratio associated with risk 
of TB disease or death [473-476]. The mechanism for this association is incompletely understood, 
but may reflect that myeloid cells serve as host cells for Mtb growth, while lymphocytes are major 
effector cells in TB immunity. HIV-infected participants have a higher baseline ML ratio than 
uninfected participants (0.4 vs. 0.2; p=0.001), but further samples were not collected to assess 
trends over treatment.  
Participants were asked to rate their health at each visit using a Likert-type scale: from excellent to 
poor (Figure 3.4). In general, more participants reported ‘good’ health as they completed treatment 
and follow-up, with no participants reporting ‘excellent’ health. 
 
 
Figure 3.4: Participant rating of health 
Participants were asked to rate their health on a Likert-type scale over the course of treatment and follow-up.  
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3.4.4.1 Treatment adherence 
Participants were asked about adherence to treatment at each study visit. 17 participants (10.8%) 
reported 1-2 missed doses, and 5 participants (3.2%) reported >=3 missed doses. Pill counts were 
performed at PK visits demonstrating good adherence to treatment. 
 
3.4.4.2 Co-administered medications 
87/157 (55.4%) participants took antimicrobials prior to the TB diagnosis as part of this illness 
episode. These antimicrobials are detailed below (Table 3.15). Amoxycillin, erythromycin, and 
doxycycline are recommended treatments for community acquired pneumonia in Malawi [477], 
whereas the variety of other antimicrobials prescribed may reflect diagnostic uncertainty or issues of 
drug availability. The use of fluoroquinolones in TB suspects should be avoided due to anti-Mtb 
activity and risk of diagnostic delay [478].  
Outside of TB treatment and ART, 3 (1.9%) participants were prescribed ferrous sulphate for 
anaemia, 1 (0.6%) phenobarbitone for epilepsy, 1 (0.6%) salbutamol for asthma, and 1 (0.6%) 
aminophylline for asthma. 
Antimicrobial n (%) 
Any 87 (55.4) 
Amoxicillin 45 (28.7) 
Cotrimoxazole 14 (8.9) 
Erythromycin  9 (5.7) 
Ciprofloxacin 9 (5.7) 
Metronidazole  6 (3.8) 
Doxycycline 5 (3.2) 
Ceftriaxone 4 (2.5) 
Fluconazole  3 (1.9) 
Penicillin 2 (1.3) 
Chloramphenicol 1 (0.6) 
 
 
3.4.5 Baseline radiology 
 
Baseline CXRs were available for 156/157 participants. These were assessed by 2 independent 
readers, and scored according to the method described by Ralph et al [459]. 
 
3.4.5.1 Inter-reader agreement 
The concordance correlation coefficient for percentage of affected lung was 0.79 (-13.51 – 21.01% 
Bland and Altman 95% limits of agreement), suggesting reasonable inter-reader agreement. Table 
Table 3.15: Pre-treatment antimicrobials 
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3.16 shows the inter-reader agreement for radiological dichotomous variables. Agreement was 
‘substantial’ or ‘almost perfect’ for most variables, except for the presence of nodules or hilar 
lymphadenopathy. 
 
Dichotomous variable Kappa Prevalence-adjusted, bias-
adjusted kappa (PABAK) 
Interpretation of PABAK 
score 
Cavitation 0.70 0.74 Substantial 
Effusion 0.64 0.74 Substantial 
Consolidation 0.80 0.86 Almost perfect 
Nodules  0.27 0.65 Substantial 
Fibrosis 0.29 0.42 Moderate 
Miliary disease - 1.00 Almost perfect 
Hilar lymphadenopathy 0.07 0.58 Moderate 
Table 3.16: Inter-reader agreement on radiological findings 
Landis and Koch guidelines used to interpret kappa values for dichotomous variables [463] (kappa ≤ 0.00, poor; 
0.00-0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; 0.81-1.00, almost perfect). 
 
A composite CXR score was calculated from the percentage of lung affected and the presence or 
absence of cavitation (maximum score 140) [459]. The median score in this cohort was 18.3 [IQR 2.5 
– 60.0]. Table 3.17 describes the radiological findings in the cohort. Consolidation was the 
commonest CXR abnormality, seen in 77.6%, with cavitation seen on 35.8% of CXRs. There were no 
significant differences in the radiological findings when stratified by HIV status. Figure 3.5 shows a 
sample of some of the CXRs with their scores. 
Both CXR score and cavitatory disease were related to baseline smear status, with those with 3+ for 
AFB at baseline more likely to have a higher CXR score and cavitation on CXR than smear-negative 
participants (p< 0.001). Participants with higher CXR scores had higher baseline bacillary loads 
(shorter TTP in liquid culture, p=0.001), and were less likely to culture convert by 2 months 
(p<0.001). Similarly, participants with cavitation on CXR were less likely to culture convert by 2 
months (p<0.001). 
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3.4.5.2 Description of baseline radiology 
 
Figure 3.5: Example baseline chest X-rays 
A: normal CXR (score 0); B: CXR showing extensive consolidation in the left hemithorax, a small effusion, and 
cavitation of the left upper zone. Scored 107 (67% affected lung + 40 for cavitation); C: Patchy consolidation of 
the left hemithorax and right upper zone, with large cavities in the left upper and mid zones. Scored 106 (66% 
affected lung + 40 for cavitation); D: extensive patchy consolidation of both lung fields, no cavitation. Scored 82 
for percentage of lung affected. 
 
CXR variable Total (n=156) 
CXR score (median [IQR]) 18.3 [2.5, 60.0] 
Percentage of lung affected (median [IQR]) 15.4 [2.5, 23.3] 
Cavitation (n, %) 56 (35.8) 
Effusions (n, %) 45 (28.8) 
Consolidation (n, %) 121 (77.6) 
Nodules (n, %) 19 (12.4) 
Fibrosis (n, %) 43 (27.6) 
Miliary disease (n, %) 0 (0) 
Hilar lymphadenopathy (n, %) 14 (11.1) 
Table 3.17: CXR findings in the study cohort 
CXR score derived from the percentage of lung affected with 40 added for the presence of cavitation [459]. 
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Figure 3.6: CXR score by diagnostic smear grade 
CXR score was greater in participants with heavily smear-positive diagnostic sputum samples. Bars show mean 
with standard error bars. 
 
3.4.5.3 Predictors of baseline radiology 
Predictors of CXR score were explored by univariate and multivariate linear regression (Table 3.18). 
Higher neutrophil count and longer duration of symptoms were both associated with a higher 
baseline CXR score. Taken together, these data suggest that CXR appearances are worse in those 
taking longer to be diagnosed with TB, with more active inflammation. 
CXR score and cavitation were closely linked. Cavitation was also associated with current 
unemployment (p=0.033) on multivariate analysis (data not shown).  
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Variable Univariate analysis Multivariate analysis 
Estimate SE p value Estimate SE p value 
Age (years) -0.637 2.376 0.789 - - - 
Male sex 3.929 5.570 0.482 - - - 
Duration of symptoms 
(weeks) 4.028 2.365 0.091 6.228 2.759 0.026 
Prior antibiotic use -2.089 4.775 0.662 - - - 
Hospitalised  8.487 7.792 0.278 - - - 
Ever smokes tobacco 3.516 4.777 0.463 - - - 
Ever drinks alcohol 6.206 4.787 0.197 - - - 
Whole sentence literacy or 
greater 1.120 7.097 0.875 - - - 
Currently unemployed 15.524 4.579 0.001 10.912 5.521 0.051 
HIV infected -6.509 4.774 0.175 - - - 
Baseline CD4 (cells/mm3) 1.924 2.381 0.420 - - - 
Change in CD4 over 
treatment (cells/mm3) -0.189 2.548 0.941 - - - 
BMI (kg/m2) -9.662 2.242 0.000 -4.587 3.138 0.147 
Change in weight over 
treatment in kg 8.310 2.418 0.001 3.899 3.184 0.224 
Baseline pulse (bpm) 4.612 2.353 0.052 -0.824 2.797 0.769 
Baseline respiratory rate 
(bpm) 5.050 2.339 0.032 -2.72 3.315 0.414 
Clinically septic at baseline* 5.368 7.243 0.460 - - - 
Baseline haemoglobin 
(g/dl) -7.495 2.296 0.001 -3.143 3.633 0.389 
Baseline white cell count 
(x103/μl) 13.448 2.126 0.000 - - - 
Baseline neutrophil count 
(x103/μl) 13.186 2.158 0.000 7.028 3.453 0.045 
Baseline monocyte count 
(x103/μl) 5.983 2.324 0.011 -3.603 3.541 0.312 
Baseline creatinine 
clearance (ml/min) 1.753 2.372 0.461 - - - 
Baseline bilirubin (μmol/l) 1.356 2.371 0.568 - - - 
Baseline ALT (IU/l) -4.265 2.355 0.072 -1.33 2.794 0.635 
Screening TTP (days) -6.333 2.317 0.007 -2.261 3.145 0.474 
Table 3.18: Univariate and multivariate analysis of factors influencing baseline CXR score 
Variables significant to p<0.10 on univariate testing included in the multivariate analysis. * Based on source of 
infection, and 2 or more of: temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 
breaths per minute, white cell count <4 or >12 x 103/µl. SE: standard error. 
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3.5 Results: predictors of treatment outcome 
3.5.1 Two-month culture conversion 
 
The relationship between 2MCC and clinical, socioeconomic, and radiological predictors is described 
in Table 3.19. On multivariate logistic regression, CXR score, baseline bacillary load (screening TTP), 
and literacy were all related to odds of 2MCC. Duration of symptoms had a univariate relationship 
only. 
 
Variable Univariate analysis Multivariate analysis 
OR 95% CI p value OR 95% CI p value 
Age (years) 0.92 0.62-1.36 0.663 - - - 
Male sex 0.75 0.30-1.79 0.523 - - - 
Duration of symptoms (weeks) 0.61 0.40-0.91 0.017 0.67 0.4-1.09 0.115 
Prior antibiotic use 1.15 0.55-2.39 0.714 - - - 
Hospitalised  1.56 0.49-5.96 0.476 - - - 
Ever smokes tobacco 0.59 0.28-1.22 0.153 - - - 
Ever drinks alcohol 0.64 0.30-1.34 0.243 - - - 
Whole sentence literacy or greater 0.18 0.03-0.66 0.025 0.13 0.02-0.56 0.015 
Currently unemployed 0.63 0.30-1.3 0.214 - - - 
HIV infected 1.67 0.81-3.48 0.168 - - - 
Baseline CD4 (cells/mm3) 0.80 0.55-1.17 0.250 - - - 
Change in CD4 over treatment (cells/mm3) 0.99 0.66-1.5 0.966 - - - 
BMI (kg/m2) 1.28 0.85-2.02 0.260 - - - 
Change in weight over treatment in kg 0.94 0.63-1.41 0.774 - - - 
Baseline pulse (bpm) 1.06 0.73-1.56 0.756 - - - 
Baseline respiratory rate (bpm) 1.49 0.99-2.31 0.063 1.57 0.94-2.74 0.094 
Clinically septic at baseline* 4.43 1.15-29.22 0.057 6.07 1.16-49.33 0.051 
Baseline haemoglobin (g/dl) 1.02 0.69-1.51 0.934 - - - 
Baseline white cell count (x103/μl) 0.81 0.55-1.18 0.276 - - - 
Baseline neutrophil count (x103/μl) 0.79 0.53-1.15 0.224 - - - 
Baseline monocyte count (x103/μl) 1.23 0.82-1.97 0.352 - - - 
Screening TTP (days) 1.93 1.19-3.48 0.016 1.88 1.07-3.73 0.046 
CXR score 0.44 0.29-0.65 <0.001 0.46 0.27-0.76 0.004 
No cavitation on CXR 3.65 1.71-7.98 0.001 - - - 
Table 3.19: Univariate and multivariate analysis of factors influencing 2-month culture conversion 
Variables significant to p<0.10 on univariate testing included in the multivariate analysis. * Based on source of 
infection, and 2 or more of: temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 
breaths per minute, white cell count <4 or >12 x 103/µl.CI: confidence interval; OR: odds ratio. 
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3.5.2 Final treatment outcome 
 
2-month culture conversion status was not predictive of final outcome (OR: 0.6; 95% CI 0.1-2.4; 
p=0.500; Table 3.20). On univariate analysis, respiratory rate and change in weight on treatment 
were associated with final outcome. After multivariate modelling, only those with greater weight 
gain on treatment were more likely to have a favourable final outcome (OR 4.03; 95% CI: 1.60-12.71; 
p=0.007). 
 
Variable Univariate analysis Multivariate analysis 
OR 95% CI p value OR 95% CI p value 
Age (years) 
0.66 0.39-1.11 0.111 - - - 
Male sex 
1.50 0.38-5.01 0.523 - - - 
Duration of symptoms (weeks) 
1.36 0.74-3.00 0.372 - - - 
Prior antibiotic use 
0.83 0.24-2.60 0.759 - - - 
Ever smokes tobacco 
1.89 0.59-7.25 0.310 - - - 
Ever drinks alcohol 
1.22 0.39-3.82 0.725 - - - 
Whole sentence literacy or greater 
1.12 0.16-4.73 0.894 - - - 
Currently unemployed 
0.96 0.31-3.00 0.944 - - - 
HIV infected 
0.35 0.08-1.19 0.121 - - - 
Baseline CD4 (cells/mm3) 
1.04 0.58-2.00 0.900 - - - 
Change in CD4 over treatment 
(cells/mm3) 0.54 0.27-1.05 0.062 - - - 
BMI (kg/m2) 
1.64 0.78-3.84 0.226 - - - 
Change in weight over treatment in kg 
3.37 1.52-8.87 0.005 4.03 1.6-12.71 0.007 
Baseline pulse (bpm) 
0.67 0.40-1.14 0.141 - - - 
Baseline respiratory rate (bpm) 
0.58 0.33-0.95 0.033 2.04 0.59-8.87 0.291 
Clinically septic at baseline* 
0.98 0.16-19.05 0.984 - - - 
Baseline haemoglobin (g/dl) 
1.30 0.73-2.49 0.395 - - - 
Baseline white cell count (x103/μl) 
0.78 0.44-1.41 0.387 - - - 
Baseline neutrophil count (x103/μl) 
0.74 0.41-1.38 0.332 - - - 
Baseline monocyte count (x103/μl) 
0.78 0.50-1.32 0.287 - - - 
Screening TTP (days) 
0.74 0.43-1.32 0.259 - - - 
2MCC  
0.61 0.13-2.37 0.500 - - - 
CXR score 
0.76 0.44-1.33 0.320 - - - 
No cavitation on CXR 
1.46 0.45-4.53 0.517 - - - 
Table 3.20: Univariate and multivariate analysis of factors influencing final outcome 
Variables significant to p<0.10 on univariate testing included in the multivariate analysis. * Based on source of 
infection, and 2 or more of: temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 
breaths per minute, white cell count <4 or >12 x 103/µl.CI: confidence interval; OR: odds ratio. 
  
Chapter 3  Clinical study description 
 
 
  Page 97 
3.6 Discussion 
 
This was a challenging study to run, involving recruitment from multiple sites, invasive investigations, 
and up to 12 study visits per participant. 86.6% of eligible participants remained in follow-up until 
the end of the intensive phase of TB treatment, 82.8% completed TB treatment in the study, and 
70.1% (to date) continued in follow up to 18 months. Very few participants were lost to follow up, 
with more transferring out of Blantyre, declining further follow-up, or dying. 51 participants 
attended for research bronchoscopy 2 months into treatment, with 41 willing to return for a second 
bronchoscopy 2 months later, testament to the careful communication and experience of the Clinical 
Investigation Unit. This agreed with earlier qualitative work exploring the acceptability of 
bronchoscopy as a research tool in Malawi [479, 480].  
Study recruitment was initially slower than anticipated given the decentralisation of TB care to 
peripheral health centres, requiring an early protocol amendment. The requirement for newly-
diagnosed patients to travel to QECH resulted in some patients having taken 1 or 2 doses of 
treatment prior to screening and first sputum collection. Furthermore, ongoing power shortages in 
Malawi during the study prevented many peripheral health centres from performing light 
microscopy on site, and instead sending samples centrally for Xpert MTB/RIF analysis. As a result, 
several patients with lower bacillary loads (by TTP) and smear-negative screening samples entered 
the study. Only those ultimately microbiologically-confirmed (by culture or Xpert MTB/RIF) remained 
in the study. 
The study cohort was predominantly male, in keeping with global trends [17, 481] and previous 
reports from Malawi [89]. Female patients were more likely to decline involvement at screening, but 
their explanations for withholding consent were not systematically captured. HIV was less common 
in the Intrapulmonary Arm, likely because of early mortality. This will not alter the conclusions of the 
PK-PD study as HIV status is entered as a covariate into the models, and the 2 arms of the study are 
not used as comparators.  
HIV co-infection rates exceeded 50% in the cohort, illustrating the central place of the HIV epidemic 
in driving TB incidence in Malawi. In 2016, Malawi adopted universal ART eligibility regardless of CD4 
count [445]. While virtually all participants reported a previous HIV test, this typically took place as 
part of the TB diagnostic pathway: nearly 60% learnt of their HIV diagnosis during this illness. Female 
participants were more likely to be aware of their HIV status before TB diagnosis, potentially 
reflecting differences in health-seeking behaviour and provision of PITC as part of maternity services 
[481-484]. Despite increased availability of ART, immunosuppression-related illnesses such as TB will 
prompt HIV testing, and the NTP will remain an important gateway to HIV treatment.  
CD4 count in TB/HIV co-infected patients generally improved with time on ART, although those 
participants taking ART for greater than 4 years had a significantly lower CD4 count than HIV-
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uninfected participants (p<0.001). This raises the possibility of ART failure in this subset of co-
infected patients, but we did not capture viral loads in the cohort. Risk of virological failure increases 
over time on ART [485, 486], and may be a risk factor for TB in those established on ART [487, 488].     
Participants were generally in poor health at recruitment. Most reported 3 out of 4 TB symptoms on 
the WHO TB screening tool [44], and many had symptoms for up to 8 weeks prior to diagnosis. Over 
half the participants had received prior-antibiotics during care-seeking for this illness. 12.1% 
participants were clinically septic at baseline, based on the 1992 Consensus Conference definitions 
[469]. HIV-infected participants were more tachycardic, had a lower baseline systolic blood pressure, 
and were more likely to have renal impairment and a lower haemoglobin at recruitment. Participants 
described only gradual improvement on treatment, with very few reporting ‘good’ or ‘excellent’ 
health by 6 months. 
CXR score and the presence of cavitation were significantly associated with baseline sputum smear 
grade, baseline bacillary load, and white cell count, but not HIV status. Both CXR score and cavitation 
were associated with the likelihood of culture-conversion at 2 months, in agreement with previous 
reports [455, 456, 459]. Furthermore, cavitation on the baseline CXR is associated with increased risk 
of relapse [34, 489], and may approach 20% in those with both baseline cavitation and 2-month 
sputum positivity [489, 490]. As a result of increased risk of poor outcome, the American Thoracic 
Society recommends prolongation of the continuation phase of treatment for a further 3 months in 
those with cavitatory disease at baseline and positive cultures at 2 months [491], but this is not 
advised in the Malawian guidelines [105]. 
In comparison to the typical urban Malawian in the DHS/IHS, study participants were poorer, more 
likely to be unemployed, and experience a degree of food insecurity. Study participants were 
recruited from multiple sites around urban Blantyre, but the majority were recruited from health 
centres in unplanned urban settlements, and likely represent a more impoverished group than the 
general urban Malawi population.  
At 62.7%, rates of culture conversion by 2 months were relatively low in this cohort. Previous studies 
have reported culture conversion in the region of 50-90% for DS-TB with RHZE, with lower rates seen 
in high-burden African settings [15, 58-60, 66, 89, 492-494]. Lower rates of 2MCC in this cohort may 
reflect use of more sensitive liquid MGIT culture techniques [495, 496], high rates of HIV co-infection 
[497, 498], and high rates of heavy smear-positivity at baseline. Despite accepting patients with any 
degree of smear-positivity or Xpert MTB/RIF confirmation, the cohort contained a high proportion of 
patients with 2+ or 3+ AFB positivity (60.5%), who were less likely to culture convert by 2 months. 
Furthermore, as a fraction of participants will have taken one or two doses of treatment before 
attending their screening visits at QECH, those patients with low bacillary loads may already be 
sputum culture negative by the time of their screening sample, removing a proportion of early 
converters from the analysis.  
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2MCC was not predictive of final outcome in this cohort. This endpoint is known to only have a 
modest correlation with late outcomes [66, 75, 76], and 3 month culture conversion may be more 
useful in this setting [66]. On multivariate analysis, only those that had greater weight gain on 
treatment were more likely to have a favourable outcome. Recurrent TB infection was diagnosed in 
3.2% of participants, in keeping with the 3% seen in the early DS-TB trials [12-15]. While 
spoligotyping has not been carried out in this cohort, the fact that most of these recurrences 
occurred in the first 6 months after treatment completion would suggest that these are more likely 
to be relapses. However, given that half of these recurrent cases were HIV-infected, re-infection may 
be contributing to these poor outcomes [30, 33, 499]. 
In conclusion, these data offer a detailed description of a cohort of adult patients with drug-sensitive 
PTB in Malawi. In general, these patients are young, relatively impoverished, with high rates of HIV 
co-infection. While rates of 2-month culture conversion are low, this is not associated with higher 
rates of unfavourable outcome to 18 months of follow up. Those with cavitation on CXR have higher 
bacillary loads, and poorer odds for culture conversion, and may be important targets for 
transmission reduction strategies. Ultimately, factors other than the clinical and socioeconomic 
variables described here may be implicated in treatment outcome: the following chapters will 
explore pharmacokinetic, pharmacodynamic, and immunological predictors of response. 
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4 Plasma pharmacokinetics 
4.1 Introduction 
 
Pharmacokinetic data is essential to understanding TB treatment response. The first-line TB regimen 
was introduced before population PK analysis and modern PK-PD science became an established part 
of the drug development pathway, and consequently the relationships between TB drug exposure 
and treatment response are incompletely understood. With emerging evidence that increased doses 
of rifampicin [500] and pyrazinamide [261] are associated with improved anti-mycobacterial activity, 
the case for dose refinement is strengthening.  
Existing plasma PK data has shown high variability in TB drug exposure despite weight-based dosing 
[131, 159, 164, 167, 168, 201]. Explanations for this variability have included genetics [146, 148, 
201], HIV co-infection [155, 324], diabetes mellitus [325, 501, 502], and drug formulation [503-505], 
but findings have been inconsistent and insufficient to support individual TDM in selected 
populations particularly in highly-endemic settings. While TB is not primarily a bloodstream 
infection, plasma samples are accessible and acceptable, and enable rich sampling strategies to 
explore drug exposure and response.  
Population PK modelling is a powerful technique that enables description of the time-course of drug 
concentration in the body, the relationship between drug concentration and effect, and exploration 
of important sources of variability in the population. From sparse samples in diverse patient 
populations, it is possible to generate summary measures of drug exposure, inter- and intra-
individual variability and measurement error, and estimated individual-level PK parameters. Table 
4.1 summarises the existing population PK studies looking at first-line anti-tuberculosis agents. 
Rifampicin has been most-extensively assessed, and most regional data generated in South African 
populations.  
This chapter describes population PK models of RHZE in a Malawian cohort of adult pulmonary TB 
patients under programmatic conditions. Important covariates that may explain variability (HIV 
status, sex, weight, etc.) are explored, and individual steady state plasma PK parameters (AUC and 
Cmax) generated for subsequent PK-PD analysis. 
 
Table 4.1: Summary of existing RHZE plasma population PK models 
Table restricted to those using mixed-effects modelling approaches. Dur: duration; FOCE-I: first-order conditional 
estimation method with ε-η interaction; ITSB: iterative two-stage Bayesian procedure; LBM: lean body mass; 
LPV/r: boosted lopinavir; MMT: absorption mean transit time; NN: number of transit compartments; NPAG: Non-
Parametric Adaptive Grid algorithm; Q: intercompartmental clearance; TBM: TB meningitis; RV: residual 
variability; VC: central compartment; VP: peripheral compartment. 
  
Drug Author, year 
and site  
Participants (n) Model Significant 
covariates 
Population PK indices 
CL/F (l/h) V/F (l) ka (h-1) Other 
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Török, 2017, 
Vietnam [506] 
Adult patients, HIV-infected, on 
treatment for TBM (n=46) 
NPAG. 1-compartment absorption model - 17.9 53.6 0.92 Lag: 0.52 
Sloan, 2017, 
Malawi [148] 
Adult patients, HIV-infected and 
uninfected, on treatment for PTB (n=174) 
FOCE-I. 1-compartment with transit compartment 
absorption. Proportional RV 
Sex on CL/F and V/F 19.6 
 
23.6 
 
0.28 
 
NN: 1.5 
MTT: 0.326 
Θsexmale: 1.2 
Svensson, 
2017, South 
Africa [507] 
Adult patients, HIV-infected and 
uninfected, on treatment for PTB (n=83). 
RIF at 10, 20, 25, 30, 35, or 40 mg/kg 
daily over 2 weeks 
FOCE-I. 1-compartment with transit compartment 
absorption and enzyme turnover. Dose-dependent 
bioavailability. Additive error on log scale 
Fat-free mass on 
CL/F and V/F 
14.9 l/h/70 kg 
 
87.2 
l/70kg 
 
1.77 
 
NN: 23.8 
MTT: 0.51 
 
Rockwood, 
2016, South 
Africa [508] 
Adult patients, HIV-infected and 
uninfected, on treatment for PTB (n=100) 
FOCE-I. 1-compartment with FO absorption and 
elimination, and absorption lag time. Additive and 
proportional RV 
HIV and LPV/r status 
on CL/F 
HIV -: 25.1 
HIV + not on 
LPV/r: 19.9 
HIV + on LPV/r: 
10.8 
 
56.4 
 
1.21 
 
Lag: 0.69 h 
Schipani, 
2016, Malawi 
[322] 
Adult (n=115) and paediatric (n=50) 
patients on treatment for TB  
FOCE-I. 1-compartment with FO absorption and 
elimination. Proportional RV 
Weight and age on 
CL/F 
23.9 
 
 44.6 
 
0.24 - 
Jing, 2016, 
China [509] 
Adult patients on treatment for PTB 
(n=54) 
FOCE-I. 1-compartment with FO absorption and 
elimination 
- 4.02  
 
 57.8 
 
1.61 - 
Chang, 2015, 
Korea [510] 
Adult patients, with or without diabetes 
mellitus, on treatment for TB (n=54) 
FOCE-I. 1-compartment with FO absorption and 
elimination. Additive and proportional RV 
Diabetes on V and ka 
BMI on CL 
6.1  
 
 48 
 
1.31 - 
Denti, 2015, 
South Africa 
[326] 
Pregnant adult females, HIV-uninfected, 
on treatment for PTB (n=33) 
FOCE-I. 1-compartment with transit compartment 
absorption. Additive and proportional RV 
Pregnancy on CL 16.2 
 
 
43.3 
 
1.67 NN: 54.6 
MTT: 1.31 h 
Seng, 2015, 
Singapore 
[174] 
Healthy adults, crossover design: 14 days 
RIF / 14 days RIF + INH 
FOCE-I. 1-compartment with transit compartment 
absorption. Additive RV 
- 10.3 
 
 30.9 
 
2.15 - 
Sturkenboom, 
2015, 
Netherlands 
[276] 
Adult patients on treatment for TB (n=55) ITSB using KinPop. 1-compartment - 15.5 
 
 0.71 l/ 
kg LBM 
 
1.14 - 
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Jeremiah, 
2014, 
Tanzania 
[321] 
Adult patients on treatment for PTB 
(n=100) 
FOCE-I. 1-compartment with transit compartment 
absorption. Additive and proportional RV 
Nutritional 
supplementation on 
MTT and ka 
HIV on bioavailability 
16.5 
 
 55.8 1.77 
 
NN: 27.6 
MTT: 1.50 h 
Chigutsa, 
2013, South 
Africa [146] 
Adult patients on treatment for PTB, 
participating in trial of micronutrients 
(n=75) 
FOCE-I. 1-compartment with transit compartment 
absorption. Additive and proportional RV 
Sex on V and MTT 
SLCO1B1 on F 
11 l/h/70 kg 
 
 50 l/70 
kg 
 
1.1 
 
NN: 19 
MTT: 1.6 h 
Milan-
Segovia, 
2013, Mexico 
[511] 
Adult patients on treatment for TB (n=94) FOCE-I. 1-compartment with FO absorption and 
elimination, and absorption lag time. Proportional RV 
Sex on V and CL 
Drug formulation on 
bioavailability 
8.17 50.1 0.39 - 
Smythe, 2012, 
South Africa 
[142] 
Adult patients on treatment for PTB, 
participating in OFLOTUB study (n=174) 
FOCE-I. 1-compartment with transit compartment 
absorption and enzyme turnover. 
HIV on V/F 10.0 86.7 - NN: 1 
MTT: 0.71 h 
Wilkins, 2008, 
South Africa 
[131] 
Adult patients on treatment for TB 
(n=261) 
FOCE-I. 1-compartment with transit compartment 
absorption. Additive and proportional RV 
Single-dose 
formulation on CL/F 
and MTT 
19.2 53.2 1.15 NN: 7.13 
MTT: 0.42 
IS
O
N
IA
ZI
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Török, 2017, 
Vietnam [506] 
Adult patients, HIV-infected, on 
treatment for TBM (n=46) 
NPAG. 1-compartment absorption model with 
absorption lag time 
- 25.4 93.9 8.1 Lag: 0.2 h 
Rockwood, 
2016, South 
Africa [508] 
Adult patients, HIV-infected and 
uninfected, on treatment for PTB (n=100) 
FOCE-I. 2-compartment with transit compartment 
absorption and first-order elimination. Additive and 
proportional RV 
Fat-free mass on 
CL/F and V/F 
HIV on CL/F 
HIV -: 26.0 
HIV +: 20.0 
VC: 31.9 
VP: 21.4 
1.2 NN: 2.04 
MTT: 0.32 h 
Q: 12.6 
Denti, 2015, 
Tanzania 
[158] 
Adult patients on treatment for PTB 
(n=100) 
FOCE-I. 2-compartment with transit compartment 
absorption. Additive and proportional RV 
NAT2 genotype on 
CL/F 
Slow NAT2: 15.5 
Rapid NAT2: 26.1 
VC: 48.2 
VP: 16.5 
- NN: 2.73 
MTT: 0.92 h 
Q: 16.1 
Seng, 2015, 
Singapore 
[512] 
Healthy adults, single dose (n=33) FOCE-I. 2-compartment with FO absorption. Additive 
error on log scale 
NAT2 derived 
phenotype on CL/F 
25.1 VC: 16.2 
VP: 16.5 
0.6 ΘNAT2inter: 0.5  
ΘNAT2slow: 0.9 
Q: 2.9 
Chigutsa, 
2013, South 
Africa  
Adult patients on treatment for PTB, 
participating in trial of micronutrients 
(n=78) 
FOCE-I. 1-compartment with transit compartment 
absorption, bimodal clearance, and FO elimination. 
Additive error on log scale 
Weight on CL/F and 
V/F 
Fast: 25 l/h/70 kg 
Slow: 13 l/h/70 kg 
126 l/70 
kg 
3.6 NN: 10 
MTT: 0.7 h 
Wilkins, 2011, 
South Africa 
[159] 
Adult patients on treatment for TB 
(n=235) 
FOCE-I. 2-compartment, FO absorption with 
absorption lag time, FO elimination. Additive error 
on log scale 
HIV on CL/F 
Sex on Vc/F 
Fast: 21.6 
Slow: 9.7 
VC: 57.7 
VP: 1730 
1.85 Lag: 0.18 
Q: 3.34 
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Chirehwa, 
2017, South 
Africa 
Adult patients, HIV-infected, on 
treatment for PTB (n=61) 
FOCE-I. 1-compartment with transit compartment 
absorption and first-order elimination. Additive and 
proportional RV 
Fat-free mass on 
CL/F and V/F 
 
3.83 (day 29) 43.2 3.54 NN: 28 
MTT: 0.54 h 
Török, 2017, 
Vietnam [506] 
Adult patients, HIV-infected, on 
treatment for TBM (n=46) 
NPAG. 1-compartment absorption model - 2.6 48.5 2.7 - 
Alsultan, 
2017, South 
Africa, 
Uganda, USA 
[513] 
Adult patients on treatment for TB (n=72) 1-compartment model with FO absorption and 
elimination. Additive and proportional model 
Sex on V/F 
Weight on CL/F and 
V/F 
4.44 44.9 3.63  
Chirehwa, 
2017, South 
Africa [514] 
HIV-infected adults on treatment for TB 
(n=61 
1-compartment with transit compartment 
absorption and first-order elimination. Additive and 
proportional RV 
Weight on CL/F and 
V/F 
3.83 43.2 3.54 NN: 28 
MTT: 0.54 h 
Rockwood, 
2016, South 
Africa [508] 
Adult patients, HIV-infected and 
uninfected, on treatment for PTB (n=100) 
1-compartment with transit compartment 
absorption and first-order elimination. Additive and 
proportional RV 
Fat-free mass on 
CL/F and V/F 
 
4.17 41.9 50 NN: 2.06 
MTT: 0.74 h 
Denti, 2015, 
Tanzania 
[158] 
Adult patients on treatment for PTB 
(n=100) 
FOCE-I. 1-compartment with transit compartment 
absorption and FO elimination. Additive and 
proportional RV 
- 3.32 40.1 - NN: 2.6 
MTT: 0.84 h 
Chigutsa, 
2013, South 
Africa  
Adult patients on treatment for PTB, 
participating in trial of micronutrients 
(n=76) 
FOCE-I. 1-compartment with FO absorption and 
elimination. Time-dependent FO absorption rate 
constant. Additive error on log scale 
Sex on bioavailability 2.6 L/H/70 kg 42 l/70 
kg 
Early: 
0.02 
Late: 
1.0 
- 
Wilkins, 2006, 
South Africa 
[164] 
Adult patients on treatment for PTB 
(n=227) 
FO.  1-compartment with FO absorption and 
elimination. Dur: duration of zero-order input to 
dose compartment. Additive and proportional RV. 
Weight on CL/F and 
V/F 
Sex on V/F 
Formulation on Dur 
3.42 39.2 Fast: 
3.56 
Slow: 
1.25 
Dur: 0.29 
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Török, 2017, 
Vietnam [506] 
Adult patients, HIV-infected, on 
treatment for TBM (n=46) 
NPAG. 1-compartment absorption model with 
absorption lag time 
- 53.6 135.3 2.3 Lag: 0.35 
Denti, 2015, 
Tanzania 
[158] 
Adult patients on treatment for PTB 
(n=100) 
FOCE-I. 2-compartment with transit compartment 
absorption and FO elimination. Additive and 
proportional RV 
Age on CL/F 
WT on CL/F and V/F 
40.7 VC: 266 
VP: 687 
- NN: 11.1 
MTT: 2.54 h 
Q: 109 
Chigutsa, 
2013, South 
Africa 
Adult patients on treatment for PTB, 
participating in trial of micronutrients 
(n=78) 
FOCE-I. 1-compartment with transit compartment 
absorption and FO elimination. Additive and 
proportional RV 
Weight on CL/F and 
V/F 
40 l/kg/70 kg 390 l/70 
kg 
2.0 NN: 5 
MTT: 2.2 h 
Jonsson, 
2011, South 
Africa [167] 
Adult patients on treatment for PTB 
(n=189) 
FOCE-I. 2-compartment with one transit 
compartment and FO elimination. Additive and 
proportional RV 
HIV on bioavailability 
Weight on CL/F and 
V/F 
39.9 VC: 82.4 
VP: 623 
0.47 NN: 1 
MTT: 0.79 h 
Q: 34.3 
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4.2 Methods 
4.2.1 Drug plasma concentration determination 
 
Blood samples were collected from participants at the bronchoscopy and plasma pharmacokinetic 
visits as described in Chapter 2. Plasma was separated by centrifugation and stored at -80oC until 
ready for shipment. RHZE concentrations in plasma were measured using a four-drug liquid 
chromatography / tandem mass spectrometry assay developed in the BAF.  
 
4.2.1.1 Reagent preparation 
Precipitation / inactivation solution was prepared by adding 20 ml acetonitrile to 80 ml methanol 
(Fisher Scientific). Mobile phase A (0.3% formic acid in deionised water) was prepared by mixing 3 ml 
formic acid with 1,000 ml deionised water and sonicating for 15 minutes. Mobile phase B (0.3% 
formic acid in methanol) was prepared similarly. Wash solvent (50:20:30 MeOH:IPA:H2O) was 
prepared by mixing 500 ml of methanol, 200 ml of propan-2-ol and 300ml of deionised water, and 
sonicating for 15 minutes. 0.1% formic acid solution was prepared by mixing 100 µl formic acid with 
100 ml of deionised water (all Sigma Aldrich).  
Stock solutions containing 1 mg/ml rifampicin, 5 mg/ml isoniazid, 10 mg/ml pyrazinamide, and 5 
mg/ml ethambutol (Sigma Aldrich) were prepared in methanol. A working internal standard solution 
containing 200 mg/ml rifampicin-d3, 500 ng/ml isoniazid-d4, 1 µg/ml pyrazinamide-15N,d3, and 200 
ng/ml ethambutol-d4-dihydrochloride (Toronto Research Chemicals) was made up in methanol.  
 
4.2.1.2 Standards and quality control samples 
Serial drug dilutions in plasma were used to generate standard curves for peak area ratios of 
drug/internal standard on the chromatogram over an appropriate concentration range. 
Concentrations of TB drugs from clinical samples were calculated from their peak area ratio against 
the calibration line. Sample runs included quality control (QC) specimens with high, medium, and low 
drug concentrations to ensure consistency of operating conditions.  
 
4.2.1.3 Protein precipitation / inactivation  
Immediately prior to shipment to the UK, samples were retrieved from storage and 100 µl of plasma 
transferred to labelled cryovials for protein precipitation and Mtb inactivation. 900 µl of 
precipitation / inactivation solution was added to each sample, vortexed, and left to incubate for 10 
minutes. Biosafety experiments performed early in assay development showed that this method 
would eliminate live Mtb organisms in 100 µl samples of H37Rv broth (data not shown), allowing 
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removal from the biological safety cabinet and shipping as non-infectious Category B material to the 
BAF. Plasma samples were sent on dry ice to Liverpool for bio-analysis.  
In the BAF, plasma samples were thawed, and 900 µl precipitation / inactivation solution was added 
to standards, QC specimens, and blanks. All samples (plasma, standards, QC specimens, and blanks) 
were vortexed for 10 seconds, centrifuged (4,000 rpm for 10 min), and 50 µl of supernatant 
transferred to a labelled 5 ml glass test tube. 
 
4.2.1.4 Liquid chromatography-tandem mass spectrometry 
A typical assay started with the standard curve, followed by low QC sample, patient samples, 
medium QC sample, patient samples, and high QC sample. 20 µl of working internal standard 
solution was added to each tube with 1 ml of 0.1% formic acid. Samples were vortexed, 200 µl 
transferred to autosampler vials, and placed in the autosampler racks. Plasma without internal 
standard was extracted with each batch and placed as blanks between samples at appropriate 
intervals. This demonstrated absence of contaminants in the matrix and minimised analyte 
carryover.  
Samples were injected sequentially (2 µl) onto an AB Sciex 5500 system (Sciex). Chromatographic 
separation was achieved using a Phenomenex Synergi 80 Å polar C18 150 x 2 mm 4µm column 
(Phenomenex), with mobile phase maintained at 300 µl/min (mobile phase A = 0.3% formic acid in 
water, mobile phase B = 0.3% formic acid in methanol). Quantification of ions resulting from 
fragmentation of parent compound was analysed by electrospray ionisation mass spectrometry with 
multiple reaction monitoring. The ion source parameters used were a source gas temperature of 
350oC, turbo heater temperature of 550oC, curtain gas pressure 40 psi, ion source gas pressure of 50 
(GS1) and 60 (GS2) psi, and a spray voltage of 5500 V. To minimise carry over, column cleaning by 
back flushing with 50:20:30 MeOH:IPA:H2O, 35 µl/sec to a volume of 750 µl, occurred after every 
run. Data acquisition and processing was performed using MultiQuant software (Sciex). Table 4.2 
summarises the final assay characteristics. Drug levels below the lower limit of quantification (LLQ) 
were omitted.  
 
Analyte Concentration range 
(ng/ml) 
Concentration for QC specimens (ng/ml) 
Low Medium High 
Rifampicin 15-7,500 39 1,952 6,400 
Isoniazid 20-10,000 52 2,623 8,600 
Pyrazinamide 200-100,000 537 26,840 88,000 
Ethambutol 7-3,500 18 915 3,000 
Table 4.2: RHZE LC-MS assay characteristics 
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4.2.2 Population pharmacokinetic analysis 
 
Population PK models for RHZE were developed using NONMEM (version 7.4.0, Icon Development 
Solutions) on a computer running GNU Fortran (GCC version 4.6.0, Free Software Foundation) and 
Perl-speaks-NONMEM (PsN, version 4.7.0). Model building steps and associated data analysis were 
managed using the software utilities Pirana (version 2.9.6), Xpose (version 4.6.1), and R (version 
3.5.0).  
The first-order conditional estimation method with ε-η interaction was used for the estimation of 
typical population PK parameters (fixed effects: θ), inter-individual variability (IIV, random effects: η), 
and residual variability (RV, ε) between observed and predicted plasma concentrations. Correlations 
between variability components were also tested.  
Model selection was achieved using the minimum objective function value (OFV; calculated using 
minus twice the log-likelihood of the data), as well as by examination of relative standard error 
values (RSE) and goodness-of-fit plots. A decrease in the OFV of 3.84 or greater corresponded to a 
statistically significant difference between models (p=0.05, χ2 distribution, 1 degree of freedom).   
One- and two- compartment models with alternative models of absorption were fitted to the data. 
Models explored included simple first-order absorption, a sequence of zero- and first-order 
absorption, or a mixture model for absorption, all with or without lag times. The effect of acetylator 
status on isoniazid elimination was investigated using mixture models for apparent clearance. 
Elimination was assumed to take place from the plasma compartment in all models tested. IIV was 
described using an exponential model; and RV using proportional, additive, or combined 
proportional and additive models.  
Once the appropriate base model was established, the following covariates were explored: age, 
weight, BMI, sex, HIV status, and creatinine clearance. Continuous covariates were explored with 
linear additive, linear centred, power models, and power models with normalised covariates.  
Categorical covariates were explored with linear additive, linear proportional, and power models to 
select the most appropriate model for potential inclusion. Stepwise generalised additive modelling 
was used to select covariates for the model.  An OFV reduction of >3.84 was used as a cut-off for 
inclusion, and an OFV change of >6.63 on stepwise deletion (corresponding to a significance level of 
1%) as a prerequisite for retention in the model once all relevant covariates were incorporated to 
the model.  
Two-thousand datasets were simulated using the parameter estimates defined by the final model 
with the SIMULATION SUBPROBLEMS option to perform a visual predictive check in PsN. New 
individuals were simulated to represent the spectrum of possible covariate configurations. From the 
simulated data, 90% prediction intervals (P5–P95) were constructed. Observed data from the 
original dataset were superimposed.  
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Estimates of AUC0–∞ were calculated from simulated values of CL/F using the following equation:  
𝐴𝑈𝐶0−∞ =
𝐷𝑜𝑠𝑒
(𝐶𝐿/𝐹)
 
where CL represents clearance at steady state in litres per hour; F is the oral bioavailability in the 
observation compartment (fixed to 1); and dose represents the dose in milligrams. To estimate Tmax 
at steady state, the equation below was used: 
𝑇𝑚𝑎𝑥 =  ln(
𝑘𝑎
𝑘𝑒
)/(𝑘𝑎 − 𝑘𝑒) 
where ka represents the first-order absorption constant, ke the first-order elimination rate constant, 
and ln the natural logarithm. Cmax was calculated as below: 
𝐶𝑚𝑎𝑥 = (
𝑘𝑎 ∗ 𝐷𝑜𝑠𝑒
𝑉 ∗ (𝑘𝑎 − 𝑘𝑒)
) ∗ (exp(−𝑘𝑒 ∗ 𝑇𝑚𝑎𝑥) − exp(−𝑘𝑎 ∗ 𝑇𝑚𝑎𝑥)) 
For participants with 2 PK sampling visits, the mean AUC0-∞, Cmax and Tmax for rifampicin and isoniazid 
was recorded.   
 
4.2.3 Plasma pharmacokinetics and treatment response 
 
The relationship between plasma pharmacokinetic indices and treatment response (2MCC and final 
outcome) was explored using logistic regression in R. The odds ratio was adjusted for the covariate 
effects of symptom duration, baseline respiratory rate, screening TTP, and CXR score, identified as 
important predictors of response in Chapter 3. The relationship with modelled bacillary elimination 
rate is explored in Chapter 6. 
MICs of baseline Mtb isolates (n=88) were generated as described in the subsequent chapter on 
pharmacodynamics (see section 6.6) and used to calculate AUC/MIC and Cmax/MIC ratios. 100,000 
simulated AUC, Cmax, and MIC values were generated from the mean and standard deviation using 
the ‘rnorm’ function in R, and used to describe the distribution of AUC/MIC and Cmax/MIC in this 
cohort. 
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4.3 Results 
4.3.1 Dosing 
 
All participants were prescribed weight-based RHZE by the NTP. Drugs were administered as FDC-
formulation tablets produced by the Stop TB Partnership Global Drug Facility. 4 (2.5%) participants 
were under-dosed for rifampicin and isoniazid according to the WHO recommended range [100], and 
5 (3.2%) for ethambutol (Figure 4.1). This was likely due to a combination of NTP prescription error, 
and mg/kg under-dosing in some participants at the upper end of their weight banding. The median 
doses of ATT received are shown in Table 4.3. 
 
 
Figure 4.1: Weight-based dosing for anti-TB therapy 
The dotted lines represent the WHO recommended mg/kg dosing for each drug, with red bars representing 
participants over- or under-dosed. Participants received FDC tablets.  
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Drug (recommended range in mg/kg) Median dose in mg/kg [IQR] 
Rifampicin (8-12) 9.4 [8.8, 10.3] 
Isoniazid (4-6) 4.7 [4.4, 5.1] 
Pyrazinamide (20-30) 25.2 [23.5, 27.4] 
Ethambutol (15-20) 17.3 [16.2, 18.8] 
Table 4.3: Median dosing of RHZE in study participants 
 
4.3.2 Rifampicin plasma pharmacokinetics 
 
A total of 741 concentration-time observations from 140 participants were modelled. The assay 
failed for 1 sample, and 36 samples were below the LLQ. The rifampicin plasma data were best 
described by a one-compartment model with first-order absorption and elimination. Two-
compartment models provided no advantage in diagnostic plots or change in OFV and were 
discarded early in the model-building process. Sequential zero and first order absorption models did 
not improve the model fit or precision of the estimates. The use of a mixture model for absorption 
suggested the existence of a small subpopulation fraction with quicker (1.9x higher) typical ka, but 
the subpopulation was too small to be well characterised and the covariance step failed. 
Exponential inter-individual random effects (IIV) were supported for the apparent clearance (CL/F) 
and volume of distribution (V/F), and inter-occasion variability (IOV) for CL/F.  An exponential model 
described the residual variability as in the equation below: 
𝑌 = 𝐹 ∗ exp (𝜀) 
where Y is the modelled value for the dependent variable (concentration) under the statistical 
model; F is the value of the scaled drug amount in the observation compartment (fixed to 1); and ε is 
the residual error.  Residual variability was normally distributed with mean 0 and variance σ2, and 
arose from model misspecification, experimental error, and unspecified within-subject variability. 
Once the appropriate structural model was established, the model was refined by stepwise 
generalised additive modelling of possible covariate relations. Only inclusion of sex as a covariate for 
CL/F and HIV as a covariate for V/F significantly improved the model fit (ΔOFV -8 and -35.7 
respectively), as shown in the equations below: 
(
𝐶𝐿
𝐹
)𝑖𝑗 = [𝑇𝑉 (
𝐶𝐿
𝐹
)
𝜃𝑠𝑒𝑥
] ∗ exp (𝜂𝐶𝐿
𝐹
,𝑖
+ 𝜅𝐶𝐿
𝐹
,𝑖𝑗
) 
(
𝑉
𝐹
)𝑖𝑗 = [𝑇𝑉 (
𝑉
𝐹
)
𝜃𝐻𝐼𝑉
] ∗ exp (𝜂𝑉
𝐹
,𝑖
) 
In these equations, (CL/F)ij and (V/F)ij represent the apparent CL and V in individual i at occasion j, 
with TV(CL/F) and TV(V/F) being the typical value for CL/F and V/F in the population. Θsex is the 
model parameter describing the effect of sex on clearance (0 for female, 1 for male), ηCL/F, i is IIV for 
CL/F for individual i and kCL/F,ij IOV for CL/F for individual i at occasion j. ΘHIV is the model parameter 
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describing the effect of HIV on volume of distribution (0 for uninfected, 1 for infected), and ηV/F,i the 
IIV on V/F.  Final estimates of the PK parameters are presented in Table 4.4, and the goodness of fit 
plots for the final model in Figure 4.2. The final control stream is included in Appendix E: Rifampicin 
plasma NONMEM control stream. 
Study participants with HIV infection were more likely to have a lower Cmax (OR: 0.57; 95% CI: 0.40-
0.79, p=0.001) and have a longer Tmax (OR: 3.11; 95% CI: 1.79-5.74, p<0.001). 
 
 
Figure 4.2: Goodness of fit plots for the final rifampicin plasma PK model 
Observed concentrations (DV) versus population predictions (PRED, top left) and individual predictions (IPRED, 
top right), in which the solid line represents the line of identity. Absolute weighted predictions (WRES) versus 
population predictions (bottom left) and time after dose (bottom right).  
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Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 12.1 9.5 9.8-14.4 
V/F (l) 23.0 11.3 17.9-28.1 
ka (h-1) 0.245 3.3 0.229-0.261 
Θsex 1.32 9.4 1.08-1.56 
ΘHIV 1.37 14.4 0.98-1.76 
IIV 
    ηCL/F 
    ηV/F 
 
0.029 
0.367 
 
68.6 
30.0 
 
 
IOV 
    ΚCL/V 
 
0.047 
 
72.6 
 
Residual variability 
    εexp 
 
0.330 
 
8.1 
 
Table 4.4: Final estimated rifampicin parameter values 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; θsex: fractional change in clearance for males; θHIV: fractional change in volume 
of distribution for HIV-infected participants; IIV: inter-individual variability; IOV; inter-occasion variability; ηCL/V: 
IIV on clearance; ηV/F: IIV on volume of distribution; κCL/V: IOV on clearance; εexp: exponential residual error. 
 
A visual predictive check of 2,000 simulated datasets showed resemblance between observed and 
predicted data, indicating that the final model performed adequately (Figure 4.3). A predicted 
rifampicin AUC0-∞, Cmax and Tmax for each participant was generated from the final parameter 
estimates. The median AUC0-∞ was 33.0 µg.h/ml [IQR 28.1-37.6], Cmax 4.1 µg/ml [IQR 3.4-4.9], and 
Tmax 2.7 h [IQR 2.2-3.2] (Figure 4.4).  
 
 
Figure 4.3: Visual predictive check for the final plasma rifampicin model 
Rifampicin concentration (log scale) is shown on the y-axis, and time post-dose on the x-axis. The lower, middle, 
and upper lines are the 5th percentile, median, and 95th percentile for the observed data. The shaded areas are 
the 95% confidence intervals for the 5th percentile, median, and 95th percentile for the simulated data. 
  
 
Figure 4.4: Histograms of estimates of rifampicin plasma AUC0-∞, Cmax, and Tmax from the final plasma model 
The blue shaded rectangles represent estimates of these steady-state parameters in patients from previous publications [131, 153-155]. 
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4.3.3 Isoniazid plasma pharmacokinetics 
 
750 concentration-time observations from 141 participants were modelled. 1 assay failed, and 27 
samples were below the LLQ. The data were best described by a one-compartment model with first 
order absorption and elimination. Two-compartment models were met with some improvement in 
the OFV, but generally poorer parameter estimates and were not taken forward. Inclusion of an 
absorption lag phase did not improve the model fit. Mixture models were used to explore the effect 
of acetylator phenotype on isoniazid clearance. The data suggested the existence of 3 
subpopulations for isoniazid clearance, but the subpopulations were small, and the model had 
problems during minimisation. Exponential IIV on CL/F and V/F was supported, but inclusion of IOV 
terms did not improve the fit. Residual variability was described by an exponential error model as for 
rifampicin. 
Covariate relations were explored by stepwise generalised additive modelling. Weight as a covariate 
for V/F (ΔOFV -8.3) and sex as a covariate for V/F (ΔOFV -3.9) were identified on stepwise forward 
analysis, but only weight was retained as a covariate after backwards elimination. The final covariate 
model for V/F is shown below. 
(
𝑉
𝐹
)
𝑖𝑗
= [𝑇𝑉 (
𝑉
𝐹
) + (𝜃𝑤𝑡 ∗ (𝑤𝑡 − 51.05))] ∗ exp (𝜂𝑉
𝐹
,𝑖
) 
In the equation, θwt represents the covariate effect for weight, centred on the population mean 
weight of 51.05 kg. Final parameter estimates of the PK parameters are presented in Table 4.5 and 
the final control stream is included in Appendix F: Isoniazid plasma NONMEM control stream. The 
goodness of fit plots for the final model (Figure 4.5) show that the population predicted values and 
the individual predictions described the observed concentrations well, and no trends were seen in 
plots of absolute individual weighted residuals versus the individual predictions. 
 
Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 14.7 6.0 13.0-16.4 
V/F (l) 70.9 4.3 64.9-76.9 
ka (h-1) 2.52 16.5 1.71-3.34 
Θwt 1.06 35.9 0.31-1.81 
IIV 
    ηCL/F 
    ηV/F 
 
0.321 
0.052 
 
14.3 
27.0 
 
 
Residual variability 
    εccv 
    εadd 
 
0.152 
0.002 
 
9.2 
28.5 
 
Table 4.5: Final estimated isoniazid parameter values 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; θweight: linear additive change in clearance by weight; IIV: inter-individual 
variability; ηCL/V: IIV on clearance; ηV/F: IIV on volume of distribution; εccv: constant coefficient of variation 
residual error; εadd: additive residual error. 
Chapter 4  Plasma pharmacokinetics 
 
Page 116 
 
Figure 4.5: Goodness of fit plots for the final isoniazid plasma PK model 
Observed concentrations (DV) versus population predictions (PRED, top left) and individual predictions (IPRED, 
top right), in which the solid line represents the line of identity. Absolute weighted predictions (WRES) versus 
population predictions (bottom left) and time after dose (bottom right). 
 
The visual predictive check of log concentration versus time post-dose for the final isoniazid plasma 
model shows that the final model describes the data well (Figure 4.6). Estimates of individual PK 
parameters from the model (Figure 4.7) show considerable range in estimates for AUC0-∞ (median 
18.9 µg.h/ml [IQR 12.2-26.0], potentially reflecting differences in clearance secondary to NAT2 
status. The estimated Cmax in this cohort was slightly lower than other reports (median 2.6 µg/ml 
[IQR 2.4-3.0]), and the median Tmax was 1.0 h [IQR 0.9-1.0]. 
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Figure 4.6: Visual predictive check for the final plasma isoniazid model 
Isoniazid concentration (log scale) is shown on the y-axis, and time post-dose on the x-axis. The lower, middle, 
and upper lines are the 5th percentile, median, and 95th percentile for the observed data. The shaded areas are 
the 95% confidence intervals for the 5th percentile, median, and 95th percentile for the simulated data. 
 
 
 
 
 
 
 
 
  
 
Figure 4.7: Histograms of estimates of isoniazid plasma AUC0-∞, Cmax, and Tmax from the final plasma model 
The blue shaded rectangles represent estimates of these steady-state parameters in patients from previous publications [154, 155, 158, 159]. 
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4.3.4 Pyrazinamide plasma pharmacokinetics 
 
Fewer pyrazinamide concentration-time observations were available due to only the first PK 
sampling visits (IPPK1 or SPPK1) occurring during the intensive phase of therapy. 409 observations 
from 131 participants were modelled. 1 assay failed, and 15 samples were below the LLQ. 
The pyrazinamide data was best described by a one-compartment model with first-order absorption 
and elimination, and exponential IIV on CL/F, V/F, and ka. Residual error was described by a constant 
coefficient of variation model. 
𝑌 = 𝐹 ∗ (1 + 𝜀) 
As before, Y is the modelled value for the dependent variable (concentration) under the statistical 
model; F is the value of the scaled drug amount in the observation compartment; and ε is the 
residual error. 
Inclusion of weight as a covariate for both CL/F and V/F significantly improved the model fit (ΔOFV    
-10.1 and -29.3 respectively).  
(
𝐶𝐿
𝐹
)𝑖𝑗 = [𝑇𝑉 (
𝐶𝐿
𝐹
) ∗ (
𝑤𝑡
51.05
)
0.75
] ∗ exp (𝜂𝐶𝐿
𝐹
) 
(
𝑉
𝐹
)𝑖𝑗 = [𝑇𝑉 (
𝑉
𝐹
) ∗ (
𝑤𝑡
51.05
)
0.75
] ∗ exp (𝜂𝑉
𝐹
) 
In the equations above, the typical value for clearance or volume of distribution are normalised by 
the population mean weight of 51.05 kg, and allometrically scaled (exponent 0.75). Final parameter 
estimates are shown in Table 4.6, goodness of fit plots in Figure 4.8, and the visual predictive check 
for 2,000 simulated datasets in Figure 4.10. The plots showed no apparent visual bias. The control 
stream is included in Appendix G: Pyrazinamide plasma NONMEM control stream. 
 
Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 3.8 3.8 3.5-4.1 
V/F (l) 41.7 3.8 38.6-44.8 
ka (h-1) 1.06 12.2 0.81-1.31 
IIV 
    ηCL/F 
    ηV/F 
    ηka 
 
0.105 
0.026 
0.418 
 
20.2 
67.6 
23.3 
 
 
Residual variability 
    εccv 
 
0.57 
 
23.3 
 
Table 4.6: Final estimated pyrazinamide parameter values 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; IIV: inter-individual variability; ηCL/V: IIV on clearance; ηV/F: IIV on volume of 
distribution; ηka: IIV on absorption constant; εccv: exponential residual error. 
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Figure 4.8: Goodness of fit plots for the final pyrazinamide plasma PK model 
Observed concentrations (DV) versus population predictions (PRED, top left) and individual predictions (IPRED, 
top right), in which the solid line represents the line of identity. Absolute weighted predictions (WRES) versus 
population predictions (bottom left) and time after dose (bottom right). 
 
The median AUC0-∞ for pyrazinamide was 322.5 µg.h/ml [IQR 291.3-382.4] (Figure 4.9). Maximum 
plasma concentration was estimated at 23.8 µg/ml [IQR 22.1, 26.2], and time to maximum 
concentration 2.5 h [IQR 2.2-3.2].  
 
 
  
 
 
Figure 4.9: Histograms of estimates of pyrazinamide plasma AUC0-∞, Cmax, and Tmax from the final plasma model 
The blue shaded rectangles represent estimates of these steady-state parameters in patients from previous publications [154, 155, 158, 159]. 
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Figure 4.10: Visual predictive check for the final plasma pyrazinamide model 
Pyrazinamide concentration (log scale) is shown on the y-axis, and time post-dose on the x-axis. The lower, 
middle, and upper lines are the 5th percentile, median, and 95th percentile for the observed data. The shaded 
areas are the 95% confidence intervals for the 5th percentile, median, and 95th percentile for the simulated data. 
 
4.3.5 Ethambutol plasma pharmacokinetics 
 
416 ethambutol concentration-time observations were modelled, 1 ethambutol assay failed, and 8 
samples were below the LLQ. The data were best described by a one-compartment model with first-
order absorption and elimination. Attempts to model two-compartments or absorption lag phase 
were met with non-convergence.  
The model supported IIV on CL/V, V/F, and ka, with off-diagonal elements to account for covariance 
between CL/F and V/F. As for pyrazinamide, a constant coefficient of variation model best accounted 
for residual error.  
Two covariates were associated with a significant drop (<3.84) in OFV: BMI on V/F (ΔOFV -6.7), and 
creatinine clearance on CL/V (ΔOFV -7.0). After stepwise backwards elimination, only creatinine 
clearance was retained as a covariate in the model. 
(
𝐶𝐿
𝐹
)
𝑖𝑗
= [𝑇𝑉 (
𝐶𝐿
𝐹
) + (𝜃𝐶𝑟𝐶𝑙 ∗ (𝐶𝑟𝐶𝑙 − 108.7))] ∗ exp (𝜂𝐶𝐿
𝐹
,𝑖
) 
In the equation above, clearance in individual i at occasion j was modelled as the typical population 
value for clearance, with a centred linear additive term for the creatinine clearance covariate (θCrCl) 
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centred on the population average of 108.7 ml/min. ηCL/F, i is the exponential IIV for clearance. The 
final parameter estimates for the ethambutol model are included in Table 4.7. 
 
 
Figure 4.11: Goodness of fit plots for the final ethambutol plasma PK model 
Observed concentrations (DV) versus population predictions (PRED, top left) and individual predictions (IPRED, 
top right), in which the solid line represents the line of identity. Absolute weighted predictions (WRES) versus 
population predictions (bottom left) and time after dose (bottom right). 
 
Goodness of fit plots (Figure 4.11) and a visual predictive check (Figure 4.12) for the final ethambutol 
model indicating satisfactory model fit are shown. Estimates of Cmax from the final model suggested 
that weight-based dosing in this population achieved a lower maximum ethambutol concentration 
than in previous cohorts (median 1.3 µg/ml [IQR 1.0-1.7]), and took longer to reach peak 
concentration (median 5.0 h [IQR 4.2-5.7 h]). 
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Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 42.8 5.5 38.2-47.4 
V/F (l) 398 9.6 323-473 
ka (h-1) 0.348 11.8 0.268-0.428 
ΘCrCl 0.115 29.2 0.049-0.181 
IIV 
    ηCL/F 
    ηV/F 
    ηka 
 
0.106 
0.092 
0.449 
 
31.5 
62.0 
5.8 
 
Covariance ηCL/F ~ ηV/F 0.099 44.3  
Residual variability 
    εccv 
 
0.139 
 
0.1 
 
Table 4.7: Final estimated ethambutol parameter values 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; IIV: inter-individual variability; ηCL/V: IIV on clearance; ηV/F: IIV on volume of 
distribution; ηka: IIV on absorption constant; εccv: exponential residual error. 
 
 
Figure 4.12: Visual predictive check for the final plasma ethambutol model 
Ethambutol concentration (log scale) is shown on the y-axis, and time post-dose on the x-axis. The lower, middle, 
and upper lines are the 5th percentile, median, and 95th percentile for the observed data. The shaded areas are 
the 95% confidence intervals for the 5th percentile, median, and 95th percentile for the simulated data. 
  
 
Figure 4.13: Histograms of estimates of ethambutol plasma AUC0-∞, Cmax, and Tmax from the final plasma model 
The blue shaded rectangles represent estimates of these steady-state parameters in patients from previous publications [154, 155, 158, 167]. 
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4.3.6 Plasma pharmacokinetics and treatment response 
 
Previous work has shown that the efficacy of RHZE is driven by AUC/MIC [261, 263-265], and 
Cmax/MIC for RHE [263-265]. The MIC results for baseline Mtb isolates are described in detail in 
section 6.6, but are used here to generate estimates of plasma AUC/MIC and Cmax/MIC. Table 4.8 
summarises the modelled plasma PK indices from this cohort. Due to limited numbers of MIC 
readings available in this cohort, the predicted AUC/MIC and Cmax/MIC from 100,000 simulations are 
shown on the right of the table.  
 
Drug Median AUC/MIC 
[IQR] 
Median Cmax/MIC 
[IQR] 
Simulated median 
AUC/MIC [IQR] * 
Simulated median 
Cmax/MIC [IQR] * 
Rifampicin 1839 [1371, 2262] 224.6 [151.8, 277.7] 2319 [1422, 3786] 285.0 [178.3, 456.2] 
Isoniazid 384 [239, 710] 70.2 [42.3, 87.8] 448 [438, 458] 75.4 [66.7, 85.3] 
Pyrazinamide † 323 [291, 382] 23.8 [22.1, 26.1] - - 
Ethambutol 28 [16, 43] 1.7 [1.0, 2.6] 64 [17, 239] 4.0 [1.1, 14.6] 
Table 4.8: Summary of PK indices from modelled plasma data  
MIC data available from 88 participants. * Using the mean and SD of AUC, Cmax, and MIC from this dataset, 
100,000 AUC/MIC and Cmax/MIC pairings generated to estimate the true data distribution.  † MIC data not 
available for pyrazinamide. AUC and Cmax shown instead.  
 
Relationships between plasma PK and 2MCC or final outcome were explored using univariate logistic 
regression (Table 4.9). Higher rifampicin AUC/MIC and Cmax/MIC were associated with poorer odds of 
2-month culture conversion on univariate analysis, but were not significant after controlling for 
covariates. Both rifampicin and isoniazid peak plasma concentrations were associated with more 
favourable final outcomes after adjusting for significant covariates (Table 4.8 and Figure 4.14). 
First-line treatment for pulmonary TB consists of concomitant administration of 4 drugs. When 
compared to reference ranges used as targets for therapeutic drug monitoring [155, 168, 268, 515], 
none of these participants had plasma drug concentrations within the reference ranges, and 58% 
had 1 or more drug with ‘very low’ plasma concentrations (Figure 4.15). Standardised dosing does 
not result in antibiotic exposure as expected for any of these participants in Malawi.  
Rifampicin was most frequently found to have low plasma concentrations. There was a trend 
towards more unfavourable final outcomes in participants with a greater number of ‘very low’ drug 
concentrations (p=0.069), but no significant relationships between number of drugs with low 
concentrations and 2MCC or final outcome were identified. 
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Drug PK index 2-month culture conversion 
OR 95% CI p value Adjusted 
OR * 
95% CI p value 
Rifampicin AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
1.80 
0.07 
 
1.34 
0.07 
0.03-128.37 
0.00-0.74 
 
0.05-33.84 
0.00-0.67 
0.784 
0.045 
 
0.856 
0.034 
1.51 
0.05 
 
2.04 
0.08 
0.01-298.93 
0.00-0.82 
 
0.05-88.96 
0.00-0.98 
0.877 
0.055 
 
0.704 
0.065 
Isoniazid AUC 
AUC/MIC 
  
Cmax  
Cmax/MIC 
 
0.64 
0.43 
 
3.94 
0.44 
0.12-3.27 
0.12-1.14 
 
0.04-391.02 
0.10-1.25 
0.591 
0.128 
 
0.554 
0.183 
0.81 
0.41 
 
7.15 
0.43 
0.11-5.84 
0.1-1.23 
 
0.04-1569 
0.08-1.42 
0.830 
0.151 
 
0.463 
0.225 
Pyrazinamide AUC 
 
Cmax  
 
0.28 
 
1.76 
0.01-10.24 
 
0-797.54 
0.482 
 
0.854 
0.06 
 
2.10 
0.00-4.86 
 
0.00-2203 
 
0.212 
 
0.832 
Ethambutol AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
0.27 
0.28 
 
0.58 
0.35 
0.01-7.65 
0.05-1.12 
 
0.03-9.95 
0.07-1.31 
0.441 
0.097 
 
0.709 
0.146 
0.47 
0.15 
 
1.38 
0.22 
0.01-21.44 
0.02-0.90 
 
0.05-38.33 
0.03-1.18 
0.695 
0.055 
 
0.848 
0.100 
Drug PK index Final outcome 
OR 95% CI p value Adjusted 
OR * 
95% CI p value 
Rifampicin AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
9.14 
1.92 
 
89.79 
3.72 
0.01-12244 
0.04-45.64 
 
0.36-33841 
0.13-82.77 
0.543 
0.702 
 
0.119 
0.409 
275.14 
1.61 
 
6392 
3.88 
0-3013259 
0.03-52.7 
 
5-53422348 
0.13-118.56 
0.215 
0.794 
 
0.031 
0.423 
Isoniazid AUC 
AUC/MIC 
  
Cmax  
Cmax/MIC 
 
8.42 
1.57 
 
4321.77 
1.55 
0.51-152.55 
0.4-4.85 
 
1.61-
21650174 
0.35-4.79 
0.137 
0.453 
 
0.042 
0.483 
6.86 
1.46 
 
104651 
1.46 
0.31-178.86 
0.35-4.82 
 
8-
15047074448 
0.32-4.88 
0.225 
0.549 
 
0.029 
0.558 
Pyrazinamide AUC 
 
Cmax  
 
1.61 
 
23.37 
0.01-1244 
 
0-1101709 
0.879 
 
0.553 
9.09 
 
3570 
0-52404 
 
0-
3796958776 
0.577 
 
0.217 
Ethambutol AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
2.06 
0.57 
 
0.74 
0.46 
0.01-512.54 
0.04-3.94 
 
0.01-69.87 
0.03-3.33 
0.795 
0.622 
 
0.896 
0.517 
1.47 
0.49 
 
0.67 
0.39 
0-1728.07 
0.03-4.39 
 
0-268.2 
0.02-3.63 
0.911 
0.569 
 
0.891 
0.471 
Table 4.9: Plasma pharmacokinetic indices and treatment response 
Modelled estimates of AUC, AUC/MIC, Cmax, and Cmax/MIC are related to rates of 2-month culture conversion and 
final outcome by logistic regression. * OR adjusted for known confounding variables identified in earlier 
chapters: CXR score, baseline bacillary load, symptom duration and baseline respiratory rate. OR: odds ratio; 
95% CI: 95% confidence interval. 
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Figure 4.14: Rifampicin and isoniazid Cmax versus final outcomes 
Cmax has been log-transformed. Boxes represent the interquartile range, and the bar the median. Whiskers show 
the range. 
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Figure 4.15: Combinations of ‘low’ and ‘very low’ drug concentrations 
Rifampicin low ≤ 8 μg/ml, very low ≤ 4 μg/ml; isoniazid low ≤ 3 μg/ml, very low ≤ 2 μg/ml; pyrazinamide low ≤ 35 
μg/ml, very low ≤ 20 μg/ml; ethambutol low ≤ 2 μg/ml, very low ≤ 2 μg/ml. R: rifampicin; H: isoniazid; Z: 
pyrazinamide; E: ethambutol. 
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4.4 Discussion 
 
Suboptimal dosing of RHZE, combined with highly variable bioavailability, may be important drivers 
of poor TB treatment response. This chapter explored the relationship between the plasma PK and 
treatment response in this cohort.  
This is a large, richly sampled dataset, taken in ‘real-world’ conditions: from Malawian patients 
receiving programmatic treatment for pulmonary TB. Most patients were receiving appropriate 
mg/kg dosing, with good reported compliance. Over half the cohort is HIV co-infected, reflecting the 
epidemiology of TB infection in sub-Saharan Africa [17].  
The estimated PK indices from this cohort are in broad agreement with those from previous 
population-PK studies (Table 4.1). Samples were taken when drugs can be expected to be in steady 
state, with 2 sampling visits allowing for estimation of inter-occasion variability for rifampicin and 
isoniazid. While patients in the Plasma Arm only supplied sparse plasma samples, reasonable 
estimates of the absorption phase were achieved in this cohort.  
These patients were on treatment for pulmonary TB, rather than bloodstream infection, and 
previous studies have not shown a consistent relationship between plasma PK and outcomes. In this 
cohort, an association between more favourable outcomes in those with higher rifampicin and 
isoniazid Cmax concentrations was seen, and subsequent chapters will explore if this can be attributed 
to improved bacillary elimination.  
This was a study of single weight-based dosing, and a limited range of AUC and Cmax estimates was 
observed. Increasing rifampicin dosing from 10 to 35 mg/kg has been associated with supra-
proportional increases in AUC and improved bacillary clearance [304, 308], with a dynamic range 
beyond the variability in AUC measurements seen here. Higher mg/kg dose increments may be more 
likely to observe any further plasma dose-response effects. 
The estimates of plasma rifampicin CL/F, V/F and ka were in broad agreement with previous 
publications [134, 174, 276, 326, 507, 516], including similar cohorts from Malawi [148, 322]. Two 
significant covariate relationships were identified: males had higher clearance (15.8 l/h vs. 12.5 l/h), 
and HIV-infected individuals a larger volume of distribution (31.5 l vs. 23.9 l). The effect of male sex 
on rifampicin clearance has been previously observed [148, 511], as has the effect of HIV on V/F 
[142]. Neither covariate had a significant effect on AUC0-∞.  
Rifampicin exposure (AUC0-∞) at steady state was calculated from the individual estimates for CL/F. 
The median AUC0-∞ was 33.0 μg.h/ml, in keeping with the literature [131, 134, 142, 148, 322, 508], 
with up to 3-fold difference in AUC0-∞ estimates between individuals. Previous work identified that 
rifampicin AUC < 13 μg.h/ml was predictive of treatment failure, relapse, or death, up to 2 years 
[288], but all patients in this cohort had rifampicin AUCs above this threshold. Pre-clinical models 
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have identified that the ratio of rifampicin AUC to the MIC of the infecting isolate is a better 
predictor of treatment response [260, 264]. The median (total) rifampicin AUC/MIC was considerably 
higher than previous reports [260, 264, 289], and may be explained by the MIC distribution in this 
cohort (described in detail in section 6.6). This cohort only recruited Malawian adults with no 
evidence of rifampicin resistance on Xpert MTB/RIF, and the median rifampicin MIC was 0.02 μg/ml 
[IQR 0.02-0.03]. Few data exist describing the Mtb MICs from this setting, and these data highlight 
the importance of use of local data on drug sensitivity. In a recent PK-PD study from South Africa, the 
modal rifampicin MIC was 0.125 μg/ml [289], considerably higher than in this cohort. 
Variable absorption for rifampicin has been well-described before [131, 140, 148, 154], and may be 
linked to concomitant medications, delayed gastric emptying, comorbidities, or drug formulation. 
The use of a mixture model suggested the existence of a small population of rapid-absorbers, but 
this population was too small to be properly characterised by the model. Participants with HIV 
infection were seen to have a lower Cmax (mean 4.0 vs. 4.6 μg/ml) and take longer to achieve 
maximum plasma concentration (mean 3.0 vs. 2.6 h). Variable absorption may have a considerable 
effect on estimates of Cmax, with slower absorption reducing the maximal concentration. In general, 
the estimates of Cmax were relatively low in this population, and may be partly explained by variable 
absorption and rifampicin auto-induction [126, 142]. Where previous studies have used an enzyme 
induction model [131, 142, 507], the PK samples in this study have been taken at least 7 weeks into 
treatment, when full enzyme induction and steady state can be expected.  
Isoniazid plasma PK was best described by a one-compartment model, with the volume of 
distribution increasing by 1.06 l for every kilogram of body weight (above the population mean of 
51.05 kg). One-compartment isoniazid pharmacokinetics have been reported in South Africa [289] 
and Vietnam [506], whereas a number of other studies have described 2-compartment PK [158, 159, 
508, 512]. Modelling 2 compartments with this dataset was met with high RSE estimates for the 
extra parameters, and was not assessed further. Had sampling extended beyond 8 hours post-dose, 
a second compartment may have been more apparent.  
While weight (or fat-free mass) has been identified as an important covariate in other work [289, 
508], NAT2 status, either by genotype or derived phenotype, is well recognised as a major driver of 
isoniazid clearance [158, 197-200, 512]. NAT2 genotype was not captured in this study, but use of a 
mixture model for clearance suggested the existence of 3 clearance subpopulations. Previous work 
in Malawi suggested nearly two-thirds of TB patients were slow acetylators [154], and about 8% fast 
acetylators [Sloan et al, unpublished data]. Isoniazid clearance was 14.7 l/h in this population – 
towards the lower limit of previous estimates [158, 159, 289] – suggesting a relatively high 
proportion of slow acetylators. As a probable consequence of acetylator status effects on clearance, 
AUC0-∞ had a broad interquartile range from 12.2 to 26.0 μg.h/l. Isoniazid AUC0-∞ of 10.52 μg.h/l 
correlates with 90% of maximal early bactericidal activity (EBA90) [517], comfortably achieved by 
most participants in this cohort. The Cmax estimate of 2.6 μg/ml in this population was low relative to 
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targets used in therapeutic drug monitoring (3-5 μg/ml)[515], and appeared to affect the final 
outcome. Isoniazid is generally considered to be important in the early bactericidal activity of a 
regimen, and it may be that early ‘debulking’ of the disease with higher isoniazid concentrations 
results in more favourable outcomes.  
Pyrazinamide is minimally protein-bound [169], so total drug concentration is a reasonable 
approximation of the free (active) component. The plasma pharmacokinetics of pyrazinamide were 
best described by a one-compartment model with first-order absorption and elimination. Estimates 
of CL/F and V/F were similar to those seen in populations from South Africa [164, 297, 508, 514], 
Tanzania [158], Vietnam [506], and Malawi [154]. As in other studies, allometric scaling for body 
weight was the only covariate that significantly improved the model fit [164, 508, 513, 514]. The 
spread of AUC0-∞ estimates for the cohort was relatively broad, with an interquartile range of 291.3-
382.4 μg.h/ml. Estimates of both AUC0-∞ and Cmax were towards the lower end of previous estimates, 
and the median AUC0-∞ of 322.5 μg.h/ml was below the threshold for poor long-term outcome [288]. 
No relationship between pyrazinamide AUC and Cmax and final outcome was identified in this study.  
Pyrazinamide MICs were not determined in this cohort due to the requirement for acidic test 
conditions: the MIC at pH 5.5 is 8-fold lower than at pH 5.95 [518]. MIC distributions from South 
Africa suggest a modal MIC of 25 μg/ml at pH 5.9 [289]. If this estimate was used in this cohort, the 
median AUC/MIC of 12.9 μg.h/ml would be above the threshold of 11.3 μg.h/ml – identified as a key 
predictor of the sterilising activity of a regimen [289].  
Finally, as a renally-excreted drug, baseline creatinine clearance was the only covariate found to 
impact on the plasma pharmacokinetics of ethambutol: active renal tubular secretion of ethambutol 
necessitates dose adjustment in renal disease [100, 242, 246]. Ethambutol was seen to distribute 
well into a single central compartment, with a large volume of distribution.  
Ethambutol absorption varied greatly between participants, with Tmax ranging from 2.1 to 7.8 hours. 
Ethambutol is thought to take 2-3 hours to achieve maximal concentration [243-245], but Cmax is 
delayed when dosed with food [243]. All study participants were asked to fast from the evening 
before PK sampling, and took their medications with a small volume of water. The relatively low Cmax 
in this cohort (median 1.3 μg/ml) may in part be secondary to this prolonged absorption. Early PK 
studies attributed variable ethambutol absorption to binding or chelation in the gastrointestinal tract 
[245, 246]. 
It is a fairly frequent criticism of TB PK-PD studies that they describe the exposure (and exposure-
response relationship) of single agents, and do not incorporate the fact that TB therapy is always 
multi-drug in nature. It was notable that all participants in this cohort had at least one ‘low’ drug, 
and over half had low concentrations for all 4 drugs. However, having more drugs with low plasma 
concentrations was not associated with more unfavourable outcomes or poorer rates of culture 
conversion. Reference ranges for TDM have largely been derived from descriptions of drug exposure 
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distributions in healthy, North American volunteers, and do not take into account treatment 
response [138, 168, 203, 230, 243, 268, 515]. These reference ranges may be less appropriate when 
applied to a cohort of Malawian adults, on treatment for active TB disease, and with high rates of 
HIV co-infection. 
There are several limitations in this chapter that merit discussion. Firstly, sampling only extended to 
8 hours post-dose due to limited patient transport options in the late evening, lack of suitable 
accommodation for overnight stay, and to avoid asking participants to return on consecutive days 
for a 24-hour sample. The rich sampling strategy up to 8 hours describes the PK parameters well, but 
does not reveal a second elimination phase as would be expected in two-compartment models. 
Previous studies have reported two-compartment PK for isoniazid [158, 159, 508, 512] and 
ethambutol [158, 167], but inclusion of a second compartment did not improve the model fit in this 
dataset.   
Secondly, while supervised drug dosing was used on PK sampling days, adherence outside study 
visits was determined by individual patient concordance. Directly observed therapy, pill counts, and 
enquiries about missed doses at each study visit reinforced the importance of compliance with the 
regimen, and can be expected to minimise the effect of poor compliance. 
Thirdly, varying drug formulation quality may impact the PK parameters [503-505, 519]. All 
participants received FDC tablets from the Malawi NTP, provided through the Stop TB Partnership 
Global Drug Facility. Drugs undergo stringent quality control to WHO standards, minimising the 
effect of formulation on PK. Alongside drug quality, co-administered medications may alter the PK of 
RHZE through DDIs. No participants were receiving co-administered medications that may be 
expected to alter the PK of first-line ATT, although one participant was receiving nevirapine-
containing ART. Rifampicin can be expected to significantly reduce plasma AUC for nevirapine, risking 
virological failure, and as such this participant was switched to efavirenz early in treatment [177-
179]. 
Finally, this chapter describes the PK of whole drug, rather than metabolite or unbound fraction. 
Isoniazid requires activation by KatG to form an active metabolite [192, 193], 50% of the activity of 
rifampicin comes from its’ metabolite 25-desacetylrifampicin [169-171], and pyrazinamide requires 
conversion to POA in an acidic environment to exert its’ effects [161, 229]. Existing literature 
typically describes the PK of parent drug, allowing comparison with these data, and may be expected 
to have a similar PK profile to active metabolites. While we do not measure the unbound fraction of 
antimicrobial in this work, published estimates for the extent of protein binding for RHZE can be 
extrapolated to these data [520], and will be of particular relevance in considering intrapulmonary 
PK and extent of diffusion across the blood-alveolar barrier in the next chapter.  
While knowledge of the plasma PK of RHZE is important, of greater interest to this study is the 
intrapulmonary PK profiles. The plasma PK models generated here will be used as the foundation for 
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the intrapulmonary PK models in Chapter 5, and the relationship between plasma drug exposure and 
effect will be explored further in Chapter 6.  
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5 Intrapulmonary pharmacokinetics 
5.1 Introduction 
 
Measurement of site of infection PK in pulmonary TB presents considerable challenges. Methods 
such as lung explant studies with spatial mass spectrometry have offered an exciting look at drug 
penetration into granulomas [53, 328, 521], but can only be performed in a small subset of patients 
with advanced disease. Bronchoscopy and bronchoalveolar lavage may be used to sample ELF and 
alveolar cells from the distal airway, and when combined with LC-MS, yield ‘near-infection’ measures 
of drug penetration in pulmonary TB. This technique has been used to measure intrapulmonary 
concentrations for a wide range of anti-infective agents [347, 522], and is applied here to first-line 
anti-tuberculosis treatment.  
Bronchoscopy is an invasive procedure, and can only be used for single time-point / sparse PK 
sampling. Through population PK modelling approaches, it is possible to model the relationship 
between plasma and intrapulmonary samples taken at different times in different individuals, and 
model the concentration-time profile in ELF and alveolar cells over the dosing interval. Non-directed 
bronchial lavage with similar population PK modelling techniques has recently been used to describe 
the intrapulmonary pharmacokinetics of tazobactam-piperacillin in critically-ill patients [432], 
enabling a far richer understanding of the dynamics of treatment than with single time-point 
sampling alone. 
Surprisingly little is known of the intrapulmonary pharmacology of first-line TB drugs, despite their 
availability for over 60 years. The most extensive work has been done by Conte et al in San Francisco 
between 1999 and 2004 [208, 233, 251, 345]. Using healthy volunteers, with or without HIV 
infection, intrapulmonary samples were taken 4 hours after a 5th dose of rifampicin, isoniazid, 
pyrazinamide, or ethambutol (summarised in Table 1.6). This work showed high concentrations of 
pyrazinamide in the ELF, high concentrations of ethambutol in the alveolar cells, and concentrations 
of rifampicin in the ELF approximately one-fifth of plasma. A further study of single dose rifampicin 
showed alveolar cell concentrations 16-fold greater than plasma [523], and the use of inhaled 
rifampicin, isoniazid, or pyrazinamide increased concentrations in ELF and alveolar cells still further 
[209]. 
These data indicate intrapulmonary drug partitioning, and lend weight to the hypothesis that 
adequate drug concentrations are not always achieved at the site of infection. Using these data, 
population PK models of intrapulmonary drug exposure for rifampicin [438, 524] and isoniazid [525] 
have been generated, in both cases identifying low intrapulmonary drug concentrations of potential 
clinical importance. However, the existing intrapulmonary PK data for RHZE comes from healthy 
volunteers, receiving single drugs, with samples taken at a single time point. It is reasonable to 
assume that the intrapulmonary PK at steady state, in patients on combination therapy, with 
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pulmonary disease and comorbidities, may be quite different from that seen in the existing 
literature. Differences in the PK parameters between TB patients and healthy volunteers have been 
described for rifampicin [153], linezolid [526], and ethionamide [527].  
Understanding differential drug penetration into different compartments will be key to dose 
optimisation and construction of new regimens. If low concentrations of a drug are achieved near 
the site of infection, particularly if approaching the MIC for the infecting organism, this would be an 
obvious candidate for dose increase. Compartmental PK may also be relevant to transmission 
reduction: higher isoniazid concentrations in ELF [208, 525] may act on fast-growing, free 
extracellular organisms, explaining the high early bactericidal activity seen in the first days of therapy 
[84, 528]. Whether these organisms, or those expectorated in sputum, are determinants of 
infectiousness however is a matter for debate [529, 530]. Successful therapy may require a 
combination of drugs with different purposes: achieving high concentrations in ELF to reduce the 
bacillary burden, high concentrations in cells to kill intracellular organisms, and good penetration of 
the avascular caseum to target slowly replicating, persister organisms. These principles may be 
applied to the development of effective MDR and XDR-TB regimens, where transmission reduction 
strategies are arguably of greater importance. 
In this chapter, drug concentrations in epithelial lining fluid and alveolar cells are described, and 
modelled using the plasma models generated in Chapter 4. Intrapulmonary measures of AUC/MIC 
and Cmax/MIC are related to 2MCC and final treatment outcome, and taken forward into the 
pharmacodynamics work in Chapter 6.  
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5.2 Methods 
5.2.1 Sample collection and processing 
 
Participants in the intrapulmonary group had 2 research bronchoscopies: the first after 2 months of 
TB treatment, the second after 4 months. The conduct of the bronchoscopy visits and technique for 
BAL sampling is described in Chapter 2. Labelled BAL samples were placed in 50 ml Falcon Tubes held 
on ice, taken immediately to the MLW Immunology Laboratory, and the volume of BAL recorded. 5 
ml of whole BAL was removed and frozen at -80oC. To remove mucous plugs, BAL was filtered 
through sterile gauze into sterile, 50 ml Falcon Tubes, aiming for approximately 40 ml per tube. 
Figure 5.1 illustrates the workflow for BAL samples. 
  
 
Figure 5.1: BAL sample workflow 
The right middle lobe was instilled with 200 ml of warm sterile saline in 4 aliquots. Samples were immediately 
aspirated and placed in 1-4 50 ml Falcon Tubes held on melting ice. Samples were taken immediately to the 
laboratory, filtered through sterile gauze, and pooled in 1-4 Falcon Tubes. The first tube, containing ~ 40 ml of 
BAL, was used for the intrapulmonary PK measurements. The remaining Falcon Tubes used in the immunology 
assays. Tube 1 was centrifuged, and samples of supernatant removed for urea measurement and ELF drug 
concentrations. The cell pellet was transferred to a skirted tube, centrifuged, and residual supernatant removed. 
BAL; bronchoalveolar lavage; ELF: epithelial lining fluid; RML: right middle lobe. 
 
10 µl of filtered BAL was removed and placed in an Eppendorf microtube for subsequent cell 
counting. Samples were centrifuged at 500 x g at 4oC for 8 minutes to obtain cell pellets. The first 50 
ml Falcon Tube was used for the pharmacokinetic assays, while the remaining tubes were used for 
the immunology assays described in Chapter 7.  
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1 ml of supernatant was removed from the centrifuged sample and stored at -80oC in the dark until 
ready for shipment. Supernatant would contain a mixture of ELF diluted in saline used at 
bronchoalveolar lavage. A further 1 ml sample was stored at -80oC for later urea measurement. The 
remaining supernatant was removed from the 50 ml Falcon Tube, leaving the cell pellet in 0.5 – 1 ml 
of supernatant at the bottom of the tube. The cell pellet was resuspended in the residual 
supernatant, transferred to a 2 ml skirted tube, and centrifuged for a further 8 minutes at 500 x g at 
4oC. The remaining supernatant was aspirated by pipette, and the cell pellet frozen at -80oC until 
ready for shipment. To minimise drug degradation, these steps were carried out in low-light 
conditions and samples stored in the dark. To minimise drug efflux from cells, samples were held on 
ice and processed immediately after bronchoscopy. 
Cell counts were performed after time-sensitive steps were completed. 10 µl of Trypan Blue (Thermo 
Fisher) was added to the 10 µl of BAL in the Eppendorf microtube, and the cells counted on a 
haemocytometer slide. The cell count (cells/ml) was used to calculate the cell count in the cell pellet 
obtained from the 40 ml BAL sample.   
Immediately prior to shipment, samples were retrieved from storage and 100 µl of the BAL 
supernatant transferred to labelled cryovials. 900 µl of 80:20 methanol:acetonitrile solution (Fisher 
Scientific) was added to the cell pellet and 100 µl supernatant samples, vortexed, and left to 
incubate for 10 minutes. Samples were sent on dry ice to Liverpool for bio-analysis. 
 
5.2.2 Epithelial lining fluid drug concentration 
 
Measurement of RHZE concentrations in BAL supernatant was performed in the BAF in Liverpool. 
The methods used were the same as those described for plasma in Chapter 4. The output of the 
liquid chromatography / tandem mass spectrometry assay was the drug concentration in ng/ml of 
BAL supernatant (CBAL). 
BAL supernatant contains a mixture of saline lavage fluid and ELF. To calculate the volume of ELF and 
drug concentrations in ELF, the urea dilution method was used [336]. BAL supernatant samples and 
paired plasma samples taken at the time of bronchoscopy were retrieved from -80oC storage and 
thawed. Urea concentration was measured in paired plasma and BAL supernatant using 
Quantichrome Urea Assay Kits (BioAssay Systems) according to manufacturer’s instructions. The 
volume of ELF in BAL was derived from the following equation: 
𝑉𝐸𝐿𝐹 =  𝑉𝐵𝐴𝐿  × (
𝑢𝑟𝑒𝑎𝐵𝐴𝐿
𝑢𝑟𝑒𝑎𝑝𝑙𝑎𝑠𝑚𝑎
) 
where VELF represents the volume of ELF, VBAL the total volume of BAL retrieved, and ureaBAL and 
ureaplasma the urea concentration in paired BAL supernatant and plasma samples respectively. ELF 
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drug concentrations were calculated from the concentration in BAL supernatant using the following 
equation: 
𝐶𝐸𝐿𝐹 =  𝐶𝐵𝐴𝐿  × (
𝑉𝐵𝐴𝐿
𝑉𝐸𝐿𝐹
) 
where CELF and CBAL represent the concentration in ELF and BAL supernatant respectively. 
 
5.2.3 Alveolar cell drug concentration 
 
Alveolar cell (AC) pellets were received in Liverpool and thawed for LC-MS. The assay was the same 
as for plasma and ELF, except that intracellular standards and QC samples were prepared in spiked 
samples of the human monocytic leukaemia cell line THP-1, at a cell count of 2 x 106 cells. 
The output of the LC-MS assay was the concentration of RHZE in ng/ml of sample. Cell counts 
(cells/ml) were obtained in Malawi prior to pelleting using a haemocytometer slide. From the 
recorded volume of BAL for PK analysis (typically 40 ml) it was possible to estimate the total number 
of cells in the pellet, and convert the LC-MS output in ng/ml into ng/106 cells (CPELLET). Given a mean 
macrophage cell volume of 2.42 µl/106 cells [531], alveolar cell drug concentration (CAC) in µg/ml 
could be estimated from: 
𝐶𝐴𝐶 =
𝐶𝑃𝐸𝐿𝐿𝐸𝑇
2.42
 
The limit of quantification for RHZE in ELF and AC was the same as for plasma. 
 
5.2.4 Population pharmacokinetic analysis 
 
Population PK models for RHZE in alveolar cells and ELF were constructed in NONMEM as in Chapter 
4. The first-order conditional estimation method with ε-η interaction was used for the estimation of 
typical population PK parameters, random inter-individual variability (IIV), and residual variability 
(RV) between observed and predicted concentrations. The final plasma models for RHZE formed the 
base models for the intrapulmonary models. 3 different structural models were attempted (Figure 
5.2). 
Chapter 5  Intrapulmonary pharmacokinetics 
 
Page 140 
 
Figure 5.2: Intrapulmonary PK structural models 
A: ELF and AC concentrations modelled as a constant ratio relative to the central plasma compartment. 
B: 3-compartment mammillary model. ELF and AC modelled as peripheral compartments off a central plasma 
compartment. 
C: 3-compartment catenary model. Drug enters the ELF from the plasma, and equilibrates between the ELF and 
AC. Drug eliminated from the central plasma compartment.   
k12/k21/k13/k31/k23/k32: distribution rate constants; ke: elimination rate constant; Q1-3: intercompartmental 
clearance; V1-3: the volume of the 3 compartments. 
 
The first model attempted was a constant ratio model (Figure 5.2A), using the individual 1-
compartment RHZE models from Chapter 4 for the base model. This model assumed instantaneous 
equilibrium between plasma and ELF / AC. Concentrations in the peripheral compartments were 
characterised as a ratio relative to their plasma concentration (RELF and RAC respectively), with IIV on 
RELF and RAC using an exponential error model.  
The second model attempted was a 3-compartment mammillary model (Figure 5.2B) using the 
ADVAN 4 TRANS 4 subroutine in NONMEM. Both ELF and AC were treated as separate 
compartments off a central plasma compartment from which all elimination took place. Exponential 
IIV and RV was modelled on all 3 compartments. 
The final model was a 3-compartment catenary model (Figure 5.2C). Drug entered a central plasma 
compartment, and was either eliminated or transferred to the ELF compartment. Some drug 
returned to the central compartment from the ELF (k21). From the ELF, drug equilibrated with the AC. 
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There was no elimination from the ELF or AC compartment. This model was constructed using the 
following system of ordinary differential equations: 
Equation 1: differential equation for amount of drug in the plasma compartment (2) at time (t).  
𝑑𝐴(2)
𝑑𝑡
=
𝑘𝑎 ∗ 𝐴(1) + 𝑘21 ∗ 𝐴(3)
𝑉
− (𝑘𝑒 + 𝑘12) ∗ 𝐴(2) 
 
Equation 2: differential equation for amount of drug in the ELF compartment (3) at time (t) 
𝑑𝐴(3)
𝑑𝑡
=
𝑘12 ∗ 𝐴(2) ∗ 𝑉 + 𝑘32 ∗ 𝐴(4) ∗ 𝑉(3)
𝑉(2)
− (𝑘21 + 𝑘23) ∗ 𝐴(3) 
 
Equation 3: differential equation for amount of drug in the AC compartment (4) at time (t) 
𝑑𝐴(4)
𝑑𝑡
=
𝑘23 ∗ 𝐴(3) ∗ 𝑉(2)
𝑉(3)
− 𝑘32 ∗ 𝐴(4) 
 
In all three equations, the numbers 1-4 refer to the compartment: depot, plasma, ELF, and AC 
respectively. A(#) refers to the amount of drug in each compartment, V(#) the volume of 
distribution, and k# the distribution rate constants. ke is the elimination rate constant.  
Model selection was achieved using the minimum OFV, examination of relative standard error 
values, goodness-of-fit plots, and biological plausibility. A decrease in the OFV of 3.84 or greater 
corresponded to a statistically significant difference between models.   
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5.3 Results 
5.3.1 Intrapulmonary PK measurements 
 
Intrapulmonary PK data was available from 51 participants, with 41 participants having both early 
and late bronchoscopies. A total of 271 ELF and 278 AC concentration-time observations for RHZE 
were available for modelling. The assay was successful in all samples, and few samples were below 
the limit of quantification for the assay (Table 5.1).  
 
Drug  Below LLQ Above ULQ Assay success 
ELF 
Rifampicin 8 0 83 
Isoniazid 3 0 88 
Pyrazinamide 0 0 50 
Ethambutol 0 0 50 
AC 
Rifampicin 0 0 89 
Isoniazid 3 0 89 
Pyrazinamide 0 0 50 
Ethambutol 0 0 50 
Table 5.1: RHZE LC-MS assay success in epithelial lining fluid (ELF) and alveolar cells (AC) 
LLQ: lower limit of quantification; ULQ: upper limit of quantification.  
 
ELF volume in BAL was estimated using the urea dilution method. The median volume of ELF 
recovered was 1.2 ml [IQR 0.83, 1.89]. The median number of alveolar macrophages retrieved was 
6.4 x 106 cells [IQR 4.6, 8.8].  
Figure 5.3 is a concentration-time scatterplot of ELF and AC observations. For all 4 drugs, 
concentrations in ELF and AC were higher than those in plasma, with isoniazid and pyrazinamide 
attaining ELF concentrations many fold higher than plasma. Ethambutol appears to concentrate 
within the alveolar cell, and the high intracellular concentrations seen provides reassurance that the 
sampling method minimised drug loss through efflux.  
Table 5.2 summarises the drug concentrations in ELF and AC at the 3 bronchoscopy timepoints: 2, 4, 
and 6-hours post-dose. Highest intrapulmonary concentrations for rifampicin and isoniazid were 
seen at the 2-hour timepoint. Pyrazinamide concentrations start to decline by the 6-hour timepoint, 
and peak ELF ethambutol concentrations are observed at 4-hours post-dose. For all 4 drugs, there 
was a wide range of concentrations observed at each timepoint.   
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Figure 5.3: Scatterplot of concentration-time observations in plasma, ELF, and AC 
The blue-shaded box shows the Cmax in plasma, and the median MIC of baseline isolates. The coloured trend lines 
are loess lines. Green triangles and dashed lines: ELF; red circles and dotted line: AC. Plasma concentration-time 
observations not shown. 
 
Drug  2-hour concentration 
in μg/ml, median 
[IQR] 
4-hour concentration 
in μg/ml, median 
[IQR] 
6-hour concentration 
in μg/ml, median 
[IQR] 
Average 
concentration in 
μg/ml, median [IQR] 
ELF  
Rifampicin 9.1 [6, 18.6] 5.2 [4.1, 8.6] 4.1 [1.9, 6.4] 6.4 [4.1, 11.1] 
Isoniazid 41.1 [22.1, 64] 16.1 [12.7, 44.8] 9.7 [3.4, 18.7] 23.2 [12, 55.1] 
Pyrazinamide 1606.7 [1270.8, 
2583.7] 
1713.7 [851.1, 
2925.8] 
655.4 [477.8, 1380.6] 1480.4 [847.6, 
2489.7] 
Ethambutol 5.8 [4.2, 8.6] 7.9 [5.4, 12.1] 4.6 [3.7, 6.3] 5.8 [4.1, 9.3] 
AC  
Rifampicin 6.5 [2.4, 14.5] 4.6 [3.4, 12.4] 3.7 [1.4, 6.7] 4.7 [3, 13.3] 
Isoniazid 2.8 [1.4, 5] 2.1 [1.4, 4.7] 1.1 [0.5, 3.8] 2.4 [1.1, 4.8] 
Pyrazinamide 124.8 [76.9, 170.6] 123.4 [57.8, 164] 60.1 [23.2, 136.8] 98.8 [56.6, 170.6] 
Ethambutol 20.6 [14, 43.1] 19.9 [15.6, 38.8] 19.1 [16, 25.7] 20 [15.2, 37.8] 
Table 5.2: RHZE concentrations in ELF and AC at 2, 4, and 6-hours post-dose 
Concentrations are presented as median [IQR]. 
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All BAL samples were collected from the right middle lobe. Given that active inflammation may 
disrupt the blood-alveolar barrier, with the potential to alter the local intrapulmonary PK, it was 
important to assess for trends in drug concentration relative to extent of RML parenchymal 
involvement. While immediate pre-bronchoscopy CXRs were unavailable, all participants had a CXR 
at treatment start, with the percentage of right midzone consolidation independently assessed by a 
radiologist and the PI (see section 3.4.5). The average of the 2 reader’s scores was recorded, and the 
concordance correlation coefficient of 0.79 demonstrated substantial inter-reader agreement. 
Figure 5.4 shows scatterplots of ELF and AC concentrations with increasing right midzone disease. No 
trends towards altered intrapulmonary PK with increasing right midzone disease were seen, nor any 
trends between intrapulmonary drug exposure and overall CXR score. No correlation between right 
midzone disease, or CXR score, and intrapulmonary PK, were observed on linear regression analysis.  
 
Figure 5.4: Intrapulmonary drug concentration versus percentage parenchymal involvement in the right 
middle zone 
The coloured trend lines are loess lines. Green triangles and dashed lines: ELF; red circles and dotted lines: AC. 
RMZ: right midzone  
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5.3.2 Intrapulmonary POP-PK models 
 
5.3.2.1 Choice of model 
The 3 structural models in section 5.2.4 were attempted in NONMEM for each first-line drug. Efforts 
to fit a 3-compartment mammillary model (Figure 5.2B) to the intrapulmonary data for any of the 4 
drugs were met with model instability. Small adjustments in the initial estimates resulted in large 
changes in the distributional process parameters, and parameters were estimated with high RSEs.  
The catenary model (Figure 5.2C) minimised, but failed the covariance step. Furthermore, the 
parameters governing the distributional processes (k12, k21, k23, k32) moved little from the initial 
estimates, and all took the same value. Given that the plasma data were essentially 1-compartment, 
and despite observing the peripheral compartments, there was insufficient multi-compartment 
character to the data to inform the distributional process parameters for either the catenary or 3-
compartment mammillary models. 
The ELF and AC data for RHZE were best described by a constant ratio model (Figure 5.2A). The 
extent of distribution to ELF and AC was described by the ELF:plasma concentration ratio (RELF) and 
AC:plasma concentration ratio (RAC). The rate of distribution to ELF and AC from plasma (kELF and kAC 
respectively) was assumed to be instantaneous. These models minimised and the covariance step 
was successful. These models were used for all subsequent analyses.  
 
5.3.2.2 Rifampicin model 
The final rifampicin intrapulmonary model was based on the 1-compartment plasma model, with IIV 
on CL/F and V/F, IOV on CL/F, and the covariate effects of sex on clearance and HIV status on volume 
of distribution. The control stream is included in Appendix I: Rifampicin intrapulmonary NONMEM 
control stream. The goodness of fit plots for ELF and AC are shown in Figure 5.5 and Figure 5.6 
respectively, demonstrating that individual predictions described the observed concentrations well, 
and no trends were seen in plots of absolute individual weighted residuals versus the individual 
predictions. RSE for all θ terms was less than 20%, and IIV was estimated on CL/F, V/F, RELF and RAC 
(Table 5.3). The extent of distribution to ELF and AC (RELF and RAC) had predicted typical values of 1.97 
(95% CI: 1.65-2.30) and 1.35 (95% CI: 0.89-1.81) respectively.  
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Figure 5.5: Goodness of fit plots for the final rifampicin ELF PK model 
Observed concentrations (DV) versus population predictions (PRED, top left) and individual predictions (IPRED, 
top right), in which the solid line represents the line of identity. Absolute weighted predictions (WRES) versus 
population predictions (bottom left) and time after dose (bottom right). 
 
Figure 5.6: Goodness of fit plots for the final rifampicin AC PK model 
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Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 12.2 9.5 9.9-14.5 
V/F (l) 22.2 11.7 17.1-27.3 
ka (h-1) 0.24 3.5 0.22-0.26 
Θsex 1.32 9.3 1.08-1.56 
ΘHIV 1.34 15.2 0.94-1.74 
RELF 1.97 8.4 1.65-2.30 
RAC 1.35 17.5 0.89-1.81 
IIV 
    ηCL/F 
    ηV/F 
    ηRELF 
    ηRAC 
 
0.028 
0.382 
0.219 
1.03 
 
55.6 
29.3 
27.4 
27.8 
 
 
IOV 
    ΚCL/V 
 
0.051 
 
49.8 
 
Residual variability 
    εplasma 
    εELF 
    εAC 
 
0.575 
0.396 
0.650 
 
3.8 
11.2 
7.6 
 
0.532-0.618 
0.309-0.483 
0.554-0.746 
Table 5.3: Final estimated rifampicin parameter values for full intrapulmonary model 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; θsex: fractional change in clearance for males; θHIV: fractional change in volume 
of distribution for HIV-infected participants; RELF: ELF/plasma concentration ratio; RAC: AC/plasma concentration 
ratio; IIV: inter-individual variability; IOV; inter-occasion variability; ηCL/V: IIV on clearance; ηV/F: IIV on volume of 
distribution; ηRELF: IIV on ELF/plasma concentration ratio; ηRAC: IIV on AC/plasma concentration ratio; κCL/V: IOV 
on clearance; εplasma: plasma residual error; εELF: ELF residual error; εAC: AC residual error. 
 
Using the parameter estimates above, a concentration-time simulation in plasma, ELF, and AC was 
run (Figure 5.7). Peak concentrations in ELF are near double the Cmax of plasma. The distribution of 
log-transformed PK indices in the 3 matrices is shown in Figure 5.8. In general, AUC and Cmax are 
greater in ELF than plasma, while there is considerable variability in the PK indices in alveolar cells. 
 
 
Figure 5.7: Concentration-time simulation for total rifampicin in plasma, ELF, and AC 
This simulation does not account for the extent of rifampicin protein-binding in plasma, ELF, or AC. Solid blue 
line: plasma prediction; dashed green line: ELF prediction; dotted red line: AC prediction.  
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Figure 5.8: Distribution of rifampicin AUC and Cmax in plasma, ELF, and AC 
AUC and Cmax are log transformed. The shaded area represents plasma estimates of these parameters at steady 
state in patients [131, 153-155] 
 
5.3.2.3 Isoniazid model 
The base isoniazid model was a 1-compartment model with IIV on CL/F, V/F, and ka, and a covariate 
effect of weight on V/F. RELF and RAC were estimated as for rifampicin. Goodness of fit plots for ELF 
and AC are shown in Figure 5.9 and Figure 5.10, and the final parameter estimates in Table 5.4. 
Parameters were generally estimated well, and RSEs for IIV terms all less than 30%.  
 
Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 13.7 5.5 12.2-15.2 
V/F (l) 78.5 4.0 72.4-84.6 
ka (h-1) 3.29 20.4 1.97-4.61 
Θweight 1.08 45 0.13-2.03 
RELF 14.6 11.8 11.2-18.0 
RAC 1.31 14.0 0.95-1.67 
IIV 
    ηCL/F 
    ηV/F 
    ηRELF 
    ηRAC 
 
0.285 
0.057 
0.528 
0.791 
 
10.8 
29.2 
22.7 
26.7 
 
Residual variability 
    εplasma 
    εELF 
    εAC 
 
0.418 
0.436 
0.557 
 
3.9 
10.3 
9.5 
 
0.386-0.450 
0.348-0.524 
0.453-0.661 
Table 5.4: Final estimated isoniazid parameter values for full intrapulmonary model 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; θweight: fractional change in volume of distribution by weight; RELF: ELF/plasma 
concentration ratio; RAC: AC/plasma concentration ratio; IIV: inter-individual variability; ηCL/V: IIV on clearance; 
ηV/F: IIV on volume of distribution; ηRELF: IIV on ELF/plasma concentration ratio; ηRAC: IIV on AC/plasma 
concentration ratio; εplasma: plasma residual error; εELF: ELF residual error; εAC: AC residual error. 
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Figure 5.9: Goodness of fit plots for the final isoniazid ELF PK model 
 
Figure 5.10: Goodness of fit plots for the final isoniazid AC PK model 
 
The extent of distribution to ELF and AC (RELF and RAC) had predicted typical values of 14.6 (95% CI: 
11.2-18.0) and 1.31 (95% CI: 0.95-1.67) respectively. The high concentrations achieved in ELF are 
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clearly demonstrated on the simulated concentration-time plot below (Figure 5.11), while the log-
transformed PK indices show the wide range of AUC and Cmax in ELF compared to plasma or alveolar 
cells (Figure 5.12). 
 
 
Figure 5.11: Concentration-time simulation for isoniazid in plasma, ELF, and AC 
Solid blue line: plasma prediction; dashed green line: ELF prediction; dotted red line: AC prediction. 
 
Figure 5.12: Distribution of isoniazid AUC and Cmax in plasma, ELF, and AC 
AUC and Cmax are log transformed. The shaded area represents plasma estimates of these parameters at steady 
state in patients [154, 155, 158, 159]. 
 
5.3.2.4 Pyrazinamide model 
The final pyrazinamide model was 1-compartment, with IIV on CL/F, V/F, and ka. Weight was 
included as a covariate on both CL/F and V/F as for the plasma model. With only 1 intrapulmonary 
observation per participant (1 bronchoscopy in the intensive phase), it was not possible to partition 
inter-individual from residual variability in ELF and AC. Given that all 4 drugs were collected and 
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processed together, and estimates of εELF and εAC for rifampicin and isoniazid were similar, these 
values were fixed at 0.4 and 0.6 respectively for both pyrazinamide and ethambutol. An exponential 
model was used to describe residual error.     
The goodness of fit plots below show that the model describes the data reasonably well, though 
there was a degree of under-prediction with the individual predictions at higher concentrations. The 
parameter estimates in Table 5.5 confirm that the data were estimated with satisfactory precision. 
 
Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 3.8 3.8 3.6-4.1 
V/F (l) 41.8 3.6 38.8-44.8 
ka (h-1) 1.09 12.1 0.83-1.35 
RELF 49.8 15.9 34.2-65.3 
RAC 3.18 20.5 1.90-4.46 
IIV 
    ηCL/F 
    ηV/F 
    ηka 
    ηRELF 
    ηRAC 
 
0.107 
0.025 
0.425 
0.243 
0.725 
 
20.6 
73.5 
24.7 
75.7 
51.0 
 
Residual variability 
    εplasma 
    εELF 
    εAC 
 
0.239 
0.4 FIX 
0.6 FIX 
 
11.6 
- 
- 
 
0.185-0.293 
- 
- 
Table 5.5: Final estimated pyrazinamide parameter values for full intrapulmonary model 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; RELF: ELF/plasma concentration ratio; RAC: AC/plasma concentration ratio; IIV: 
inter-individual variability; ηCL/V: IIV on clearance; ηV/F: IIV on volume of distribution; ηka: IIV on absorption 
constant; ηRELF: IIV on ELF/plasma concentration ratio; ηRAC: IIV on AC/plasma concentration ratio; εplasma: plasma 
residual error; εELF: ELF residual error; εAC: AC residual error. 
 
Pyrazinamide was well distributed in ELF, achieving an ELF:plasma concentration ratio of 49.8 (Table 
5.5 and Figure 5.15). Pyrazinamide concentrations in alveolar cells was 3.18-fold greater than in 
plasma. The range of AUC and Cmax estimates in ELF (Figure 5.16) was smaller than seen with 
isoniazid.   
 
Chapter 5  Intrapulmonary pharmacokinetics 
 
Page 152 
 
Figure 5.13: Goodness of fit plots for the final pyrazinamide ELF PK model  
 
Figure 5.14: Goodness of fit plots for the final pyrazinamide AC PK model 
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Figure 5.15: Concentration-time simulation for pyrazinamide in plasma, ELF, and AC 
Solid blue line: plasma prediction; dashed green line: ELF prediction; dotted red line: AC prediction. 
 
Figure 5.16: Distribution of pyrazinamide AUC and Cmax in plasma, ELF, and AC 
AUC and Cmax are log transformed. The shaded area represents plasma estimates of these parameters at steady 
state in patients [154, 155, 158, 159]. 
 
5.3.2.5 Ethambutol model 
The final ethambutol intrapulmonary model was a 1-compartment plasma model, with IIV on CL/F, 
V/F, ka, RELF and RAC. Off-diagonal elements accounted for covariance between CL/F and V/F. As for 
pyrazinamide, residual error in ELF and AC (εELF and εAC) was fixed at 0.4 and 0.6 with an exponential 
residual error model. Goodness of fit plots (Figure 5.17 and Figure 5.18) and final parameter 
estimates (Table 5.6) are included opposite. 
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Figure 5.17: Goodness of fit plots for the final ethambutol ELF PK model  
 
Figure 5.18: Goodness of fit plots for the final ethambutol AC PK model 
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Parameter Typical value % RSE * 95% CI † 
CL/F (l/h) 43.0 4.2 39.4-46.5 
V/F (l) 401.0 6.4 350.8-451.2 
ka (h-1) 0.36 9.3 0.30-0.43 
ΘCRCL 0.12 36.4 0.03-0.20 
RELF 4.0 7.8 3.3-4.6 
RAC 15.0 12.3 11.4-18.6 
IIV 
    ηCL/F 
    ηV/F 
    ηKa 
    ηRELF 
    ηRAC 
 
0.098 
0.063 
0.463 
0.139 
0.204 
 
29.8 
63.7 
33.3 
48.3 
43.3 
 
 
 
 
Covariance ηCL/F ~ ηV/F 0.079 43.6  
Residual variability 
    εplasma 
    εELF 
    εAC 
 
0.377 
0.4 FIX 
0.6 FIX 
 
5.9 
- 
- 
 
0.333-0.421 
- 
- 
Table 5.6: Final estimated ethambutol parameter values for full intrapulmonary model 
* relative standard error; † 95% confidence interval. CL/F: clearance, V/F: apparent volume of distribution; ka: 
first-order absorption constant; θCRCL: fractional change in clearance by creatinine clearance; RELF: ELF/plasma 
concentration ratio; RAC: AC/plasma concentration ratio; IIV: inter-individual variability; ηCL/V: IIV on clearance; 
ηV/F: IIV on volume of distribution; ηka: IIV on absorption constant; ηRELF: IIV on ELF/plasma concentration ratio; 
ηRAC: IIV on AC/plasma concentration ratio; εplasma: plasma residual error; εELF: ELF residual error; εAC: AC residual 
error. 
 
In contrast to the other 3 first-line drugs, highest ethambutol levels were seen in the alveolar cells 
(alveolar cell:plasma concentration ratio 15, Figure 5.19 and Figure 5.20). Concentrations in ELF 
were 4-fold higher than plasma.   
 
 
Figure 5.19: Concentration-time simulation for ethambutol in plasma, ELF, and AC 
Solid blue line: plasma prediction; dashed green line: ELF prediction; dotted red line: AC prediction. 
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Figure 5.20: Distribution of ethambutol AUC and Cmax in plasma, ELF, and AC 
AUC and Cmax are log transformed. The shaded area represents plasma estimates of these parameters at steady 
state in patients [154, 155, 158, 167]. 
 
5.3.3 Predictors of ELF:plasma and AC:plasma concentration ratios  
 
Individual estimates of ELF:plasma concentration ratio (RELF) and AC:plasma concentration ratio (RAC) 
were generated for RHZE for each participant in the Intrapulmonary Arm. Univariate linear 
regression was used in an exploratory analysis of predictors of intrapulmonary penetration for each 
drug (Table 5.7 and Table 5.8). 
Isoniazid penetration into ELF (RELF) was greater in smokers (21/51; estimate: 7.106; SE: 3.178; 
p=0.030) and lower in those with sepsis at baseline (2/51; estimate: -11.592; SE: 5.720; p=0.049). 
Smoking was also associated with higher RELF for ethambutol (21/51; estimate: 0.819; SE: 0.352; 
p=0.024). Older participants had a marginally higher ethambutol RELF (estimate: 0.056; SE: 0.023; 
p=0.016). 
Several variables were associated with alveolar cell concentration ratio (RAC). RAC was greater for 
both rifampicin and isoniazid in those with HIV infection (23/51; estimate: 1.247; SE: 0.533; p=0.024; 
and estimate: 1.822; SE: 0.379; p<0.001 respectively). There also appeared to be a univariate 
relationship between higher BMI and ethambutol RAC, and baseline ALT and isoniazid RAC. However, 
the danger of over-interpreting the results of multiple comparisons should be borne in mind. 
 
   
Drug Rifampicin Isoniazid Pyrazinamide Ethambutol 
Estimate SE p value Estimate SE p value Estimate SE p value Estimate SE p value 
Age (years) 0.009 0.018 0.613 0.060 0.213 0.781 -0.087 0.424 0.838 0.056 0.023 0.016 
Male sex -0.099 0.391 0.802 -4.895 4.619 0.295 -12.915 9.043 0.160 -0.113 0.522 0.830 
Duration of 
symptoms (weeks) 
-0.044 0.030 0.157 -0.418 0.365 0.258 -0.742 0.717 0.306 -0.063 0.040 0.120 
Ever smoked 
tobacco 
0.459 0.272 0.098 7.106 3.178 0.030 11.069 6.375 0.089 0.819 0.352 0.024 
Ever drank alcohol 0.289 0.275 0.298 1.383 3.320 0.679 0.194 6.498 0.976 0.564 0.358 0.122 
HIV infected 0.295 0.275 0.288 1.527 3.318 0.648 1.983 6.492 0.761 0.669 0.354 0.065 
Baseline CD4 
(cells/mm3) 
0.000 0.001 0.808 0.004 0.007 0.603 0.006 0.014 0.669 -0.001 0.001 0.169 
BMI (kg/m2) 0.079 0.082 0.344 1.713 0.959 0.081 3.364 1.946 0.090 0.020 0.113 0.861 
Baseline respiratory 
rate (bpm) 
-0.022 0.031 0.483 -0.621 0.362 0.093 -0.835 0.722 0.253 -0.042 0.041 0.315 
Clinically septic at 
baseline * 
-0.420 0.496 0.401 -11.592 5.720 0.049 -18.981 11.476 0.105 -0.912 0.654 0.170 
Baseline 
haemoglobin (g/dl) 
-0.071 0.063 0.265 -0.750 0.755 0.326 -0.268 1.568 0.865 -0.032 0.089 0.722 
Baseline white cell 
count (x103/μl) 
-0.029 0.049 0.559 -0.91 0.576 0.121 -1.259 1.147 0.278 -0.123 0.063 0.057 
Baseline monocyte-
lymphocyte ratio 
-0.055 0.238 0.817 -1.783 2.832 0.532 -7.683 5.893 0.199 0.133 0.339 0.697 
Baseline creatinine 
clearance (ml/min) 
0.001 0.004 0.802 -0.006 0.047 0.898 0.057 0.089 0.524 -0.004 0.005 0.417 
Baseline bilirubin 
(μmol/l) 
-0.031 0.032 0.334 -0.267 0.379 0.484 -0.240 0.734 0.745 -0.060 0.041 0.148 
Baseline ALT (IU/l) -0.001 0.006 0.813 -0.034 0.071 0.635 -0.002 0.139 0.990 0.009 0.008 0.251 
CXR score 0.002 0.005 0.688 0.016 0.057 0.781 0.066 0.114 0.565 -0.004 0.006 0.533 
Table 5.7: Univariate linear regression – predictors of epithelial lining fluid:plasma penetration ratio for RHZE 
* Based on source of infection, and 2 or more of: temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 breaths per minute, white cell count <4 or >12 x 103/µl.  SE: 
standard error. 
 
  
 
Drug Rifampicin Isoniazid Pyrazinamide Ethambutol 
Estimate SE p value Estimate SE p value Estimate SE p value Estimate SE p value 
Age (years) 0.002 0.036 0.952 0.046 0.029 0.122 0.023 0.068 0.736 0.162 0.103 0.123 
Male sex 0.632 0.787 0.426 0.598 0.647 0.360 1.284 1.462 0.384 1.258 2.302 0.587 
Duration of 
symptoms (weeks) 
-0.066 0.062 0.290 -0.015 0.052 0.780 0.110 0.115 0.341 -0.003 0.181 0.988 
Ever smoked 
tobacco 
-0.162 0.567 0.777 0.051 0.467 0.913 -1.455 1.028 0.164 3.142 1.579 0.052 
Ever drank alcohol 0.670 0.555 0.233 0.391 0.461 0.400 0.025 1.037 0.981 2.731 1.575 0.090 
HIV infected 1.247 0.533 0.024 1.822 0.379 <0.001 1.767 1.005 0.085 -0.313 1.624 0.848 
Baseline CD4 
(cells/mm3) 
-0.002 0.001 0.121 -0.002 0.001 0.03 -0.003 0.002 0.224 0.003 0.003 0.382 
BMI (kg/m2) 0.095 0.167 0.573 -0.024 0.138 0.863 -0.125 0.320 0.697 0.973 0.481 0.049 
Baseline respiratory 
rate (bpm) 
-0.084 0.062 0.180 -0.097 0.050 0.059 -0.003 0.117 0.981 -0.009 0.183 0.962 
Clinically septic at 
baseline * 
-0.512 1.009 0.614 -0.850 0.824 0.307 -0.452 1.883 0.811 -3.386 2.910 0.250 
Baseline 
haemoglobin (g/dl) 
-0.191 0.126 0.137 -0.198 0.102 0.059 -0.416 0.243 0.093 0.275 0.390 0.485 
Baseline white cell 
count (x103/μl) 
-0.063 0.100 0.533 -0.042 0.082 0.610 0.033 0.185 0.860 -0.451 0.283 0.118 
Baseline monocyte-
lymphocyte ratio 
0.448 0.477 0.353 0.370 0.393 0.351 -0.081 0.957 0.933 -1.159 1.490 0.441 
Baseline creatinine 
clearance (ml/min) 
0.006 0.008 0.418 -0.001 0.007 0.882 0.013 0.014 0.374 0.042 0.022 0.057 
Baseline bilirubin 
(μmol/l) 
-0.041 0.064 0.524 -0.106 0.051 0.042 -0.090 0.117 0.442 -0.350 0.177 0.054 
Baseline ALT (IU/l) 0.022 0.012 0.060 0.017 0.010 0.088 0.028 0.022 0.198 -0.036 0.034 0.301 
CXR score -0.001 0.010 0.894 -0.001 0.008 0.885 0.033 0.018 0.070 -0.031 0.028 0.285 
Table 5.8: Univariate linear regression – predictors of alveolar cell:plasma penetration ratio for RHZE 
* Based on source of infection, and 2 or more of: temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 breaths per minute, white cell count <4 or >12 x 103/µl. SE: 
standard error. 
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5.3.4 Intrapulmonary PK indices 
 
Individual-level plasma estimates for AUC0-∞ and Cmax were generated in NONMEM from the final 
models. Estimates for ELF and AC were generated algebraically by multiplying the plasma estimates 
by the participants individual ELF:plasma concentration ratio (RELF) and AC:plasma concentration 
ratio (RAC). The final PK parameter estimates for the intrapulmonary models are summarised below 
(Table 5.9). 
 
Drug PK index Matrix 
Plasma 
(median [IQR]) 
ELF 
(median [IQR]) 
AC 
(median [IQR]) 
Rifampicin AUC (μg.h/ml) 
 
Cmax (μg/ml) 
 
30.6 [27.3, 36.7] 
 
4.0 [3.5, 4.8] 
56.0 [41.3, 81.7] 
 
7.9 [5.9, 10.1] 
47.4 [20.3, 84.8] 
 
5.9 [2.9, 11.9] 
Isoniazid AUC (μg.h/ml) 
 
Cmax (μg/ml) 
 
18.3 [11.2, 26.0] 
 
2.5 [2.3, 3.0] 
284.4 [134.5, 406.6] 
 
39.2 [20.6, 63.7] 
21.5 [12.9, 42.6] 
 
3.6 [2.2, 5.7] 
Pyrazinamide AUC (μg.h/ml) 
 
Cmax (μg/ml) 
 
305.7 [282.9, 387.0] 
 
23.8 [21.7, 26.3] 
15,573 [11,076, 20,286] 
 
1166 [868, 1429] 
1055 [674, 1730] 
 
81.7 [48.4, 114.2] 
 
Ethambutol AUC (μg.h/ml) 
 
Cmax (μg/ml) 
 
2.7 [2.2, 3.1] 
 
1.3 [1.1, 1.7] 
10.0 [8.1, 12.6] 
 
4.9 [4.2, 6.9] 
40.6 [30.6, 53.5] 
 
20.0 [15.3, 27.1] 
Table 5.9: Final steady state parameter estimates for AUC0-∞ and Cmax in plasma, ELF, and AC 
 
5.3.5 Intrapulmonary pharmacokinetics and treatment response 
 
Logistic regression was used to evaluate the relationship between intrapulmonary PK indices and 
2MCC or final outcome at 18-months (Table 5.10 and Table 5.11). The baseline MICs for rifampicin, 
isoniazid, and ethambutol were used to generate AUC/MIC and Cmax/MIC estimates for the subset of 
participants with complete data.  
Higher ethambutol AUC/MIC or Cmax/MIC, in either ELF or alveolar cells, was associated with poorer 
rates of 2MCC after adjusting for baseline bacillary load, CXR score, respiratory rate and symptom 
duration (Figure 5.21 and Table 5.10). The difference in median AUC/MIC or Cmax/MIC between 
culture converters and non-converters was small, and accompanied by wide inter-quartile ranges 
(Figure 5.21): these results should be interpreted with caution.   
Rifampicin Cmax in ELF was associated with final treatment outcome after adjusting for baseline 
bacillary load, CXR score, respiratory rate and symptom duration (Table 5.11). There was a trend 
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towards more favourable outcomes in participants with higher drug exposure for rifampicin, 
isoniazid, or pyrazinamide, but not ethambutol.  
 
 
Figure 5.21: Intrapulmonary PK and 2MCC 
Ethambutol AUC/MIC and Cmax/MIC in ELF or alveolar cells were associated with poorer odds of 2-month culture 
conversion. AC: alveolar cells; ELF: epithelial lining fluid.
   
Drug PK index Epithelial lining fluid Alveolar cells 
OR 95% CI p value Adjusted OR * 95% CI p value OR 95% CI p value Adjusted OR * 95% CI p value 
Rifampicin AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
9.59 
0.19 
 
5.67 
0.19 
0.55-211.40 
0.02-1.56 
 
0.47-81.38 
0.02-1.37 
0.134 
0.148 
 
0.184 
0.120 
13.07 
0.22 
 
9.04 
0.25 
0.50-417.97 
0.01-2.42 
 
0.53-184.69 
0.02-2.51 
0.129 
0.239 
 
0.135 
0.264 
1.76 
0.33 
 
1.63 
0.33 
 
0.38-8.38 
0.06-1.36 
 
0.39-6.91 
0.07-1.29 
0.467 
0.158 
 
0.498 
0.142 
1.98 
0.31 
 
1.97 
0.37 
0.34-11.73 
0.04-1.76 
 
0.39-10.12 
0.06-1.82 
0.441 
0.224 
 
0.409 
0.251 
Isoniazid AUC 
AUC/MIC 
  
Cmax  
Cmax/MIC 
 
1.30 
0.54 
 
3.74 
0.60 
0.36-4.73 
0.19-1.37 
 
0.63-25.35 
0.19-1.59 
0.686 
0.223 
 
0.157 
0.333 
2.04 
0.56 
 
6.47 
0.65 
0.46-9.49 
0.17-1.62 
 
0.85-60.22 
0.18-2.00 
0.351 
0.310 
 
0.081 
0.478 
0.78 
0.38 
 
1.26 
0.39 
0.22-2.61 
0.11-0.99 
 
0.23-7.04 
0.10-1.10 
0.682 
0.075 
 
0.791 
0.117 
0.97 
0.36 
 
1.63 
0.39 
0.22-4.13 
0.09-1.11 
 
0.22-11.77 
0.08-1.31 
0.972 
0.106 
 
0.627 
0.176 
Pyrazinamide AUC 
 
Cmax  
 
0.77 
 
3.36 
0.05-11.27 
 
0.14-92.24 
0.844 
 
0.458 
1.38 
 
15.47 
0.06-31.57 
 
0.44-678.90 
0.839 
 
0.137 
0.24 
 
0.48 
0.02-1.97 
 
0.05-3.94 
0.196 
 
0.501 
0.30 
 
1.06 
0.02-4.09 
 
0.08-13.12 
0.384 
 
0.966 
Ethambutol AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
2.42 
0.42 
 
0.86 
0.20 
0.46-12.85 
0.11-1.35 
 
0.05-15.57 
0.03-0.96 
0.294 
0.168 
 
0.917 
0.068 
1.49 
0.13 
 
1.48 
0.07 
0.2-11.17 
0.02-0.70 
 
0.05-42.01 
0.00-0.53 
0.695 
0.031 
 
0.817 
0.023 
2.06 
0.35 
 
0.59 
0.15 
0.40-10.66 
0.09-1.14 
 
0.04-8.91 
0.02-0.74 
0.386 
0.102 
 
0.701 
0.036 
0.83 
0.09 
 
0.33 
0.04 
0.11-6.22 
0.01-0.50 
 
0.01-8.12 
0.00-0.35 
0.861 
0.014 
 
0.499 
0.009 
Table 5.10: Intrapulmonary pharmacokinetic indices and 2MCC treatment response 
As only 39 culture-conversion outcomes were recorded in the Intrapulmonary Arm, the PK estimates for the whole cohort assessed here (n=121). Modelled estimates of AUC, AUC/MIC, Cmax, 
and Cmax/MIC are related to rates of 2-month culture conversion by logistic regression. * OR adjusted for known confounding variables identified in earlier chapters: CXR score, baseline bacillary 
load, symptom duration and baseline respiratory rate. OR: odds ratio; 95% CI: 95% confidence interval. 
 
 
 
  
 
Drug PK index Epithelial lining fluid Alveolar cells 
OR 95% CI p value Adjusted OR * 95% CI p value OR 95% CI p value Adjusted OR * 95% CI p value 
Rifampicin AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
10.99 
3.25 
 
57.05 
5.75 
0.11-2179 
0.1-77.6 
 
0.62-10619 
0.23-137 
0.344 
0.472 
 
0.102 
0.270 
53.93 
2.96 
 
918.25 
6.18 
0.13-65926 
0.09-92.01 
 
2-2159897 
0.23-197.04 
0.230 
0.529 
 
0.048 
0.275 
0.91 
0.87 
 
1.57 
1.24 
0.08-9.26 
0.05-7.9 
 
0.15-14.7 
0.11-9.88 
0.941 
0.910 
 
0.702 
0.851 
0.73 
0.59 
 
1.95 
1.06 
0.02-14.91 
0.03-7.65 
 
0.09-29.37 
0.07-10.92 
0.860 
0.717 
 
0.646 
0.963 
Isoniazid AUC 
AUC/MIC 
  
Cmax  
Cmax/MIC 
 
6.2 
1.83 
 
7.16 
1.77 
0.63-74.6 
0.45-6.31 
 
0.36-133.31 
0.41-5.96 
0.129 
0.351 
 
0.187 
0.381 
5.24 
1.71 
 
8.65 
1.69 
0.43-82.66 
0.41-6.3 
 
0.33-243.09 
0.38-6.09 
0.208 
0.425 
 
0.191 
0.438 
2.36 
1.34 
 
1.75 
1.28 
0.3-19.82 
0.32-4.2 
 
0.1-30.43 
0.27-4.08 
0.419 
0.644 
 
0.704 
0.700 
1.53 
1.18 
 
1.16 
1.15 
0.14-17 
0.24-4.27 
 
0.04-32.84 
0.2-4.22 
0.722 
0.812 
 
0.932 
0.847 
Pyrazinamide AUC 
 
Cmax  
 
3.09 
 
9.47 
0.05-461.89 
 
0.05-2113.1 
0.632 
 
0.408 
12.29 
 
55.84 
0.04-8856 
 
0.08-70818 
 
0.417 
 
0.243 
2.66 
 
3.15 
0.07-91.64 
 
0.11-85.04 
0.589 
 
0.500 
2.16 
 
2.79 
0.03-180.3 
 
0.05-202.33 
0.729 
 
0.630 
Ethambutol AUC 
AUC/MIC  
 
Cmax  
Cmax/MIC 
 
0.29 
0.54 
 
1.61 
0.56 
0.01-4.27 
0.05-3.06 
 
0.02-129.88 
0.03-4.24 
0.399 
0.535 
 
0.827 
0.632 
0.33 
0.38 
 
1.32 
0.51 
0.01-9.13 
0.03-2.77 
 
0-513.82 
0.03-4.46 
0.532 
0.400 
 
0.923 
0.590 
0.38 
0.63 
 
4.22 
0.71 
0.02-5.88 
0.07-3.46 
 
0.05-497.73 
0.05-4.95 
0.518 
0.629 
 
0.539 
0.758 
0.49 
0.47 
 
3.65 
0.66 
0.01-12.9 
0.04-3.22 
 
0.02-1765 
0.05-5.35 
0.682 
0.489 
 
0.654 
0.720 
Table 5.11: Intrapulmonary pharmacokinetic indices and final treatment response 
As only 2 unfavourable outcomes were recorded in the Intrapulmonary Arm, the PK estimates for the whole cohort assessed here (n=121). Modelled estimates of AUC, AUC/MIC, Cmax, and 
Cmax/MIC are related to rates of favourable/unfavourable final outcomes by logistic regression. * OR adjusted for known confounding variables identified in earlier chapters: CXR score, baseline 
bacillary load, symptom duration and baseline respiratory rate. OR: odds ratio; 95% CI: 95% confidence interval. 
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5.4 Discussion 
 
This is the largest study of the intrapulmonary pharmacokinetics of first-line anti-TB therapy to date, 
using steady-state samples from patients with active pulmonary TB. These data show that the four 
first-line drugs have different abilities to penetrate epithelial lining fluid and alveolar cells, and all 
achieve higher concentrations in the lung than plasma.  
Given the conflicting data from plasma PK studies, it was hypothesised that site of infection PK may 
explain response to TB treatment. Similar to plasma, peak concentration of rifampicin in ELF was 
associated with more favourable final outcomes. There was a non-significant trend towards more 
favourable outcomes at 18-months in those with higher AUC and Cmax for rifampicin, isoniazid, and 
pyrazinamide in ELF and ACs, but this analysis was limited by a low number of unfavourable events in 
the cohort.  
Participants with lower ethambutol AUC/MIC or Cmax/MIC in alveolar cells or epithelial lining fluid 
had improved rates of 2 month culture conversion on adjusted analysis. Box and whisker plots show 
little difference in drug exposure between culture converters and non-converters, and this seems 
unlikely to be a real effect. This likely represents an incidental association as a result of outlying data 
points, or a spurious finding secondary to multiple comparisons, which may not be reproducible or of 
clinical significance. The following chapter will relate these PK indices to a continuous measure of 
bacillary elimination, and will offer greater resolution on any intrapulmonary PK-PD relationships.  
All patients in this study were receiving weight-based dosing of ATT according to international 
guidelines [100], and most patients were on appropriate mg/kg dosing (Chapter 4). While a range of 
drug exposures in plasma, ELF, and AC was seen, more pronounced PK-PD responses may be 
observed with increased dose. For rifampicin, doses up to 35 mg/kg result in “super-proportional” 
increases in plasma AUC, with improved early bactericidal activity [304, 308].  
Drug concentrations in epithelial lining fluid were several fold higher than plasma: nearly 50-fold for 
pyrazinamide, 15-fold for isoniazid, 4-fold for ethambutol, and 2-fold for rifampicin, and suggests 
that considerable anti-tuberculosis activity is present in this compartment. This differs from prior 
work by Conte et al in San Francisco, reporting that pyrazinamide ELF concentrations were 20-fold 
higher than plasma [233], isoniazid 3-fold higher in slow acetylators [208], but rifampicin ELF 
concentrations were one-fifth of plasma [345]. Where previous work occurred in healthy volunteers 
(with or without HIV infection), the samples in this study came from a cohort of adult patients with 
active pulmonary TB, many of whom were significantly immunosuppressed. Active inflammation, 
with increased permeability, cellular influx, and disruption of the blood-alveolar barrier may alter 
tissue drug penetration in those with ongoing infection, and partly explain the higher concentrations 
observed here [329]. Indeed, smoking, HIV-infection, and sepsis at baseline were all identified as 
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possible modulators of intrapulmonary drug penetration. However, no clear trends in ELF drug 
concentration with increasing right mid zone parenchymal involvement at baseline CXR were seen. 
There are some other important differences between this study and the previous work that explain 
the variances in PK profiles. Where previous work took single intrapulmonary samples after 5 days of 
single-drug treatment, this cohort had been taking quadruple therapy for 7-8 weeks by the time their 
first sample was taken. By this time, drugs will have reached steady-state, particularly important 
considering rifampicin auto-induction [141]. Additionally, samples were taken here at 3 timepoints 
post-dose. Peak intrapulmonary concentrations for rifampicin and isoniazid were seen 2-hours after 
drug administration, suggesting that single PK measurements at 4-hours post-dose will 
underestimate drug exposure. Furthermore, the volunteers in the previous studies were taking lower 
mg/kg doses of RHZE than the weight-based therapeutic doses prescribed in this study [208, 233, 
251, 345]. 
Previous data reported an association between slow acetylator status and higher intrapulmonary 
isoniazid concentrations [208]. Genotypic data were not collected here, but previous work on TB 
patients in Malawi found a high prevalence of slow acetylators [154][Sloan et al, unpublished data], 
that could also contribute to the higher isoniazid AUCs seen here.  
Differential drug penetration to ELF and AC can be explained by both the physicochemical properties 
of the drug, and the effects of active transport or drug efflux. Of the 4 first line drugs, pyrazinamide 
and isoniazid are smaller molecules, less protein-bound, and more hydrophilic than rifampicin [329, 
532]. These characteristics allow for greater penetration of ELF from alveolar capillaries, and will also 
enable rapid equilibration and good penetration of the caseum of granulomas [53, 210, 340]. By 
contrast, spatial LC-MS has demonstrated that rifampicin distributes slowly, but gradually 
accumulates in avascular caseum with repeated doses and remains detectable even after levels in 
plasma and uninvolved lung become undetectable [210]. As a large, hydrophobic molecule, 
rifampicin and its’ metabolites bind non-specifically to extracellular macromolecules or proteins in 
the caseum [210]. The data presented here demonstrate some accumulation within macrophages, 
but less than that seen for ethambutol. Macrophage uptake, and physicochemical properties that 
favour protein-binding in the caseum, may lead to sustained accumulation of rifampicin in cells and 
the caseum over time [210]. By these means, combined with potency against non-replicating bacilli 
[532, 533], rifampicin achieves excellent sterilising activity.   
Ethambutol concentrations in alveolar cells were nearly 15-fold greater than plasma, in agreement 
with previous studies [251, 329, 534]. Ethambutol has high macrophage uptake, but less caseum 
binding, with subsequent slow but substantial diffusion into caseum [534]. In contrast to rifampicin, 
ethambutol is poorly active against non-replicating Mtb [532, 534], and is unlikely to sterilise the 
caseum despite its’ favourable distribution. Instead, active transport of ethambutol into 
macrophages achieves high intracellular concentrations [349], and points to intracellular bacilli as a 
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main target of its’ anti-TB effectiveness. Resident macrophages are thought to derive from 
circulating monocytes during active disease, and measurement of concentrations of rifampicin and 
ethambutol in peripheral blood mononuclear cells of TB patients have shown comparable 
intracellular concentrations [535, 536]. Further drug partitioning may occur within intracellular 
compartments, and it is important to note that these concentrations represent whole cell only. 
Technical factors, errors, and assumptions made in the collection and analysis of BAL PK samples 
may lead to spurious conclusions if not considered. For one, samples taken at BAL do not represent 
true site of infection samples, but rather ‘near infection’ PK samples. The drug concentrations in ELF 
are of relevance to activity against free extracellular organisms, while intracellular drug 
concentrations may be extrapolated to those levels in the cellular mantle of granulomas. 
Furthermore, understanding the physicochemical properties of the drug allow us to assume that 
small, polar molecules such as isoniazid and pyrazinamide, having achieved high concentrations in 
ELF, will also penetrate the caseous material well.  
All intrapulmonary PK measurements were taken from the right middle lobe, with the assumption 
that they are representative of the whole lung. Ventilation-perfusion mismatch will result in greater 
drug exposure in the lower lobes of the lung [537], and disruption of the blood-tissue barrier at sites 
of infection may increase drug exposure as seen for fluoroquinolones in CNS TB [352].  No 
relationship between drug concentration and extent of parenchymal involvement was observed. By 
sampling from the same location in every participant it is possible to make comparisons between 
individuals. 
The method of BAL sampling introduces sources of variability into the PK measurements. Instillation 
of 200 ml of saline during the procedure results in an over 100-fold dilution of ELF. The LC-MS assay 
was successful in detecting drug in most samples at these low concentrations, but measures 
concentration in BAL rather than ELF. Assuming the urea concentration in plasma and ELF are in 
equilibrium, the urea dilution method estimates ELF volume in the BAL return [347, 348]. This 
method is imperfect: with longer BAL fluid dwell times, more urea diffuses into the BAL, artificially 
increasing the estimated of ELF volume, and reducing the estimates of ELF drug concentration. To 
minimise this, BAL dwell times were kept below 10 seconds. Traumatic BAL sampling, or right middle 
lobe inflammation may further alter the BAL urea measurements. 
Drug efflux from alveolar cells may follow the instillation of a large volume of BAL fluid, further 
compounded by cell lysis during sampling [329, 330, 349].  Moreover, the processing required to 
separate cell pellet from supernatant will result in additional drug loss. Previous work as part of the 
PI’s MRes project demonstrated that rapid centrifugation and separation of the cell pellet, and 
keeping samples cool, would reduce drug efflux and lysis during sampling (data not shown), built on 
work on intracellular accumulation of protease inhibitors [538]. In vitro studies of intracellular 
protease inhibitor efflux showed that 80% of saquinavir is lost within 5 minutes with washing and 
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extraction at 37oC, whereas use of cold centrifugation and ice-cold PBS in sample processing steps 
resulted in retention of >80% of cell-associated drug at 60 minutes. While ice-cold saline could not 
be used to collect clinical samples, BAL was placed immediately on ice, and centrifuged within 10 
minutes of collection. The high AC:ELF ratio for ethambutol, in agreement with previous work [251, 
534], shows that drug has successfully been retained in the cells by this sampling method. Though 
not possible to quantify the effect of cell lysis or drug efflux in these samples, consistency in the 
sample processing techniques here should minimise the effects of laboratory manipulation, and 
allow for comparison between study participants. 
Measurement of intracellular drug concentration is based on several assumptions; firstly that most 
of the cells retrieved are alveolar macrophages. AMs represent more than 90% of cells retrieved in 
healthy subjects [430], and immunophenotyping of BAL in Chapter 7 demonstrated that AMs were 
the most abundant cells retrieved. The first BAL aliquot will contain a greater proportion of epithelial 
cells, and as such, all samples were pooled. Given the mix of cells obtained, results are recorded as 
μg/ml of alveolar cells rather than μg/ml of alveolar macrophages. 
Secondly, the typical alveolar macrophage has a volume of 2.42 μl/106 cells. It was not possible to 
measure the cell volume in this work, and an estimate from the literature was used [329, 531]. This 
value has been used by other studies allowing ready comparison of the results [208, 233, 251, 345]. 
Alveolar macrophages are large cells, and the calculation of drug concentration for ‘alveolar cells’ 
using a volume denominator of 2.42 μl/106 cells will result in an underestimation of intracellular drug 
concentration. The high proportion of AMs retrieved in BAL will minimise this effect.  
Thirdly, the cell count is accurate. The cell count was obtained from the first pooled BAL Falcon Tube, 
immediately before centrifugation. Cell loss during centrifugation will result in fewer cells recovered 
than counted, and an underestimation of intracellular drug concentration by up to 20% [539]. Single 
centrifugation and minimal handing of the cell pellet will reduce this effect. Furthermore, only 
macrophages were counted at haemocytometry, with the effect that the measure of drug/106 cells 
would be over-estimated. Again, as macrophages form the majority of cells recovered, these effects 
are likely to be minimal, and the AC concentration is mainly a reflection of drug concentration in 
alveolar macrophages. Taken together, the effect of these sampling assumptions would 
underestimate the drug concentrations in the AMs.  
Use of block sampling and population PK modelling allows for some of the dynamics of tissue 
penetration to be seen, and in general, the intrapulmonary PK tended to mirror that of plasma. 
Despite observing concentrations in ELF and AC, attempts to fit 3-compartment mammillary or 
catenary models were unsuccessful. The parent plasma PK models were all 1-compartment in 
nature, and even when these peripheral compartments are observed, there was insufficient multi-
compartment character to the data to enable a stable fit. Modelling elimination from the peripheral 
lung compartments, such as in sputum or exhaled breath, may improve the model fit, but is likely to 
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lead to problems with model identifiability [540]. Extending the plasma sampling window out to 24 
hours might identify 2-compartment plasma PK for isoniazid or ethambutol [159, 167], but was 
impractical in this cohort. Even with intrapulmonary samples at different timepoints, the model 
struggles to predict the compartmental PK with high precision. 
The final models described a constant ratio between plasma and ELF or AC, with inter-individual 
variability. This model fit for all 4 drugs, and the estimates for RELF and RAC were in keeping with the 
trends seen on the scatterplots. Describing intrapulmonary PK by ELF:plasma or AC:plasma 
concentration ratios is typical in the literature [208, 233, 251, 345, 347, 522]. While this gives an 
indication of the extent of distribution to the intrapulmonary compartment, it cannot capture 
system hysteresis or the dynamics of intrapulmonary drug penetration. As these models assume 
instantaneous equilibration, if the equilibration is not rapid, exposure in plasma will not be a good 
marker of intrapulmonary exposure.  
Finally, all PK measurements here are for total drug (protein-unbound plus bound), whereas only the 
unbound fraction is pharmacologically active and able to be transported or diffuse in to the ELF [329, 
520]. This is particularly important for rifampicin, where up to 80% in plasma may be protein-bound 
[329]. ELF protein concentrations in children are around 10% of plasma [541, 542], and lacking a 
more relevant value for this population, it is reasonable to assume negligible protein binding in ELF. 
Failing to account for the extent of protein binding would incorrectly suggest poor penetration into 
this compartment. 
Descriptions of CSF:plasma ratio are met with similar challenges, and it is recommended that 
corrections are made for plasma protein binding for rifampicin or fluoroquinolones [352, 543, 544]. 
Given an unbound fraction of rifampicin in plasma of 20% [126, 329], the RELF/unbound-plasma ratio will be 
approximately five-fold greater than the RELF/total-plasma recorded here: 9.85 compared to 1.97. 
Estimating the effect and extent of protein binding within the cellular compartment is more 
challenging to account for, and as such must be reported as a RELF/total-plasma ratio. Differences in the 
extent of protein binding between plasma and alveolar cells limits the usefulness of this ratio for 
rifampicin.  
In conclusion, the data in this chapter show high concentrations of RHZE in epithelial lining fluid and 
alveolar cells, well in excess of baseline MICs for drug-sensitive Mtb. Differences in drug partitioning 
within the intrapulmonary compartment may be important when developing new regimens, both to 
reduce transmission, and to ensure adequate sterilisation of lesions.  
 
  
Chapter 5  Intrapulmonary pharmacokinetics 
 
Page 168 
  
Chapter 6  Pharmacodynamics 
 
  Page 169 
6 Pharmacodynamics 
6.1 Introduction 
 
In this cohort of patients with microbiologically-confirmed pulmonary TB, 37.3% of those with 
sufficient data remained culture positive at 2 months into treatment. Of the 114 participants with 
final outcome data at 18-months, 14 (12.3%) had an unfavourable outcome (treatment failure, 
death, or relapse). In this chapter, pharmacodynamic and microbiological endpoints are explored as 
early continuous measures of response to treatment, and related to the plasma and intrapulmonary 
pharmacokinetics of first-line drugs. 
Commonly used surrogates for relapse-free cure include 2MCC and time to culture conversion. While 
binary endpoints such as 2MCC and treatment failure or post-treatment relapse are simple to 
understand and interpret, the former has only modest correlation with final outcomes [66, 75, 76], 
and the latter requires lengthy follow up and large sample sizes [65]. Time to culture conversion 
offers a continuous measure of treatment response and more information than 2MCC alone, but is 
dependent on sampling frequency. 
The widespread adoption of automated liquid culture techniques has facilitated serial quantitative 
measures of bacillary load, offering greater resolution in monitoring response to treatment. Serial 
measures of TTP in culture, combined with mathematical modelling of bacillary elimination rates, 
have shown promise as an early surrogate marker of treatment response [89], but analysis can be 
computationally challenging. Furthermore, culture-based methods remain expensive, are prone to 
contamination, and can take up to 6 weeks to obtain a result.  As a treatment monitoring tool, they 
are limited to those with culture-confirmed PTB at baseline. 
DNA-based testing may address some of the limitations of culture-based methods. The Xpert 
MTB/RIF assay is a rapid, sensitive, commercially available PCR test that can accurately measure Mtb 
load beyond the detection limit of 131 organisms/ml in an in vitro suspension [545]. It is thought to 
only detect DNA from intact organisms, and may detect organisms not grown on conventional 
culture. Previous work has shown that Xpert MTB/RIF positivity may persist out to the end of TB 
treatment for up to a quarter of patients, when most smear and culture results have converted to 
negative [85]. Furthermore, Xpert MTB/RIF provides a semi-quantitative measure of bacillary load – 
the cycle threshold – that correlates well with the results of solid and liquid culture [546-548]. 
Mixed-effects modelling of serial cycle-threshold data, with partial likelihood modelling to account 
for negative / above limit of quantification samples [549, 550], may be a novel approach to using 
Xpert MTB/RIF as a treatment monitoring tool, and is explored in a pilot study in this chapter.  
Baseline minimum inhibitory concentrations for rifampicin, isoniazid, and ethambutol are described. 
RHZE efficacy is driven by AUC/MIC [261, 263-265], and to a lesser extent, the Cmax/MIC for RHE 
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[263-265], but limited data exists describing Mtb MIC distributions from most high-incidence TB 
settings [156, 279, 280]. At the end of this chapter, the PK indices generated in the preceding 
chapters are related to drug sensitivity (MIC) and bacillary elimination rates to better understand the 
interplay between drug exposure and microbiological response. 
 
  
Chapter 6  Pharmacodynamics 
 
  Page 171 
6.2 Methods 
6.2.1 Sputum smear microscopy 
 
Spot and overnight sputum samples were collected from participants at 5 points during the intensive 
phase of TB treatment, and once at the end of treatment. Samples were brought to the study office 
early in the morning on the day of collection, and transported to the MLW/CoM TB Laboratory as 
described in Chapter 2. On arrival at the laboratory, samples were logged and prepared for smear 
microscopy and liquid MGIT culture. 
Two microscopy methods were used: Auramine Phenol (AP) staining for serial sputum samples, and 
Ziehl Neelsen (ZN) staining of positive MGIT cultures. Slides were prepared in the same manner for 
both stains: glass slides were labelled with the participant ID number and the laboratory number, 
and the densest particles of sputa were selected and aspirated with a Pasteur pipette. The specimen 
was spread in a circular motion over an area of 1 x 2 cm, creating a thin smear on the slide. Slides 
were left to dry on a slide dryer for 5 minutes, then fixed by passing the slide through a flame 3-4 
times with the smear uppermost. A known positive and negative smear was included in every batch 
as a quality control measure, and whenever a newly prepared stain used.  
 
6.2.1.1 Auramine Phenol staining and microscopy 
6.2.1.1.1 Preparation of reagents 
AP solution 1 was made by dissolving 1 g of auramine in 100 ml 70% ethanol; solution 2 by dissolving 
30 g of phenol crystals in 900 ml distilled water. Solution 1 was filtered into solution 2. Decolourising 
solution (0.5% acid-alcohol) was prepared by mixing 5 ml of hydrochloric acid with 1000 ml 70% 
ethanol. Potassium permanganate counter stain was prepared by dissolving 5 g of potassium 
permanganate in 1000 ml of distilled water. All solutions were stored in amber bottles for a 
maximum of 3 months. 
 
6.2.1.1.2 Staining procedure 
Fixed slides were flooded with AP solution and stained for 15 minutes. Slides were rinsed with 
distilled water, and decolourised with 0.5% acid-alcohol for 2 minutes. Slides were again rinsed with 
distilled water, and flooded with potassium permanganate counter stain for 2 minutes. After a final 
rinse with distilled water, slides were air dried and read as soon as possible.  
 
6.2.1.1.3 Reading procedure 
Each slide was read by 2 independent readers. A third reader was employed in the event of 
discordant results. The positive control slide was read first. Slides were examined with the 40x 
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objective, making a series of systematic sweeps over the length of the smear (Figure 6.1). Mtb 
appeared as rod-shaped or curved, bright yellow emitting, bacilli against a dark background. A 
minimum of 70 fields were read before reporting as negative. AP slides were interpreted as per 
Table 6.1.  
 
 
Figure 6.1: Systematic smear microscopy 
Slides were moved longitudinally after examining a field to read the field immediately to the right. 
Grading Fields Interpretation 
‘negative’ 70 No bacilli seen 
‘doubtful’ 70 1-2 bacilli seen 
‘scanty’ or actual number counted 70 1 to 19 bacilli seen 
‘1+’ 50 2 to 18 bacilli seen 
‘2+’ 10 4 to 36 bacilli seen 
‘3+’ 1 10 to 90 bacilli seen 
Table 6.1: Interpretation of AP staining results 
 
6.2.1.2 Ziehl Neelsen staining and microscopy 
6.2.1.2.1 Preparation of reagents 
Carbol fuschin solution 1 was made by dissolving 3 g of basic fuschin in 100 ml 96% ethanol; solution 
2 by dissolving 50 g of phenol crystals in 900 ml distilled water. Solution 1 was added to solution 2 
and filtered into an amber bottle. Decolourising solution (3% acid-alcohol) was prepared by mixing 3 
ml of hydrochloric acid with 97 ml 70% ethanol. Methylene blue counter stain was prepared by 
dissolving 3 g of methylene blue in 1000 ml of distilled water. All solutions were stored in amber 
bottles; carbol fuschin and methylene blue for up to 12 months, decolourising agent for up to 6 
months. 
 
6.2.1.2.2 Staining procedure 
Fixed slides were flooded with carbol fuschin solution and stained for 15 minutes. During staining, 
slides were heated slowly until they were steaming, but not allowed to boil dry. Slides were heated 
to steaming 3 times at 5-minute intervals using a low or intermittent heat. Slides were rinsed with 
distilled water, and decolourised with 3% acid-alcohol for 3 minutes. If the carbol fuchsin stain was 
retained in the smear, the slide was under-decolourised and 3% acid-alcohol added for a further 
minute. Slides were again rinsed with distilled water, and flooded with methylene blue counter stain 
for 30 seconds. After a final rinse with distilled water, slides were air dried and read as soon as 
possible.  
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6.2.1.2.3 Reading procedure 
Slides were read in duplicate as for AP stained slides. Slides were examined with the 100x oil 
immersion objective, making a series of systematic sweeps over the length of the smear (Figure 6.1). 
Mtb appeared as fine red rods, slightly curved, 1-10 µm long. The bacilli may appear isolated, or in 
pairs or groups, standing out clearly against the blue background. A minimum of 100 fields were read 
before reporting as negative. ZN slides were interpreted as per Table 2.2.  
 
6.2.2 Xpert MTB/RIF 
 
The Xpert MTB/RIF assay (Cepheid) is an automated real time PCR assay that simultaneously detects 
Mtb and rifampicin resistance through identification of mutations in the rpoB gene [547]. Screening 
sputum samples were all processed using the Xpert MTB/RIF assay unless already performed by the 
NTP and the printed result seen. 
 
6.2.2.1 Sample preparation 
Raw sputum was used for this assay, without NALC-NaOH decontamination, as per manufacturer’s 
instructions [551]. In brief, Sample Reagent at a 2:1 ratio (v/v) was added to the raw sputum sample. 
The sample container’s lid was secured, and the sample shaken vigorously 10-20 times. The sample 
was left to liquefy at room temperature for 15 minutes, with further shaking halfway through the 
incubation.  
The liquefied sample was added to the sample chamber of the Xpert MTB/RIF cartridge using a 
sterile transfer pipette. The lid was secured, and the GeneXpert Instrument System turned on. The 
participant’s details were entered, the cartridge barcode scanned, and the cartridge loaded into the 
instrument module door. After 2 hours, the test would be complete, and the result available on 
screen for printing.  
 
6.2.2.2 Interpretation of results 
The assay is semi-quantitative, with a linear relationship between the Mtb-specific cycle threshold 
(CT) and the log of Mtb colony forming units present in the sample [552]. The assay has 5 rpoB 
probes, and automatically assigns each sample a semi-quantitative grade based on the CT of the first 
positive probe (‘High’: CT ≤ 16; ‘Medium’: CT > 16 and ≤22; ‘Low’: CT > 22 and ≤ 28; ‘Very low: CT >28 
and ≤38). ‘MTB DETECTED’ is reported when at least two probes result in CT values within the valid 
range and a delta CT min (the smallest CT difference between any pair of probes) is less than 2.0. ‘Rif 
Resistance DETECTED’ is reported if the delta CT max is >4.0 [551]. 
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All participants were required to have a positive result (‘MTB DETECTED’) with no evidence of 
rifampicin resistance. Results were captured onto a spreadsheet (‘Negative’, ‘Positive, rifampicin 
resistance NOT detected’, ‘Positive, rifampicin resistance detected’ or ‘Invalid / error’), and the CT 
value recorded. 
 
6.2.2.3 Monitoring tuberculosis treatment using Xpert MTB/RIF 
This was a nested sub study performed by Aaron Chirambo, SPITT Study Laboratory Technician, 
supported by the Helse Nord Tuberculosis Initiative. Raw sputum samples from the 50 participants in 
the Intrapulmonary Arm were retrieved from storage, thawed, and processed using the Xpert 
MTB/RIF assay. In addition, BAL supernatant was thawed, vortexed, and 15 ml transferred to 2 kDa 
NMWL Amicon Ultra-15 Centrifugal Filter Units (Merck). Samples were centrifuged at 2,700 x g for 
40 minutes to achieve a concentrated solution of 600 – 5,000 µl. 1.5 ml of Sample Reagent was 
added to 500 µl of concentrated BAL, and processed using the Xpert MTB/RIF assay. Results were 
recorded as a binary positive / negative, and the CT value of positive samples documented. 
This created a dataset of Xpert MTB/RIF results consisting of sputum samples taken at screening 
(week 0), S2 (weeks 3-4), S4 (weeks 7-8), and end of treatment (week 26), alongside BAL concentrate 
collected at weeks 7-8 and 15-16. Data analysis was performed by Aaron and the PI. The relationship 
between sputum smear grade, time-to-positivity in liquid culture, and Xpert MTB/RIF cycle threshold 
at the different time points was explored using logistic and linear regression. Bacillary elimination in 
sputum by Xpert MTB/RIF was modelled using the ‘nlme’ package in R and NONMEM as described 
later for the serial TTP results. 
 
6.2.3 Liquid MGIT culture 
 
6.2.3.1 Sputum sample decontamination 
Use of selective media supports mycobacterial growth, but may be contaminated by mycobacteria 
other than tuberculosis (MOTT), bacterial, and fungal pathogens [553] that overgrow any Mtb 
present. Contamination rates in the region of 2-30% of samples have been reported [496, 553-557], 
and as such, clinical specimens from non-sterile sites must be decontaminated before culture. 
Insufficient decontamination will result in high sample loss to contamination, whereas excessive 
decontamination may kill Mtb resulting in false negatives and underestimated measures of bacillary 
load [558, 559]. 
All study sputum samples collected were cultured in liquid media. Samples were processed within 24 
hours of receipt at the laboratory. Sputum samples were transferred to a 50 ml Falcon Tube by 
Pasteur pipette, and an equal volume of N-acetyl-L-cysteine / sodium hydroxide 3% (NALC-NaOH) 
added. Samples were decontaminated for 15 minutes, vortexing once during this time. 
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NALC-NaOH was neutralised by adding sterile pH 6.8 phosphate buffer up to the 50 ml mark of the 
centrifuge tube. The sample was inverted several times, and centrifuged at 3,000 x g for 20 minutes. 
Supernatant was discarded in Surfanios, and the pellet resuspended in the residual fluid and 0.5 ml 
of PBS. 
 
6.2.3.2 Liquid culture using BACTEC MGIT 960 
Liquid culture was performed using the BACTEC MGIT 960 automated mycobacterial detection 
system (Becton Dickinson) following manufacturer’s instructions. In brief, this system uses an 
oxygen-sensitive fluorescent compound embedded in silicone at the bottom of the culture tube 
(Figure 6.2). This compound is sensitive to the presence of oxygen dissolved in the broth, and 
fluoresces as the oxygen is used up by respiring organisms [553]. An instrument-positive tube 
contains approximately 105 to 106 CFU/ml [560]. 
 
Figure 6.2. MGIT tube and serpentine cording 
A: MGIT tube. The tube contains 7 ml of modified Middlebrook 7H9 broth, and OADC growth supplement and 
PANTA antibiotic mixture added before use. The orange at the bottom of the tube is the oxygen-sensitive 
fluorescent compound embedded in silicone. B: Serpentine cording of Mtb-complex in liquid media. From [561]. 
 
MGIT bottles containing 7 ml of modified Middlebrook 7H9 Broth base were labelled with participant 
and laboratory ID, and date. 1 vial of antibiotic mixture (PANTA: 6000 units polymyxin B, 600 µg 
amphotericin B, 2400 µg naladixic acid, 600 µg trimethoprim, 600 µg azlocillin) was reconstituted in 
15 ml of MGIT growth supplement (OADC) and 0.8 ml added to each MGIT tube before specimen 
inoculation. Using a sterile pipette, 0.5 ml of well-mixed concentrated specimen was added to the 
appropriately labelled MGIT tube, and mixed by inverting the tube several times. A positive (H37Rv 
or any known positive) and negative control were included in every batch. 
MGIT tubes were taken to the automated mycobacterial detection system and scanned in. Samples 
were placed in the assigned station in the drawer, and incubated at 37oC until the instrument flags 
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them as positive. After a maximum of 6 weeks, the instrument flags the tube as negative if no 
growth has been detected. 
 
6.2.3.3 Confirming culture positivity 
All positive MGIT cultures were further examined to confirm the presence of Mtb, and to identify any 
contaminants. A range of possible outcomes of these tests were possible, as described for 2MCC in 
Chapter 3, and illustrated in Figure 6.3. 
 
 
Figure 6.3: Flowchart for assigning TB culture results 
A positive result from liquid MGIT culture may indicate Mtb, contaminated Mtb growth (bacterial / fungal), or 
MOTT. ZN staining, MTP64 antigen testing, cording and growth on LJ slopes under different conditions were all 
used to differentiate between these conditions.  
 
Positive samples were removed from the automated detection system, concentrated by 
centrifugation, and a ZN smear prepared from the resuspended pellet as described above. Negative 
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ZN smears were returned to the incubator for a further 2 weeks. If subsequently confirmed 
identification as Mtb, these samples were reported as ‘initial contamination’. If not confirmed after 2 
weeks, the sample would be re-cultured from the stored pellet, and if still ZN negative, reported as 
‘final contamination’.  
Positive samples with AFB identified on ZN staining underwent further tests to confirm the presence 
of Mtb: examination for cording, MTP64 antigen testing, and culture on blood agar to identify 
contaminants. Mtb grown in liquid media display serpentine cording, with the AFB orientated in 
parallel along the long axis of the cord (Figure 6.2) [562]. Cord formation had a positive predictive 
value of 98.5%, and could be used for the presumptive identification of Mtb-complex [561]. As cord 
formation is typically absent in cultures of MOTT, this was used as one of the criteria to identify Mtb-
complex. 
A second test used a lateral flow immunochromatographic assay to detect the Mtb-complex-specific 
MTP64 antigen. This assay detects the secreted protein MTP64, found in unheated culture fluids 
from Mtb-complex [563-565]. The presence of Mtb rather than MOTT was confirmed using the MGIT 
TBc Identification Test with 100 µl of resuspended cell pellet (Becton Dickinson) [566, 567]. 
Confirmation of Mtb required identification of cording on ZN staining, and MTP64 antigen positivity. 
Confirmation of Mtb culture positivity did not exclude the possibility of contamination with 
additional bacterial or fungal organisms in the culture. As the TTP was used as a measure of bacillary 
load, contaminating organisms may shorten the TTP and give a false measure of bacillary burden. 50 
µl of cell pellet from positive cultures, with Mtb confirmed by cording and MTP64 antigen testing, 
was plated onto blood agar and incubated for 48 hours at 37oC. Should any bacterial or fungal 
organisms grow, the sample was reported as ‘mixed contamination’. 
Positive samples with no cording on ZN stain, or MTP64 antigen negative, underwent further 
investigation for MOTT by assessing for growth at different temperatures with and without 
paranitrophenol benzoic acid (PNB). MOTT will grow on Lowenstein-Jensen (LJ) at 25oC, 37oC, and 
45oC, in the presence or absence of PNB [568, 569]. Mtb will only grow on the LJ slopes at 37oC with 
no additional PNB. 
LJ slopes were prepared as per WHO/IUATLD guidelines [570]. Positive samples were inoculated 
onto 3 LJ-only slopes, incubated at 25oC, 37oC, or 45oC, and 1 LJ slope containing 500 mg/l PNB 
incubated at 37oC. Positive and negative controls were included with every batch. Growth only on 
the LJ-only slope indicated Mtb, whereas growth on any of the other slopes indicated MOTT. As 
before, samples identified as Mtb were cultured on blood agar to identify mixed contamination. 
Mtb-positive isolates were stored in 30% glycerol at -80oC. 
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6.2.3.4 Determining time-to-positivity 
The BACTEC MGIT 960 automated mycobacterial detection system scans the MGIT tubes every 60 
minutes for increasing fluorescence. Time to positivity is output by the instrument as the time 
between the start of incubation and the detection of growth to the nearest hour.  
Final culture results (Figure 6.3) with the TTP were recorded on a spreadsheet and uploaded to the 
study server. TTP results for negative (> 42 days), contaminated, re-cultured, and MOTT cultures 
were not included in the analysis. 
 
6.2.4 Mixed effects modelling of TTP data 
 
Mixed effects modelling of TTP data was performed using the ‘nlme’ package in R. Participants 
required 2 or more TTP measurements from serially collected sputum samples collected in the 
intensive phase of treatment for this analysis. TTP data were transformed into the log of the 
reciprocal (log10(1/TTP)), subsequently referred to as the transformed TTP, to show a decline in 
bacillary load over time. 
Several different models were attempted: a linear mixed effects model of Mtb-positive TTP results 
only, linear mixed effects models with an imputed TTP value of 43 days for the first negative culture, 
and non-linear mixed effects models. Attempts to model curvature with quadratic and spline 
functions were met with non-convergence, and consequently a linear mixed effects model was 
adopted. This took the form: 
 log10(
1
𝑇𝑇𝑃
) = 𝑎 + 𝑏 ∗ 𝑑𝑎𝑦𝑠 𝑜𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
where a represented the intercept (modelled baseline bacillary load), and b the slope (bacillary 
elimination rate: BER). Random effects on a and b were included in the model.  
To account for TTP results above the limit of quantification (LOQ, 42 days using the BACTEC MGIT 
960), a partial likelihood approach using the M3 method (Laplacian) was adopted [549, 550]. 
Observations above the LOQ are treated as fixed-point censored observations, and the maximum 
likelihood estimation method used to fit the PD model to all the observations. The likelihoods for the 
above LOQ observations are taken to be the likelihoods that these observations are indeed above 
LOQ. The partial likelihood method was performed in NONMEM VII version 3.0 (Icon Development 
Solutions), and the control stream included in Appendix J: Pharmacodynamics NONMEM control 
stream.  
Basic goodness-of-fit diagnostics were used to evaluate systematic errors and model 
misspecification. The minimal OFV (equal to -2 log likelihood) was used as a goodness-of-fit metric 
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with a decrease of 3.84 corresponding to a statistically significant difference between models 
(p=0.05, χ2 distribution, one degree of freedom). Residual plots were also examined.  
 
6.2.5 MIC determination 
 
For an antibiotic dose to effectively kill an organism, it must achieve a certain threshold exposure 
above the MIC at the site of infection [571]. AUC/MIC and Cmax/MIC are key PK-PD indices in 
understanding drug efficacy. Baseline drug susceptibility of screening isolates was measured on 
custom-made microtitre plates (UKMYC3 Sensititre, Thermo Scientific). These assays used 96 well 
plates with increasing concentrations of rifampicin (0.015-16 µg/ml), isoniazid (0.015-16 µg/ml), and 
ethambutol (0.25-16 µg/ml) (Figure 6.4). Pyrazinamide was not assessed due to its’ need for acidic 
test conditions.  
84 plates were available, with each plate containing space for 1.5 samples run in duplicate. Only 
participants with uncontaminated isolates of Mtb on screening samples were included in this 
analysis. Mtb isolates were retrieved from -80oC storage, and revived by incubating in liquid MGIT 
culture. Once flagged as positive on the automated mycobacterial detection system (approximately 
105 to 106 CFU/ml [560]), the Mtb isolates were inoculated onto LJ slopes and read weekly 
thereafter. Mtb colonies appeared as rough, crumbly, waxy, non-pigmented or cream/yellow 
coloured colonies, and microscopic confirmation using ZN staining confirmed that the colonies were 
AFB. 
All MIC work was completed in the Containment Level 3 facility at the MLW/CoM Hit TB Hard 
Laboratory. Colonies were scraped from the LJ slope and emulsified in a tube containing saline, 0.2% 
Tween, and glass beads. Samples were vortexed for 30 seconds, and allowed to settle for 15 
minutes. Turbidity was adjusted to 0.5 McFarland standard (approximately 1.5 x 108 cfu/ml, 
absorbance 0.08 to 0.1) using a 600 nm optical density reader (Biochrom). 100 µl of the suspension 
was transferred to a Falcon Tube containing 10 ml 7H9 broth supplemented with 10% OADC, 
vortexed for 30 seconds, and allowed to settle for 15 minutes. 100 µl was transferred into each well 
of the microtitre plate, sealed, and placed in the incubator at 37oC. Plates were incubated for 10 
days before inspection for growth. If growth was poor after 10 days, the plates were rechecked at 14 
and 21 days. 
Plates were read when growth was clearly visible in the 3 positive control wells for each sample 
(Figure 6.4). The MIC was recorded as the lowest concentration with no visible growth for each 
antibiotic. Each plate was read independently by 2 readers, and each sample duplicated. Samples 
were repeated from a fresh inoculum if there was a discrepancy between the results from duplicate 
assessment or between the 2 readers. 
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Figure 6.4. MIC microtitre plates 
A: Layout of MIC plates. 3 samples, or 1.5 in duplicate, could be run per plate. Each sample has 3 positive 
controls in the top row, with the 3 antibiotics at increasing concentration in the remaining wells. B: MIC plate 
(underside) showing Mtb growth. Mtb colonies appear as chalky circles in the bottom of the well. The positive 
controls (boxed, red) must show growth for the plate to be read. Plate photographed from underside to better 
show colonies. POS CON: positive control; RIF: rifampicin; INH: isoniazid; EMB: ethambutol. Concentrations in 
µg/ml. 
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6.2.6 PK-PD Modelling 
 
The plasma, ELF, and AC PK indices (AUC0-∞ and Cmax) generated in Chapters 4 and 5 were used to 
inform the PK-PD modelling. AUC/MIC and Cmax/MIC were calculated from measurements of baseline 
MIC above.  
Two pharmacodynamic responses were assessed: BER from mixed effects modelling of serial 
transformed TTP data, and time-to-negativity (TTN). Both give slightly different pharmacodynamic 
information: the BER measures the decline in bacillary load over time on treatment, and the TTN 
combines information on both BER and baseline bacillary load. 
Log-transformed PK indices were included as covariates in the final BER model developed in 6.2.4 
above. Covariates were added to the base model as shown below. 
𝑇𝑉(𝐵𝐸𝑅) = 𝜃𝐵𝐸𝑅 + (𝜃𝑃𝐾 ∗ (
𝑃𝐾
𝑚𝑒𝑎𝑛𝑃𝐾
)) 
The typical value for BER (TV(BER)) was calculated from the sum of the fixed/population effect for 
BER (θBER) and the fixed effect for the log-transformed PK parameter (θPK), multiplied by the 
standardised PK parameter. Inter-individual effects were included on TV(BER). Analysis was 
restricted to those with observations in the compartment of interest. PK-BER relationships were 
considered significant if associated with a decrease in OFV (>3.84, p=0.05, χ2 distribution, one degree 
of freedom), with improved goodness of fit plots and parameter estimate precision. 
TTN was calculated using the equation below: 
𝑇𝑇𝑁 =
𝐿𝐿𝑄 − 𝑎
𝑏
 
where LLQ was the transformed TTP limit of quantification (log10(1/42 days)), a the intercept, and b 
the slope, generated from mixed effects modelling above. Univariate linear regression was used to 
explore the relationships between PK indices and TTN. 
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6.3 Results: smear, culture, and Xpert MTB/RIF conversion 
6.3.1 Sample collection and contamination 
 
A total of 990 sputum samples were collected and analysed by smear microscopy and liquid culture. 
138 (14%) cultures were contaminated (Figure 6.5), of which 62 were initial or mixed contamination 
with Mtb also identified in the sample. Only 2 samples were identified as containing a MOTT. 
Bacillary load data from contaminated samples were discarded. 460/990 (46.5%) of samples grew 
pure cultures of Mtb.  
 
 
Figure 6.5: Sputum culture contamination rates at different study visits 
Pre-treatment: samples collected at TB diagnosis as part of extended monitoring and evaluation; Screening: 
week 0; S1: weeks 1-2; S2: weeks 3-4; S3: weeks 5-6; S4: weeks 7-8; EOT: end-of-treatment at week 26.   
 
6.3.2 Two-month smear conversion 
 
926 sputum smear microscopy results were available. 836 were collected by the study, and a further 
90 diagnostic sample results were made available by the NTP and Hit TB Hard Study.  
The number of smear-positive samples declined over time, with only 4 participants remaining smear-
positive after 6 months of treatment. 35 (22.4%) were already smear-negative on their screening 
sample. This spot sample was typically taken on day 0 of treatment, but ranged up to a maximum of 
5 days into treatment. After 1 or 2 doses of RHZE, some participants with lower bacillary loads may 
be expected to have already smear-converted. Scanty and doubtful smear results were counted as 
positive, though may be reported as inconclusive in some laboratories. 
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Smear 
status 
NTP 
diagnostic 
sample  
(n=90) 
Screening  
Week 0 
(n=156) 
S1  
Weeks 1-2 
(n=147) 
S2 
Weeks 3-4 
(n=140) 
S3  
Weeks 5-6 
(n=131) 
S4 
Weeks 7-8 
(n=136) 
End-of-
treatment 
Week 26 
(n=126) 
Negative 
(n, %) 
0 (0.0) 35 (22.4) 48 (32.7) 61 (43.6) 70 (53.4) 90 (66.2) 122 (96.8) 
Positive 
(n, %) 
 
Scanty 
1+ 
2+ 
3+ 
90 (100.0) 
 
 
4 (4.4) 
17 (18.9) 
24 (26.7) 
45 (50) 
121 (77.6) 
 
 
11 (7.1) 
21 (13.5) 
26 (16.7) 
63 (40.4) 
99 (67.3) 
 
 
11 (7.5) 
15 (10.2) 
26 (17.7) 
47 (32) 
79 (56.4) 
 
 
16 (11.4) 
16 (11.4) 
22 (15.7) 
25 (17.9) 
61 (46.6) 
 
 
15 (11.5) 
20 (15.3) 
16 (12.2) 
10 (7.6) 
46 (33.8) 
 
 
16 (11.8) 
11 (8.1) 
13 (9.6) 
6 (4.4) 
4 (3.2) * 
 
 
3 (2.4) 
1 (0.8) 
0 (0.0) 
0 (0.0) 
Table 6.2: Sputum smear status over time on treatment 
* Patients with any degree of smear-positivity at end of treatment were referred back to the NTP for 
consideration of re-treatment. 
Smear conversion required a positive smear at baseline, converting to negative smear, without 
subsequent reversion to positive (stable conversion). 130/157 (82.8%) participants had at least one 
positive smear result, and 115/157 (73.3%) participants had sufficient data to assign a two-month 
smear conversion (2MSC) outcome. 70/115 (60.9%) had smear converted by 2 months (Figure 6.6).  
 
6.3.3 Two-month culture conversion 
 
142/157 (90.4%) participants had at least one confirmed Mtb culture. Additional ‘pre-treatment’ 
culture results were available from the Hit TB Hard extended monitoring and evaluation (M&E) 
programme. Sputum samples were collected from the NTP offices at the time of TB diagnosis, and 
cultured using the same liquid MGIT culture protocol, in the same laboratory, by the same 
personnel. Pre-treatment culture results were available for 140 study participants. Sputum culture 
results are summarised in Table 6.3. Participants with no positive culture results were withdrawn 
from this analysis. 
Culture status 
Total participants 
n=142 
M&E pre-
treatment 
sample  
(n=140) 
Screening  
Week 0 
(n=141) 
S1  
Weeks 1-2 
(n=133) 
S2 
Weeks 3-4 
(n=126) 
S3  
Weeks 5-6 
(n=117) 
S4 
Weeks 7-8 
(n=122) 
End-of-
treatment 
Week 26 
(n=111) 
Negative 
(n, %) 
 
Culture negative 
Final contamination 
MOTT 
18 (12.9) 
 
 
16 (11.4) 
0 (0.0) 
2 (1.4) 
12 (8.5) 
 
 
10 (7.1) 
2 (1.4) 
0 (0.0) 
23 (17.3) 
 
 
18 (13.5%) 
5 (3.8%) 
0 (0%) 
55 (43.7) 
 
 
45 (35.7) 
10 (7.9) 
0 (0.0) 
56 (47.9) 
 
 
45 (38.5) 
11 (9.4) 
0 (0.0) 
75 (61.5) 
 
 
66 (54.1) 
9 (7.4) 
0 (0.0) 
110 (99.1) 
 
 
101 (91.0) 
9 (8.1) 
0 (0.0) 
Positive 
(n, %) 
 
Positive, Mtb 
Initial contamination 
Mixed contamination 
122 (87.1) 
 
 
115 (82.1) 
7 (5.0) 
0 (0.0) 
129 (91.5) 
 
 
116 (82.3) 
7 (5.0) 
6 (4.3) 
110 (82.7) 
 
 
91 (68.4) 
14 (10.5) 
5 (3.8) 
71 (56.3) 
 
 
55 (43.7) 
14 (11.1) 
2 (1.6) 
61 (52.1) 
 
 
46 (39.3) 
12 (10.3) 
3 (2.6) 
47 (38.5) 
 
 
37 (30.3) 
8 (6.6) 
2 (1.6) 
1 (0.9) * 
 
 
0 (0.0) 
1 (0.9) 
0 (0.0) 
Table 6.3: Sputum culture status over time on treatment 
Serial sputum samples were decontaminated and cultured in MGIT. Only the 142 participants with at least one 
positive culture are shown here. * Participants with a positive culture at end of treatment were referred back to 
the NTP for consideration of re-treatment.   
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38.5% of samples remained culture-positive for Mtb at the end of the intensive phase. 2MCC was 
defined as positive Mtb culture at baseline, converting to negative culture by week 8 of treatment, 
without subsequent reversion to positive (stable culture conversion). 126 participants had sufficient 
data to assign this endpoint, with 79/126 (62.7%) culture converting by 2 months. Figure 6.6 is a 
Kaplan-Meier plot of time to smear and culture conversion. The time to culture conversion (TTCC) 
was taken as the midpoint between the last positive and first negative culture for each participant. 
The median TTCC was 30 days [IQR 15-42 days]. 
 
 
Figure 6.6: Kaplan-Meier plot of time to smear and culture conversion 
Smear conversion: blue dotted line (n=115); culture conversion: red solid line (n=126). 
 
6.3.4 Xpert MTB/RIF conversion 
 
These data were collected and analysed by the study laboratory technician and the PI. Samples from 
43 of the participants in the Intrapulmonary Arm were assessed. 197 sputum samples taken during 
the intensive phase and at treatment completion were processed, alongside 74 concentrated BAL 
samples. Only one BAL sample, taken at the first bronchoscopy, was positive on Xpert MTB/RIF 
testing.  
There was a clear relationship between both smear grade, transformed TTP, and cycle threshold, and 
in keeping with the trends in smear and culture status on treatment, cycle threshold increased over 
time (Figure 6.7). 4/34 (11.8%) of samples remained Xpert MTB/RIF-positive at the end of TB 
treatment (Figure 6.8). Section 6.5.6 explores the use of modelled BER by serially collected Xpert 
MTB/RIF cycle threshold as a treatment monitoring tool.  
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Figure 6.7. Sputum cycle threshold and bacillary load 
A: Sputum cycle threshold on Xpert MTB/RIF was closely correlated with smear grade. The red dashed line 
represents the limit of detection. B: Sputum cycle threshold on Xpert MTB/RIF was closely correlated with 
transformed TTP in liquid (MGIT) culture. Transformed TTP (log10(1/TTP)) is a measure of bacillary load. TTP and 
cycle threshold data from all participants pooled for these plots. 
 
Figure 6.8: Sample positivity by diagnostic modality 
4/34 (11.8%) of samples remained positive by Xpert MTB/RIF testing after 26 weeks of treatment. 
 
 
 
 
 
 
A B 
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6.4 Results: microbiological predictors of response 
6.4.1 Two-month culture conversion 
 
Predictors of 2MCC are explored in Chapter 3. The relationship between plasma and intrapulmonary 
pharmacokinetics of ATT and 2MCC were explored in Chapters 4 and 5.  
 
6.4.2 Baseline bacillary load 
The time-to-positivity in liquid culture was used as a measure of bacillary load, with greater 
transformed TTP values representing a heavier bacillary burden. On exploratory univariate linear 
regression (Table 6.4), CXR score, cavitation on baseline CXR, and baseline haemoglobin were 
associated with baseline bacillary load. On multivariate analysis, only CXR score had a significant 
relationship to baseline bacillary load (estimate: 0.002; SE: 0.001; p=0.030), with higher CXR scores 
associated with higher bacillary loads. Those with higher bacillary loads were less likely to culture 
convert by 2 months (Figure 6.9). 
 
Variable Univariate analysis Multivariate analysis 
Estimate SE p value Estimate SE p value 
Age (years) -0.003 0.002 0.210 - - - 
Male sex -0.012 0.052 0.813 - - - 
Duration of symptoms 
(weeks) 0.007 0.005 0.194 - - - 
Ever smoked tobacco 0.052 0.044 0.246 - - - 
Ever drank alcohol -0.009 0.044 0.835 - - - 
HIV infected -0.008 0.044 0.866 - - - 
Baseline CD4 (cells/mm3) 0.000 0.000 0.312 - - - 
Change in CD4 (cells/mm3) 0.000 0.000 0.982 - - - 
BMI (kg/m2) -0.012 0.009 0.175 - - - 
Change in weight over 
treatment in kg 0.005 0.006 0.367 - - - 
Baseline pulse (bpm) 0.000 0.001 0.696 - - - 
Baseline respiratory rate 
(bpm) -0.004 0.005 0.392 - - - 
Clinically septic at baseline* -0.056 0.064 0.382 - - - 
Baseline haemoglobin 
(g/dl) -0.021 0.012 0.091 -0.017 0.012 0.166 
Baseline white cell count 
(x103/μl) 0.011 0.008 0.160 - - - 
Baseline monocyte-
lymphocyte ratio 0.027 0.049 0.58 - - - 
Baseline creatinine 
clearance (ml/min) 0.000 0.001 0.561 - - - 
Baseline bilirubin (μmol/l) 0.001 0.003 0.69 - - - 
Baseline ALT (IU/l) 0.002 0.001 0.106 - - - 
CXR score 0.002 0.001 0.019 0.002 0.001 0.030 
No cavitation on CXR -0.076 0.044 0.083 - - - 
Table 6.4: Univariate and multivariate analysis of factors influencing baseline transformed TTP 
Transformed TTP (log10(1/TTP)) is a measure of bacillary load.  Variables significant to p<0.10 on univariate 
testing included in the multivariate analysis. Cavitation not included in the multivariate analysis due to 
collinearity with CXR score. * Based on source of infection, and 2 or more of: temperature <36oC or >38oC, pulse 
>90 beats per minute, respiratory rate >20 breaths per minute, white cell count <4 or >12 x 103/µl. SE: standard 
error. 
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Figure 6.9: Two-month culture conversion versus baseline transformed TTP 
Transformed TTP (log10(1/TTP)) is a measure of bacillary load. Participants with lower bacillary loads were more 
likely to convert. 
 
6.4.3 Time-to-culture conversion 
 
TTCC was associated with multiple predictor variables on exploratory univariate analysis: age, male 
sex, HIV status, baseline CD4, baseline pulse, baseline white cell count, creatinine clearance, ALT, 
CXR score and presence of cavitation. On multivariate analysis, male sex (estimate: -9.097; SE: 3.654; 
p=0.016) and higher baseline pulse (estimate: -0.229; SE: 0.084; p=0.009) were associated with 
shorter TTCC. Participants with a higher baseline bacillary load had a shorter time to culture 
conversion (p=0.004, Figure 6.10).  
 
Figure 6.10: Time to culture conversion versus baseline transformed TTP 
Participants taking longer to culture convert were more likely to have a higher baseline transformed TTP. 
Transformed TTP (log10(1/TTP)) is a measure of bacillary load. 
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6.5 Results: modelling bacillary elimination rate 
6.5.1 Description of dataset 
 
TTP data from Mtb-positive cultures were used to model changes in bacillary load over time. From 
990 sputum cultures, 522 (52.7%) grew Mtb. 62 of these samples were contaminated and their TTP 
result discarded. Pre-treatment TTP results were available for several participants, collected through 
the extended M&E programme (see Chapter 2) and included in this total. As participants could only 
have one baseline result, the criteria below were used to choose the baseline specimen: 
• Screening culture Mtb positive at day 0 – this was the baseline TTP 
• Screening culture Mtb negative, but M&E result positive – the latter was the baseline TTP 
• M&E culture Mtb positive at day 0 and screening culture Mtb positive at day 1 or later – the 
former was the baseline TTP, the latter counted as a ‘late screening’ result 
• M&E culture negative and screening culture Mtb positive at day 1 or later – the latter was 
the baseline TTP  
By adopting these criteria, it was possible to increase the size of the dataset, and collect more results 
as close to the start of TB treatment as possible. For 110 participants, the TTP data collected by the 
SPITT Study were used for the baseline bacillary load, and in 17 participants, the M&E data were 
used. In 30 participants, the M&E data were used for the baseline, with an additional data point 
provided by the later SPITT screening sample. As pharmacodynamic modelling requires at least 2 
positive results per participant, the final dataset for modelling contained TTP data from 390 cultures. 
TTP results were transformed into the log of their reciprocal (transformed TTP) prior to modelling. 
Transformed TTP, and therefore bacillary load, decreased on treatment, though there was 
considerable variability in results over time. Figure 6.11 shows the trends in transformed TTP over 
time by participant.  
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Figure 6.11. Transformed TTP over time 
A: Transformed TTP decreases over time on treatment. Transformed TTP (log10(1/TTP)) is a measure of bacillary 
load. The distinction between ‘screening’ and ‘late screening’ is described in the text. S1: weeks 1-2; S2: weeks 3-
4; S3: weeks 5-6; S4: weeks 7-8. The red line represents the limit of detection in MGIT culture: log10(1/42 days). 
Samples that have not flagged positive after 42 days in culture were recorded as negative. B: Spaghetti plot of 
Mtb-positive results over time, each colour representing a different participant. The black line represents the line 
of best fit. 
 
A 
B 
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Figure 6.12: Facet plot of transformed TTP versus days on treatment by participant 
The numbers represent the participant ID. Only Mtb-positive samples are shown, and contaminants removed. 
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6.5.2 Modelling approaches 
 
6.5.2.1 Structural model 
Four main structural models were attempted to describe the pharmacodynamic data: monophasic 
linear, biphasic linear, curvilinear quadratic, and nonlinear biexponential models (Table 6.5). The 
latter model failed to converge, and inclusion of a quadratic term did not significantly improve the 
model fit. Despite considerable variability (Figure 6.11 and Figure 6.12), the relationship between 
transformed TTP and time appeared to be linear. 
Biphasic decline in bacillary load has been described using serial log10CFU/ml counts [72, 74, 77]. 
While possible to fit a biphasic model to the transformed TTP data, this made little impact on the AIC 
(biphasic AIC: 1135.975; monophasic AIC: 1136.802), and the alpha slope parameters were 
estimated poorly (estimate -0.626, SE 1.317, CV 210%). Subsequent models were constructed using 
linear mixed effects (LME) modelling with monophasic decline in transformed TTP. 
Structural model Equation Parameter estimates AIC 
Parameter Estimate SE %CV 
Monophasic linear  𝑦 = 𝑎 + 𝑏𝑥 a 
b 
-0.993 
-0.008 
0.016 
0.001 
1.6 
10.6 
1136.802 
Biphasic linear α slope: 
𝑦 = 𝑎𝛼 + 𝑏𝛼𝑥 
* 
β slope: 
𝑦 = 𝑎𝛽 + 𝑏𝛽𝑥 
† 
 
aα 
bα  
aβ 
bβ 
 
-1.756 
-0.626 
-1.036 
-0.007 
 
0.202 
1.317 
0.030 
0.001 
 
11.5 
210.4 
2.9 
17.6 
1135.975 
Curvilinear / 
quadratic 
𝑦 = 𝑎 + 𝑏𝑥 + 𝑐𝑥2 a 
b 
c 
-0.917 
-0.012 
0.00007 
0.020 
0.002 
0.00005 
- 
- 
- 
-12.622 
Nonlinear negative 
biexponential 
Non-convergence 
Table 6.5: Structural model building process 
* α slope represents the initial decline in bacillary load: the early bactericidal activity. † β slope represents the 
sterilising activity. AIC: Akaike information criterion. 
 
6.5.2.2 Handling missing data 
Samples not flagged as positive after 42 days in MGIT culture are recorded as negative, but in reality 
have a TTP result ranging from 43 days to infinity. Several approaches may be used to handle data 
above or below the limit of quantification [549]. The approaches attempted here included: 
• Original dataset: discard observations below the lower limit of quantification (LLQ 
log10(1/TTP)=-1.623) and apply extended least squares to remaining Mtb-positive 
observations (Beal Method 1, M1). 
• Imputed dataset: replace first observation below LLQ with an imputed value of -1.633 (TTP 
43 days) and discard remaining negative observations (Beal Method 7, M7). 
• Partial likelihood dataset: maximise the likelihood for all the data, treating below LLQ 
observations as censored (Beal Method 3, M3, Laplacian).  
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6.5.3 Linear mixed effects modelling of transformed TTP data 
 
6.5.3.1 Original dataset 
110/157 (70.1%) participants had two or more TTP results for LME modelling. A total of 361 
observations were available in this dataset. The maximum likelihood method was used to fit an LME 
model to the data, with random effects on the intercept and slope. Table 6.6 summarises the model. 
 
 
The LME model of the original dataset estimates a baseline transformed TTP of -0.927 (intercept, a), 
with a decrease in transformed TTP of -0.009 per day on TB treatment (slope, b), or by -0.063 per 
week. Figure 6.13 shows the diagnostic plots for the LME model. Other than a few outlying points, 
the standardised residuals and random effects are near-normally distributed, and there is no 
systematic increase in the variance as the level of the observed response increases. As such, the LME 
model assumptions are not violated. 
 
LME model fit by maximum likelihood (original dataset) 
AIC -51.316 -logLik 31.658 
Fixed effects, log10(1/TTP) ~ days on treatment 
 Estimate SE p value 
Intercept (a) -0.927 0.017 <0.001 
Slope (b) -0.009 0.001 <0.001 
Random effects, ~1 + days | participant  
 SD  
Intercept (a) 0.101 
Slope (b) 0.002 
Residual 0.193 
Table 6.6: Parameter estimates for LME model of original dataset 
Model fit by maximum likelihood. The intercept (a) represents the baseline bacillary load, and the slope (b) the 
bacillary elimination rate. AIC: Akaike information criterion; -logLik: negative log likelihood; SE: standard error; 
SD: standard deviation.  
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Figure 6.13: Diagnostic plots for LME model of original dataset 
A: distribution of standardised residuals versus fitted values. Few samples had residuals greater than ±2, and the 
residuals were mainly clustered around 0. There was no heteroscedasticity seen. B: Q-Q plot of standardised 
residuals versus quantiles of standard normal distribution. Other than a few outlying values, the plot is near 
linear and symmetrical around 0. C: Q-Q plot of random effects versus quantiles of standard normal distribution. 
  
6.5.3.2 Imputed dataset 
By including an imputed value of log10(1/43 days) for the first negative sputum result, it was possible 
to model serial transformed TTP data from 115/157 (73.2%) participants using 368 samples. The 
model fit is summarised in Table 6.7. By including first negative results, the estimate of BER is 
increased to -0.015 per day on treatment (-0.105 per week). The LME model fit was poorer with the 
imputed dataset, with a higher AIC and greater residuals.  
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6.5.3.3 Partial likelihood dataset 
Partial likelihood modelling (PLM) was used to handle data below LLQ, implemented in NONMEM. 
This approach used a dataset containing all non-contaminated transformed TTP results, with an 
additional variable flagging observations below LLQ. Several structural models were attempted - 
random effects on slope and/or intercept, a covariance block, or variance function - and the data 
were best described by a LME model with random effects on intercept and slope (Table 6.8, 
Appendix J: Pharmacodynamics NONMEM control stream). An additive model was used for random 
effects. 
531 observations from 130/157 (82.8%) participants were modelled using the PLM method. The 
model estimated a baseline transformed TTP of -0.900, with a decrease in transformed TTP of -0.016 
per day on treatment (-0.112 per week). Residual standard error on the fixed effects was less than 
10%, and on random effects less than 30%. Model diagnostic plots are shown in Figure 6.14. The 
residuals increase with the size of the fitted values. Figure 6.15 shows the modelled BER for each 
participant.  
 
 
 
 
 
 
 
LME model fit by maximum likelihood (imputed dataset) 
AIC 75.033 -logLik -31.516 
Fixed effects, log10(1/TTP) ~ days on treatment 
 Estimate SE p value 
Intercept (a) -0.963 0.019 <0.001 
Slope (b) -0.015 0.001 <0.001 
Random effects, ~1 + days | participant  
 SD  
Intercept (a) 0.110 
Slope (b) 0.004 
Residual 0.229 
Table 6.7. Parameter estimates for LME model of imputed dataset 
Model fit by maximum likelihood. The intercept (a) represents the baseline bacillary load, and the slope (b) the 
BER. AIC: Akaike information criterion; -logLik: negative log likelihood; SE: standard error; SD: standard 
deviation. 
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Figure 6.14. Diagnostic plots for PLM LME model 
A: Distribution of standardised residuals versus fitted values. B: Histogram and density plot for ETA1 (random 
effects on intercept) and ETA2 (random effects on slope). C: Q-Q plot of plot of random effects versus quantiles 
of standard normal distribution. 
 
PLM LME model fit by maximum likelihood (partial likelihood dataset) 
Fixed effects, log10(1/TTP) ~ days on treatment 
 Estimate SE RSE (%) 
Intercept (a) -0.900 0.006 4.7 
Slope (b) -0.016 0.001 7.9 
Sigma -0.270 0.044 8.2 
Random effects, ~1 + days | participant  
 Estimate SE RSE (%) 
Intercept (a) 0.267 0.077 28.8 
Slope (b) 0.456 0.070 15.4 
Table 6.8. Parameter estimates for PLM LME model 
Model fit by maximum likelihood with observations below the limit of detection treated as censored. The 
intercept (a) represents the baseline bacillary load, and the slope (b) the BER. Sigma represents the 
parameterised standard deviation on the residual error. SE: standard error; RSE: residual standard error. 
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Figure 6.15: Facet plot of modelled transformed TTP versus days on treatment by participant 
Partial likelihood modelling used to estimate the transformed TTP observations. The numbers represent the 
participant ID.   
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6.5.3.4 Comparison of models 
The PLM LME model was selected for further analysis. This model made the most efficient use of the 
data, and is likely to lead to the most precise parameter estimates [549, 550]. When the three 
models are compared (Figure 6.16), the PLM LME model gives the steepest bacillary elimination 
slope as a result of including estimated observations below the LLQ.  
 
6.5.4 Predictors of bacillary elimination rate 
 
A selection of clinical and socioeconomic variables were chosen a priori and their relationship with 
BER explored using univariate linear regression. HIV status, baseline pulse, white cell count, ALT, 
cavitation and CXR score were all associated with bacillary elimination on univariate analysis. On 
multivariate analysis, increasing CXR score was associated with slower bacillary elimination, and 
higher baseline ALT and pulse with more rapid decline in bacillary load. Pharmacokinetic 
relationships are discussed later. 
 
Variable Univariate analysis Multivariate analysis 
Estimate SE p value Estimate SE p value 
Age (years) -0.0001 0.0001 0.459 - - - 
Male sex -0.0013 0.0021 0.539 - - - 
Duration of symptoms 
(weeks) 0.0003 0.0002 0.225 - - - 
Ever smoked tobacco 0.0001 0.0018 0.959 - - - 
Ever drank alcohol 0.0007 0.0018 0.692 - - - 
HIV infected -0.0035 0.0018 0.058 0.0005 0.0018 0.769 
Baseline CD4 (cells/mm3) 0.0000 0.0000 0.058 - - - 
Change in CD4 (cells/mm3) 0.0000 0.0000 0.840 - - - 
BMI (kg/m2) 0.0001 0.0004 0.737 - - - 
Change in weight over 
treatment in kg 0.0001 0.0002 0.808 - - - 
Baseline pulse (bpm) -0.0001 0.0000 0.007 -0.0001 0.0000 0.002 
Baseline respiratory rate 
(bpm) -0.0003 0.0002 0.136 - - - 
Clinically septic at baseline* -0.0026 0.0028 0.354 - - - 
Baseline haemoglobin 
(g/dl) 0.0003 0.0005 0.591 - - - 
Baseline white cell count 
(x103/μl) 0.0008 0.0003 0.023 0.0005 0.0003 0.128 
Baseline monocyte-
lymphocyte ratio -0.002 0.002 0.309 - - - 
Baseline creatinine 
clearance (ml/min) 0.0001 0.0000 0.042 0.0000 0.0000 0.103 
Baseline bilirubin (μmol/l) -0.0001 0.0001 0.617 - - - 
Baseline ALT (IU/l) -0.0002 0.0001 0.001 -0.0001 0.0001 0.027 
CXR score 0.0001 0.0000 0.001 0.0001 0.0000 0.024 
No cavitation on CXR -0.0054 0.0018 0.003 - - - 
Table 6.9: Univariate and multivariate analysis of factors influencing bacillary elimination rate 
Variables significant to p<0.10 on univariate testing included in the multivariate analysis. Cavitation not included 
in the multivariate analysis due to collinearity with CXR score. * Based on source of infection, and 2 or more of: 
temperature <36oC or >38oC, pulse >90 beats per minute, respiratory rate >20 breaths per minute, white cell 
count <4 or >12 x 103/µl. SE: standard error. 
  
 
 
 
                   
Figure 6.16: Modelled transformed TTP over time 
A: Scatterplot of transformed TTP versus days on treatment for the 3 modelled datasets. Transformed TTP (log10(1/TTP)) is a measure of bacillary load. The red dotted line and circles represent 
the original dataset, with Mtb-positive transformed TTP results only. The blue dashed line and squares represent the imputed dataset, with a transformed TTP value of -1.633 imputed for the 
first negative result. The green solid line and triangles represents the PLM LME model with estimated observations. The dashed horizonal line is the LLQ for MGIT data at -1.623. B: Spaghetti 
plot of modelled BER with the PLM dataset. Each line represents an individual participant.  
A B 
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6.5.5 Bacillary elimination rate and treatment response 
  
The relationship between modelled BER and treatment response was explored by logistic regression. 
There was a clear relationship between BER and 2MCC, with those culture converting by 2 months 
likely to have a steeper BER (-0.021 [IQR -0.016, -0.027] vs. -0.012 [IQR -0.010, -0.016], p<0.001). 
They were also more likely to have a lower bacillary load at baseline (lower transformed TTP) as per 
Table 6.10 . This is summarised in Figure 6.18. Those culture converting by 2 months took median 
30.3 days [IQR 23.0 – 40.2] to become culture negative, compared to a projected 60.6 days [IQR 53.4 
– 69.6] for culture non-converters. No relationship between BER and final outcome was seen. 
   
Figure 6.17: Modelled bacillary elimination rate on treatment, stratified by 2MCC 
In both panels, solid blue lines and points represent samples from those that culture converted by 2 months, 
dashed red lines and hollow points those participants that failed to culture convert. In the left panel, each line 
represents an individual participant. In the right panel, the line summarises the bacillary elimination rate for 
converters and non-converters.  
 
Figure 6.18: Boxplots of modelled BER versus 2MCC and final outcome 
The more negative the BER, the greater the reduction in bacillary load over time. 
Chapter 6  Pharmacodynamics 
Page 200 
 n Mean (SD) Median [IQR] p value 
Bacillary elimination rate (slope) 
 
Culture converters 
Culture non-converters 
 
Favourable final outcome 
Unfavourable final outcome 
 
 
74 
47 
 
88 
11 
 
 
-0.023 (0.011) 
-0.014 (0.008) 
 
-0.018 (0.011) 
-0.023 (0.011) 
 
 
-0.021 [-0.027, -0.016] 
-0.012 [-0.016, -0.010] 
 
-0.016 [-0.024, -0.012] 
-0.027 [-0.032, -0.015] 
 
 
<0.001 
 
 
0.186 
Baseline bacillary load (intercept) 
 
Culture converters 
Culture non-converters 
 
Favourable final outcome 
Unfavourable final outcome 
 
 
74 
47 
 
88 
11 
 
 
-1 (0.2) 
-0.856 (0.207) 
 
-0.914 (0.203) 
-0.960 (0.214) 
 
 
-1 [-1.1, -0.9] 
-0.903 [-0.956, -0.848] 
 
-0.941 [-1.015, -0.868] 
-1.042 [-1.091, -0.835] 
 
 
<0.001 
 
 
0.186 
Table 6.10: Bacillary elimination rate and baseline bacillary load versus 2MCC and final outcome 
 
6.5.6 Bacillary elimination rate by modelled Xpert MTB/RIF cycle threshold 
 
Mixed effects modelling of serially collected Xpert MTB/RIF cycle thresholds was implemented in 
NONMEM. As for the TTP data, CT was transformed into the logarithm of the reciprocal, and missing 
data below the LLQ estimated using Beal’s M3 method [549]. Data were available from 43 
participants. The model fit is summarised in Table 6.11.  
 
 
As for the transformed TTP dataset, it was possible to generate an individual cycle threshold BER. 
This was found to have a significant association with 2MCC (p<0.001), but not final outcome 
(p=0.149). Whilst there was a relationship between BER determined from serially-collected TTP and 
CT measurements (Figure 6.20), the R-squared was only 0.164. 
 
PLM LME model fit by maximum likelihood (partial likelihood dataset) – Xpert MTB/RIF cycle threshold 
Fixed effects, log10(1/CT) ~ days on treatment 
 Estimate SE RSE (%) 
Intercept (a) -1.329 0.003 6.7 
Slope (b) -0.003 0.003 10.6 
Sigma 0.224 0.025 10.9 
Random effects, ~1 + days | participant  
 Estimate SE RSE (%) 
Intercept (a) 0.098 0.040 40.4 
Slope (b) 0.280 0.042 15.0 
Table 6.11: Parameter estimates for PLM LME model using serially collected Xpert MTB/RIF cycle thresholds 
Model fit by maximum likelihood with observations below the limit of detection treated as censored. The 
intercept (a) represents the baseline bacillary load, and the slope (b) the BER. Sigma represents the 
parameterised standard deviation on the residual error. SE: standard error; RSE: residual standard error. 
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Figure 6.19: Modelled cycle threshold bacillary elimination rate on treatment, stratified by 2MCC 
Samples below the LLQ were estimated using partial likelihood modelling (M3 method). In the panel on the left, 
each line represents each individual’s cycle threshold BER. In the panel on the right, solid blue lines and points 
represent samples from those that culture converted by 2 months, dashed red lines and hollow points those 
participants that failed to culture convert. The red dashed line represents the LLQ: log10(1/40). 
 
Figure 6.20: Relationship between bacillary elimination rate from serially-collected sputum TTP results versus 
Xpert MTB/RIF results 
BER calculated by mixed effects modelling with below LLQ results handled by partial likelihood estimation.  
 
6.6 Results: baseline drug sensitivity 
 
MICs for rifampicin, isoniazid, and ethambutol, were determined from 88 Mtb screening isolates 
(Figure 6.21). Not all participants had baseline MICs recorded due to contaminated or unavailable 
screening samples, limitations in the number of MIC plates available, or invalid results. No 
Chapter 6  Pharmacodynamics 
Page 202 
participants had rifampicin-resistance detected, but rifampicin-resistance on baseline Xpert MTB/RIF 
was an exclusion criterion. 6/88 (6.8%) participants had isoniazid mono-resistance detected, and one 
further participant had MICs above breakpoints for both isoniazid and ethambutol. 4/88 (4.6%) 
participants had ethambutol MICs above 5 µg/ml. There was no significant relationship between 
isoniazid resistance and BER (p=0.674), 2MCC (p=0.642), or final outcome (p=1.000).  
 
 
Figure 6.21: Baseline MICs for Mtb isolates 
Sensitivity breakpoints taken from [156] 
 
6.7 Results: PK-PD modelling 
6.7.1 Bacillary elimination rate 
 
The relationship between log transformed PK parameters and modelled bacillary elimination rate 
were explored in NONMEM. Each PK parameter (AUC, AUC/MIC, Cmax, Cmax/MIC) in plasma/ELF/ACs 
was added to the base model and considered significant if associated with a significant reduction in 
OFV (>3.84, p=0.05, χ2 distribution, one degree of freedom) and improvement in goodness of fit plots 
and parameter estimate precision. 
Initially, none of the PK parameters had a significant association with bacillary elimination rate. The 
transformed TTP model fit was mainly determined by the extent of inter-individual variability on the 
intercept (baseline bacillary load); inclusion of PK covariates on the slope (BER) only marginally 
improved the fit overall. Baseline bacillary load was closely associated with CXR score (section 6.4.2), 
and by including CXR score as a covariate on the intercept it was possible to adjust for baseline 
(radiological) severity of disease (Appendix K: PK-PD NONMEM control stream). This was associated 
with a drop in objective function of -5.536, and improved RSE on parameter estimates. Table 6.12 
shows the results of the different model fittings after adjusting for baseline extent of disease. 
Four parameters were significantly associated with the modelled bacillary elimination rate: 
rifampicin ELF Cmax and AUC, and isoniazid ELF Cmax and AUC. Example goodness of fit plots for the 
rifampicin ELF AUC PK-PD model are shown in Figure 6.22, demonstrating that the model described 
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the data well. Bacillary elimination rate increased with greater ELF exposure to rifampicin and 
isoniazid (Figure 6.23). 
Overall, increased exposure (by measure of AUC or Cmax) to rifampicin, isoniazid, pyrazinamide, or 
ethambutol, in plasma or ELF, was associated with a trend towards more rapid bacillary elimination 
in sputum (Table 6.12). Drug concentrations in alveolar cells were not significantly associated with 
bacillary elimination.  
The relationship between BER generated by partial likelihood modelling of the pilot Xpert MTB/RIF 
data and plasma and intrapulmonary PK indices did not identify any significant associations on 
univariate linear regression and was not explored further. 
 
Drug Matrix Model fit: no MIC data Model fit: including MIC data 
PK 
index 
n Trend ΔOFV PK index n Trend ΔOFV 
RIFAMPICIN 
PLASMA 
AUC 125 ↑ BER 0.000 AUC/MIC 70 ↓ BER -2.047 
Cmax 125 ↓ BER -1.954 Cmax/MIC 70 ↑ BER -2.002 
ELF 
AUC 42 ↑ BER -6.014 AUC/MIC 30 ↑ BER -2.808 
Cmax 42 ↑ BER -5.009 Cmax/MIC 30 ↑ BER -1.069 
AC 
AUC 42 ↑ BER -0.070 AUC/MIC 30 ↑ BER -0.921 
Cmax 42 ↑ BER -0.003 Cmax/MIC 30 ↑ BER -1.710 
ISONIAZID 
PLASMA 
AUC 125 ↓ BER -0.166 AUC/MIC 70 ↑ BER -0.283 
Cmax 125 ↓ BER -0.112 Cmax/MIC 70 ↑ BER -0.159 
ELF 
AUC 42 ↑ BER -5.248 AUC/MIC 30 ↑ BER -2.646 
Cmax 42 ↑ BER -4.741 Cmax/MIC 30 ↑ BER -2.120 
AC 
AUC 42 ↑ BER -0.210 AUC/MIC 30 ↓ BER -0.149 
Cmax 42 ↑ BER -0.001 Cmax/MIC 30 ↓ BER -0.332 
PYRAZINAMIDE 
PLASMA 
AUC 125 ↑ BER -0.816 - -  - 
Cmax 125 ↑ BER -0.017 - -  - 
ELF 
AUC 42 ↑ BER -2.544 - -  - 
Cmax 42 ↑ BER -2.289 - -  - 
AC 
AUC 42 ↓ BER -0.681 - -  - 
Cmax 42 ↓ BER -1.242 - -  - 
ETHAMBUTOL 
PLASMA 
AUC 125 ↑ BER -2.301 AUC/MIC 70 ↑ BER -1.857 
Cmax 125 ↑ BER -0.052 Cmax/MIC 70 ↑ BER -0.010 
ELF 
AUC 42 ↓ BER -0.005 AUC/MIC 30 ↑ BER -2.041 
Cmax 42 ↑ BER -0.013 Cmax/MIC 30 ↑ BER -1.511 
AC 
AUC 42 ↓ BER -1.063 AUC/MIC 30 ↓ BER -0.092 
Cmax 42 ↓ BER -0.804 Cmax/MIC 30 ↓ BER -0.007 
Table 6.12: PK parameters influencing BER 
PK parameters added to base BER model as a covariate on slope. Analysis restricted to those with observations 
in the matrix / compartment of interest. Trend shows the effect of the PK parameter on the bacillary elimination 
rate. ↑: faster elimination (negative BER estimate); ↓: slower elimination (positive BER estimate). Models 
adjusted for baseline extent of disease by including CXR score as a covariate on intercept. AC: alveolar cells; AUC: 
area under the curve; Cmax: maximal concentration; ELF: epithelial lining fluid; OFV: objective function value; 
MIC: minimum inhibitory concentration 
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Figure 6.22: Example goodness of fit plots for the transformed TTP partial likelihood model.   
Rifampicin plasma Cmax covariate effect on slope. Observed concentrations (DV) versus population predictions 
(PRED, top left) and individual predictions (IPRED, top right), in which the solid line represents the line of identity. 
Absolute weighted predictions (WRES) versus population predictions (bottom left) and time after dose (bottom 
right). 
  
 
Figure 6.23: PK versus bacillary elimination rate 
Higher rifampicin (Left) and isoniazid (Right) ELF AUC were associated with more rapid sputum bacillary 
elimination. Line of best fit shown. PK data have been log-transformed. BER: bacillary elimination rate. ELF: 
epithelial lining fluid. 
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6.7.2 Modelled time-to-negativity 
 
TTN is a measure of both baseline bacillary load and BER. Greater rifampicin and isoniazid AUC and 
Cmax in plasma and ELF were associated with shorter sputum time-to-negativity on univariate analysis 
(Table 6.13). Multivariate analysis, adjusting for CXR score, baseline respiratory rate, and symptom 
duration, identified rifampicin and isoniazid Cmax in plasma, and rifampicin AUC and Cmax in ELF, as 
important determinants of sputum time-to-negativity.  
 
Drug Matrix PK parameter Univariate analysis Multivariate analysis 
Estimate SE p value Estimate SE p value 
R
IF
A
M
P
IC
IN
 
Plasma AUC -125.854 56.305 0.031 -89.734 49.381 0.077 
AUC/MIC 15.207 21.596 0.487 - - - 
Cmax -110.266 49.528 0.032 -108.183 41.001 0.012 
Cmax/MIC 11.314 20.864 0.592 - - - 
ELF AUC -66.972 28.167 0.022 -56.945 23.906 0.022 
AUC/MIC -5.885 19.652 0.767 - - - 
Cmax -68.216 27.406 0.017 -67.979 22.635 0.005 
Cmax/MIC -7.915 19.122 0.682 - - - 
AC AUC -11.756 15.84 0.462 - - - 
AUC/MIC -0.414 12.203 0.973 - - - 
Cmax -11.847 15.136 0.438 - - - 
Cmax/MIC -1.254 11.736 0.916 - - - 
IS
O
N
IA
ZI
D
 
Plasma AUC -68.18 24.775 0.009 -38.694 23.365 0.106 
AUC/MIC -2.096 9.119 0.820 - - - 
Cmax -168.643 58.735 0.006 -116.753 52.961 0.034 
Cmax/MIC -1.975 9.714 0.840 - - - 
ELF AUC -31.019 15.269 0.049 -19.748 13.701 0.158 
AUC/MIC -9.581 9.396 0.316 - - - 
Cmax -22.47 17.861 0.215 - - - 
Cmax/MIC -10.264 9.923 0.310 - - - 
AC AUC -15.042 14.811 0.316 - - - 
AUC/MIC 0.728 8.594 0.933 - - - 
Cmax -4.444 17.913 0.805 - - - 
Cmax/MIC 1.141 8.99 0.900 - - - 
P
Y
R
A
ZI
N
A
M
ID
E 
Plasma AUC 6.013 53.106 0.910 - - - 
Cmax -75.099 93.561 0.427 - - - 
ELF AUC 5.581 31.228 0.859 - - - 
Cmax -5.866 34.781 0.867 - - - 
AC AUC 5.408 23.506 0.819 - - - 
Cmax -0.404 22.6 0.986 - - - 
ET
H
A
M
B
U
TO
L 
Plasma AUC 3.379 54.174 0.951 - - - 
AUC/MIC -6.246 14.436 0.669 - - - 
Cmax 1.785 52.939 0.973 - - - 
Cmax/MIC -8.451 14.125 0.555 - - - 
ELF AUC 2.604 41.721 0.951 - - - 
AUC/MIC -10.685 14.262 0.461 - - - 
Cmax 1.662 41.15 0.968 - - - 
Cmax/MIC -12.701 13.925 0.370 - - - 
AC AUC 2.412 36.845 0.948 - - - 
AUC/MIC -2.548 14.221 0.859 - - - 
Cmax 1.748 37.21 0.963 - - - 
Cmax/MIC -4.764 13.883 0.734 - - - 
Chapter 6  Pharmacodynamics 
Page 206 
Table 6.13: Univariate and multivariate analysis of factors influencing sputum time-to-negativity 
Variables significant to p<0.10 on univariate testing included in the multivariate analysis. Multivariate analysis 
performed by controlling for the covariate effects of symptom duration, baseline respiratory rate, and CXR score. 
Estimate shows the change in TTN associated with a log-change in the PK parameter. AC: alveolar cells; AUC: 
area under the curve; Cmax: maximal concentration; ELF: epithelial lining fluid; MIC: minimum inhibitory 
concentration; SE: standard error.  
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6.8 Discussion 
 
Improvements in tuberculosis chemotherapy are hindered by the absence of an early predictor of 
outcome. Detailed interrogation of pharmacokinetic-pharmacodynamic responses may highlight 
drivers of TB treatment response for treatment optimisation, or identify clinically-relevant 
surrogates for use in phase II trials.  
Three surrogates for TB treatment response were explored in detail: 2-month culture conversion, 
bacillary elimination rate, and modelled time to negativity. 2MCC is commonly used as an early 
marker of treatment efficacy in clinical trials [72-74]; BER has been shown to correlate with late 
outcomes [89]; and modelled TTN – capturing elements of both bacillary elimination and baseline 
bacillary load – was included as an early surrogate of late response. Both BER and TTN, as continuous 
measures of pharmacodynamic response, were closely correlated with rates of culture-conversion, 
but provide additional information over a binary outcome at a single time point. 
Modelling serial transformed TTP data showed a monophasic decline in bacillary load over time on 
treatment. While serial sputum colony counting has shown separate early bactericidal and sterilising 
phases of treatment [72, 74, 77], this is often not seen in serial TTP data likely as a consequence of 
specimen handling: sputum decontamination kills some actively replicating organisms [572, 573], 
and broth provides a better medium for revival of persister organisms [84, 85]. As such, the BERs 
generated here are typically considered a measure of the sterilising activity of a regimen: a key 
determinant of treatment duration [58, 89, 97, 435, 574].  
Several factors were identified that affect these early endpoints: notably pharmacokinetics, and the 
radiological extent of disease on chest X-ray. Rifampicin and isoniazid AUC and Cmax in plasma and 
ELF were related to treatment response across several endpoints. Peak concentrations of both drugs 
in plasma were associated with a shorter time to sputum negativity, and more favourable final 
outcomes. AUC or Cmax in ELF were associated with more rapid bacillary elimination, shorter time to 
sputum negativity, and for rifampicin Cmax in plasma, more favourable late outcomes.   
These data are significant, and address the hypothesis that site of infection PK may explain response 
to treatment. Increased intrapulmonary exposure to rifampicin and isoniazid were associated with 
more rapid bacillary clearance. Rifampicin was instrumental in reducing treatment duration to 6 
months [15], and these data suggest that favourable intrapulmonary tissue penetration is an 
important determinant of the sterilising activity of a regimen. Isoniazid by contrast is not generally 
considered a sterilising drug, and has previously been shown to achieve rapid reductions in the 
bacillary load in the first few days of treatment [90, 211]. Isoniazid was observed to achieve ELF 
concentrations nearly 15-fold greater than plasma, and higher concentrations in ELF may be playing 
an important role in debulking the disease. 
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Prior work has implicated pyrazinamide exposure as an important predictor of treatment response 
[286-288]. In this study, higher pyrazinamide Cmax in plasma or ELF was associated with a trend 
towards faster bacillary elimination and shorter modelled time-to-negativity, but these relationships 
were not statistically significant. Furthermore, no relationships between pyrazinamide exposure and 
2MCC or late outcome were identified. This may be partly explained by a relatively narrow range of 
pyrazinamide exposures in this cohort (median plasma Cmax 23.8 μg/ml [IQR 21.7-26.3]), all patients 
having ‘low’ peak concentrations [268], and the analysis methods used. Previous work used 
classification and regression tree analysis [288] to assess multiple interacting variables - such as co-
administered drugs - and their relationship to treatment response, identifying a hierarchy of 
predictors. Future work may re-appraise this dataset using alternative statistical techniques or 
machine learning methods to identify additional predictors of response. 
Notably, alveolar cell drug exposure was not associated with late outcomes, bacillary elimination 
rate, or modelled sputum time-to-negativity, despite alveolar macrophages representing the main 
reservoir of intracellular mycobacteria [339]. This may be secondary to some of the technical 
challenges of measuring PK in this compartment. Firstly, drug concentrations were measured in the 
cell pellet as a whole, with the assumption that most of the cells retrieved were alveolar 
macrophages. Variability in the differential cell count in BAL will reduce the accuracy of this 
measurement. Secondly, no wash steps were performed on the cell pellet to minimise the impact of 
drug efflux. Consequently, cell-associated drug will be measured in addition to intracellular drug, 
further increasing the variability in cell pellet concentrations. Thirdly, drug may partition further 
within the cell, reducing the usefulness of a measure of total drug concentration for the cell. Analysis 
with fractionation may be required to measure drug at the subcellular level where the intracellular 
mycobacteria reside. These limitations may reduce our ability to detect a PK-PD relationship for TB 
drugs in the alveolar cells. 
Alongside intrapulmonary PK, cavitation on baseline CXR, or a simple numerical CXR score [459], was 
a leading predictor of baseline bacillary load, TTN, BER and 2MCC in this cohort. The relationship 
between bacillary load and CXR cavitation is well-recognised [455, 575, 576], with resected cavities 
containing as many as 107-109 organisms as compared to 102-104 in caseous necrosis [577]. The high 
bacillary load and lung destruction seen in cavitatory disease may drive higher rates of treatment 
failure and relapse [76, 489, 578], and these patients may benefit from treatment prolongation 
[491]. Interestingly, these data suggest that those with more severe disease on baseline CXR have 
slower bacillary elimination rates: lung destruction may adversely affect the ability of drugs or the 
immune system to efficiently kill the Mtb. Use of simple CXR scoring tools at baseline may identify 
patients that would benefit from early treatment intensification [459]. 
Higher sputum bacillary load, demonstrated by a shorter TTP in liquid culture, is an important risk 
factor for transmission [575]. Furthermore, as higher bacillary loads have been associated with more 
tissue destruction [579], more rapid reduction in bacillary load may reduce morbidity of pulmonary 
Chapter 6  Pharmacodynamics 
 
  Page 209 
TB. Strategies that increase bacillary elimination rates in sputum, by optimising intrapulmonary PK or 
intensifying treatment in those with more extensive radiological disease, may limit further tissue 
damage, reduce the period of infectiousness, and are of public health importance. 
Rates of 2MCC were relatively low in this cohort - 62.7% - but this was not reflected in a higher rate 
of poor outcomes to 18-months of follow-up. There are several explanations for these low rates: the 
use of stable culture conversion as the definition, the use of liquid rather than solid media [495], and 
general trends towards delayed culture conversion in African cohorts [15, 66, 494]. Sampling times 
may also reduce rates of 2MCC. Patients were recruited to the study based on a positive smear or 
Xpert MTB/RIF taken at referral health centres by the NTP. Given that a proportion of participants 
arrived for screening a few days after treatment commenced, those with low smear grades may have 
already culture-converted prior to the first sputum culture being collected. As such, rates of 2MCC 
are likely to be higher than estimated here. Similarly, rates of smear-conversion are low. By including 
‘doubtful’ smear results as positive, a higher proportion of positive smears may be seen to two 
months.  
None of the early markers of treatment response were predictive of final treatment outcome in this 
cohort. Relapse-free cure to 18-months was included as a secondary endpoint, but the study was not 
powered to assess this endpoint. Low rates of 2MCC, the limited variability in BER measurements at 
a uniform mg/kg dosing, and relatively few unfavourable outcomes meant that a significantly larger 
sample size would be required to demonstrate any relationship between early markers of response 
and relapse-free cure. Earlier work from the same setting in a larger cohort has shown a correlation 
between bacillary elimination rate and final treatment outcome [89], and suggested its’ 
development as a surrogate in future Phase II trials. Peak plasma rifampicin and isoniazid 
concentrations were associated with final outcome, and this may be linked to higher intrapulmonary 
drug exposure and bacillary clearance. 
AUC/MIC and Cmax/MIC for first-line drugs have been described as major drivers of treatment 
efficacy in pre-clinical models [261, 263-265], but local variation in MICs of non-genotypically 
resistant Mtb isolates against first-line ATT have not been well described. Using finely-graded MIC 
plates, baseline isolates in Malawi were seen to be remarkably sensitive to rifampicin, with a modal 
MIC of 0.015 μg/ml. This compares to 0.25 μg/ml in Sweden (predominately imported disease) [156] 
and 0.125 μg/ml in South Africa [289]. This demonstrates the effectiveness of a robust and 
responsive National TB Programme. Compared to its’ neighbours, Malawi has readily adopted new 
TB control measures such as DOTS [426], has low rates of DR-TB [107], and these data suggest that a 
strong tuberculosis control programme may be able to preserve first-line drug sensitivity for longer. 
High plasma and intrapulmonary AUC/MIC and Cmax/MIC ratios are achieved in these patients as a 
result of preserved drug sensitivity, particularly for rifampicin. These PK indices were well in excess 
of any threshold for poor response: the case for rifampicin dose escalation may be strongest in 
settings with higher MICs. 
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Isoniazid mono-resistance was seen in 6.8% of participants, compared to 3.2% in new cases in 2010 
[107]. These differences may be attributed to different laboratory methodologies to determine MIC, 
though would be in keeping with global trends [580]. While not seen in this cohort, isoniazid mono-
resistance is associated with poorer outcomes [581, 582], and is frequently undiagnosed in settings 
with treatment algorithms based on Xpert MTB/RIF [581]. 
The pilot work using serial Xpert MTB/RIF cycle threshold data with partial likelihood modelling may 
represent an avenue for future research. Cycle threshold correlates with both smear grade and TTP 
in culture [583], Xpert MTB/RIF remains positive for longer than smear and culture [584], and serial 
cycle threshold data may be amenable to mixed-effects modelling as for TTP data [85, 585]. One 
previous study has shown a relationship between higher doses of rifapentine and cycle threshold 
BER [585]. Compared to liquid (MGIT) culture, generation of cycle threshold data is simple, rapid, 
sensitive, and less prone to contamination [552]. The imperfect relationship seen here between BER 
generated from modelling TTP versus Xpert data may be a result the different sensitivities of the 
tests. By detecting DNA from viable, intact, organisms in various metabolic states, as well as DNA 
fragments from lysed or dying bacteria [85], longitudinal Xpert MTB/RIF data may give more 
complete information on bacillary elimination over time. Furthermore, while decontamination steps 
for liquid culture may kill rapidly replicating organisms, the absence of this step for Xpert may allow 
for rapid early kill to be captured and modelled [585]. However, variation in cycle threshold data 
between instruments and laboratories may limit its clinical usefulness [586], and the WHO has 
argued that risk of detection of non-viable bacteria should preclude its use as a treatment 
monitoring tool [587]. With a larger dataset, PK-PD relationships with first-line ATT and longitudinal 
Xpert MTB/RIF data may offer new insights. 
Pharmacodynamic analysis of the TTP dataset met four major challenges: the degree of variability in 
TTP readings, data beyond the limit of quantification, missing data, and uniform mg/kg dosing across 
the cohort. High variability in quantitative sputum-based assays is to be expected, given that 
specimen quality depends on the strength of the cough, diligence in overnight collection, storage 
and transport to the clinic, and risk of sample contamination. Furthermore, the use of spot rather 
than overnight samples for the first sample may increase variability in the baseline bacillary load. 
Despite this variability, it was possible to fit linear mixed effects models with random effects on 
slope for each of the datasets reviewed. This enabled modelling of inter-individual variability on BER. 
Most inter-individual variability in the modelled transformed TTP dataset was around the baseline 
bacillary load (the intercept), rather than the bacillary elimination rate (the slope). Adjusting for the 
baseline radiological extent of disease using CXR score as a covariate on intercept significantly 
improved the description of the data, and identified rifampicin and isoniazid in ELF as important 
drivers of bacillary elimination. Those with low concentrations of multiple drugs may be more likely 
to have slower bacillary elimination, but models with multiple PK covariates were overparameterised 
and failed to converge. 
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Multiple approaches to handling data beyond the limit of quantification were explored, and the final 
choice of a Laplacian approach enabled the construction of a PD model with random effects on both 
intercept and slope incorporating data above the limit of 42 days. Restricting analysis to only positive 
samples will bias the model, underestimating the BER [549]. Adopting this method allowed for 
estimation of BER for more participants, and generated a steeper BER at the population level. 
Missingness in the MIC data restricted the pool of participants with full AUC/MIC and Cmax/MIC 
estimates, and thus analysis of relationships with BER or TTN was restricted only to those 
participants with data. Baseline isolates have been stored, and it may be possible to collect further 
MIC data, including pyrazinamide MICs, from these samples later.  
Finally, most patients were receiving mg/kg doses according to current guidelines [100]. While 
associations between BER and PK parameters were observed with standard dosing, more 
pronounced PK-PD relationships may be identified with dose-escalation. In the HIRIF studies, in 
settings where baseline rifampicin MICs are likely to be higher, an exposure-response relationship 
was not seen with doses of rifampicin of up to 35 mg/kg when conventional statistical methods were 
used [304]. However, when mixed effects modelling and Laplacian estimation were adopted, higher 
rifampicin exposure was seen to significantly improve bacterial kill [308].  
In conclusion, the work in this chapter has shown that the plasma and intrapulmonary 
pharmacokinetics of first-line therapy, and the radiological extent of disease, are drivers of TB 
treatment response. Identifying and targeting factors that improve rates of culture-conversion or 
bacillary elimination has a number of potential benefits: by reducing the bacillary burden, 
transmissibility and infectiousness may be reduced; the infection controlled; and progression of lung 
damage terminated. Dose escalation, or intensive phase prolongation, may offer treatment 
shortening potential.  
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7 Intrapulmonary immunology 
7.1  Introduction 
  
Having explored pharmacokinetic and pharmacodynamic aspects of TB treatment, this chapter 
considers host immune factors important in the control of TB infection, primarily focussing on how 
time on treatment and HIV status impact on some of the key innate immune functions of the 
alveolar macrophage. Using fluorochrome-labelled beads tagged with a substrate, macrophage 
phagocytosis was assessed ex vivo, alongside superoxide burst and bulk proteolytic activity within 
the phagosome. These processes are essential for ingestion of inhaled organisms, microbial kill [357, 
367], and antigen presentation to the adaptive arm of the immune system [357, 588, 589].  
To prevent damage to the delicate alveolar structures through an over-exuberant inflammatory 
response, these functions are tightly regulated to favour degradative functions over immune 
mediator release [339]. Indeed, macrophage phagosomes typically show high proteolytic activity 
[377, 590], which is reduced in the presence of IFN-γ activation to enable enhanced antigen 
processing [588]. Previous work from Malawi has shown impairment of some of these alveolar 
macrophage effector functions after exposure to household air pollution [374], or in the presence of 
HIV [365, 591]. In HIV infection, alveolar macrophage proteolytic function is blunted, and not 
restored until after 4 years of suppressive ART [591]. Impairment of these innate immune functions 
is implicated in the pathogenesis of respiratory infections [592].  
Mtb itself will alter some of these functions in the macrophage. As a host-adapted intracellular 
organism, Mtb can survive within the alveolar macrophage by disrupting phagolysosomal fusion 
[387, 388], or interrupting assembly of NADPH oxidase required for the superoxide burst [392]. In 
this chapter, alveolar macrophage function in patients with pulmonary TB infection, in the presence 
or absence of HIV, is described. Whereas previously conducted work on alveolar macrophage 
function in HIV infection has been cross-sectional [365, 591], these assays were performed at 2 and 4 
months into TB treatment to capture some of the dynamics of the innate immune response in these 
patients during treatment. In addition, immunophenotyping of whole BAL was used to quantify the 
proportion and relative cell counts of alveolar macrophages as well as CD4+ and CD8+ T lymphocytes 
in the alveolar space over the course of treatment.  
Accompanying and coordinating the cellular response runs the humoral response to infection. 
Several cytokines regulate the intrapulmonary inflammatory response to Mtb, with IFN-γ pivotal to 
the control of TB infection [593-595]. IFN-γ is predominantly produced by CD4+ T cells in response to 
Mtb-specific antigens [594], and activates macrophages to increase the intensity of the superoxide 
burst [370] and downregulate proteolysis [377]. In animal models, loss of the IFN-γ response to 
infection is associated with rampant Mtb replication and death [596], and in humans, HIV-related 
depletion of IFN-γ-producing cells may predispose to lower respiratory tract infections such as TB 
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[591, 597]. IFN-γ concentrations in the alveolar space of these patients were measured to explain the 
macrophage functional assay results, and to assess the pro- and anti-inflammatory balance in the 
lungs of TB mono-infected and TB/HIV co-infected patients early and late in treatment. Additional 
cytokines quantified included the pro-inflammatory tumour necrosis factor alpha (TNF-α), and the 
anti-inflammatory cytokines transforming growth factor beta (TGF-β) and interleukin-10 (IL-10). The 
latter 2 cytokines suppress macrophage activation and responsiveness to IFN-γ [598, 599], while 
TNF-α activates infected macrophages and recruits macrophages and lymphocytes to form the 
granuloma [600-604]. 
Development of a method to measure intraphagosomal pH was a secondary aim in this chapter. 
Phagolysosomal acidification is a marker of phagosome maturation, and important in bactericidal 
activity [605, 606]. Late macrophage phagolysosomes can acidify to a luminal pH of ≤ 5.0, impairing 
viability of microbes and creating an optimal environment for the activity of proteases and lysosomal 
hydrolases [605, 607]. Furthermore, the intracellular pH is of key importance to the 
antimycobacterial activity of pyrazinamide. Pyrazinamide requires conversion to POA within the cell, 
only occurring in an acidic environment [161, 608]. Pyrazinamide only appears to be effective in the 
first 2 months of treatment [13, 14, 122], and the reasons for this are incompletely understood; 
assessing changes in the intracellular acid-alkali balance over the course of treatment may help 
explain the pharmacodynamics of that drug. 
Finally, this chapter reviews co-infection in patients with pulmonary TB using multiplex PCR on 
sputum and BAL. TB treatment involves prolonged antimicrobial therapy, which may alter the 
intrapulmonary microbiome [609]. Furthermore, co-infecting organisms may disturb the balance of 
pro-inflammatory / anti-inflammatory responses in TB, potentially impacting on local TB control, and 
even outcome (cure, or long-term respiratory morbidity). For example, influenza A exposure prior to 
Mtb infection in mouse models is associated with enhanced mycobacterial growth and decreased 
survival [610], potentially through downregulation of the IFN-γ receptor and effects on macrophage 
activation [611]. Previous work with sputum cultures has identified bacterial co-infection in samples 
from up to 30% of TB cases [612], with Klebsiella pneumoniae, Mycoplasma pneumonia, 
Haemophilus influenzae among the commonest [612], while 16S sequencing has identified wider 
shifts in the pulmonary microbiome [613, 614]. This exploratory work will attempt to identify co-
infecting pathogens in sputum and BAL in patients receiving treatment for pulmonary TB. 
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7.2 Methods 
7.2.1 Collection and processing of BAL 
 
The conduct of the bronchoscopy visits and technique for BAL sampling is described in Chapters 2 
and 5. Labelled BAL samples were placed in 50 ml Falcon Tubes held on ice, taken immediately to the 
MLW Immunology Laboratory, and the volume of BAL recorded. 5 ml of whole BAL were removed 
and frozen at -80oC. BAL was filtered through sterile gauze to remove mucous plugs into sterile, 50 
ml Falcon Tubes, aiming for approximately 40 ml per tube. 
Samples were centrifuged at 500 x g at 4oC for 8 minutes to obtain cell pellets. The first 50 ml Falcon 
Tube was used for the pharmacokinetic assays described in Chapter 5 (Figure 5.1), while the 
remaining tubes were used for the immunology assays. Not all assays were performed on all samples 
due to limitations in cell numbers. Superoxide burst / phagocytosis assays were prioritised, followed 
by bulk proteolysis, and finally, intracellular pH or immunophenotyping analysis. 15 ml and 50 ml 
aliquots of BAL supernatant were removed by electronic pipettor and archived at -80oC, and 
remaining supernatant discarded. After the BAL for PK assessment had been removed, a maximum 
of 3 cell pellets in 50 ml Falcon Tubes were available for immunological assessment. 
Cell pellets were resuspended and 25 ml of cold phosphate-buffered saline (PBS) added. Cell 
suspensions were pooled, vortexed for 10 seconds, then centrifuged at 500 x g at 4oC for 8 minutes. 
The supernatant was discarded and 25 ml of RPMI-1640 culture medium added (Life Technologies). 
Again, the sample was vortexed, centrifuged, and the supernatant discarded. 5 ml of culture medium 
(RPMI-1640 + 10% foetal bovine serum + 2 mM L-glutamine (2%), Sigma-Aldrich) were added to the 
resuspended cell pellet and vortexed. 5 µl of suspension were removed, added to 45 µl Trypan Blue 
(VWR), and the macrophages counted using a haemocytometer. 
The concentration of the cell suspension was adjusted to 1 x 106 cells/ml by dilution with culture 
media. 3 million cells (3 ml) were added to each well of a 6-well tissue culture plate and incubated at 
37°C, 5% CO2 for 2 hours to allow macrophage adherence. After 2 hours, macrophage confluency 
was assessed by light microscopy, and the media and non-adherent cells removed by careful 
pipetting. 2 ml of media (RPMI 1640 + 10% foetal bovine serum + 2 mM L-glutamine) pre-warmed to 
37oC were added to each well in preparation for the functional assays below. 
 
7.2.2 Assessment of alveolar macrophage function 
 
Alveolar macrophage function was assessed using quantitative flow cytometry-based reporter bead 
assays as described previously [357]. In brief, the assays exploit silica beads derivatized with a 
calibration fluorochrome (Alexa 633 or Alexa 405-SE) and the fluorogenic reporter substrates 
Oxyburst Green, succinimidyl ester (H2DCFDA-SE) for superoxide burst or DQ Green BSA for bulk 
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proteolysis. When the beads are internalised by alveolar macrophages, they gain fluorescence 
intensity proportional to the degree of activity in the phagosome.  
 
7.2.2.1 Generation of reporter beads 
250 µl of carboxylate-modified silica beads (Kisker Biotech) were washed 3 times in 1 ml PBS by brief 
vortexing and centrifugation at 2000 x g for 60 seconds. Beads were resuspended in PBS (pH 7.2) 
with 25 mg/ml of cyanamide (Sigma-Aldrich) and incubated for 20 minutes at room temperature 
with agitation. Again, beads were washed 3 times in 1 ml PBS to remove as much buffer as possible. 
Coupling buffer was made by dissolving 0.1 M sodium borate in double distilled water, and adjusted 
to pH 8.0 with 10 M sodium hydroxide.  
 
7.2.2.1.1 Superoxide burst beads 
900 µl of coupling buffer, 100 µl of defatted BSA (10 mg/ml, Sigma-Aldrich) and 10 µl of murine IgG 
(10 mg/ml, Sigma-Aldrich) were added to the bead pellet. Beads were conjugated on the mixer 
overnight, then washed 3 times with coupling buffer. The pellet was resuspended in a further 900 µl 
of coupling buffer, and a mixture of 5 µl OxyBurst Green, succinimidyl ester (H2DCFDA-SE, 25 mg/ml 
in DMSO in aliquots at -20oC, Molecular Probes) and 95 µl DMSO added to the beads. This was left to 
couple for 60 minutes, rinsed in coupling buffer, and repeated once to maximise OxyBurst labelling.  
Beads were washed twice in coupling buffer, resuspended in 1 ml of coupling buffer, and 5 µl Alexa 
405 or Alexa 633 (5 mg/ml in DMSO, stored in aliquots at -20oC, Molecular Probes) added. Beads 
were incubated on the mixer for 60 minutes at room temperature before a final 2 washes with 
coupling buffer, and 1 with PBS. Labelled beads were stored in the dark at 4oC in 500 µl of PBS with 
0.02% sodium azide. 
OxyBurst Green fluoresces at 519 nm following excitation at 488 nm. The calibration fluorochrome 
Alexa 633-SE fluoresces at 647 nm following excitation at 635 nm, and Alexa 405 fluoresces at 421 
nm following excitation at 405 nm. The 633-labelled Oxyburst beads were not stable and underwent 
spontaneous oxidation (in the first 16 samples). As such, only those using the Alexa 405-SE 
calibration fluorochrome were included in the superoxide burst analysis. 
 
7.2.2.1.2 Bulk proteolysis beads 
1 ml of coupling buffer with 3 mg of DQ Green BSA (Molecular Probes) and 10 µl of murine IgG (10 
mg/ml, Sigma-Aldrich) were added to the bead pellet. This was conjugated on the mixer overnight, 
before washing 3 times with coupling buffer. The remaining conjugation with calibration 
fluorochrome and wash steps occurred as for the superoxide burst beads.   
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7.2.2.2 Preparation of reporter bead suspension 
Prior to performing the functional assays, 5 µl of bead suspension per experimental well were 
removed, and an extra 10 µl added to provide sufficient beads to calibrate the flow cytometer. Beads 
were washed twice in 1 ml of media (RPMI 1640 + 10% foetal bovine serum + 2 mM L-glutamine) in a 
microfuge (1000 x g, 1 minute) to remove the sodium azide. Beads were resuspended in 100 µl of 
media per experimental well prior to use. Preparation was done in semi-darkness to prevent 
degradation, with the bead suspensions wrapped in aluminium foil when not in use. 
 
7.2.2.3 Performance of alveolar macrophage functional assays  
Phagocytosis of reporter beads is rapid, typically occurring within 2-3 minutes of addition of beads, 
and as such the first timepoint (OXY 10 and DQ 10) was collected at t = 10 minutes [372]. Superoxide 
burst reaches maximal activity 30 minutes after phagocytosis [370, 372, 615], with samples collected 
at t = 60 minutes (OXY 60); whereas as bulk proteolysis, requiring efficient acidification and delivery 
of lysosomal enzyme delivery to the phagosome, is a slower process and was harvested at t = 240 
minutes (DQ 240) [372, 615]. 
Plates were set up as per Figure 7.1 below. 100 µl of bulk proteolysis beads (DQ Green BSA) were 
added to the DQ 10 and 240 wells, and 100 µl of superoxide burst beads to the OXY 10 and 60 wells. 
The plate was agitated gently to distribute the beads, and incubated at 37°C, 5% CO2. This was time 0 
(t = 0 min). The control well had no reporter beads added to enable the gates on the flow cytometer 
to be set prior to analysis of the experimental wells. Figure 7.2 shows the confluent macrophage 
monolayer with reporter beads. 
 
 
Figure 7.1: Plate layout for functional assays 
3 million cells were plated into each well. DQ 240: bulk proteolysis 240 minutes; DQ 10: bulk proteolysis, 10 
minutes; OXY 60: superoxide burst 60 minutes; OXY 10: superoxide burst 10 minutes; CONT: control, no beads. 
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After 10 minutes, the first timepoint (t = 10 minutes) was taken.  The plate was agitated gently, and 
the media and unbound beads removed from the OXY 10 and DQ 10 wells. 1 ml of cold PBS was 
added, and the cells scraped into suspension. The cell suspensions were transferred into 5 ml round 
bottom FACS tubes, centrifuged at 500 x g for 5 minutes at 4oC, and the supernatant discarded. The 
cells were fixed in 1 ml of 3.7% paraformaldehyde (Sigma-Aldrich) for 20 minutes then washed 3 
times with 1 ml of PBS, before resuspension in 500 µl PBS and refrigeration at 4oC in the dark until 
ready to acquire on the flow cytometer. 
The media in the remaining wells was removed gently and replaced with 2 ml of media (RPMI 1640 + 
10% foetal bovine serum + 2 mM L-glutamine) at 37oC. This removed unbound beads from the wells. 
At t = 60 minutes (superoxide burst, OXY 60) or t = 240 minutes (bulk proteolysis, DQ 240), the cells 
were harvested as described above. At the conclusion of the assay, 50 μl of unused reporter beads 
were added to 2 ml of PBS with 3.7% paraformaldehyde, washed 3 times with 1 ml of PBS, and 
placed in the dark at 4˚C with the other samples. 
 
 
Figure 7.2: Macrophage monolayer with reporter beads 
After 2 hours of incubation, the alveolar macrophages form a confluent monolayer on the bottom of the 6-well 
plate. The small round beads are the reporter beads, some of which have already been phagocytosed in this light 
microscopy image. 
 
7.2.2.4 Flow cytometry 
The samples were analysed by flow cytometry, using the CyAn ADP 9-Colour flow cytometer 
(Beckman Coulter). Data were analysed using FlowJo software version 10.4 (Tree Star). 200,000 
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events were acquired for each sample. First, reporter beads alone were run and their relative 
fluorescence recorded, graphing calibration fluorochrome (PB channel, 450 nm) against the reporter 
fluorochrome (FITC channel, 530 nm) shown in Figure 7.3A. Second, cells alone were acquired to set 
the forward (FS) and side scatter (SS) gates at the appropriate level. The major cell populations were 
defined initially by their FS and SS characteristics, identifying a population of alveolar macrophages 
and lymphocytes (Figure 7.3B). The identity of the cell populations was subsequently confirmed by 
demonstrating the gated cell populations labelled with anti-CD206 and anti-HLA-DR (alveolar 
macrophages), and anti-CD3, anti-CD4 and anti-CD8 (T lymphocytes), discussed later.   
Finally, the cells from the experimental conditions were acquired. Figure 7.3D shows a 
representative dot plot following 10 minutes of incubation with superoxide burst reporter beads. 3 
populations are seen: alveolar macrophages that had not internalised beads at the bottom of the 
plot, and alveolar macrophages with internalised reporter beads at the top of the plot (oxidised and 
unoxidised populations). Reporter beads within the phagosome are progressively oxidised by the 
superoxide burst, and are thought to respond predominantly to H2O2 [357, 615]. The fluorescence 
emission of OxyBurst Green increases following oxidation, and is seen as increased fluorescence on 
the FITC channel after 60 minutes of incubation and a shift to the right of the AM population with 
internalised reporter beads (Figure 7.3E). 
Bulk proteolytic activity within the phagosome is captured by the DQ reporter beads. Internalised 
beads are hydrolysed by protease enzymes within the phagosome, releasing fluorescence [615]. This 
increased fluorescence on the FITC channel was read after 240 minutes of incubation. This assay 
reports the sum total of multiple steps in the phagosome maturation process, as total proteolytic 
activity will be influenced by pH, activation of lysosomal hydrolases, and fusion with pre-existing 
lysosomal compartments [615]. 
The readout for the superoxide burst and bulk proteolysis assays was the Activity Index, a ratio of 
the substrate fluorescence to the calibration fluorescence. This was calculated by first determining 
the ratio of median fluorescence intensity of the reporter over calibration fluorescence at 10 and 60 
minutes (for superoxide burst) or 10 and 240 minutes (for bulk proteolysis) time points, and then 
dividing the ratio at 60 or 240 minutes by the ratio at 10 minutes. This provides an internal 
correction for dosage, and allows for comparison between samples. 
The readout for phagocytosis was the proportion of cells that had internalised the superoxide burst 
reporter beads after 60 minutes. Baseline superoxide burst, bulk proteolytic, and phagocytic activity 
were related to HIV status, clinical and radiological predictors, and bacteriological endpoints. Change 
in activity between bronchoscopy 1 and 2 was captured and related to bacteriological and clinical 
endpoints. 
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Figure 7.3: Representative flow cytometry gating strategy and dot plots for alveolar macrophage reporter 
bead assays 
A: Flow cytometry dot plot showing reporter beads only. Reporter beads alone were acquired, plotting 
calibration fluorescence (PB: Pacific Blue fluor, vertical axis) against reporter fluorescence (FITC fluor, horizontal 
axis).  
B: Gates were reset, and cells alone acquired. The populations of alveolar macrophages (AMs) and lymphocytes 
were identified by their forward scatter (FS, linear scale) and side scatter (SS, log scale) characteristics.  
C: Dot plot of alveolar macrophages alone (no reporter beads) 
D: Dot plot of alveolar macrophages after incubation with superoxide burst beads for 10 minutes. Macrophages 
with internalised beads are seen at the top of the plot. Some of the beads have already been oxidised, seen as a 
shift in the cell population to the right. 
E: After 60 minutes, oxidative activity within the phagosome is seen as increased fluorescence on the FITC 
channel. 
 
 
7.2.2.5 Statistical analysis 
Flow cytometry data were log transformed and analysed using one-way analysis of variance, 
Student’s t-test or Welch’s t-test (unequal variances). Differences were considered statistically 
significant at p less than 0.05. All statistical analysis was performed using the open-source statistical 
software R version 3.5.0 [439]. 
Paired results were not available from all participants due to assay failure, low cell recovery, or 
failure to attend. These data were considered ‘missing completely at random’. Restricting the 
functional assay analysis to only paired or unpaired samples makes inefficient use of the data, and 
thus multiple imputation techniques were adopted to handle this missing data. Multiple imputation 
by chained equations was implemented in the ‘mice’ package in R. In brief, the package creates 
multiple imputations for multivariate missing data, and imputes plausible data values drawn from a 
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distribution designed for each missing data point. Predictive mean matching was used for 
imputation, and 25 imputed data sets generated. 
 
7.2.3 Intrapulmonary cytokine measurement 
 
IFN-γ, TNF-α, IL-10, and TGF-β were measured in BAL supernatant using commercially available ELISA 
kits according to manufacturer’s instructions (Thermo Fisher). BAL supernatant was thawed, 
vortexed, and 15 ml transferred to 3 kDa NMWL Amicon Ultra-15 Centrifugal Filter Units (Merck). 
Samples were centrifuged at 2,700 x g for 40 minutes to achieve a concentrated solution of 600 – 
5,000 µl. The volume of ELF in concentrated BAL supernatant was calculated by the urea dilution 
method as described in Chapter 5. 
In brief, concentrated BAL was added to 96-well plates coated with anti-human IFN-γ (50 μl sample), 
anti-human TNF-α (100 μL sample), anti-human IL-10 (50 μl sample) or anti-human Latency 
Associated Peptide (precursor to TGF-β1, 10 μl sample) in duplicate. Each plate included a standard 
curve and blank wells. Assay characteristics are summarised in Table 7.1.  
Plates were incubated for 2 hours, washed, and incubated with Streptavidin-HRP. After a further 30-
minute incubation, plates were washed again, substrate solution reactive with HRP added, and 
incubated in the dark for a final 30 minutes. A blue coloured product is formed in proportion to the 
amount of substrate in the sample. The reaction was terminated by the addition of stop solution, 
yielding a yellow product, and plates read on an ELISA plate reader set at 450 nm.  
 
Assay Assay range (pg/ml) Sensitivity (pg/ml) Intra-assay %CV 
IFN-γ 25.6-1000 <2 3.71 
TNF-α 15.6-1000 1.7 3.84 
IL-10 15.36-600 <3 7.10 
TGF-β (Latency Associated Peptide) 0.16-10 0.098 5.84 
Table 7.1: Cytokine assay characteristics 
Latency associated peptide was measured instead of TGF-β. This is a precursor peptide, cleaved to form active 
TGF-β. Measuring LAP rather than TGF-β avoids the need for pre-treatment with acid. 
 
Standard curves were plotted for each plate, and used to calculate the concentration of cytokine in 
BAL concentrate. Cytokine concentrations in ELF were calculated from the equation below.  
𝑐𝑜𝑛𝑐𝐸𝐿𝐹 = 𝑐𝑜𝑛𝑐𝐵𝐴𝐿𝐶𝑂𝑁𝐶 ∗ (
𝑣𝑜𝑙𝐵𝐴𝐿𝐶𝑂𝑁𝐶
15
) ∗ (
𝑣𝑜𝑙𝐵𝐴𝐿
𝑣𝑜𝑙𝐸𝐿𝐹
) 
The dilution factor is calculated by dividing the volume of concentrated BAL returned by the 15 ml of 
BAL supernatant placed in the concentrator. volBAL represents the volume of BAL returned at 
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bronchoscopy, volELF the volume of ELF in the sample calculated from the urea dilution method, and 
concBALCONC the cytokine concentration in concentrated BAL.  
 
7.2.4 Surface immunophenotyping of BAL cells 
 
Surface immunophenotyping of whole BAL was performed to differentiate and to quantify the cell 
populations. 1 million cells from whole BAL were transferred to each of 3 FACS tubes and centrifuged 
at 500 x g for 8 minutes. The supernatant was discarded and cell pellet resuspended. The first tube 
served as the control containing unstained cells, to which 100 µl of PBS were added. In the second 
tube, the AM panel, cells were stained with 10 µl anti-CD45 PE, 15 µl anti-CD206 FITC, 10 µl anti-
HLA-DR AlexaFluor700, and the volume was made up to 100l by adding 65 µl PBS. The final tube, 
the T cell panel, was stained with 5 µl anti-CD3 PE-Cy5, 5 µl anti-CD4 BV421, 10 µl anti-CD8 PC7 and 
10 µl anti-CD45 PE. The volume was made up to 100l by adding 70 µl PBS. All antibodies were from 
BD Bioscience. 
Samples were vortexed and incubated in the dark for 20 minutes. Cells were washed once in 1 ml 
cold PBS (centrifuged at 500 x g, 8 minutes), resuspended in 500 µl PBS, and acquired on the flow 
cytometer. Figure 7.4 shows the gating strategy used for surface immunophenotyping of whole BAL.  
Proportions of alveolar macrophages, T cells, CD4+ T cells, and CD8+ T cells at the early and late 
bronchoscopy timepoints were compared by HIV status. Relative absolute cell counts were 
calculated using methods described previously [616]. In brief, macrophages in whole BAL were 
counted using a haemocytometer, and converted into cells x106 /100 ml BAL. The T cell/alveolar 
macrophage ratio was calculated from the proportions obtained from the flow cytometer leukocyte 
gate (Figure 7.4B), and multiplied by the alveolar macrophage count to generate a T cell count. 
Relative absolute CD4+ and CD8+ T cell counts were similarly calculated based on the approximate 
CD3+ T cell count and the frequencies of CD4+ and CD8+ T cells relative to the flow cytometry parent 
gate. 
  
Chapter 7  Intrapulmonary immunology 
 
  Page 223 
 
 
Figure 7.4: Flow cytometry gating strategy for surface immunophenotyping of BAL cells 
A: Leukocytes were gated by anti-CD45 (leukocyte common antigen, PE fluor: phycoerythrin) 
B: The populations of alveolar macrophages and lymphocytes were gated on their forward scatter (FS) and side 
scatter (SS) characteristics.  
C: Alveolar macrophage panel. The identities of the cell populations were then confirmed by demonstrating the 
gated cell populations with anti-CD206 (mannose receptor, FITC fluor: fluorescein isothiocyanate) and anti-HLA-
DR (major histocompatibility complex class II, AF700: Alexa Fluor 700).  
D and E: T cell panel. The identity of the gated cell population was confirmed by demonstrating the gated cell 
populations with anti-CD3 (T lymphocyte, PC5 fluor: phycoerythrin cyanin 5.1), followed by anti-CD4 (BV421 
fluor: Brilliant Violet 421) and anti-CD8 (PE-Cy7 fluor: phycoerythrin-Cy7).  
 
7.2.5 Intracellular pH measurement 
 
The pHrodo phagocytosis bead labelling kit (Molecular Probes) was adapted to measure pH within 
the alveolar macrophage phagosome. The pHrodo dye is almost non-fluorescent at neutral pH, and 
fluoresces brightly in acidic environments [617]. By coupling with biological particles, for example 
bacteria, it is possible to assess phagocytic activity in whole blood samples by flow cytometry.  
Lyophilised E. coli (Sigma Aldrich) were labelled with pHrodo for these assays. 60 mg of lyophilised E. 
coli were washed and resuspended in 100 mM sodium bicarbonate buffer. A 10 mM solution of 
amine-reactive pHrodo SE was prepared by resuspending 1 mg of dye in 150 µl DMSO, and added to 
the E. coli to achieve a final concentration at 0.5 mM labelling. After 45 minutes incubation, 
unincorporated dye was removed by washing with methanol [617]. pHrodo dye-labelled E. coli were 
kept at 4oC until ready for use.  
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Prior to use, the pHrodo dye-labelled E. coli were diluted with buffer to obtain a 5 mg/ml suspension. 
For optimal assay conditions, a ratio of > 20:1 pHrodo particles to phagocytosing cells was 
recommended [617]. In practice, this meant that 20 µl of particle suspension were added to 100 µl 
of whole blood. The particle suspension was vortexed, sonicated, and held on ice for 10 minutes 
prior to use. 
For each sample, 4 tubes were set up as per Table 7.2. The manufacturer recommends the use of 
whole blood [617]. Whole blood was used to optimise the assay, and latterly a suspension of alveolar 
macrophages. 3 million cells (3 ml) were added to the empty well of a 6-well tissue culture plate 
(Figure 7.1) and incubated at 37°C, 5% CO2 for 2 hours to allow the alveolar macrophages to adhere. 
After 2 hours, the media and non-adherent cells were removed, and the alveolar macrophages 
scraped into suspension with 1 ml of cold PBS. 100 µl of this suspension were used for the pH assay. 
Samples, with or without particles, were placed on ice or in a 37oC water bath, initially for 15 
minutes. In later experiments, 30 or 45 minute incubations were used, and a rotating incubator used 
to minimise macrophage adherence to the FACS tubes. 
 
 Tube Name Volume of whole blood / 
macrophage suspension 
pHrodo dye-labelled particles 
1 Negative control on ice 100 µl - 
2 Negative control at 37oC 100 µl - 
3 Positive control on ice 100 µl > 2 x 107 beads / 20 µl 
4 Positive control at 37oC 100 µl > 2 x 107 beads / 20 µl 
Table 7.2: Intracellular pH assay experimental conditions 
For each sample, 4 tubes were set up. 100 µl of whole blood or alveolar macrophage suspension was required. 
 
After the incubation, all tubes were placed on ice, and ammonium-chloride-based lysis buffer added 
[617]. This lyses erythrocytes, with minimal effect on leukocytes. Cells were resuspended in 0.5 ml 
wash buffer for flow cytometry analysis on the CyAn ADP 9-Colour flow cytometer (Beckman 
Coulter). The optimal absorption of the pHrodo dye-labelled particles is approximately 560 nm, and 
fluorescence emission maxima of 585 nm [617]. The manufacturers report that the fluorophore is 
readily excited with the 488 nm argon-ion laser. To analyse samples, FS versus SS was plotted first, 
followed by FS versus fluorescence on the PE channel. Figure 7.5 shows the gating strategy for whole 
blood and alveolar macrophages.  
The degree of fluorescence on the PE channel was compared between tubes 3 and 4: a control 
where phagocytosis was inhibited by incubating on ice, and the experimental condition. The sample 
held on ice showed very little fluorescence as the pHrodo particles were not in acidic phagosome 
compartments, whereas the sample incubated at 37oC showed increased fluorescence emission.  
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The pHrodo assay was ran only on a subset of BAL samples with sufficient cells after the functional 
assays and immunophenotyping experiments had been run. The manufacturer suggested a greater 
than 5-fold increase in fluorescence signal between the control and experimental samples as a good 
result [617]. In whole blood, greater than 96% phagocytosing granulocytes could be expected. 
 
 
Figure 7.5: Representative dot plots of intracellular pH measurement using pHrodo-labelled E. coli  
A-C: Granulocyte intracellular pH measurement. In A, the granulocyte population in whole blood is selected 
based on its’ forward (FS, linear scale) and side scatter (SS, log scale) characteristics. The gated population of 
granulocytes was plotted against fluorescence on the Y axis. Negative controls (no particles) are not shown 
here. B shows a population of cells with particles in the positive control on ice (tube 3). Increased fluorescence 
is seen in C (tube 4) – positive control at 37oC. Quantification of fluorescence (by MFI) and comparison between 
B and C gives a measure of intracellular acidification.  
D-F: the same assay using alveolar macrophages. Again, the population of macrophages is selected based on FS 
and SS characteristics.  
  
7.2.6 Multiplex PCR for co-infection 
 
Multiplex PCR on sputum and BAL samples from the SPITT Study was performed as part of a MSc in 
Tropical and Infectious Diseases by Dr David Cox. While the methods have been described in detail in 
his master’s dissertation, they are summarised below. The data were reanalysed for this thesis. 
 
7.2.6.1 Sample selection 
All BAL supernatant samples were retrieved from -80oC for analysis. A subset of participants had 
their screening and S3/S4 sputum samples (paired with their first bronchoscopy) analysed. This was 
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restricted to those that were Mtb culture-confirmed, with a complete set of BAL and corresponding 
sputum samples. 
 
7.2.6.2 Sample processing 
Samples of raw sputum were retrieved from -20oC storage, 300 µl removed and homogenised with 
an equal volume of 1 g/l 1,4-dithiotheitol (Sputasol, Oxoid).  
BAL supernatant was thawed, vortexed, and 15 ml transferred to 3 kDa NMWL Amicon Ultra-15 
Centrifugal Filter Units (Merck). Samples were centrifuged at 2,700 x g for 40 minutes to achieve a 
concentrated solution of 600 – 5,000 µl. 
 
7.2.6.3 Multiplex PCR 
Total nucleic acids were extracted from 300 µl of specimen in batch with the Qiagen BioRobot 
Universal System, using the QIAamp One-For-All nucleic acid kit (Qiagen). 10 µl of eluate were used 
with the FTD Respiratory pathogens 33 (Fast-Track Diagnostics) real-time reverse transcriptase 
multiplex PCR kits according to manufacturer’s instructions, in combinations with the AgPath one-
step qRT-PCR reagents (Applied Biosystems). Samples were run on the Applied Biosystems 7500 or 
Viia 7 Real-time PCR Systems (Thermo Fisher Scientific), alongside positive and negative controls. 
Samples with exponential amplification below a cycle threshold (CT) of ≤ 38 were recorded as 
positive. 
Viral pathogens included in the FTD kit were: influenza A, B, C, and A (H1N1) swine-lineage viruses; 
coronaviruses OC43, NL63, HKU1 and 229E; parainfluenza viruses 1-4; respiratory syncytial viruses A 
and B; enterovirus; human metapneumoviruses A/B; rhinovirus; adenovirus; bocavirus; and 
parechovirus. Bacterial pathogens included Mycoplasma pneumoniae, Chlamydia pneumoniae, 
Streptococcus pneumoniae, Haemophilus influenzae type B, Staphylococcus aureus, Moraxella 
catarrhalis, Bordetella spp., Klebsiella pneumoniae, Legionella pneumophila/Legionella longbeachae, 
Salmonella species and Haemophilus influenza. Pneumocystis jirovecii was also included. 
One-way ANOVA and chi-squared tests were used to identify clinical or radiological predictors of the 
presence of organism in BAL or sputum. Co-infection in BAL was related to 2MCC, bacillary 
elimination, and final outcome by logistic or linear regression. 
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7.3 Results 
7.3.1 BAL recovery 
 
92 research bronchoscopies were performed; 51 early bronchoscopies (2 months into TB treatment), 
41 late bronchoscopies (4 months into TB treatment). The first bronchoscopies occurred at median 
48 days into treatment [IQR 44-50], the second at 108 days into treatment [IQR 106-112]. The 
median BAL return was 129 ml [IQR 115-140]. 
 
7.3.2 Alveolar macrophage function 
 
The alveolar macrophage functional assays (phagocytosis, superoxide burst, and bulk proteolysis) 
were attempted on all participants attending for bronchoscopy. However, paired samples from early 
and late bronchoscopies were available from a minority of participants. Assay failure, insufficient BAL 
return, insufficient cell counts, and failure to attend for the second bronchoscopy restricted the 
samples available for analysis. Multiple imputation, by allowing for paired analysis of functional 
assays at 2 and 4 months, made more efficient use of the data. The analysis below describes how 
alveolar macrophage functions change over time on TB treatment, or how function differs between 
those with or without HIV co-infection. 
 
7.3.2.1 Phagocytosis 
Alveolar macrophage phagocytic function was assessed in 65 samples: 32 early, 33 late, and 20 
paired. Data distribution was explored using summary statistics and plots: phagocytic activity was 
right skewed.  
There was no significant difference in phagocytic activity at the early and late bronchoscopy 
timepoints (median 72.5% cells with beads [IQR 60-77] vs. 72% [IQR 62-79]; p=0.652). When 
stratified by HIV status (Figure 7.6), there was a significant increase in the phagocytic activity in HIV-
infected participants by 4 months into TB treatment (median 61% cells with beads [IQR 56-68.5] vs. 
75 [IQR 69.5-79]; p=0.020), but not in HIV-uninfected participants (median 72% cells with beads [IQR 
53-75] vs. 71 [IQR 63-75]; p=0.476). 
Predictors of alveolar macrophage phagocytic activity were explored by univariate and multivariate 
linear regression, measured against the activity index at the 2 month bronchoscopy (closer to the 
start of treatment). There were too few HIV-infected participants established on ART to explore the 
effect of ART duration on phagocytic activity, but there was no relationship between baseline CD4 
count on univariate analysis (p=0.675). Those with a greater change in CD4 count over treatment 
tended to have poorer phagocytic function at the time of the first bronchoscopy (estimate: -0.036; 
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SE: 0.017; p=0.042). This may reflect greater immunosuppression (due to HIV or TB) at baseline, or 
an effect of immune reconstitution. Phagocytic activity at 2 months was not associated with 2MCC 
(OR: 1.0; 95% CI: 0.96-1.05; p=0.913), bacillary elimination rate (p=0.656), or final outcome (OR: 
1.09; 95% CI: 0.97-1.39; p=0.225). 
 
Figure 7.6: Alveolar macrophage phagocytic function early (2 months) and late (4 months) into TB treatment, 
stratified by HIV status 
Paired data only. Bars represent mean proportion of cells with beads. Comparisons between early and late 
bronchoscopy made by paired t-test.  
 
7.3.2.2 Superoxide burst 
Alveolar macrophage superoxide burst was assessed in 42 samples: 30 early, 22 late, and 16 paired. 
Log-transformed activity index was normally-distributed. In pooled samples, there was no change in 
superoxide burst activity index over time (median 0.48 [IQR 0.25-0.68] at 2 months vs. 0.47 [IQR 
0.35-0.63] at 4 months; p=0.783).  
Differences in superoxide burst activity between 2 and 4 months of TB treatment seemed to be 
largely driven by HIV status (Figure 7.7): HIV-infected participants had higher superoxide burst 
activity late in treatment compared to HIV-uninfected participants (0.57 [IQR 0.45-0.67] vs. 0.42 [IQR 
0.34-0.48]; p=0.008), and compared to HIV-infected participants at 2 months into treatment (0.57 
[IQR 0.45-0.67] vs. 0.48 [IQR 0.24-0.67]; p=0.024). There was a trend towards reduced superoxide 
burst activity at 2 months into treatment in HIV-infected compared to HIV-uninfected participants 
(0.48 [IQR 0.24-0.67] vs. 0.64 [IQR 0.27-0.74]; p=0.089), but this was not significant on paired testing. 
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These differences in superoxide burst activity by HIV status and time were seen when the dataset 
was restricted to only those with paired data, but multiple imputation was required to detect 
statistical significance given the low numbers.   
 
 
Figure 7.7: Alveolar macrophage superoxide burst early (2 months) and late (4 months) into TB treatment, 
stratified by HIV status 
Bars represent mean log-transformed activity index. The transparent data points are example points from the 
first of the 25 imputed datasets. Comparisons between early and late bronchoscopy made by paired t-test.  
 
No predictor variables were associated with 2 month superoxide burst activity on exploratory 
univariate linear regression. Superoxide burst was not associated with treatment response by 2MCC 
(OR: 0.2; 95% CI: 0.0-7.8; p=0.380), modelled bacillary elimination rate (p=0.887), or final outcome 
(OR: 0.0; 95% CI: 0.0-16.6; p=0.293). 
 
7.3.2.3 Bulk proteolysis 
Bulk proteolytic activity was assessed in 43 samples: 29 early, 24 late, 17 paired. Figure 7.8 shows 
bulk proteolytic activity over time by HIV status. No significant differences in proteolytic activity 
were seen at the 2 timepoints, or between HIV-infected/uninfected individuals. Bulk proteolytic 
activity was slightly reduced in HIV-infected participants at the late bronchoscopy compared to the 
early, but this was not statistically significant (0.31 [IQR 0.22-0.59] vs. 0.52 [IQR 0.33-0.62]; p=0.079). 
When the analysis was restricted to only those participants with paired data, HIV-infected 
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participants had lower bulk proteolytic function compared to HIV-uninfected participants at 4 
months into treatment (0.30 [IQR 0.23-0.31] vs. 0.41 [IQR 0.24-0.58]; p= 0.030). 
 
 
Figure 7.8. Alveolar macrophage bulk proteolytic function early (2 months) and late (4 months) into TB 
treatment, stratified by HIV status 
Bars represent mean log-transformed activity index. The transparent data points are example points from the 
first of the 25 imputed datasets. Comparisons between early and late bronchoscopy made by paired t-test.  
 
There were too few HIV-infected participants established on ART to assess the effect of ART duration 
on proteolytic function: more than half of participants were newly diagnosed with HIV at the time of 
TB diagnosis. Several variables had a univariate association with bulk proteolytic activity at the early 
bronchoscopy: a history of smoking (estimate: -0.180; SE: 0.058; p=0.004), baseline pulse (estimate: 
0.003; SE: 0.001; p=0.029), and baseline white cell count (estimate: 0.035; SE: 0.013; p=0.013). None 
of these associations remained significant on multivariate regression analysis. 
Alveolar macrophage proteolytic function was a poor predictor of 2MCC (OR: 0.12; 95% CI: 0.0-24.7, 
p=0.451) or bacillary elimination rate (p=0.923). There were too few unfavourable outcomes to 
assess relationships between proteolytic activity and final outcome.  
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7.3.3 Intrapulmonary cytokine micro-environment 
 
Intrapulmonary cytokines were measured in 46 IPPK1 and 38 IPPK2 samples (IFN-γ & IL-10), or 43 
IPPK1 and 37 IPPK2 samples (TNF-α & TGF-β). Table 7.3 summarises the pooled ELF cytokine 
concentrations. There was considerable variability in the cytokine concentrations recorded in ELF. 
 
Cytokine N * Mean concentration 
(SD) in pg/ml 
Median concentration 
[IQR] in pg/ml 
IFN-γ 84 41.42 (63.08) 18.85 [5.62, 47.66] 
TNF-α 80 234 (239) 157.1 [41.73, 357.8] 
IL-10 84 8.89 (15.61) 0.32 [0, 11.86] 
TGF-β (Latency Associated Peptide) 80 5.77 (7.98) 3.16 [1.15, 6.33] 
Table 7.3: Cytokine concentrations in ELF 
* early and late bronchoscopy results are pooled. SD: standard deviation; IQR: interquartile range 
 
7.3.3.1 Intrapulmonary cytokines by HIV status and time 
Concentrations of the pro-inflammatory cytokine IFN-γ decreased significantly between the 2 
bronchoscopies (early 27.1 pg/ml [IQR 15.1, 63.5] vs. 7.1 [2.3, 35.6]; p=0.002). This was largely driven 
by the reduction in IFN-γ in HIV-uninfected participants (Figure 7.9). Compared to HIV-uninfected 
participants, those with HIV had persistently elevated concentrations of IFN-γ in the alveolar space 
out to 4 months of treatment (median 17.5 pg/ml [IQR 5.0-60.5] vs. 3.3 [IQR 1.9-10.4]; p=0.010). 
Overall, HIV-infected participants had higher concentrations of IFN-γ in their ELF as compared to HIV-
uninfected participants (p=0.006).  
In contrast, concentrations of TNF-α were seen to be higher at 4 months into treatment (early 96.2 
pg/ml [IQR 32.4, 245.5] vs. 224.5 [89.6, 480]; p=0.014), again largely driven by changes in the HIV-
uninfected participants (median 224.5 pg/ml [IQR 36.6-563.71] at 2 months vs. 87.7 [IQR 17.3-173.0] 
at 4 months; p=0.009, Figure 7.10). This relationship held true if pooled or paired samples were 
analysed. 
Concentrations of the anti-inflammatory cytokines IL-10 and TGF-β were low in ELF, and often below 
the limit of quantification. No significant changes over time, or by HIV status, were identified, though 
there was a trend to reduced IL-10 concentrations by 4 months in paired samples (Figure 7.11). 
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Figure 7.9: Epithelial lining fluid IFN-γ concentrations early (2 months) and late (4 months) into TB treatment, 
stratified by HIV status 
Bars represent mean concentration in pg/ml. Comparisons between early and late bronchoscopy made by paired 
t-test. 
 
Figure 7.10: Epithelial lining fluid TNF-α concentrations early (2 months) and late (4 months) into TB 
treatment, stratified by HIV status 
Bars represent mean concentration in pg/ml. Comparisons between early and late bronchoscopy made by paired 
t-test.  
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Figure 7.11: Epithelial lining fluid IL-10 concentrations early (2 months) and late (4 months) into TB treatment 
 
7.3.3.2 Intrapulmonary cytokines and alveolar macrophage function 
The relationships between intrapulmonary concentrations of IFN-γ, TNF-α, IL-10 and TGF-β, and 
alveolar macrophage phagocytosis, superoxide burst, and bulk proteolysis were explored by linear 
regression, assessing 2 and 4 month samples separately. No significant relationships were identified. 
 
7.3.3.3 Intrapulmonary cytokines and response to treatment 
An exploratory analysis of intrapulmonary cytokine concentrations at 2 months versus treatment 
response (2MCC, BER, and final outcome) was performed. Those that had sputum culture converted 
by 2 months had lower TNF-α concentrations in their 2 month ELF compared to those still culture 
positive (median 124.3 pg/ml [IQR 22.1-283.3] vs. 209.3 [77.7-425]; p=0.048; Figure 7.12). 
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Figure 7.12: ELF TNF-α versus 2-month culture conversion 
Bars represent mean concentration in pg/ml. Comparisons between culture converters and non-converters made 
by unpaired t-test.  
 
7.3.4 Surface immunophenotyping of BAL 
 
Surface immunotyping was performed on 31 whole BAL samples: 19 early, 12 late. The alveolar 
macrophage was the most abundant cell type in whole BAL (median 55.7% [IQR 40.9-73.3]), 
identified by anti-CD45, anti-CD206, and anti-HLA-DR staining.  
Table 7.4 compares the proportion of cell types in whole BAL stratified by HIV status at 2 months 
into treatment. HIV-infected participants were found to have a lower proportion of CD4+ T cells 
(anti-CD45, anti-CD3, and anti-CD4 staining), higher proportion of CD8+ T cells (anti-CD45, anti-CD3, 
and anti-CD8 staining), and a lower CD4+/CD8+ ratio.  
Figure 7.13 shows the proportions and relative absolute cell count for participants stratified by HIV 
status. As only 3 HIV-infected participants had samples available for surface immunophenotyping 4 
months into treatment, the results from the early and late bronchoscopy timepoints have been 
pooled. 
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Figure 7.13: Cell subsets in BAL, stratified by HIV status 
Proportions of alveolar macrophages and T cells calculated as a proportion of leukocytes. Proportions of CD4+ 
and CD8+ cells reported as proportion of T cells. Relative absolute cell counts calculated with reference to the 
macrophage cell count. Bars represent geometric mean.  
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Characteristic HIV uninfected (n=12) HIV infected (n=7) p value * 
% alveolar macrophages (mean (SD)) 65.2 (18.6) 51.2 (21.8) 0.153 
% T cells (median [IQR]) 11.8 [6.4, 25.1] 6.0 [2.1, 26.6] 0.398 
% CD4+ cells (mean (SD)) 51.2 (18.2) 21.6 (19.7) 0.004 
% CD8+ cells (median [IQR]) 20.8 [15.7, 41.2] 52.9 [40.9, 70.5] 0.018 
Alveolar macrophages x 106/100ml BAL 
(median [IQR]) 
14.0 [12.0, 20.5] 16.0 [16.0, 19.0] 0.265 
T cells x 106/100ml BAL (median [IQR]) 2.8 [1.6, 8.6] 4.0 [1.2, 9.5] 0.800 
CD4+ cells x 106/100ml BAL (median [IQR]) 1.5 [0.8, 4.0] 0.4 [0.2, 2.1] 0.176 
CD8+ cells x 106/100ml BAL (median [IQR]) 1.1 [0.5, 1.5] 2.1 [0.7, 2.7] 0.398 
CD4+/CD8+ ratio (median [IQR]) 2.6 [0.9, 4.0] 0.2 [0.2, 0.7] 0.005 
Male sex (%) 9 (75.0) 7 (100.0) 0.430 
Age in years (median [IQR]) 28 [23, 30] 37 [33, 39] 0.004 
ART duration (%) 
- HIV infected, not yet on ART 
- Established on ART 
  
- 4 (57.1) 
- 3 (42.9) 
- 
Baseline CD4 in cells/mm3 (median [IQR]) 428 [338, 667] 106 [57, 181] 0.003 
Table 7.4: Surface immunophenotyping of BAL cells at 2-months into treatment 
Relative absolute cell counts and proportions of alveolar macrophages, T cells, and CD4+ / CD8+ T lymphocytes 
(as a proportion of T lymphocytes), stratified by HIV status at baseline. Immunophenotyping data from early 
bronchoscopy samples only.  * compared by chi-squared or Fisher’s exact test. 
 
7.3.4.1 Kinetics of alveolar macrophages during anti-TB treatment 
Alveolar macrophages in whole BAL were identified by their forward and side scatter characteristics, 
anti-CD45, anti-CD206, and anti-HLA-DR staining. The proportion of alveolar macrophages retrieved 
from BAL reduced over time in HIV-uninfected participants (median 65.8% [IQR 54.7-81.3] vs. 50.3% 
[IQR 42.3-65.3]; p=0.021), but absolute relative cell counts were unchanged. There were too few 
HIV-infected participants with immunophenotyping data at 4 months to assess changes in this group.  
 
7.3.4.2 Kinetics of BAL T cells during anti-TB treatment 
The T cell population in whole BAL was characterised by anti-CD45 and anti-CD3 surface staining. T 
cells represented 19.7% (median, IQR [7.7-38.3]) of the total leukocyte population. There was no 
significant change in the relative abundance of T cells in HIV-infected participants, but only 2 samples 
were available at 4 months. The proportion of T cells increased in HIV-uninfected participants 
between the 2 bronchoscopies (median 13.1% [IQR 7.1-26.5] vs. 33.4% [IQR 18.5-42.3]; p=0.019). 
 
7.3.4.3 Kinetics of CD4 and CD8 T lymphocytes during anti-TB treatment 
The relative abundance of CD4+ and CD8+ T lymphocytes in whole BAL was calculated by gating on 
the anti-CD3 population (Figure 7.4). Samples were reported as a proportion of anti-CD3 cells (T 
cells). There were significant differences in the proportions of CD4+ and CD8+ lymphocytes by HIV 
status (Table 7.4 and Figure 7.14).  
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HIV-infected participants had a lower proportion of CD4+ T cells in the alveolar space at 2 months 
compared to HIV-uninfected participants (15.0% [IQR 8.7-27.5] vs. 52.3% [IQR 36.9-61.5], p=0.007), 
and a higher proportion of CD8+ T cells (52.9% [IQR 40.9-70.5] vs. 20.8% [IQR 15.7-41.2], p=0.024). 
The same trends were seen in absolute relative cell counts, but this was not statistically significant. 
With only 2 HIV-infected participants having a 4-month bronchoscopy, it is not possible to assess 
changes in proportions or absolute counts over time in HIV-infected participants. However, when 
samples from early and late bronchoscopies are pooled (as in Figure 7.13), HIV-infected individuals 
are seen to have a lower proportion and count of intrapulmonary CD4+ cells, and a greater 
proportion of intrapulmonary CD8+ cells. 
 
 
Figure 7.14: Relative proportion and absolute counts of CD4 and CD8 T lymphocytes over time and by HIV 
status 
Proportion of CD4 / CD8 cells is measured as percentage of CD45+ CD3+ T cells. There was a significant reduction 
in the proportion of CD4 cells at 2 months (early) and increase in CD8 cells in HIV-infected participants. 
Immunophenotyping data for HIV-infected participants at 4 months was only available in 3 participants. Bars 
represent mean. 
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Many of the co-infected participants were diagnosed with HIV in the course of care-seeking for TB, 
and typically started ART within the first 2 weeks of TB treatment (section 3.4.2). ART initiation and 
immune reconstitution may alter the proportion and count of alveolar CD4+ T lymphocytes. The 
number of participants established on ART was too few (n=3) to identify any difference in % CD4+ T 
lymphocytes by duration on ART, but a linear relationship between intrapulmonary and peripheral 
CD4 count was observed (p=0.04, Figure 7.15). Given that peripheral CD4 count in HIV-infected 
participants increased by median 61 cells/mm3 [IQR 4, 116] over the 6 months of TB treatment, 
increases in the alveolar CD4+ T lymphocyte count may also be expected. This may contribute to 
increased ELF concentrations of IFN-γ (section 7.3.3.1), and increased superoxide burst activity at 4-
months into treatment (section 7.3.2.2). 
 
      
Figure 7.15: Plasma versus intrapulmonary CD4 count 
 
7.3.5 Intracellular pH measurement 
 
Attempts were made to measure intracellular phagosomal pH in 15 participants. In 7 participants, 
granulocyte intracellular pH in whole blood was also assessed. All samples, bar one, were taken at 
the early bronchoscopy timepoint. Representative dot plots are shown Figure 7.5. 
 
7.3.5.1 Granulocyte intracellular pH 
Four incubation times were used in this assay: 15 minutes (as per manufacturer’s instructions), 30 
minutes, 45 minutes and 1 hour (additional timepoints during optimisation). The median percentage 
granulocytes that phagocytosed particles was 70% [IQR 26-91], with a 1.9-fold [IQR 1.1-2.0] increase 
in fluorescence (Table 7.5). The greatest percentage of phagocytosing cells was seen after 45 
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minutes of incubation (median 91%, [IQR 90-92]), and the greatest increase in fluorescence after 60 
minutes incubation (2.74-fold). These results were lower than expected (96% phagocytosing 
granulocytes, 5-fold increase in fluorescence). 
Incubation time n % phagocytosing cells 
(median [IQR]) 
Increase in fluorescence 
(median [IQR]) 
15 minutes 2 7 [4, 11] 0.9 [0.9, 0.9] 
30 minutes 2 66 [52, 80] 1.6 [1.5, 1.8] 
45 minutes 2 91 [90, 92] 2.0 [1.9, 2.0] 
60 minutes * 1 70 2.7 
TOTAL 7 70 [26, 91] 1.9 [1.1, 2.0] 
Table 7.5: Whole blood intracellular pH measurement 
Whole blood was incubated for 15-60 minutes with pHrodo-labelled E. coli. The % phagocytosing cells and 
increase in fluorescence (between samples at 37oC and samples held on ice) was measured by flow cytometry. * 
n=1 – no summary statistics included 
 
7.3.5.2 Alveolar macrophage intracellular pH 
The same experiments were attempted on 100 µl of AM suspension. Cellular recovery after 
incubation with pHrodo-labelled E. coli was minimal, with a median of 7% [IQR 3-31] phagocytosing 
cells (Table 7.6). While the highest % phagocytosing cells was seen after 45 minutes of incubation 
(29% [26-32]), few cells were recovered and this timepoint was abandoned. Use of a rotating 
incubator improved the cell yield slightly. As for the whole blood assay, a five-fold increase in 
fluorescence between samples held on ice, and samples at 37oC was anticipated [617]. The median 
increase was 1.0-fold [IQR 1.0-1.3]. Given that the assay was not running optimally by the time of the 
last early bronchoscopies, these experiments were discontinued to focus on the 
immunophenotyping work. 
Incubation time n % phagocytosing cells 
(median [IQR]) 
Increase in fluorescence 
(median [IQR]) 
15 minutes 2 1 [0, 1] 1.0 [1.0, 1.0] 
30 minutes 11 7 [5, 31] 1.1 [1.0, 1.3] 
45 minutes 2 29 [26, 32] 1.2 [1.1, 1.3] 
TOTAL 15 7 [3, 31] 1.0 [1.0, 1.3] 
Table 7.6: Alveolar macrophage intracellular pH measurement 
100 µl alveolar macrophage suspension was incubated for 15-45 minutes with pHrodo-labelled E. coli. The % 
phagocytosing cells and increase in fluorescence (between samples at 37oC and samples held on ice) was 
measured by flow cytometry.  
 
7.3.6 Multiplex PCR for co-infection 
 
156 respiratory samples were analysed by multiplex PCR, from the 51 participants undergoing 
research bronchoscopy. 51 IPPK1, 41 IPPK2, 32 screening sputum samples, and 32 S3/S4 sputum 
samples were available for analysis. 32 participants had a complete set of sputum and BAL samples 
for analysis. 
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7.3.6.1 Co-infecting organisms 
A total of 41 organisms were identified across the 156 respiratory samples: 11 viruses (26.8%), and 
30 bacteria (73.2%). Some participants had multiple organisms detected on a single sputum or BAL 
sample. Table 7.7 summarises the organisms identified by time of sampling and specimen type, and 
Table 7.8 by individual participant. Fewer organisms were recovered from BAL (n=9), compared to 
the screening sputum sample (n=32). Rhinovirus was the commonest virus isolated, K. pneumoniae 
the commonest bacteria. S. pneumoniae and H. influenzae were relatively common, and seen 
predominantly in sputum samples. 
 
 
Organism Sputum  
month 0  
 n=32, (%) 
Sputum  
month 2  
 n=32, (%) 
BAL  
month 2  
 n=50, (%) 
BAL  
month 4  
 n=40, (%) 
Total: 
organisms  
 n (%) 
Adenovirus 1 (3.1) - - - 1 (2.4) 
Coronavirus 63 2 (6.2) - 1 (2) - 3 (7.3) 
Coronavirus 229 - - 1 (2) 1 (2.5) 2 (4.9) 
Enterovirus / Parechovirus 1 (3.1) - - - 1 (2.4) 
Rhinovirus 2 (6.2) 1 (3.1) 1 (2) - 4 (9.8) 
Total: viruses 6 (18.8) 1 (3.1) 3 (6) 1 (2.5) 11 (26.8) 
Haemophilus influenzae 6 (18.8) 2 (6.2) 1 (2) 1 (2.5) 10 (24.4) 
Klebsiella pneumoniae 4 (12.5) 4 (12.5) 1 (2) 2 (5) 11 (26.8) 
Staphylococcus aureus 2 (6.2) 1 (3.1) - - 3 (7.3) 
Streptococcus pneumoniae 5 (15.6) 1 (3.1) - - 6 (14.6) 
Total: bacteria 17 (53.1) 8 (25) 2 (4) 3 (7.5) 30 (73.2) 
Overall total 23 (71.9) 9 (28.1) 5 (10) 4 (10) 41 (100) 
Table 7.7: Summary of co-infecting organisms identified by multiplex PCR in BAL and sputum from 
bronchoscopy patients 
156 respiratory samples were analysed. Bacterial organisms were identified more frequently than viral, with K. 
pneumoniae the most abundant organism in sputum and BAL. ‘Month’ refers to time into TB treatment.  
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Figure 7.16: Relative abundance of co-infecting pathogens in sputum and BAL over time 
The red shaded area represents the proportion of specimens in which no organisms were identified. The 
remaining colours represent the proportion of co-infecting pathogens in positive samples. ‘Month’ refers to time 
into TB treatment.  The screening sputum sample (month 0) had the highest proportion of organisms identified, 
mainly H. influenzae, S. pneumoniae, and K. pneumoniae. Fewer organisms were identified later in treatment, 
and in BAL.  
 
Figure 7.16 shows the relative abundance of co-infecting pathogens by sample type, and time on TB 
treatment. The screening sputum sample had the most organisms identified in the most participants 
(in 53% of participants), and BAL relatively few (8% participants). The proportion of rifampicin-
sensitive organisms (H. influenzae, S. pneumoniae, S. aureus) identified in sputum samples 
significantly reduced between months 0 and 2 of TB treatment (p=0.024). 
Table 7.8 shows the positive results by individual participant. 4 participants had the same organism 
identified in more than one sample:  H. influenzae in participants 55 and 94, K. pneumoniae in 
participants 31 and 41. Though numbers are few, there did not appear to be a relationship between 
the organisms detected in month 2 BAL and paired sputum. 
 
 
 
 
Chapter 7  Intrapulmonary immunology 
 
Page 242 
Participant 
ID 
Sputum  
month 0  
 n=32 
Sputum  
month 2  
 n=32 
BAL 
month 2  
 n=50 
BAL 
month 4  
 n=40 
11 Coronavirus 63 
S. pneumoniae 
- - - 
12 Rhinovirus 
S. pneumoniae 
- - - 
13 K. pneumoniae - - - 
14 K. pneumoniae - Coronavirus 63 - 
26 S. pneumoniae - - - 
31 K. pneumoniae K. pneumoniae 
S. aureus 
- - 
32 Enterovirus/Parechovirus - - - 
34 H. influenzae - - - 
38 H. influenzae - - - 
41 S. aureus K. pneumoniae - K. pneumoniae 
51 Rhinovirus 
H. influenzae 
S. pneumoniae 
- - - 
55 H. influenzae H. influenzae - H. influenza 
94 Adenovirus 
H. influenzae 
H. influenzae 
S. pneumoniae 
- - 
97 K. pneumoniae - - - 
100 S. aureus 
S. pneumoniae 
- - - 
107 - K. pneumoniae H. influenza 
Rhinovirus 
- 
114 - - - Coronavirus 229 
K. pneumoniae 
115 - - Coronavirus 229 - 
119 H. influenzae - K. pneumoniae - 
120 - Rhinovirus 
K. pneumoniae 
- - 
122 Coronavirus 63 - - - 
Table 7.8: Organisms identified by multiplex PCR by individual study participants 
Colours correspond to the key on Figure 7.16. Some organisms are repeatedly isolated from the same 
participant.  
 
7.3.6.2 Predictors of co-infecting organism 
Given the small numbers of organisms identified in these samples, participants were grouped into 
those with any organism detected, and those without, for further analysis. The baseline clinical, 
demographic, and radiological data were interrogated for predictors of co-infecting organism. None 
of the predictor variables assessed were associated with the likelihood of co-infecting organism in 
sputum or BAL.   
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7.4 Discussion 
 
The work in this chapter demonstrates temporal changes in the local immune response to 
pulmonary TB infection, modulated by HIV co-infection. In the natural history of TB infection, inhaled 
Mtb in the alveolar space are phagocytosed, and the macrophage activated by pro-inflammatory 
signalling, chiefly by locally secreted IFN-γ [357, 618, 619]. Macrophage activation increases the 
activity of the superoxide burst to enhance microbial kill [370], and downregulates proteolysis to 
enable more efficient antigen presentation [377]. Secretion of TNF-α, IL-12, and chemokines from 
infected AMs encourages cellular influx [400, 401]. As treatment progresses, there is a rapid early 
down-regulation of expression of inflammatory markers as the bacterial load is debulked by 
isoniazid, followed by slower changes as dormant bacilli are eliminated [620].  
In HIV-uninfected participants, this pattern appears to hold true. Levels of IFN-γ in the alveolar space 
decline between 2 and 4 months of treatment, and there is a trend towards reduced superoxide 
burst activity later into treatment. In contrast, those with HIV co-infection show a very different 
pattern of macrophage activity over time. By 4 months, phagocytic capacity and superoxide burst 
activity increased, and there is a trend towards reduced proteolysis. Asymptomatic HIV-infected 
individuals already have high IFN-γ concentrations in the lungs [379], and it appears that IFN-γ 
concentrations remain elevated 4 months into treatment in TB/HIV co-infected patients. Given that 
bacillary elimination rates were not affected by HIV status (Chapter 6), delayed bacillary clearance in 
HIV-infected individuals is unlikely to explain these differences in alveolar macrophage function. 
With more than half of the HIV-infected cohort ART-naïve at baseline, immune reconstitution and 
influx of IFN-γ-producing CD4+ T cells may lead to a prolonged inflammatory response and ongoing 
active inflammation in the lungs of these patients at least until 4 months of treatment [621]. 
Alternatively, lymphocytic alveolitis secondary to increased alveolar CD8+ T cells  [379, 622], with 
persistent cell-free and cell-associated HIV in the lung [376, 591], may also be contributing to a 
prolonged inflammatory environment.  
TNF-α plays multiple roles in immune and pathologic responses to Mtb infection [623]. Alveolar 
macrophage infection induces TNF-α secretion [624], and TNF-α works synergistically with IFN-γ to 
activate macrophages and induce nitric oxide synthase [600]. By inducing expression of adhesion 
molecules, chemokines, and chemokine receptors, TNF-α appears central to the formation of an 
organised granuloma [602, 623]. Participants that failed to culture convert by 2 months had higher 
BAL levels of TNF-α than those that converted, in keeping with Mtb-induced TNF-α production and 
ongoing inflammation. No significant differences were seen in levels of TNF-α between HIV-infected 
and HIV-uninfected individuals, though HIV-uninfected participants had increased TNF-α at 4 
months. This may be due to a further role in the resolution of inflammation: neutrophil clearance by 
efferocytosis being mediated by TNF-α [625]. 
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Intrapulmonary concentrations of the primarily anti-inflammatory cytokines IL-10 and TGF-β were 
quantified in BAL. There was a trend towards reduced IL-10 over time in paired samples, but this was 
not statistically significant, and likely reflects the small sample size. Produced by macrophages and T 
cells during Mtb infection, IL-10 is involved in the down-regulation of macrophage activation and 
IFN-γ production [623]: its’ reduction here may be in keeping with resolution of infection in response 
to treatment. TGF-β, important in macrophage activation [626] and down-regulation of T cell 
proliferation [627], has previously been shown at elevated levels in BAL in new pulmonary TB 
patients [628]. This was not observed here, and may be partly explained by the collection of the 
earliest BAL sample after participants had already taken 2 months of therapy. While it was possible 
to observe trends in cytokine concentrations between 2 and 4 months of treatment, these 
concentrations may not reflect the pre-treatment situation ex vivo or in the lung. 
No relationship was seen between individual cytokine concentrations and key macrophage effector 
functions. While some of the differences in macrophage function may be explained by local levels of 
IFN-γ, it is important to acknowledge that cytokines exist in a homeostatic network of pro- and anti-
inflammatory signalling, and it can be difficult to unpick individual effects [629]. 
There was insufficient immunophenotyping data in the HIV-infected cohort to identify a CD4+ T cell 
influx by 4 months of treatment. However, given that peripheral and BAL CD4 T cell counts were 
correlated, and that peripheral CD4 T cell count improved over the course of TB treatment (Chapter 
3), we may expect a degree of intrapulmonary CD4 T cell reconstitution. The absolute relative T cell 
count increased in HIV-uninfected participants between months 2 and 4, in keeping with a delayed 
adaptive immune response [630] and potentially expansion of the pool of T regulatory cells in the 
lung [631]. 
Lymphocytic alveolitis has been described in HIV infection [632]. While HIV-infected participants had 
a lower proportion of alveolar CD4+ T cells, and higher proportion of CD8+ T cells, this did not 
translate into a higher absolute relative cell count. The small number of HIV-infected participants 
with immunophenotyping data limits this analysis. 
The use of multiplex PCR on respiratory samples from TB patients generated some interesting pilot 
data. There was a significant reduction in organisms expected to be rifampicin-sensitive (H. 
influenzae, S. pneumoniae, S. aureus) in sputum samples at 0 and 2 months of treatment, likely 
reflecting wider changes in the intrapulmonary microbiome. Animal models and 16S rRNA 
sequencing have shown that 6 months of RHZ induces rapid changes in intestinal microbial 
community structure, persisting for at least 3 months following cessation of treatment [633]. 
Furthermore, rifampicin, as a broad-spectrum antimicrobial, appeared to be the major driver of 
these changes. Similar intrapulmonary longitudinal microbiome studies are yet to be performed, but 
may provide useful insights into associations with local and systemic immune responses, particularly 
in the setting of HIV infection. Cross-sectional studies using 16S sequencing on the sputum of 
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patients with a new TB diagnosis, recurrent TB, treatment failure, or healthy controls suggests 
differences in the microbiota between these groups, and implicate dysbiosis in treatment response 
[634].  
The commonest co-pathogen identified was Klebsiella pneumoniae. Increased prevalence of 
Klebsiella in pulmonary tuberculosis patients compared to healthy volunteers has been described in 
China [613], and TB / Klebsiella co-infection in reports from India [635] and China [612]. Commonly 
considered a healthcare-associated infection, Klebsiella may present with cavitating pneumonia, and 
is not covered by first-line anti-tuberculosis medications.  
The finding of multiple organisms in sputum does not necessarily indicate infection, but may be 
explained by nasopharyngeal carriage of organisms. Relatively few organisms were retrieved from 
BAL. Nasopharyngeal carriage of Streptococcus pneumoniae may account for some of the positive 
results in sputum, but may also involve some cases of pneumococcal / Mtb co-infection [636]. 
Pneumococcal infection (invasive pneumococcal disease) has been temporally linked with TB 
infection [637], and superimposed pneumococcal pneumonia may prompt presentation with acute 
pneumonic symptoms in culture-confirmed TB in settings of high HIV and TB prevalence [638, 639]. 
Any relationship between nasopharyngeal carriage of S. pneumoniae and TB is less clear, and the 
numbers assessed in this study were too few to reach any conclusions. 
Assessment of temporal changes in intrapulmonary immunology and microbiology was limited by 
the sampling timepoints in this study: bronchoscopies were only performed at 2 and 4 months into 
treatment, and not at treatment initiation. This was a cohort of microbiologically-confirmed 
pulmonary TB patients, and thus research bronchoscopy at treatment initiation would pose a health 
risk to both participants and Clinical Investigation Unit staff. By sampling at 2 and 4 months, it is 
possible to get an indication of trends in immune response. Furthermore, given that a third of 
participants were still culture-positive by 2 months, active disease is still ongoing.  
Rates of HIV co-infection in the bronchoscopy arm were lower than in the main cohort (Chapter 3: 
45.1% vs. 64.2%, p<0.05). Participants were sequentially allocated to the 2 arms of the study, but 
only remained in the bronchoscopy arm if they attended for bronchoscopy at weeks 7-8 of 
treatment. Most HIV-infected participants were ART-naïve, and numbers on ART were too few to 
assess the impact of ART duration on macrophage function or cell subsets. 
Similarly, the surface immunophenotyping dataset was limited by sample numbers. 
Immunophenotyping was only performed on a small number of participants undergoing 
bronchoscopy, with results only available for 12 late bronchoscopies. It was not possible to assess 
changes in the intrapulmonary cell subsets over time in HIV-infected participants with only 3 late 
bronchoscopy results available. Previous work has described CD8+ T cell alveolitis in HIV-infected 
individuals [591, 640, 641], but could not be reliably assessed here given the low numbers. 
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Finally, BAL was performed exclusively in the right middle lobe of participants, regardless of the likely 
site of their infection. BAL return from the RML is typically greater than from upper or lower lobes, 
the RML is easily accessible, and is a standard sampling site in research bronchoscopy practice [430]. 
However, sampling from only the RML may miss the diagnosis of active alveolitis in interstitial lung 
disease [642, 643], and in sarcoidosis, cell differentials vary by sampling site [644]. Nevertheless, 
FDG-PET/CT scanning has shown that patients with subclinical TB infection may have more diffuse 
disease than previously thought [645], and bronchogenic spread in post-primary TB may be one of 
the earliest manifestations of pulmonary TB, resulting in a more widespread disease process [645, 
646]. As such, RML immune functions in pulmonary TB may give an indication of immunity 
elsewhere. Similarly, the function of alveolar macrophages in the interstitium or in the developing 
granuloma may differ from those retrieved from the alveolar space, but cannot be readily sampled 
for ex vivo functional analysis. As such, these data may be considered ‘near-infection’ immunology, 
rather than site of infection. 
In conclusion, pulmonary TB infection is associated with increased alveolar macrophage oxidative 
burst activity, and decreased proteolytic activity, in HIV-infected patients out to 4 months of 
treatment. This may reflect CD4+ T cell reconstitution on ART, high levels of IFN-γ, and ongoing, 
active inflammation despite TB treatment and reduction in the bacillary load. 
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8 General discussion 
8.1 Introduction 
 
Shorter, more efficacious, treatments for TB are essential to achieve the desired decline in global 
incidence by 2035, and must be informed by knowledge of the contribution of drug therapy and the 
immune system to successful cure. While not exclusively a lung disease, pulmonary tuberculosis is 
the commonest and most-recognised form of the disease. This thesis argued that drug exposure and 
host immune function at the pulmonary site of infection may be important determinants of 
response, and potential targets for therapeutic interventions to shorten or optimise TB treatment.   
This thesis addressed two hypotheses, summarised in Figure 8.1.  
1. Predictive PK-PD science:  Antibiotic exposure at the site of infection may determine the 
rate of bacterial clearance and clinical treatment response in TB patients. 
2. Immunological dysfunction: HIV and/or Mtb impair alveolar macrophage function, despite 
therapy, and impair the ability of the immune system to eradicate Mtb.  
Figure 8.1: Study hypotheses 
 
This study aimed to address the hypotheses by answering the following research questions: 
1. What is the relationship between the plasma and intrapulmonary pharmacokinetics of anti-
TB therapy? 
2. What is the relationship between intrapulmonary pharmacokinetics and TB treatment 
response? 
3. How does alveolar macrophage function change over time on anti-TB therapy; and how is 
this related to TB treatment response? 
This final chapter of the thesis will consider how effectively these hypotheses and questions have 
been addressed, summarise the key findings, consider their implications, and priorities for future 
work. 
 
8.2 Description of the cohort: who gets TB in Blantyre? 
 
To address these hypotheses, a large cohort of Malawian adults with microbiologically-confirmed 
pulmonary TB were recruited to a PK-PD and intrapulmonary immunology study. These patients 
were established on standard first-line therapy for TB, and intensively sampled over the treatment 
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period. Study retention was excellent, with 82.8% followed-up until the end of treatment, and 72.6% 
(death and EOS) to 18-months, with a further 19 continuing in follow-up.  
The study population was young, predominantly male, with high rates of TB/HIV co-infection. Co-
infection rates of more than 50% were to be expected [17], but over half of HIV-infected study 
participants were newly diagnosed in the course of care-seeking for this illness. Malawi has adopted 
a pro-active approach to HIV testing and treatment in line with the 90-90-90 targets [425], but these 
data suggest that a sizable proportion of HIV-infected adults are only testing in the presence of 
serious immunosuppression-related illnesses. Reaching these individuals earlier will be key to 
preventing TB disease and reducing TB incidence [442]. Once diagnosed and registered, the NTP was 
successful at starting nearly all new HIV-infected participants on ART within the first 2 weeks of TB 
treatment in keeping with local and international guidelines [47-49, 647].  
Female participants were more likely to be established on ART for more than 4 years, reflecting 
differences in health-seeking and HIV testing as part of antenatal care [481-484]. The few 
participants taking ART for more than 4 years still had significantly lower CD4 counts than HIV-
uninfected participants. Though the data are cross-sectional in nature, this raises the spectre of ART 
failure as a driver of future TB incidence, and will be challenging to manage in settings with limited 
options for second- and third-line ART.  
Several participants were clinically septic by time of presentation, with participants reporting up to 8 
weeks of symptoms before receiving a TB diagnosis. 55% had received prior antibiotics. Healthcare 
access, diagnostic uncertainty, and initial visits to healthcare facilities with few diagnostic resources 
can result in prescription of empirical antibiotics for unconfirmed indications, and delays in TB 
diagnosis [648]. Considering most participants were heavily smear-positive, health systems 
strengthening will be essential for transmission reduction efforts. 
Finally, these participants were largely poor. Most patients were recruited from peri-urban informal 
settlements around Blantyre, characterised by high population densities, poor living conditions, and 
limited healthcare access [427]. Addressing the proportion of people living in slums and informal 
settlements as part of the Sustainable Development Goals can be expected to reduce TB incidence, 
but will be challenging in the face of rapid urbanisation in Africa and Asia [17, 649, 650].  
Taken together, these data suggest that the study cohort was representative of TB patients in 
Malawi, and the findings may be applied to similar low-resource, high-TB-burden countries in sub-
Saharan Africa.  
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8.3 How do we determine response to treatment?  
 
Any new TB treatment regimen must be evaluated in Phase IIb and III studies, typically against the 
endpoint of relapse-free cure to 18 or 24-months of follow-up. Earlier surrogate markers of long-
term response will facilitate dose optimisation and regimen development for both drug-sensitive and 
drug-resistant disease. This study included several markers of TB treatment response. 
2-month culture conversion was the primary endpoint for the study, but was not predictive of 
favourable final outcome (OR: 0.61; 95% CI: 0.13-2.37; p=0.500). 2MCC is known to have only 
modest correlation with late outcomes, and delays in attending for screening may have removed 
some early culture-converters from this cohort. While 37.3% had not culture converted by 2 months, 
later culture conversion was not reflected in more unfavourable responses by 18-months. Delayed 
culture conversion is recognised in African cohorts [15, 66, 494].   
Regardless of any relationship with late clinical outcome, 2MCC remains an important endpoint; 
earlier conversion to culture-negative may be assumed to reduce the period over which the patient 
is infectious. Those with cavitation, higher smear-grade disease, or higher bacillary load – all collinear 
– were less likely to culture-convert by 2 months. Previous attempts to shorten treatment in patients 
with non-cavitatory disease and culture conversion at 2 months were unsuccessful [62], but perhaps 
the converse approach may be beneficial: continuation phase extension in those with cavitation at 
baseline. This is included as an ‘expert opinion’ in the current American Thoracic Society guidelines 
for the treatment of DS-TB [491]. 
Bacillary elimination rates (BER), generated from serial quantitative measures of bacillary load in 
liquid culture coupled with mixed-effects modelling, have shown promise as a surrogate of long-term 
response [89], but have been incompletely validated as a marker of late response. BER was not 
associated with late outcomes in this cohort. This may be due to a low number of unfavourable final 
outcomes and potential contamination of late unfavourable outcomes by exogenous reinfection. 
Without resources to genotype cases of recurrent TB, re-infection with new strains of Mtb will 
contaminate the final outcome endpoint. 
Modelled BER from serial TTP in liquid culture may also fail to completely characterise the sterilising 
activity of a regimen. Studies using resuscitation promoting factor or culture filtrate with liquid 
culture demonstrate that a significant proportion of persister bacilli are not captured using standard 
techniques [86, 87]. Considering that sterilising activity is determined by activity against these 
differentially-culturable bacilli [72, 74, 77], failure to capture this population will dilute any 
association with long-term outcomes.  
Determination of BER is computationally-challenging, and requires careful consideration of how to 
handle results beyond the LOQ. Partial likelihood modelling accounts for negative samples (TTP > 42 
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days), and reduces bias in the estimates [549, 550]. Provided participants had submitted more than 2 
sputum samples, it was possible to estimate a BER for them. When fitting the models, inter-
individual variability (IIV) on the co-efficient for intercept – baseline bacillary load – was far more 
important to the model fit than IIV on the rate coefficient for bacillary elimination. This suggests that 
once on treatment, there was relatively little variation in the speed of bacillary elimination on 
standard mg/kg dosing. Baseline CXR score and cavitation both decreased BER: potentially secondary 
to anatomical disruption, altered intrapulmonary pharmacokinetics, or loss of immunological control 
of infection. 
Application of these modelling techniques to cycle threshold measurements from Xpert MTB/RIF will 
require further evaluation. As PCR should enumerate DNA from all organisms – including inert, 
persister bacilli – and is less affected by contamination, BERs generated may be more representative 
of intrapulmonary sterilisation. Extensive variability between laboratories [586], and potential 
contamination by non-viable bacteria has limited its use as a treatment monitoring tool to date 
[587]. 
TB relapse was seen in 2.5% of participants, in keeping with data from early treatment trials [12-15]. 
Treatment success rates in new and retreatment cases in Malawi are estimated at 85% [17], whereas 
unfavourable final outcomes – a composite outcome of TB death, treatment failure, or recurrent TB 
– were seen in 12.2% of study participants. Despite having drug-sensitive disease, and even with 
intensive follow-up and adherence support, a sizeable fraction of participants do not do well. This 
could not be explained by PK-PD or compartmental immunology, and may be due to programmatic 
or clinical factors.  
Ultimately, the microbiological and pharmacodynamic methods assessed here do not correlate well 
with long-term outcome, but further evaluation of BERs by Xpert MTB/RIF or MGIT with 
resuscitation-promotion factors are proposed. Identification of factors associated with more rapid 
bacillary elimination may be important for interruption of transmission, even if inconsistently related 
to rates of relapse-free cure. 
 
8.4 What is the relationship between the plasma and intrapulmonary 
pharmacokinetics of anti-TB treatment? 
 
The first two research questions addressed the hypothesis that site of infection PK is an important 
determinant of bacterial clearance and treatment response. The work presented in Chapters 4 and 5 
demonstrates that drug concentrations in epithelial lining fluid and alveolar cells differ significantly 
from plasma. Intrapulmonary concentrations were seen to exceed concentrations in plasma, exceed 
the MICs for the infecting organism, and exceed cut-offs for poor response by therapeutic drug 
monitoring [168] or in vitro studies [288].  
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Bronchoscopy and BAL sampling, coupled with population PK modelling, is a powerful tool for 
assessing ‘near-infection’ PK. As Mtb is an intracellular organism, anti-TB drugs must achieve 
sufficient concentration within the cell to effect microbial kill. All 4 drugs reached higher 
concentrations in the cell than plasma, particularly ethambutol, indicating that considerable anti-
tuberculosis activity exists within the macrophage. RHZE distributed well into ELF, with pyrazinamide 
and isoniazid achieving especially high concentrations. 
These data complement spatial mass-spectrometry [53, 210, 521] and physicochemical data [532], 
and support a mechanism of action for first-line ATT. High concentrations of isoniazid in ELF explains 
its’ early bactericidal activity against rapidly-replicating extracellular organisms [90, 211]. 
Pyrazinamide achieves homogenous distribution across the caseum, where it can act against semi-
dormant, non-growing Mtb [161], enabling treatment shortening [15, 118, 121]. Ethambutol is 
largely bacteriostatic against intracellular organisms. Finally, rifampicin is most complex: it has 
moderate macrophage uptake and physicochemical properties that do not favour extensive 
distribution into ELF or caseum [532]. Through non-specific binding to macromolecules in the 
caseum, and with potency against non-replicating bacilli [532, 533], over repeated dosing rifampicin 
will accumulate and sterilise the caseum [210]. These data support the view that successful TB 
treatment requires drug therapy with multiple mechanisms of action.  
Ultimately, the relationship between plasma and intrapulmonary PK was best described by 1-
compartment plasma models with the extent of distribution described by the alveolar cell:plasma 
and ELF:plasma concentration ratios. These models assumed instantaneous equilibration and do not 
capture any system hysteresis, however concentration-time scatterplots did not suggest any 
significant lag in intrapulmonary penetration. The model parameters were estimated well, 
interindividual variability was estimated, and the ratios reflected the patterns seen in the raw data, 
suggesting that the models used are a satisfactory representation of the plasma and intrapulmonary 
PK relationship. 
 
8.5 What is the relationship between intrapulmonary pharmacokinetics and 
TB treatment response? 
 
The second research question considered the relationship between PK at the site of infection and 
response to treatment, comparing intrapulmonary PK with plasma. Four endpoints were considered: 
2-month culture conversion, modelled sputum bacillary elimination rate, sputum time-to-negativity, 
and relapse-free cure to 18-months of follow-up.  
Concentrations of rifampicin and isoniazid, in plasma or ELF, were important predictors of TB 
treatment response. Cmax or AUC in ELF were associated with more rapid bacillary elimination, and 
shorter time to sputum negativity, and peak rifampicin concentrations in ELF were associated with 
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more favourable final outcomes. In general, there was a trend towards greater bacillary clearance 
and more favourable outcomes with increasing ELF concentrations of rifampicin, isoniazid, or 
pyrazinamide.  
While higher ethambutol AUC/MIC and Cmax/MIC in ELF and alveolar cells was related to poorer odds 
of culture conversion, there was no relationship with final outcome, bacillary elimination rate, or 
time-to-negativity, and this appears likely to be a spurious relationship. No consistent relationships 
between alveolar cell drug exposure and treatment response were identified.  
AUC or Cmax in ELF and alveolar cells was directly proportional to AUC and Cmax in plasma, and though 
there was some inter-individual variability in the extent of drug penetration to ELF (RELF) or alveolar 
cells (RAC), this was unlikely to significantly alter the dose-response relationships. Ultimately, the 
plasma PK was a reasonable surrogate for the drug exposure in the ELF. Improved early bactericidal 
activity with increasing rifampicin mg/kg dosing [308] may be attributed to higher drug exposure in 
the intrapulmonary compartment.  
The baseline MICs for rifampicin, isoniazid, and ethambutol were generally lower than reported 
elsewhere in the region [289], indicating preserved drug sensitivity. Measures of intrapulmonary 
AUC or Cmax was typically many fold higher than the MIC for all 4 drugs. The intrapulmonary dose-
response relationship may be more pronounced in regions with higher baseline MICs. 
Taken together, these data suggest that higher concentrations of rifampicin and isoniazid in the ELF 
improve bacillary elimination from the sputum, and may be associated with more favourable late 
outcomes. The results of ongoing dose-escalation studies may allow for optimisation of regimens for 
DS-TB. 
 
8.6 How does alveolar macrophage function change over time on anti-TB 
treatment; and how is this related to TB treatment response? 
 
The second hypothesis considered compartmental immune responses, and whether HIV and/or Mtb 
infection impaired alveolar macrophage function and the ability of the immune system to eradicate 
Mtb. The data presented in Chapter 7 demonstrate that HIV infection modulates alveolar 
macrophage innate immune functions in pulmonary TB, and this may reflect a prolonged pro-
inflammatory environment in the lungs. 
With 2 bronchoscopies per participant it was possible to assess changes in the immune 
microenvironment between the intensive and continuation phases of treatment. In HIV-infected 
participants, concentrations of interferon-γ remained elevated at 4 months into treatment, with 
corresponding high superoxidative burst activity and blunted phagocytosis. HIV-uninfected 
participants displayed trends towards resolution of the pro-inflammatory environment by 4 months, 
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presumably as the disease was debulked by treatment. This could not be explained by slower 
clearance of Mtb during TB/HIV co-infection: bacillary load or bacillary elimination rate were not 
affected by HIV status. 
Alternative explanations for delayed resolution of the intrapulmonary inflammatory environment in 
HIV-infected participants are proposed. Macrophage infection with Mtb may increase superoxidative 
burst activity [372], and ongoing intracellular infection in HIV-infected participants may account for 
high superoxidative burst activity at 4 months. Alternatively, as most HIV-infected participants were 
ART-naïve on recruitment, a degree of immune reconstitution may account for differences with HIV-
uninfected individuals. Finally, persistent cell-free and cell-associated HIV in the lung may favour a 
prolonged inflammatory environment [376, 591]. Alterations in the immune environment within the 
lungs of patients with TB/HIV co-infection may impair control of TB infection, and increase the risk of 
recurrent TB disease after treatment completion (although not observed in this cohort). 
Direct comparison with healthy volunteers without TB was not possible, nor was it possible to obtain 
intrapulmonary samples at the onset of treatment. Regardless, these data show differences in the 
trajectory of immune response based on HIV status. Alveolar macrophage function was not related 
to 2MCC, but those that failed to culture convert by 2 months were observed to have higher 
concentrations of TNF-α in the alveolar space. This may reflect ongoing Mtb-induced TNF-α 
production from infected cells [624]. As for the PK data, these samples were taken from the right 
middle lobe in all participants, and the microenvironment in areas of active infection may differ still 
further.   
 
8.7 Future research 
 
This study provides novel information on intrapulmonary dose-response and local immunology in 
patients with pulmonary TB, and generates important questions for further research. 
The MIC data from this cohort show largely preserved drug sensitivity to first-line anti-TB therapy 
among new TB patients in Malawi. Mtb MIC data from high-burden settings is largely absent, and 
understanding local patterns of drug-sensitivity will be important when trying to justify dose 
increases. Assuming intrapulmonary penetration ratios are similar in settings with higher baseline 
MICs, sufficient concentrations in ELF and AC are still likely to be achieved. Detailed information on 
global MIC distributions from the CRyPTIC project, sequencing Mtb genomes to identify mutations 
conferring resistance, may highlight regions where dose increases are most likely to be of benefit 
[651].  
Bacillary elimination rates from serial TTP measurement offer a continuous measure of 
pharmacodynamic response, but were not related to final outcome in this cohort. Serial cycle 
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threshold measurement from Xpert MTB/RIF, or Xpert MTB/RIF Ultra, coupled with partial likelihood 
modelling to account for beyond LOQ data, may be a more convenient and readily-available method 
to measure bacillary elimination, with the added benefit that it should capture all Mtb in 
expectorated sputum regardless of metabolic state. Alternatively, the molecular bacterial load assay 
shows promise for deployment in future PK-PD studies. By quantifying Mtb 16S ribosomal RNA, the 
assay may also detect nonculturable bacilli in sputum [652-654], but as ribosomal RNA has a shorter 
half-life than mycobacterial DNA, is less likely to quantify dead Mtb in expectorated samples than 
Xpert MTB/RIF [652].  
Other compartments where repeated sampling is not possible may benefit from the PK modelling 
techniques used here. Central nervous system TB meningitis has a high mortality, and drug 
penetration across the blood-brain barrier can be expected to differ significantly from plasma or lung 
[655]. Some PK modelling of first-line therapy has been completed [207], but few data exist on the 
CNS PK of newer agents used as second-line therapy. Equally, the intrapulmonary PK of second-line 
therapy is poorly understood. 
Finally, the use of multiplex PCR to detect pathogens in respiratory samples from patients on TB 
treatment generated some interesting pilot data. The significant reduction in rifampicin-sensitive 
organisms would suggest that wider changes in the pulmonary microbiota are occurring. 
Relationships between intrapulmonary microbiota, local immunology, and treatment response merit 
further research. The frequent retrieval of Klebsiella pneumoniae should be taken into consideration 
in empiric regimens for pneumonia in TB patients. 
 
8.8 Final conclusions 
 
In the 7 decades since the first treatments for tuberculosis, no regimen has been developed that can 
treat drug-sensitive TB in less than 6 months with satisfactory rates of cure. While new drugs are in 
development, they are likely to be reserved for use in second-line treatments. Efforts to abbreviate 
or improve treatment for drug-sensitive disease will require a comprehensive understanding of host, 
drug, and organism factors that determine treatment success. 
This study is a detailed examination of intrapulmonary immunology, plasma and lung drug exposure, 
and Mtb microbiology in a large cohort of Malawians receiving treatment in ‘real-world’ conditions. 
Mtb exists in discrete microenvironments, in different metabolic states, and combination 
antimicrobial therapy with multiple mechanisms of action may be key to satisfactory response.  
The work described in this thesis has improved our knowledge of the contribution of drug therapy 
and the immune system to successful cure. Three major findings are described: 1) the constituents of 
first-line anti-TB therapy achieve higher concentrations in the lung than in plasma; 2) higher peak 
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concentrations of rifampicin and isoniazid in the epithelial lining fluid are associated with improved 
treatment response; and 3) TB/HIV co-infection is associated with ongoing active inflammation in the 
lungs of these patients until at least 4 months into TB treatment.  
The present study adds to the growing body of research that indicates that dose increases - 
particularly for rifampicin in first-line treatment - may offer real potential to improve treatment 
outcomes in drug-sensitive disease. In addition, combining agents with good intra- and extra-cellular 
drug penetration may be an important strategy in the design of new regimens for TB. Furthermore, 
this study suggested that TB/HIV co-infection was associated with greater mortality, and ongoing, 
active inflammation in the alveolar space that may contribute to respiratory morbidity. Public health 
efforts to identify new cases of HIV-infection and initiate early ART may reduce the number of 
patients diagnosed with HIV in the course of care-seeking for TB symptoms, with potential to 
improve morbidity and mortality in TB/HIV co-infection. 
  
Chapter 8  General discussion 
 
Page 256 
 
  References 
 
  Page 257 
9 References 
 
 
1. Hayman J. Mycobacterium ulcerans: an infection from Jurassic time? Lancet. 1984; 2(8410): 
1015-6. 
2. Gutierrez MC, Brisse S, Brosch R, Fabre M, Omais B, Marmiesse M, Supply P, Vincent V. 
Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog. 
2005; 1(1): e5. 
3. Daniel TM. The history of tuberculosis. Respir Med. 2006; 100(11): 1862-70. 
4. Daniel VS, Daniel TM. Old Testament biblical references to tuberculosis. Clin Infect Dis. 
1999; 29(6): 1557-8. 
5. Kraus AK. Tuberculosis and Public Health. Am Rev Tuberc. 1928; 18: 271-322. 
6. Wilson LG. Commentary: Medicine, population, and tuberculosis. Int J Epidemiol. 2005; 
34(3): 521-4. 
7. Alling DW, Bosworth EB. The after-history of pulmonary tuberculosis. VI. The first fifteen 
years following diagnosis. Am Rev Respir Dis. 1960; 81: 839-49. 
8. Cox GL. Sanatorium treatment contrasted with home treatment. After-histories of 4,067 
cases. Br J Tuberc. 1923; 17: 27-30. 
9. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity 
against gram-positive and gram-negative bacteria. 1944. Clin Orthop Relat Res. 2005; (437): 3-6. 
10. British Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br 
Med J. 1948; 2(4582): 769-82. 
11. Medical Research Council. Various combinations of isoniazid with streptomycin or with 
P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council 
by their Tuberculosis Chemotherapy Trials Committee. Br Med J. 1955; 1(4911): 435-45. 
12. British Thoracic Society. A controlled trial of 6 months' chemotherapy in pulmonary 
tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. 
Br J Dis Chest. 1984; 78(4): 330-6. 
13. East African/British Medical Research Councils. Controlled clinical trial of five short-course 
(4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. Lancet. 
1978; 2(8085): 334-8. 
14. East African/British Medical Research Councils. Controlled clinical trial of five short-course 
(4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am 
Rev Respir Dis. 1981; 123(2): 165-70. 
References 
Page 258 
15. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the 
British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent 
publications. Int J Tuberc Lung Dis. 1999; 3(10 Suppl 2): S231-79. 
16. WHO Global Tuberculosis Programme. TB : a global emergency, WHO report on the TB 
epidemic. Geneva: World Health Organization, 1994. 
17. World Health Organization. Global Tuberculosis Report 2017. Geneva: 2017. 
18. World Health Organization. Global Tuberculosis Report 2015. Geneva: WHO, 2015. 
19. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing 
burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 
163(9): 1009-21. 
20. World Health Organization. The End-TB Strategy. World Health Organization, 2015. 
21. Global TB Programme. Use of high burden country lists for TB by WHO in the post-2015 era. 
Geneva: 2015. 
22. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid 
prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 
1999; 13(4): 501-7. 
23. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Jr., Hopewell PC. 
An outbreak of tuberculosis with accelerated progression among persons infected with the human 
immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 
1992; 326(4): 231-5. 
24. Shafer RW, Singh SP, Larkin C, Small PM. Exogenous reinfection with multidrug-resistant 
Mycobacterium tuberculosis in an immunocompetent patient. Tuber Lung Dis. 1995; 76(6): 575-7. 
25. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland 
GH. A prospective study of the risk of tuberculosis among intravenous drug users with human 
immunodeficiency virus infection. N Engl J Med. 1989; 320(9): 545-50. 
26. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV 
epidemic on the spread of other diseases: the case of tuberculosis. AIDS. 2000; 14 Suppl 3: S47-56. 
27. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent 
risks of disease and the role of reinfection. Epidemiol Infect. 1997; 119(2): 183-201. 
28. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being 
infected with tubercle bacilli. Adv Tuberc Res. 1976; 19: 1-63. 
29. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and 
recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African 
mineworkers. Lancet. 2001; 358(9294): 1687-93. 
  References 
 
  Page 259 
30. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, Fine PE, 
Glynn JR. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in 
Malawi. AIDS. 2010; 24(3): 417-26. 
31. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated 
systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV 
infection. Clin Infect Dis. 2012; 55(8): 1154-63. 
32. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens 
and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006; 174(10): 1153-8. 
33. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, Ramachandran 
R, Locht C, Jawahar MS, Narayanan PR. Impact of HIV infection on the recurrence of tuberculosis in 
South India. J Infect Dis. 2010; 201(5): 691-703. 
34. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-
related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004; 170(10): 1124-
30. 
35. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell 
PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 
2007; 175(11): 1199-206. 
36. Unis G, Ribeiro AW, Esteves LS, Spies FS, Picon PD, Dalla Costa ER, Rossetti ML. Tuberculosis 
recurrence in a high incidence setting for HIV and tuberculosis in Brazil. BMC Infect Dis. 2014; 14(1): 
548. 
37. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the 
manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus 
infection. Am Rev Respir Dis. 1993; 148(5): 1292-7. 
38. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, De Cock KM, Hayes RJ, 
Williams BG, Churchyard GJ. Human immunodeficiency virus and the prevalence of undiagnosed 
tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004; 170(6): 673-9. 
39. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, Cole BF, Vuola JM, Tvaroha 
S, Kreiswirth B, Pallangyo K, von Reyn CF. High rates of clinical and subclinical tuberculosis among 
HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis. 2005; 40(10): 1500-7. 
40. Swaminathan S, Paramasivan CN, Kumar SR, Mohan V, Venkatesan P. Unrecognised 
tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis. 2004; 
8(7): 896-8. 
41. Gilks CF, Brindle RJ, Otieno LS, Bhatt SM, Newnham RS, Simani PM, Lule GN, Okelo GB, 
Watkins WM, Waiyaki PG, et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive 
patients presenting to the acute medical services in Nairobi. AIDS. 1990; 4(10): 981-5. 
42. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in 
resource-limited settings. Lancet Infect Dis. 2009; 9(3): 173-84. 
References 
Page 260 
43. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies 
of HIV-infected adults and children in resource-limited settings: a systematic review and meta-
analysis. AIDS. 2015; 29(15): 1987-2002. 
44. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, 
Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma JK. Development of 
a standardized screening rule for tuberculosis in people living with HIV in resource-constrained 
settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011; 8(1): 
e1000391. 
45. Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, Muttai H, Heilig 
CM, Nakashima AK, Cain KP. Performance of Clinical Screening Algorithms for Tuberculosis 
Intensified Case Finding among People Living with HIV in Western Kenya. PLoS One. 2016; 11(12): 
e0167685. 
46. Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, Chaisson RE, 
Martinson NA. High Prevalence of Pulmonary Tuberculosis but Low Sensitivity of Symptom Screening 
among HIV-Infected Pregnant Women in South Africa. PLoS One. 2013; 8(4): e62211. 
47. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, 
Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of 
antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362(8): 697-706. 
48. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, 
Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, 
Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash 
A, Moko E, Sawe F, Andersen J, Sanne I, A ACTGS. Timing of antiretroviral therapy for HIV-1 infection 
and tuberculosis. N Engl J Med. 2011; 365(16): 1482-91. 
49. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan 
S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, 
Delfraissy JF, Goldfeld AE, Team CS. Earlier versus later start of antiretroviral therapy in HIV-infected 
adults with tuberculosis. N Engl J Med. 2011; 365(16): 1471-81. 
50. Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The impact of 
antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic 
review and meta-analysis. PLoS One. 2014; 9(11): e112017. 
51. Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological 
interactions between rifampicin and antiretroviral drugs: challenges and research priorities for 
resource-limited settings. Ther Drug Monit. 2015; 37(1): 22-32. 
52. United Nations. Transforming our world: The 2030 agenda for sustainable development. 
New York: United Nations, 2015. 
53. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. 
Nat Rev Microbiol. 2014; 12(3): 159-67. 
54. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current 
status in Africa. AIDS. 1997; 11 Suppl B: S115-23. 
  References 
 
  Page 261 
55. Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW. Population-level impact of 
shorter-course regimens for tuberculosis: a model-based analysis. PLoS One. 2014; 9(5): e96389. 
56. Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sanchez MS, Porco TC, Borgdorff MW. 
Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 2006; 3(8): 
e273. 
57. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Jr., Dye C, Halloran ME. 
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl 
Acad Sci U S A. 2009; 106(33): 13980-5. 
58. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, 
Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, Gatifloxacin for TBst. A Phase II study of the 
sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc 
Lung Dis. 2008; 12(2): 128-38. 
59. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah 
B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, 
Olliaro PL, Lienhardt C, Project OFGfT. A four-month gatifloxacin-containing regimen for treating 
tuberculosis. N Engl J Med. 2014; 371(17): 1588-98. 
60. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, 
Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, 
Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, 
Team RT. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 
371(17): 1599-608. 
61. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips 
PP, Nunn AJ, Consortium RE. Four-month moxifloxacin-based regimens for drug-sensitive 
tuberculosis. N Engl J Med. 2014; 371(17): 1577-87. 
62. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, 
Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening 
treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit 
Care Med. 2009; 180(6): 558-63. 
63. World Health Organization. Global Tuberculosis Report 2016. Geneva: 2016. 
64. Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-
resistant tuberculosis patients [press release]. Geneva: World Health Organization,, 12/05/2016 
2016. 
65. Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment 
regimens. Curr Respir Med Rev. 2013; 9(3): 200-10. 
66. Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for 
tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013; 8(5): e63840. 
67. Horsburgh CR, Jr., Barry CE, 3rd, Lange C. Treatment of Tuberculosis. N Engl J Med. 2015; 
373(22): 2149-60. 
References 
Page 262 
68. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database 
Syst Rev. 2007; (4): CD003343. 
69. Moodley Y, Govender K. A systematic review of published literature describing factors 
associated with tuberculosis recurrence in people living with HIV in Africa. Afr Health Sci. 2015; 
15(4): 1239-46. 
70. Houben RM, Glynn JR, Mboma S, Mzemba T, Mwaungulu NJ, Mwaungulu L, Mwenibabu M, 
Mpunga J, French N, Crampin AC. The impact of HIV and ART on recurrent tuberculosis in a sub-
Saharan setting. AIDS. 2012; 26(17): 2233-9. 
71. World Health Organization. Definitions and reporting framework for tuberculosis 2014 
[cited 2015 1st April]. Available from: 
http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf. 
72. Mitchison DA, Davies GR. Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open 
Infect Dis J. 2008; 2: 59-76. 
73. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by 
culture at 2 months. Am Rev Respir Dis. 1993; 147(4): 1062-3. 
74. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of 
mycobacterial disease. Soc Appl Bacteriol Symp Ser. 1996; 25: 72S-80S. 
75. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. Sputum 
monitoring during tuberculosis treatment for predicting outcome: a systematic review and meta-
analysis. Lancet Infect Dis. 2010; 10(6): 387-94. 
76. Phillips PP, Fielding K. Surrogate markers for poor outcome to treatment for tuberculosis: 
results from extensive multi-trial analysis. Int J Tuberc Lung Dis. 2008; 2008(12): S146-7. 
77. Davies GR. Early clinical development of anti-tuberculosis drugs: science, statistics and 
sterilizing activity. Tuberculosis (Edinb). 2010; 90(3): 171-6. 
78. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple 
regression: a bad idea. Stat Med. 2006; 25(1): 127-41. 
79. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, 
Wells CD, Leimane V. Time to sputum culture conversion in multidrug-resistant tuberculosis: 
predictors and relationship to treatment outcome. Ann Intern Med. 2006; 144(9): 650-9. 
80. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics 
of the rifamycin antibacterials. Clin Pharmacokinet. 2001; 40(5): 327-41. 
81. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, 
Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger 
EL, Villarino M, Vernon A, Chaisson RE, Tuberculosis Trials C. Substitution of moxifloxacin for 
isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 
2009; 180(3): 273-80. 
  References 
 
  Page 263 
82. Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsai YC. Comparative evaluation of the BACTEC MGIT 
960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis. 2003; 7(6): 569-
74. 
83. Barr DA, Kamdolozi M, Nishihara Y, Ndhlovu V, Khonga M, Davies GR, Sloan DJ. Serial image 
analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum 
during treatment of pulmonary TB. Tuberculosis (Edinburgh, Scotland). 2016; 98: 110-5. 
84. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis 
drugs during the first 14 days. Am J Respir Crit Care Med. 2003; 167(10): 1348-54. 
85. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PPJ, Venter A, 
Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon 
AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early 
sputum biomarker of response to tuberculosis treatment. The Lancet Respiratory Medicine. 2013; 
1(6): 462-70. 
86. Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, Warren 
R, Otwombe K, Martinson N, Kana BD. Detection and Quantification of Differentially Culturable 
Tubercle Bacteria in Sputum from Patients with Tuberculosis. Am J Respir Crit Care Med. 2016; 
194(12): 1532-40. 
87. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting 
factors reveal an occult population of tubercle bacilli in Sputum. Am J Respir Crit Care Med. 2010; 
181(2): 174-80. 
88. Sloan DJ, Corbett EL, Butterworth AE, Mwandumba HC, Khoo SH, Mdolo A, Shani D, 
Kamdolozi M, Allen J, Mitchison DA, Coleman DJ, Davies GR. Optimizing outpatient serial sputum 
colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol. 
2012; 50(7): 2315-20. 
89. Sloan DJ, Mwandumba HC, Garton NJ, Khoo SH, Butterworth AE, Allain TJ, Heyderman RS, 
Corbett EL, Barer MR, Davies GR. Pharmacodynamic modelling of bacillary elimination rates and 
detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of 
pulmonary tuberculosis. Clin Infect Dis. 2015. 
90. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in 
patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980; 121(6): 939-49. 
91. Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR. Time to 
detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early 
bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis. 2010; 29(12): 1561-5. 
92. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to liquid culture 
positivity can substitute for colony counting on agar plates in early bactericidal activity studies of 
antituberculosis agents. Clin Microbiol Infect. 2012; 18(7): 711-7. 
93. Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, van Helden P. Time to 
detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony 
counting. Int J Tuberc Lung Dis. 2008; 12(7): 792-8. 
References 
Page 264 
94. Mitchison DA. Basic mechanisms of chemotherapy. Chest. 1979; 76(6 Suppl): 771-81. 
95. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Kam 
KM, Lam CW, Sole KM, Mitchison DA. A multicentre study of the early bactericidal activity of anti-
tuberculosis drugs. J Antimicrob Chemother. 2000; 45(6): 859-70. 
96. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, 
van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. Early bactericidal activity 
and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. 
Antimicrob Agents Chemother. 2008; 52(8): 2831-5. 
97. Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixed-effects analysis for 
improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob 
Agents Chemother. 2006; 50(9): 3154-6. 
98. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley 
CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months 
of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006; 174(3): 331-8. 
99. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, 
Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial treatment of 
tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009; 373(9670): 1183-9. 
100. World Health Organization. Guidelines for treatment of tuberculosis. Geneva: WHO; 2010. 
101. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and 
management of tuberculosis, and measures for its prevention and control. London: 2011. 
102. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of 
tuberculosis. MMWR Recomm Rep. 2003; 52(RR-11): 1-77. 
103. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, British Infection S. British 
Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous 
system in adults and children. J Infect. 2009; 59(3): 167-87. 
104. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous 
pericarditis. Cochrane Database Syst Rev. 2002; (4): Cd000526. 
105. Ministry of Health Malawi. National Tuberculosis Control Programme Manual 7th Edition. 
2012; (7th Edition). 
106. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, Smith I, Suarez P, Antunes 
ML, George AG, Martin-Casabona N, Simelane P, Weyer K, Binkin N, Raviglione MC. Determinants of 
drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001; 5(10): 887-93. 
107. Abouyannis M, Dacombe R, Dambe I, Mpunga J, Faragher B, Gausi F, Ndhlovu H, Kachiza C, 
Suarez P, Mundy C, Banda HT, Nyasulu I, Squire SB. Drug resistance of Mycobacterium tuberculosis in 
Malawi: a cross-sectional survey. Bull World Health Organ. 2014; 92(11): 798-806. 
  References 
 
  Page 265 
108. Cohen DB. Addressing the challenges of recurrent tuberculosis in Malawi: University of 
Liverpool; 2015. 
109. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet. 1946; 1(6384): 
15. 
110. British Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin 
and para-aminosalicylic acid; a Medical Research Council investigation. Br Med J. 1950; 2(4688): 
1073-85. 
111. Grunberg E, Schnitzer RJ. Studies on the activity of hydrazine derivatives of isonicotinic acid 
in the experimental tuberculosis of mice. Q Bull Sea View Hosp. 1952; 13(1): 3-11. 
112. Murray JF. A century of tuberculosis. Am J Respir Crit Care Med. 2004; 169(11): 1181-6. 
113. British Medical Research Council. The chemotherapy of tuberculosis. Br Med J. 1950; 
2(4688): 1102-3. 
114. Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis--
current problems. J Antimicrob Chemother. 1992; 29(5): 477-93. 
115. Canetti G. The eradication of tuberculosis: theoretical problems and practical solutions. 
Tubercle. 1962; 43: 301-21. 
116. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) 
in the treatment of pulmonary tuberculosis in East Africa. Third Report of Fifth Investigation. A co-
operative study in East Africian hospitals, clinics and laboratories with the collaboration of the East 
African and British Medical Research Councils. Tubercle. 1973; 54(3): 169-79. 
117. East African/British Medical Research Council. Controlled clinical trial of short-course (6-
month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972; 1(7760): 
1079-85. 
118. East African/British Medical Research Council. Controlled clinical trial of four short-course 
(6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. 
Lancet. 1973; 1(7816): 1331-8. 
119. East African/British Medical Research Council. Controlled clinical trial of four short-course 
regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first 
report: Third East African/British Medical Research Councils study. Am Rev Respir Dis. 1978; 118(1): 
39-48. 
120. East African/British Medical Research Council. Controlled clinical trial of four short-course 
regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second 
report. Third East African/British Medical Research Council Study. Tubercle. 1980; 61(2): 59-69. 
121. East African/British Medical Research Council. Controlled clinical trial of four 6-month 
regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British 
Medical Research Council Study. Am Rev Respir Dis. 1976; 114(3): 471-5. 
References 
Page 266 
122. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 
months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary 
tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and 
pyrazinamide. Results at 30 months. Am Rev Respir Dis. 1991; 143(4 Pt 1): 700-6. 
123. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: 
effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990; 112(6): 
397-406. 
124. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary 
tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev 
Respir Dis. 1982; 126(3): 460-2. 
125. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of 
newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004; 
364(9441): 1244-51. 
126. Douglas JG, McLeod MJ. Pharmacokinetic factors in the modern drug treatment of 
tuberculosis. Clin Pharmacokinet. 1999; 37(2): 127-46. 
127. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983; 5 Suppl 3: 
S407-11. 
128. Sensi P, Margalith P, Timbal MT. Rifomycin, a new antibiotic; preliminary report. Farmaco 
Sci. 1959; 14(2): 146-7. 
129. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983; 5 Suppl 3: S402-6. 
130. Maggi N, Pasqualucci CR, Ballotta R, Sensi P. Rifampicin: a new orally active rifamycin. 
Chemotherapy. 1966; 11(5): 285-92. 
131. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a 
semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 2008; 52(6): 
2138-48. 
132. Boman G. Serum concentration and half-life of rifampicin after simultaneous oral 
administration of aminosalicylic acid or isoniazid. Eur J Clin Pharmacol. 1974; 7(3): 217-25. 
133. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and 
pharmacodynamics. J Pharm Sci. 2010; 99(3): 1107-22. 
134. te Brake LH, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, 
Russel FG, Burger DM, Alisjahbana B, Wieringa F, van Crevel R, Aarnoutse RE. Exposure to total and 
protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. 
Antimicrob Agents Chemother. 2015; 59(6): 3233-9. 
135. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978; 3(2): 108-27. 
  References 
 
  Page 267 
136. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 
Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011; 55(7): 3067-74. 
137. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, 
isoniazid and pyrazinamide. Tuber Lung Dis. 1995; 76(2): 109-13. 
138. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting 
conditions, with food, and with antacids. Chest. 1999; 115(1): 12-8. 
139. Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol. 
1983; 23(10): 433-7. 
140. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population 
pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 
1997; 41(12): 2670-9. 
141. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral 
and intravenous rifampicin during chronic administration. Klin Wochenschr. 1985; 63(23): 1205-11. 
142. Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro 
PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US. A semimechanistic pharmacokinetic-
enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents 
Chemother. 2012; 56(4): 2091-8. 
143. Jeanes CW, Jessamine AG, Eidus L. Treatment of chronic drug-resistant pulmonary 
tuberculosis with rifampin and ethambutol. Can Med Assoc J. 1972; 106(8): 884-8. 
144. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug 
disposition. Eur J Clin Invest. 2003; 33 Suppl 2: 1-5. 
145. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C 
(SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol 
Exp Ther. 2003; 304(1): 223-8. 
146. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, 
Maartens G, Owen A, McIlleron H. The SLCO1B1 rs4149032 polymorphism is highly prevalent in 
South Africans and is associated with reduced rifampin concentrations: dosing implications. 
Antimicrob Agents Chemother. 2011; 55(9): 4122-7. 
147. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-
Sizemore E, Johnson JL, Vernon A. Effects of tuberculosis, race, and human gene SLCO1B1 
polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010; 54(10): 4192-200. 
148. Sloan DJ, McCallum AD, Schipani A, Egan D, Mwandumba HC, Ward SA, Waterhouse D, 
Banda G, Allain TJ, Owen A, Khoo SH, Davies GR. Genetic determinants of the pharmacokinetic 
variability of rifampicin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents 
Chemother. 2017. 
149. Ramesh K, Hemanth Kumar AK, Kannan T, Vijayalakshmi R, Sudha V, Manohar Nesakumar S, 
Bharathiraja T, Lavanya J, Swaminathan S, Ramachandran G. SLCO1B1 gene polymorphisms do not 
References 
Page 268 
influence plasma rifampicin concentrations in a South Indian population. Int J Tuberc Lung Dis. 2016; 
20(9): 1231-5. 
150. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular 
mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006; 5: 3. 
151. Verbeeck RK, Gunther G, Kibuule D, Hunter C, Rennie TW. Optimizing treatment outcome of 
first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol. 2016; 
72(8): 905-16. 
152. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, 
Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 
1993; 341(8846): 647-50. 
153. Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, 
Requena-Mendez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, 
Swaminathan S, McIlleron H, Davies G. Pharmacokinetics of rifampicin in adult TB patients and 
healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018. 
154. van Oosterhout JJ, Dzinjalamala FK, Dimba A, Waterhouse D, Davies G, Zijlstra EE, Molyneux 
ME, Molyneux EM, Ward S. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-
Negative Adults in Malawi. Antimicrob Agents Chemother. 2015; 59(10): 6175-80. 
155. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, 
isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. 
Antimicrob Agents Chemother. 2006; 50(4): 1170-7. 
156. Schon T, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Werngren J, Kahlmeter G, Hoffner 
SE, Angeby KA. Evaluation of wild-type MIC distributions as a tool for determination of clinical 
breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother. 2009; 64(4): 786-93. 
157. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid 
resistance of Mycobacterium tuberculosis. Nature. 1992; 358(6387): 591-3. 
158. Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, Castel S, Wiesner L, 
Hagen CM, Christiansen M, Changalucha J, McIlleron H, Friis H, Andersen AB. Pharmacokinetics of 
isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. 
PLoS One. 2015; 10(10): e0141002. 
159. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Variability in the 
population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 
2011; 72(1): 51-62. 
160. Mc DW, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in 
vitro. Am Rev Tuberc. 1954; 70(4): 748-54. 
161. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc 
Lung Dis. 2003; 7(1): 6-21. 
  References 
 
  Page 269 
162. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR, Jr. Pyrazinamide inhibits the 
eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000; 6(9): 
1043-7. 
163. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, 3rd, Wang H, Zhang W, Zhang Y. 
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011; 333(6049): 
1630-2. 
164. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the 
population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin 
Pharmacol. 2006; 62(9): 727-35. 
165. Takayama K, Armstrong EL, Kunugi KA, Kilburn JO. Inhibition by ethambutol of mycolic acid 
transfer into the cell wall of Mycobacterium smegmatis. Antimicrob Agents Chemother. 1979; 16(2): 
240-2. 
166. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR, Telenti A, 
Musser JM. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. 
Antimicrob Agents Chemother. 1997; 41(8): 1677-81. 
167. Jonsson S, Davidse A, Wilkins J, Van der Walt JS, Simonsson US, Karlsson MO, Smith P, 
McIlleron H. Population pharmacokinetics of ethambutol in South African tuberculosis patients. 
Antimicrob Agents Chemother. 2011; 55(9): 4230-7. 
168. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an 
update. Drugs. 2014; 74(8): 839-54. 
169. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 
1984; 9(6): 511-44. 
170. Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and their 
metabolism by human liver esterases. Xenobiotica. 1997; 27(10): 1015-24. 
171. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, Yokoi T. Human 
arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and 
rifapentine. Biochem Pharmacol. 2011; 82(11): 1747-56. 
172. Shimizu M, Fukami T, Ito Y, Kurokawa T, Kariya M, Nakajima M, Yokoi T. Indiplon is 
hydrolyzed by arylacetamide deacetylase in human liver. Drug Metab Dispos. 2014; 42(4): 751-8. 
173. Song SH, Chang HE, Jun SH, Park KU, Lee JH, Lee EM, Song YH, Song J. Relationship between 
CES2 genetic variations and rifampicin metabolism. J Antimicrob Chemother. 2013; 68(6): 1281-4. 
174. Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. Population pharmacokinetics of 
rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. J Antimicrob Chemother. 2015; 70(12): 
3298-306. 
175. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions 
with rifampicin : clinical relevance. Clin Pharmacokinet. 2003; 42(9): 819-50. 
References 
Page 270 
176. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and 
rifapentine drug interactions. Curr Med Res Opin. 2013; 29(1): 1-12. 
177. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, Ruiz I, Pahissa A. Pharmacokinetic 
interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir 
Immune Defic Syndr. 2001; 28(5): 450-3. 
178. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew 
K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM. Nevirapine plasma 
concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. 
Antivir Ther. 2005; 10(8): 937-43. 
179. Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Effect of 
rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults 
with HIV-associated tuberculosis. J Antimicrob Chemother. 2008; 61(2): 389-93. 
180. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas 
S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R. 
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-
associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011; 53(7): 716-24. 
181. World Health Organization. WHO Guidelines Approved by the Guidelines Review 
Committee.  Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations 
for a Public Health Approach: 2010 Revision. Geneva: World Health Organization.; 2010. 
182. Moreno S, Hernandez B, Dronda F. Antiretroviral therapy in AIDS patients with tuberculosis. 
AIDS Rev. 2006; 8(3): 115-24. 
183. Rolla VC, da Silva Vieira MA, Pereira Pinto D, Lourenco MC, de Jesus Cda S, Goncalves 
Morgado M, Ferreira Filho M, Werneck-Barroso E. Safety, efficacy and pharmacokinetics of ritonavir 
400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with 
tuberculosis. Clin Drug Investig. 2006; 26(8): 469-79. 
184. Nijland HM, L'Homme R F, Rongen GA, van Uden P, van Crevel R, Boeree MJ, Aarnoutse RE, 
Koopmans PP, Burger DM. High incidence of adverse events in healthy volunteers receiving 
rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008; 22(8): 931-5. 
185. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, 
Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given 
twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy 
subjects. J Acquir Immune Defic Syndr. 2013; 62(1): 21-7. 
186. Gupta A, Juneja S, Vitoria M, Habiyambere V, Nguimfack BD, Doherty M, Low-Beer D. 
Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income 
countries: a forecast analysis 2015-2025. PLoS One. 2016; 11(10): e0164619. 
187. Sunpath H, Winternheimer P, Cohen S, Tennant I, Chelin N, Gandhi RT, Murphy RA. Double-
dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South 
Africa. Int J Tuberc Lung Dis. 2014; 18(6): 689-93. 
  References 
 
  Page 271 
188. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax. 1996; 
51(2): 111-3. 
189. Bernstein J, Lott WA, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. V. 
Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc. 1952; 65(4): 357-64. 
190. Jones DS. The health care experiments at Many Farms: the Navajo, tuberculosis, and the 
limits of modern medicine, 1952-1962. Bull Hist Med. 2002; 76(4): 749-90. 
191. British Medical Research Council. Treatment of pulmonary tuberculosis with isoniazid; an 
interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials 
Committee. Br Med J. 1952; 2(4787): 735-46. 
192. Lei B, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid. Activation by 
Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J Biol Chem. 
2000; 275(4): 2520-6. 
193. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell 
growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1972; 2(1): 29-
35. 
194. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation 
by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents 
Chemother. 2004; 48(8): 3006-9. 
195. Mitchison DA, Selkon JB. Bacteriological aspects of a survey of the incidence of drug-
resistant tubercle bacilli among untreated patients. Tubercle. 1957; 38(2): 85-98. 
196. British Medical Research Council. Long-term chemotherapy in the treatment of chronic 
pulmonary tuberculosis with cavitation. Tubercle. 1962; 43(3): 201-67. 
197. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt 
BJ, Donald PR, van Jaarsveld PP. Trimodality of isoniazid elimination: phenotype and genotype in 
patients with tuberculosis. Am J Respir Crit Care Med. 1997; 155(5): 1717-22. 
198. Bonicke R, Reif W. [Enzymatic inactivation of isonicotinic acid hydrizide in human and 
animal organisms]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1953; 220(4): 321-3. 
199. Evans DA, Manley KA, Mc KV. Genetic control of isoniazid metabolism in man. Br Med J. 
1960; 2(5197): 485-91. 
200. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, 
Doroshyenko O, Sorgel F, Fuhr U. Should we use N-acetyltransferase type 2 genotyping to 
personalize isoniazid doses? Antimicrob Agents Chemother. 2005; 49(5): 1733-8. 
201. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the 
pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis 
therapy. Clin Infect Dis. 2012; 55(2): 169-77. 
References 
Page 272 
202. Garcia-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, Doll MA, Figueroa JD, 
Baris D, Schwenn M, Kogevinas M, Johnson A, Chatterjee N, Moore LE, Moeller T, Real FX, Chanock S, 
Rothman N. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 
phenotype in populations of European background. Pharmacogenet Genomics. 2011; 21(4): 231-6. 
203. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting 
conditions, with food, and with antacids. Int J Tuberc Lung Dis. 1999; 3(8): 703-10. 
204. Back DJ, Rogers SM. Review: first-pass metabolism by the gastrointestinal mucosa. Aliment 
Pharmacol Ther. 1987; 1(5): 339-57. 
205. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979; 
4(6): 401-22. 
206. Woo J, Cheung W, Chan R, Chan HS, Cheng A, Chan K. In vitro protein binding characteristics 
of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. 
Clin Biochem. 1996; 29(2): 175-7. 
207. Pouplin T, Bang ND, Toi PV, Phuong PN, Dung NH, Duong TN, Caws M, Thwaites GE, Tarning 
J, Day JN. Naive-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma 
and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis. 2016; 
16(1): 144. 
208. Conte JE, Jr., Golden JA, McQuitty M, Kipps J, Duncan S, McKenna E, Zurlinden E. Effects of 
gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob 
Agents Chemother. 2002; 46(8): 2358-64. 
209. Katiyar SK, Bihari S, Prakash S. Low-dose inhaled versus standard dose oral form of anti-
tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum. 
J Postgrad Med. 2008; 54(3): 245-6. 
210. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, 
Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE, 3rd, Dartois V. The 
association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 
2015; 21(10): 1223-7. 
211. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc 
Lung Dis. 2000; 4(9): 796-806. 
212. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. Isoniazid's 
bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium 
tuberculosis in the log phase of growth. J Infect Dis. 2007; 195(2): 194-201. 
213. Devadatta S, Gangadharam PR, Andrews RH, Fox W, Ramakrishnan CV, Selkon JB, Velu S. 
Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960; 23: 587-98. 
214. Snider DE, Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980; 61(4): 
191-6. 
215. Carlson  HB, Anthony  EM, Russell  WFJ, Middlebrook  G. Prophylaxis of isoniazid 
neuropathy with pyridoxine. New England Journal of Medicine. 1956; 255(3): 118-22. 
  References 
 
  Page 273 
216. Kopanoff DE, Snider DE, Jr., Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service 
cooperative surveillance study. Am Rev Respir Dis. 1978; 117(6): 991-1001. 
217. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-
tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012; 16(5): 589-95. 
218. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and 
management. J Clin Exp Hepatol. 2013; 3(1): 37-49. 
219. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-
analysis. Chest. 1991; 99(2): 465-71. 
220. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release 
of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with 
regimens containing isoniazid and rifampin. Am Rev Respir Dis. 1986; 133(6): 1072-5. 
221. Solotorovsky M, Gregory FJ, Ironson EJ, Bugie EJ, O'Neill RC, Pfister R, 3rd. Pyrazinoic acid 
amide; an agent active against experimental murine tuberculosis. Proc Soc Exp Biol Med. 1952; 
79(4): 563-5. 
222. Malone L, Schurr A, Lindh H, Mc KD, Kiser JS, Williams JH. The effect of pyrazinamide 
(aldinamide) on experimental tuberculosis in mice. Am Rev Tuberc. 1952; 65(5): 511-8. 
223. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of 
pulmonary tuberculosis. Am Rev Tuberc. 1952; 65(5): 523-46. 
224. Muschenheim C, Mc DW, Mc CR, Deuschle K, Ormond L, Tompsett R. Pyrazinamide-isoniazid 
in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy. 
Am Rev Tuberc. 1954; 70(4): 743-7. 
225. Muschenheim C, Organick A, McCune RM, Jr., Batten J, Deuschle K, Tompsett R, McDermott 
W. Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide. 
Am Rev Tuberc. 1955; 72(6): 851-5. 
226. Matthews JH. Pyrazinamide and isoniazid used in the treatment of pulmonary tuberculosis. 
American Review of Respiratory Disease. 1960; 81(3): 348-51. 
227. Tarshis MS, Weed WA, Jr. Lack of significant in vitro sensitivity of Mycobacterium 
tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc. 1953; 67(3): 391-5. 
228. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum 
as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary 
tuberculosis. BMC Pulm Med. 2001; 1: 2. 
229. Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of 
tubercle bacilli. Am Rev Respir Dis. 1967; 95(3): 461-9. 
230. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of 
pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 1998; 18(6): 
1205-11. 
References 
Page 274 
231. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, Chirgwin K, 
Salomon N, Hafner R. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with 
tuberculosis. Clin Infect Dis. 2004; 38(4): 556-64. 
232. Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, Lafont O. 
Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol. 
1989; 36(4): 395-400. 
233. Conte JE, Jr., Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations 
of pyrazinamide. Antimicrob Agents Chemother. 1999; 43(6): 1329-33. 
234. Pyle MM, Pfuetze KH, Pearlman MD, Huerga Jdl, Hubble RH. A four-year clinical 
investigation of ethambutol in initial and re-treatment cases of tuberculosis. American Review of 
Respiratory Disease. 1966; 93(3P1): 428-41. 
235. Thomas JP, Baughn CO, Wilkinson RG, Shepherd RG. A new synthetic compound with 
antituberculous activity in mice: ethambutol (dextro-2, 2′- (ethylenediimino)-di-1-butanol). American 
Review of Respiratory Disease. 1961; 83(6): 891-3. 
236. Carr RE, Henkind P. Ocular manifestations of ethambutol, Toxic amblyopia after 
administration of an experimental antituberculous drug. Arch Ophthalmol. 1962; 67: 566-71. 
237. Ferebee SH, Doster BE, Murray FJ. Ethambutol: a substitute for para-aminosalicylic acid in 
regimens for pulmonary tuberculosis. Ann N Y Acad Sci. 1966; 135(2): 910-20. 
238. Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of 
pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis. 
1973; 107(2): 177-90. 
239. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a 
controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev 
Respir Dis. 1987; 136(6): 1339-42. 
240. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-
weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 
1981; 1(8213): 171-4. 
241. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary 
tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet. 1976; 
2(7995): 1102-4. 
242. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, 
Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, 
Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease 
Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J 
Respir Crit Care Med. 2003; 167(4): 603-62. 
243. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of 
ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 
1999; 43(3): 568-72. 
  References 
 
  Page 275 
244. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, 
Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA. Pharmacokinetics of ethambutol in children and 
adults with tuberculosis. Int J Tuberc Lung Dis. 2004; 8(11): 1360-7. 
245. Lee CS, Gambertoglio JG, Brater DC, Benet LZ. Kinetics of oral ethambutol in the normal 
subject. Clin Pharmacol Ther. 1977; 22(5 Pt 1): 615-21. 
246. Lee CS, Brater DC, Gambertoglio JG, Benet LZ. Disposition kinetics of ethambutol in man. J 
Pharmacokinet Biopharm. 1980; 8(4): 335-46. 
247. Peets EA, Sweeney WM, Place VA, Buyske DA. The absorption, excretion, and metabolic fate 
of ethambutol in man. Am Rev Respir Dis. 1965; 91: 51-8. 
248. Pilheu JA, Maglio F, Cetrangolo R, Pleus AD. Concentrations of ethambutol in the 
cerebrospinal fluid after oral administration. Tubercle. 1971; 52(2): 117-22. 
249. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and 
children. Tuberculosis (Edinb). 2010; 90(5): 279-92. 
250. Gundert-Remy U, Klett M, Weber E. Concentration of ethambutol in cerebrospinal fluid in 
man as a function of the non-protein-bound drug fraction in serum. Eur J Clin Pharmacol. 1973; 6(2): 
133-6. 
251. Conte JE, Jr., Golden JA, Kipps J, Lin ET, Zurlinden E. Effects of AIDS and gender on steady-
state plasma and intrapulmonary ethambutol concentrations. Antimicrob Agents Chemother. 2001; 
45(10): 2891-6. 
252. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci. 
1966; 135(2): 904-9. 
253. Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatric Respiratory 
Reviews. 2011; 12(1): 22-6. 
254. Trebucq A. Should ethambutol be recommended for routine treatment of tuberculosis in 
children? A review of the literature. Int J Tuberc Lung Dis. 1997; 1(1): 12-5. 
255. World Health Organization. Ethambutol efficacy and toxicity: literature review and 
recommendations for daily and intermittent dosage in children. WHO/HTM/TB/2006.365. Geneva, 
Switzerland: 2006. 
256. Rapid advice : treatment of tuberculosis in children. [press release]. Geneva: World Health 
Organization,2010. 
257. Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron 
HM, Hesseling AC. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants 
dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents 
Chemother. 2016; 60(4): 2171-9. 
258. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development 
of anti-tuberculosis drugs. Tuberculosis (Edinb). 2008; 88 Suppl 1: S65-74. 
References 
Page 276 
259. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, 
Bharath S, Kantharaj E, Balasubramanian V. Isoniazid pharmacokinetics-pharmacodynamics in an 
aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2004; 48(8): 2951-7. 
260. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, 
Shandil RK, Kantharaj E, Balasubramanian V. Pharmacokinetics-pharmacodynamics of rifampin in an 
aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003; 47(7): 2118-24. 
261. Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide 
in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of 
new antituberculosis drugs. Antimicrob Agents Chemother. 2009; 53(8): 3197-204. 
262. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of 
hollow fiber model of tuberculosis experiments. Clin Infect Dis. 2015; 61 Suppl 1: S10-7. 
263. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid 
bactericidal activity and resistance emergence: integrating pharmacodynamics and 
pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents 
Chemother. 2007; 51(7): 2329-36. 
264. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-
dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob 
Agents Chemother. 2007; 51(11): 3781-8. 
265. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple 
drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the 
pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis. 2010; 201(8): 1225-31. 
266. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations between the 
hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and 
confirm. Clin Infect Dis. 2015; 61 Suppl 1: S18-24. 
267. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not 
due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011; 
204(12): 1951-9. 
268. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, 
Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA. Serum concentrations of antimycobacterial 
drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005; 41(4): 461-9. 
269. McCallum AD, Sloan DJ. The importance of clinical pharmacokinetic–pharmacodynamic 
studies in unraveling the determinants of early and late tuberculosis outcomes. International Journal 
of Pharmacokinetics. 2017; 2(3): 195-212. 
270. Lee K, Jun S-H, Han M, Song SH, Park JS, Lee JH, Park KU, Song J. Multiplex assay of second-
line anti-tuberculosis drugs in dried blood spots using ultra-performance liquid chromatography-
tandem mass spectrometry. Annals of Laboratory Medicine. 2016; 36(5): 489-93. 
271. Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, 
Gumbo T, Peloquin CA, Bisson GP, Vinnard C. Urine colorimetry to detect low rifampin exposure 
during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis. 2016; 16: 242. 
  References 
 
  Page 277 
272. Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, Gratz J, Aarnoutse 
RE, Kibiki GS, Houpt ER. Plasma drug activity assay for treatment optimization in tuberculosis 
patients. Antimicrob Agents Chemother. 2011; 55(12): 5819-25. 
273. Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, 
Kosterink JG, Alffenaar JW. Limited sampling strategies for therapeutic drug monitoring of amikacin 
and kanamycin in patients with multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2015; 
46(3): 332-7. 
274. Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar 
JW. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with 
tuberculosis. Ther Drug Monit. 2011; 33(3): 350-4. 
275. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Limited 
sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant 
tuberculosis. Ther Drug Monit. 2010; 32(1): 97-101. 
276. Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost 
JH, Kosterink JG, van der Werf TS, Alffenaar JW. Pharmacokinetic modeling and optimal sampling 
strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrob 
Agents Chemother. 2015; 59(8): 4907-13. 
277. Requena-Mendez A, Davies G, Moore DA. Reply to "adequate design of pharmacokinetic-
pharmacodynamic studies will help optimize tuberculosis treatment for the future". Antimicrob 
Agents Chemother. 2015; 59(4): 2475. 
278. Sturkenboom MG, Akkerman OW, Bolhuis MS, de Lange WC, van der Werf TS, Alffenaar JW. 
Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis 
treatment for the future. Antimicrob Agents Chemother. 2015; 59(4): 2474. 
279. Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment 
outcome. Expert Opin Drug Metab Toxicol. 2014; 10(6): 813-23. 
280. Pasipanodya J, Srivastava S, Gumbo T. New susceptibility breakpoints and the regional 
variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 
2012; 56(10): 5428. 
281. Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, Namaganda C, Mboowa G, 
Nakayita G, Armakovitch S, Chien G, Cho SN, Via LE, Barry CE, 3rd, Ellner JJ, Alland D, Dorman SE, 
Joloba ML. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to 
first- and second-line drugs. Antimicrob Agents Chemother. 2014; 58(1): 11-8. 
282. Abuali MM, Katariwala R, LaBombardi VJ. A comparison of the Sensititre(R) MYCOTB panel 
and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J 
Clin Microbiol Infect Dis. 2012; 31(5): 835-9. 
283. Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL. 
Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium 
tuberculosis complex against first- and second-line agents. J Clin Microbiol. 2012; 50(11): 3732-4. 
References 
Page 278 
284. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, 
Zhao Z, Hodge T, Tuberculosis Trials C. Association between acquired rifamycin resistance and the 
pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 
2005; 40(10): 1481-91. 
285. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, 
Hodge T, Tuberculosis Trials C. Low isoniazid concentrations and outcome of tuberculosis treatment 
with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003; 167(10): 1341-7. 
286. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, 
Kenyon TA, Moeti TL, Tappero JW. Isoniazid, rifampin, ethambutol, and pyrazinamide 
pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults 
with tuberculosis from Botswana. Clin Infect Dis. 2009; 48(12): 1685-94. 
287. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van 
Crevel R, Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to 
treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 
2013; 57(8): 3614-9. 
288. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug 
concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9): 1464-73. 
289. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, 
McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill 
rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother. 2015; 59(1): 38-
45. 
290. Prahl JB, Johansen IS, Cohen AS, Frimodt-Moller N, Andersen AB. Clinical significance of 2 h 
plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J 
Antimicrob Chemother. 2014; 69(10): 2841-7. 
291. Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, Long R, Kunimoto D, Cooper R. Serum 
drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. 
Int J Tuberc Lung Dis. 2015; 19(2): 210-5. 
292. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung 
WM. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin 
Microbiol Infect Dis. 2008; 27(6): 467-72. 
293. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, Ashkin D. 
Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human 
immunodeficiency virus status, and other risk factors. Clin Infect Dis. 2001; 32(3): 515-7. 
294. Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. Serum levels of 
antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob Agents 
Chemother. 2015; 60(1): 92-8. 
295. Requena-Mendez A, Davies G, Waterhouse D, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, 
Moore DA. Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian 
tuberculosis patients. Antimicrob Agents Chemother. 2014; 58(12): 7164-70. 
  References 
 
  Page 279 
296. Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sanchez P, Sambeat 
MA, Colomer J, Lopez-Colomes JL, Crespo M, Falco V, Ocana I, Pahissa A. Pharmacokinetic interaction 
between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-
infected patients with tuberculosis. J Antimicrob Chemother. 2007; 59(4): 690-7. 
297. Chigutsa E, Patel K, Denti P, Visser M, Maartens G, Kirkpatrick CM, McIlleron H, Karlsson 
MO. A time-to-event pharmacodynamic model describing treatment response in patients with 
pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. 
Antimicrob Agents Chemother. 2013; 57(2): 789-95. 
298. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and 
dose-response relationships of antituberculosis drugs: recommendations and standards for industry 
and academia. J Infect Dis. 2015; 211 Suppl 3: S96-s106. 
299. Hanna D, Romero K, Schito M. Advancing tuberculosis drug regimen development through 
innovative quantitative translational pharmacology methods and approaches. Int J Infect Dis. 2017; 
56: 208-11. 
300. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. Higher-dose 
rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 
2011; 15(3): 305-16. 
301. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, 
Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two 
pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012; 56(8): 
4331-40. 
302. de Steenwinkel JE, Aarnoutse RE, de Knegt GJ, ten Kate MT, Teulen M, Verbrugh HA, Boeree 
MJ, van Soolingen D, Bakker-Woudenberg IA. Optimization of the rifampin dosage to improve the 
therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med. 
2013; 187(10): 1127-34. 
303. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald 
PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis 
evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007; 51(8): 2994-6. 
304. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, 
McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger 
D, Plemper van Balen G, Aarnoutse RE, Pan AC. A dose-ranging trial to optimize the dose of rifampin 
in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191(9): 1058-65. 
305. Jindani A, Borgulya G, de Patino IW, Gonzales T, de Fernandes RA, Shrestha B, Atwine D, 
Bonnet M, Burgos M, Dubash F, Patel N, Checkley AM, Harrison TS, Mitchison D, International 
Consortium for Trials of Chemotherapeutic Agents in Tuberculosis SGsUoL. A randomised Phase II 
trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc 
Lung Dis. 2016; 20(6): 832-8. 
306. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, 
Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, 
Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van 
Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M. High-dose rifampicin, moxifloxacin, and SQ109 for 
References 
Page 280 
treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017; 
17(1): 39-49. 
307. Velasquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vasquez D, Sanchez Garavito E, 
Calderon RI, Jimenez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, 
Mitnick CD. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis: a randomized 
controlled trial. Am J Respir Crit Care Med. 2018. 
308. Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, 
Boeree MJ, Simonsson USH. Greater early bactericidal activity at higher rifampicin doses revealed by 
modeling and clinical trial simulations. J Infect Dis. 2018. 
309. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, 
Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the 
antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012; 91(5): 881-8. 
310. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the 
treatment of Human Immunodeficiency Virus-related tuberculosis. Clin Infect Dis. 1999; 28(3): 419-
29; quiz 30. 
311. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza 
LA, Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with 
lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009; 49(9): 
1305-11. 
312. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, 
Peloquin CA. Population pharmacokinetic modeling of pyrazinamide in children and adults with 
tuberculosis. Pharmacotherapy. 2002; 22(6): 686-95. 
313. Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide 
is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother. 2010; 
54(7): 2847-54. 
314. Smythe W, Merle CS, Rustomjee R, Gninafon M, Lo MB, Bah-Sow O, Olliaro PL, Lienhardt C, 
Horton J, Smith P, McIlleron H, Simonsson US. Evaluation of initial and steady-state gatifloxacin 
pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. 
Antimicrob Agents Chemother. 2013; 57(9): 4164-71. 
315. Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE. 
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect 
Dis. 2007; 45(8): 1001-7. 
316. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy 
effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin 
Infect Dis. 2013; 57(1): 21-31. 
317. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. 
Nature. 2004; 429(6990): 464-8. 
318. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. 
N Engl J Med. 2003; 348(6): 538-49. 
  References 
 
  Page 281 
319. Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS. Low rifampicin 
concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries. 2014; 8(8): 987-93. 
320. Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, 
Hoffmann MM, Weiss J. SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: 
relevance for African and worldwide precision medicine. Omics. 2016; 20(9): 538-45. 
321. Jeremiah K, Denti P, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, Castel S, Wiesner L, 
Hagen CM, Christiansen M, Changalucha J, McIlleron H, Friis H, Andersen AB. Nutritional 
supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. 
Antimicrob Agents Chemother. 2014; 58(6): 3468-74. 
322. Schipani A, Pertinez H, Mlota R, Molyneux E, Lopez N, Dzinjalamala FK, van Oosterhout JJ, 
Ward SA, Khoo S, Davies G. A simultaneous population pharmacokinetic analysis of rifampicin in 
Malawian adults and children. Br J Clin Pharmacol. 2016; 81(4): 679-87. 
323. Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, 
Deshpande D, Nuermberger E, Gumbo T. Drug concentration thresholds predictive of therapy failure 
and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis. 2016; 
63(suppl 3): S63-S74. 
324. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith 
PJ, Onyebujoh PC. Reduced antituberculosis drug concentrations in HIV-infected patients who are 
men or have low weight: implications for international dosing guidelines. Antimicrob Agents 
Chemother. 2012; 56(6): 3232-8. 
325. Requena-Mendez A, Davies G, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, Moore DA. 
Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes 
or HIV. Antimicrob Agents Chemother. 2012; 56(5): 2357-63. 
326. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, 
Chaisson RE, McIlleron H, Dooley KE. Population pharmacokinetics of rifampin in pregnant women 
with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015; 
60(3): 1234-41. 
327. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes 
related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC 
Infect Dis. 2017; 17(1): 125. 
328. Dartois V, Barry CE, 3rd. A medicinal chemists' guide to the unique difficulties of lead 
optimization for tuberculosis. Bioorg Med Chem Lett. 2013; 23(17): 4741-50. 
329. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial 
lining fluid. Antimicrob Agents Chemother. 2008; 52(1): 24-36. 
330. Cazzola M, Blasi F, Ewig S. Antibiotics and the lung2004. 275 p. 
331. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be 
incorporated into pharmacodynamic analyses? Curr Opin Pharmacol. 2007; 7(5): 498-504. 
References 
Page 282 
332. Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of 
anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004; 48(5): 1441-53. 
333. Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis. 1981; 
3(1): 67-73. 
334. Valcke Y, Pauwels R, Van der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur 
Respir J. 1990; 3(6): 715-22. 
335. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. Adv 
Drug Deliv Rev. 2001; 46(1-3): 3-26. 
336. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J 
Appl Physiol (1985). 1986; 60(2): 532-8. 
337. Honeybourne D. Antibiotic penetration into lung tissues. Thorax. 1994; 49(2): 104-6. 
338. Cohen GM. Pulmonary metabolism of foreign compounds: its role in metabolic activation. 
Environ Health Perspect. 1990; 85: 31-41. 
339. Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Semin 
Immunopathol. 2013; 35(5): 563-83. 
340. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, 3rd, Dartois V. 
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary 
lesions. Antimicrob Agents Chemother. 2012; 56(1): 446-57. 
341. Kempker RR, Barth AB, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, 
Gogishvili S, Singh RS, Guarner J, Derendorf H, Peloquin CA, Blumberg HM. Cavitary penetration of 
levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 
2015; 59(6): 3149-55. 
342. Vadwai V, Daver G, Udwadia Z, Sadani M, Shetty A, Rodrigues C. Clonal population of 
Mycobacterium tuberculosis strains reside within multiple lung cavities. PLoS One. 2011; 6(9): 
e24770. 
343. du Plessis DG, Warren R, Richardson M, Joubert JJ, van Helden PD. Demonstration of 
reinfection and reactivation in HIV-negative autopsied cases of secondary tuberculosis: multilesional 
genotyping of Mycobacterium tuberculosis utilizing IS 6110 and other repetitive element-based DNA 
fingerprinting. Tuberculosis (Edinb). 2001; 81(3): 211-20. 
344. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE, Jr., Jelliffe RW. Population 
modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis 
pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009; 53(7): 2974-81. 
345. Conte JE, Golden JA, Kipps JE, Lin ET, Zurlinden E. Effect of sex and AIDS status on the 
plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet. 2004; 43(6): 395-
404. 
  References 
 
  Page 283 
346. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin concentrations in 
bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg 
oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2002; 50(6): 
1011-5. 
347. Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary 
epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011; 50(10): 637-64. 
348. Marcy TW, Merrill WW, Rankin JA, Reynolds HY. Limitations of using urea to quantify 
epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis. 1987; 135(6): 1276-80. 
349. Johnson JD, Hand WL, Francis JB, King-Thompson N, Corwin RW. Antibiotic uptake by 
alveolar macrophages. J Lab Clin Med. 1980; 95(3): 429-39. 
350. Steinberg TH. Cellular transport of drugs. Clin Infect Dis. 1994; 19(5): 916-21. 
351. O'Brien JK, Doerfler ME, Harkin TJ, Rom WN. Isoniazid levels in the bronchoalveolar lavage 
fluid of patients with pulmonary tuberculosis. Lung. 1998; 176(3): 205-11. 
352. Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Torok ME, Van Wart SA, Mai PP, Reynolds 
DK, Caws M, Dung NT, Hien TT, Kulawy R, Farrar J, Ambrose PG. Randomized pharmacokinetic and 
pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents 
Chemother. 2011; 55(7): 3244-53. 
353. Te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, Ruslami R, van Crevel R, 
Aarnoutse R. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing 
rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents. 2015; 45(5): 496-
503. 
354. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, 
van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: 
an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013; 13(1): 27-35. 
355. Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, Chau NV, Hien TT, Dung NH, Lan 
NT, Lan NH, Lan NN, Phong le T, Vien NN, Hien NQ, Yen NT, Ha DT, Day JN, Caws M, Merson L, Thinh 
TT, Wolbers M, Thwaites GE, Farrar JJ. Intensified antituberculosis therapy in adults with tuberculous 
meningitis. N Engl J Med. 2016; 374(2): 124-34. 
356. Yunivita V, Dian S, Ganiem AR, Hayati E, Hanggono Achmad T, Purnama Dewi A, Teulen M, 
Meijerhof-Jager P, van Crevel R, Aarnoutse R, Ruslami R. Pharmacokinetics and safety/tolerability of 
higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J 
Antimicrob Agents. 2016; 48(4): 415-21. 
357. Russell DG, Vanderven BC, Glennie S, Mwandumba H, Heyderman RS. The macrophage 
marches on its phagosome: dynamic assays of phagosome function. Nat Rev Immunol. 2009; 9(8): 
594-600. 
358. Aberdein JD, Cole J, Bewley MA, Marriott HM, Dockrell DH. Alveolar macrophages in 
pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial 
killing. Clin Exp Immunol. 2013; 174(2): 193-202. 
References 
Page 284 
359. Awuh JA, Flo TH. Molecular basis of mycobacterial survival in macrophages. Cell Mol Life Sci. 
2017; 74(9): 1625-48. 
360. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat 
Rev Immunol. 2007; 7(3): 179-90. 
361. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1): 23-35. 
362. Martí-Lliteras P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, Agustí AGN, Bengoechea 
JA, Garmendia J. Nontypeable Haemophilus influenzae clearance by alveolar macrophages Is 
impaired by exposure to cigarette smoke. Infect Immun. 2009; 77(10): 4232-42. 
363. Berenson CS, Kruzel RL, Eberhardt E, Sethi S. Phagocytic dysfunction of human alveolar 
macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013; 208(12): 
2036-45. 
364. Martinez N, Ketheesan N, West K, Vallerskog T, Kornfeld H. Impaired recognition of 
Mycobacterium tuberculosis by alveolar macrophages from diabetic mice. J Infect Dis. 2016; 214(11): 
1629-37. 
365. Jambo KC, Banda DH, Kankwatira AM, Sukumar N, Allain TJ, Heyderman RS, Russell DG, 
Mwandumba HC. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired 
phagocytic function. Mucosal Immunol. 2014; 7(5): 1116-26. 
366. Minakami R, Sumimotoa H. Phagocytosis-coupled activation of the superoxide-producing 
phagocyte oxidase, a member of the NADPH oxidase (nox) family. Int J Hematol. 2006; 84(3): 193-8. 
367. Nathan C. Role of iNOS in human host defense. Science. 2006; 312(5782): 1874-5; author 
reply -5. 
368. Slauch JM. How does the oxidative burst of macrophages kill bacteria? Still an open 
question. Mol Microbiol. 2011; 80(3): 580-3. 
369. Fang FC. Antimicrobial actions of reactive oxygen species. MBio. 2011; 2(5). 
370. VanderVen BC, Yates RM, Russell DG. Intraphagosomal measurement of the magnitude and 
duration of the oxidative burst. Traffic. 2009; 10(4): 372-8. 
371. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-
inducible LRG-47. Science. 2003; 302(5645): 654-9. 
372. Podinovskaia M, Lee W, Caldwell S, Russell DG. Infection of macrophages with 
Mycobacterium tuberculosis induces global modifications to phagosomal function. Cell Microbiol. 
2013; 15(6): 843-59. 
373. Buvelot H, Posfay-Barbe KM, Linder P, Schrenzel J, Krause KH. Staphylococcus aureus, 
phagocyte NADPH oxidase and chronic granulomatous disease. FEMS Microbiol Rev. 2017; 41(2): 
139-57. 
  References 
 
  Page 285 
374. Rylance J, Fullerton DG, Scriven J, Aljurayyan AN, Mzinza D, Barrett S, Wright AK, Wootton 
DG, Glennie SJ, Baple K, Knott A, Mortimer K, Russell DG, Heyderman RS, Gordon SB. Household air 
pollution causes dose-dependent inflammation and altered phagocytosis in human macrophages. 
Am J Respir Cell Mol Biol. 2015; 52(5): 584-93. 
375. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, 
Rosen MJ, Mangura BT, Hopewell PC. Bacterial pneumonia in persons infected with the Human 
Immunodeficiency Virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 
333(13): 845-51. 
376. Cribbs SK, Lennox J, Caliendo AM, Brown LA, Guidot DM. Healthy HIV-1-infected individuals 
on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. AIDS Research 
and Human Retroviruses. 2015; 31(1): 64-70. 
377. Yates RM, Hermetter A, Taylor GA, Russell DG. Macrophage activation downregulates the 
degradative capacity of the phagosome. Traffic. 2007; 8(3): 241-50. 
378. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis 
in antigen-presenting cells determines antigen fate. Science. 2005; 307(5715): 1630-4. 
379. Twigg HL, 3rd, Spain BA, Soliman DM, Knox K, Sidner RA, Schnizlein-Bick C, Wilkes DS, 
Iwamoto GK. Production of interferon-gamma by lung lymphocytes in HIV-infected individuals. Am J 
Physiol. 1999; 276(2 Pt 1): L256-62. 
380. Rubin EJ. The granuloma in tuberculosis--friend or foe? N Engl J Med. 2009; 360(23): 2471-3. 
381. Rajaram MVS, Ni B, Dodd CE, Schlesinger LS. Macrophage immunoregulatory pathways in 
tuberculosis. Seminars in immunology. 2014; 26(6): 471-85. 
382. Schlesinger LS, Kaufman TM, Iyer S, Hull SR, Marchiando LK. Differences in mannose 
receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of 
Mycobacterium tuberculosis by human macrophages. J Immunol. 1996; 157(10): 4568-75. 
383. Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. Mycobacterium 
tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking 
mannose receptor recognition to regulation of immune responses. J Immunol. 2010; 185(2): 929-42. 
384. DesJardin LE, Kaufman TM, Potts B, Kutzbach B, Yi H, Schlesinger LS. Mycobacterium 
tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased 
expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, 
FcgammaRII and the mannose receptor. Microbiology. 2002; 148(Pt 10): 3161-71. 
385. Russell DG, Barry CE, 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. 
Science. 2010; 328(5980): 852-6. 
386. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression 
of the human tuberculosis granuloma. Nat Immunol. 2009; 10(9): 943-8. 
387. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V. Mechanism of phagolysosome 
biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2005; 102(11): 
4033-8. 
References 
Page 286 
388. Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, 
with observations on fusion of lysosomes with phagosomes. J Exp Med. 1971; 134(3 Pt 1): 713-40. 
389. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis protein tyrosine 
phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification. Proc Natl 
Acad Sci U S A. 2011; 108(48): 19371-6. 
390. Hmama Z, Pena-Diaz S, Joseph S, Av-Gay Y. Immunoevasion and immunosuppression of the 
macrophage by Mycobacterium tuberculosis. Immunol Rev. 2015; 264(1): 220-32. 
391. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ. 
M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. 
Cell. 2007; 129(7): 1287-98. 
392. Sun J, Wang X, Lau A, Liao TY, Bucci C, Hmama Z. Mycobacterial nucleoside diphosphate 
kinase blocks phagosome maturation in murine RAW 264.7 macrophages. PLoS One. 2010; 5(1): 
e8769. 
393. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, 
Orme IM, Derrick SC, Morris SL, Jacobs WR, Jr., Porcelli SA. Enhanced priming of adaptive immunity 
by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest. 2007; 117(8): 2279-88. 
394. Chang ST, Linderman JJ, Kirschner DE. Multiple mechanisms allow Mycobacterium 
tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages. 
Proc Natl Acad Sci U S A. 2005; 102(12): 4530-5. 
395. Hestvik AL, Hmama Z, Av-Gay Y. Mycobacterial manipulation of the host cell. FEMS 
Microbiol Rev. 2005; 29(5): 1041-50. 
396. Ali F, Lee ME, Iannelli F, Pozzi G, Mitchell TJ, Read RC, Dockrell DH. Streptococcus 
pneumoniae-associated human macrophage apoptosis after bacterial internalization via 
complement and Fcgamma receptors correlates with intracellular bacterial load. J Infect Dis. 2003; 
188(8): 1119-31. 
397. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, Kornfeld H. 
Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect 
Immun. 1997; 65(1): 298-304. 
398. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade 
apoptosis of infected alveolar macrophages. J Immunol. 2000; 164(4): 2016-20. 
399. Martin CJ, Peters KN, Behar SM. Macrophages clean up: efferocytosis and microbial control. 
Curr Opin Microbiol. 2014; 17: 17-23. 
400. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates 
chemokine induction essential for cell recruitment, granuloma formation, and clearance of 
mycobacterial infection. J Immunol. 2002; 168(9): 4620-7. 
401. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection 
with Mycobacterium tuberculosis. J Immunol. 1997; 159(2): 635-43. 
  References 
 
  Page 287 
402. Orme IM, Robinson RT, Cooper AM. The balance between protective and pathogenic 
immune responses in the TB-infected lung. Nat Immunol. 2015; 16(1): 57-63. 
403. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. Initiation of the 
adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the 
local lymph node, not the lungs. J Exp Med. 2008; 205(1): 105-15. 
404. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium 
tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect 
Immun. 2002; 70(8): 4501-9. 
405. Samstein M, Schreiber HA, Leiner IM, Susac B, Glickman MS, Pamer EG. Essential yet limited 
role for CCR2(+) inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. 
Elife. 2013; 2: e01086. 
406. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of 
a new paradigm for protective immunity to TB. Nat Rev Microbiol. 2014; 12(4): 289-99. 
407. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T 
cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med. 2010; 207(7): 
1409-20. 
408. Urdahl KB. Understanding and overcoming the barriers to T cell-mediated immunity against 
tuberculosis. Semin Immunol. 2014; 26(6): 578-87. 
409. Srivastava S, Ernst JD. Cutting edge: Direct recognition of infected cells by CD4 T cells is 
required for control of intracellular Mycobacterium tuberculosis in vivo. J Immunol. 2013; 191(3): 
1016-20. 
410. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on 
murine infection with Mycobacterium tuberculosis. Infect Immun. 1995; 63(2): 736-40. 
411. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of 
tuberculosis. Nat Rev Immunol. 2011; 11(5): 343-54. 
412. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, 
Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM. IL-23 and IL-17 in the 
establishment of protective pulmonary CD4+ T cell responses after vaccination and during 
Mycobacterium tuberculosis challenge. Nat Immunol. 2007; 8(4): 369-77. 
413. Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of Human 
Immunodeficiency Virus infection on the host granulomatous response to Mycobacterium 
tuberculosis. Microbes Infect. 2002; 4(6): 635-46. 
414. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, 
Ramaswamy SV, Walther G, Steyn LM, Barry CE, 3rd, Bekker LG. Mycobacterium tuberculosis growth 
at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003; 71(12): 7099-
108. 
References 
Page 288 
415. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex 
class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc 
Natl Acad Sci U S A. 1992; 89(24): 12013-7. 
416. Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role 
in immunity. Crit Rev Immunol. 2006; 26(4): 317-52. 
417. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, Pedrosa J, Cooper AM, Castro AG. Cutting 
edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during 
mycobacterial infection. J Immunol. 2006; 177(3): 1416-20. 
418. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and 
function. Annu Rev Immunol. 2012; 30: 531-64. 
419. Central Intelligence Agency. Malawi 2017 [cited 2017 January 17]. Available from: 
https://www.cia.gov/library/publications/the-world-factbook/geos/mi.html. 
420. African Health Observatory. Comprehensive Analytical Profile: Malawi: World Health 
Organization,; 2017 [cited 2017 January 2017]. Available from: 
http://www.aho.afro.who.int/profiles_information/index.php/Malawi:Index. 
421. National Statistical Office. Malawi Demographic and Health Survey. Zomba: National 
Statistical Office, 2016. 
422. National Statistical Office. Integrated household survey 2010-2011. Zomba, Malawi: 2012 
2012. Report No. 
423. National Statistical Office. Statistical Yearbook. Zomba: National Statistical Office, 2015. 
424. United Nations Development Programme. Malawi: United Nations Development 
Programme; 2015 [cited 2017 January 17]. Available from: 
http://www.mw.undp.org/content/malawi/en/home/countryinfo.html. 
425. Malawi National AIDS Commission. Malawi AIDS Response Progress Report. Zomba: 2015. 
426. Harries AD, Kwanjana JH, Hargreaves NJ, Van Gorkom J, Salaniponi FM. Resources for 
controlling tuberculosis in Malawi. Bull World Health Organ. 2001; 79(4): 329-36. 
427. United Nations Human Settlements Programme (UN-HABITAT). Malawi: Blantyre urban 
profile. Nairobi: 2011. 
428. Lumb R, Van Deun A, Bastian I, Fitz-Gerald M. Laboratory diagnosis of tuberculosis by 
sputum microscopy: the handbook. 2nd. ed. Adelaide: International Union Against Tuberculosis and 
Lung Disease; 2013. 
429. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, 
Navani N, Rahman NM, Wrightson JM, Munavvar M. Summary of the British Thoracic Society 
guideline for diagnostic flexible bronchoscopy in adults. Thorax. 2013; 68(8): 786-7. 
  References 
 
  Page 289 
430. Collins AM, Rylance J, Wootton DG, Wright AD, Wright AK, Fullerton DG, Gordon SB. 
Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield. J Vis Exp. 2014; (85). 
431. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-
55. 
432. Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, Bentley AM, Hope WW. 
Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther. 
2014; 96(4): 438-48. 
433. Jensen PA, Lambert LA, Iademarco MF, Ridzon R, Cdc. Guidelines for preventing the 
transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 
2005; 54(RR-17): 1-141. 
434. Larson JL, Ridzon R, Hannan MM. Sputum induction versus fiberoptic bronchoscopy in the 
diagnosis of tuberculosis. Am J Respir Crit Care Med. 2001; 163(5): 1279-80. 
435. Carroll NM, Uys P, Hesseling A, Lawrence K, Pheiffer C, Salker F, Duncan K, Beyers N, van 
Helden PD. Prediction of delayed treatment response in pulmonary tuberculosis: use of time to 
positivity values of Bactec cultures. Tuberculosis (Edinb). 2008; 88(6): 624-30. 
436. Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium 
tuberculosis in liquid culture is associated with relapse after therapy. J Clin Microbiol. 2012; 50(2): 
538. 
437. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd Edition ed. 
New York: Springer; 2011. 
438. Clewe O, Goutelle S, Conte JE, Jr., Simonsson US. A pharmacometric pulmonary model 
predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--
using rifampicin as an example. Eur J Clin Pharmacol. 2015; 71(3): 313-9. 
439. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R 
Foundation for Statistical Computing; 2017. 
440. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately 
treated patients are still at high risk. Int J Tuberc Lung Dis. 2007; 11(8): 828-37. 
441. Charalambous S, Grant AD, Moloi V, Warren R, Day JH, van Helden P, Hayes RJ, Fielding KL, 
De Cock KM, Chaisson RE, Churchyard GJ. Contribution of reinfection to recurrent tuberculosis in 
South African gold miners. Int J Tuberc Lung Dis. 2008; 12(8): 942-8. 
442. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, 
Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults 
with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9(7): e1001270. 
443. Joint United Nations Programme on HIV/AIDS. Global AIDS Update 2016. Geneva, 
Switzerland: 2016. 
References 
Page 290 
444. Kanyerere H, Girma B, Mpunga J, Tayler-Smith K, Harries AD, Jahn A, Chimbwandira FM. 
Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative 
tuberculosis. Public Health Action. 2016; 6(4): 247-51. 
445. National AIDS Commission. National Strategic Plan for HIV and AIDS 2015-2020. Lilongwe: 
National AIDS Commission; 2014. 
446. Spence DP, Hotchkiss J, Williams CS, Davies PD. Tuberculosis and poverty. Br Med J. 1993; 
307(6907): 759. 
447. Oxlade O, Murray M. Tuberculosis and poverty: why are the poor at greater risk in India? 
PLoS One. 2012; 7(11): e47533. 
448. Odone A, Crampin AC, Mwinuka V, Malema S, Mwaungulu JN, Munthali L, Glynn JR. 
Association between socioeconomic position and tuberculosis in a large population-based study in 
rural Malawi. PLoS One. 2013; 8(10): e77740. 
449. Kirenga BJ, Ssengooba W, Muwonge C, Nakiyingi L, Kyaligonza S, Kasozi S, Mugabe F, Boeree 
M, Joloba M, Okwera A. Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: 
implications for tuberculosis control. BMC Public Health. 2015; 15: 13. 
450. Madan J, Lönnroth K, Laokri S, Squire SB. What can dissaving tell us about catastrophic 
costs? Linear and logistic regression analysis of the relationship between patient costs and financial 
coping strategies adopted by tuberculosis patients in Bangladesh, Tanzania and Bangalore, India. 
BMC Health Serv Res. 2015; 15: 476. 
451. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, Lonnroth K, Evans CA. 
Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with 
multi-drug resistance: a prospective cohort study, Peru. PLoS Med. 2014; 11(7): e1001675. 
452. World Health Organization, editor Global Strategy and targets for tuberculosis prevention, 
care and control after 2015. World Health Assembly; 2014; Geneva. 
453. Fullerton DG, Suseno A, Semple S, Kalambo F, Malamba R, White S, Jack S, Calverley PM, 
Gordon SB. Wood smoke exposure, poverty and impaired lung function in Malawian adults. Int J 
Tuberc Lung Dis. 2011; 15(3): 391-8. 
454. Lin H-H, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a 
systematic review and meta-analysis. PLoS Med. 2007; 4(1): e20. 
455. Perrin FMR, Woodward N, Phillips PPJ, McHugh TD, Nunn AJ, Lipman MCI, Gillespie SH. 
Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary 
tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2010; 14(12): 1596-602. 
456. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting 
persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after 
treatment. Int J Tuberc Lung Dis. 2003; 7(1): 58-64. 
457. Dominguez-Castellano A, Muniain MA, Rodriguez-Bano J, Garcia M, Rios MJ, Galvez J, Perez-
Cano R. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. 
Int J Tuberc Lung Dis. 2003; 7(5): 432-8. 
  References 
 
  Page 291 
458. Zellweger JP, Heinzer R, Touray M, Vidondo B, Altpeter E. Intra-observer and overall 
agreement in the radiological assessment of tuberculosis. Int J Tuberc Lung Dis. 2006; 10(10): 1123-
6. 
459. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori 
G, Tjitra E, Sandjaja, Kenagalem E, Pontororing GJ, Anstey NM, Kelly PM. A simple, valid, numerical 
score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010; 
65(10): 863-9. 
460. Bekker A, Schaaf HS, Draper HR, Kriel M, Hesseling AC. Tuberculosis disease during 
pregnancy and treatment outcomes in HIV-infected and uninfected women at a referral hospital in 
Cape Town. PLoS One. 2016; 11(11): e0164249. 
461. Kriel M, Lotz JW, Kidd M, Walzl G. Evaluation of a radiological severity score to predict 
treatment outcome in adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015; 19(11): 1354-
60. 
462. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993; 46(5): 423-9. 
463. Landis JR, Koch GG. The measurement of observer agreement for categorical data. 
Biometrics. 1977; 33(1): 159-74. 
464. Kony SJ, Hane AA, Larouze B, Samb A, Cissoko S, Sow PS, Sane M, Maynart M, Diouf G, 
Murray JF. Tuberculosis-associated severe CD4+ T-lymphocytopenia in HIV-seronegative patients 
from Dakar. SIDAK Research Group. J Infect. 2000; 41(2): 167-71. 
465. Jones BE, Oo MM, Taikwel EK, Qian D, Kumar A, Maslow ER, Barnes PF. CD4 cell counts in 
Human Immunodeficiency Virus-negative patients with tuberculosis. Clin Infect Dis. 1997; 24(5): 988-
91. 
466. Pérez-Padilla R, Pérez-Guzmán C, Báez-Saldaña R, Torres-Cruz A. Cooking with biomass 
stoves and tuberculosis: a case control study. The International Journal of Tuberculosis and Lung 
Disease. 2001; 5(5): 441-7. 
467. Mishra VK, Retherford RD, Smith KR. Biomass cooking fuels and prevalence of tuberculosis 
in India. International Journal of Infectious Diseases. 1999; 3(3): 119-29. 
468. Payongayong E, Benson T, Ahmed A, Kanyanda S, Chakanza C, Mwanza P, Chiplopa K, Banda 
N, Mphonda A. Simple household poverty assessment models for Malawi. Washington, DC, USA: 
International Food Policy Research Institute, 2002. 
469. American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies 
in sepsis. Crit Care Med. 1992; 20(6): 864-74. 
470. Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions 
for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8): 801-10. 
471. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. 
Ann Hematol. 1997; 75(5-6): 179-87. 
References 
Page 292 
472. Kerkhoff AD, Meintjes G, Opie J, Vogt M, Jhilmeet N, Wood R, Lawn SD. Anaemia in patients 
with HIV-associated TB: relative contributions of anaemia of chronic disease and iron deficiency. Int J 
Tuberc Lung Dis. 2016; 20(2): 193-201. 
473. Agarwal A, Bhat MS, Kumar A, Shaharyar A, Mishra M, Yadav R. Lymphocyte/monocyte ratio 
in osteoarticular tuberculosis in children: a haematological biomarker revisited. Trop Doct. 2016; 
46(2): 73-7. 
474. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane 
H, Fletcher H. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of 
incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis. 2014; 
209(4): 500-9. 
475. Naranbhai V, Kim S, Fletcher H, Cotton MF, Violari A, Mitchell C, Nachman S, McSherry G, 
McShane H, Hill AV, Madhi SA. The association between the ratio of monocytes:lymphocytes at age 3 
months and risk of tuberculosis (TB) in the first two years of life. BMC Med. 2014; 12: 120. 
476. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, 
Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying 
tuberculosis infection and disease stages. PLoS One. 2017; 12(2): e0171358. 
477. Ministry of Health Malawi. Malawi Standard Treatment Guidelines. 5th ed. Lilongwe, 
Malawi: Ministry of Health; 2015. 
478. Hogan CA, Puri L, Gore G, Pai M. Impact of fluoroquinolone treatment on delay of 
tuberculosis diagnosis: A systematic review and meta-analysis. Journal of Clinical Tuberculosis and 
Other Mycobacterial Diseases. 2017; 6(Supplement C): 1-7. 
479. McCallum AD, Nyirenda D, Lora W, Khoo SH, Sloan DJ, Mwandumba HC, Desmond N, Davies 
GR. Perceptions of research bronchoscopy in Malawian adults with pulmonary tuberculosis: a cross-
sectional study. PLoS One. 2016; 11(10): e0165734. 
480. Mtunthama N, Malamba R, French N, Molyneux ME, Zijlstra EE, Gordon SB. Malawians 
permit research bronchoscopy due to perceived need for healthcare. J Med Ethics. 2008; 34(4): 303-
7. 
481. Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex differences in 
tuberculosis burden and notifications in low- and middle-income countries: a systematic review and 
meta-analysis. PLoS Med. 2016; 13(9): e1002119. 
482. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, Chirwa Z, 
Ng'ambi W, Bakali A, Phiri S, Myer L, Valeri F, Zwahlen M, Wandeler G, Keiser O. Retention in care 
under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option 
B+') in Malawi. AIDS. 2014; 28(4): 589-98. 
483. Auld AF, Shiraishi RW, Mbofana F, Couto A, Fetogang EB, El-Halabi S, Lebelonyane R, Pilatwe 
PT, Hamunime N, Okello V, Mutasa-Apollo T, Mugurungi O, Murungu J, Dzangare J, Kwesigabo G, 
Wabwire-Mangen F, Mulenga M, Hachizovu S, Ettiegne-Traore V, Mohamed F, Bashorun A, Nhan do 
T, Hai NH, Quang TH, Van Onacker JD, Francois K, Robin EG, Desforges G, Farahani M, Kamiru H, 
Nuwagaba-Biribonwoha H, Ehrenkranz P, Denison JA, Koole O, Tsui S, Torpey K, Mukadi YD, van 
Praag E, Menten J, Mastro TD, Hamilton CD, Abiri OO, Griswold M, Pierre E, Xavier C, Alfredo C, 
Jobarteh K, Letebele M, Agolory S, Baughman AL, Mutandi G, Preko P, Ryan C, Ao T, Gonese E, 
  References 
 
  Page 293 
Herman-Roloff A, Ekra KA, Kouakou JS, Odafe S, Onotu D, Dalhatu I, Debem HH, Nguyen DB, Yen le N, 
Abdul-Quader AS, Pelletier V, Williams SG, Behel S, Bicego G, Swaminathan M, Dokubo EK, Adjorlolo-
Johnson G, Marlink R, Lowrance D, Spira T, Colebunders R, Bangsberg D, Zee A, Kaplan J, Ellerbrock 
TV. Lower levels of antiretroviral therapy enrollment among men with HIV compared with women - 
12 Countries, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015; 64(46): 1281-6. 
484. Bor J, Rosen S, Chimbindi N, Haber N, Herbst K, Mutevedzi T, Tanser F, Pillay D, 
Barnighausen T. Mass HIV treatment and sex disparities in life expectancy: demographic surveillance 
in rural South Africa. PLoS Med. 2015; 12(11): e1001905; discussion e. 
485. Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, 
Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, 
Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen 
YQ, Cohen MS, Fogel JM. Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin 
Trials. 2017; 18(3): 100-9. 
486. Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line 
antiretroviral therapy durability in a 10-year cohort of naive adults started on treatment in Uganda. J 
Int AIDS Soc. 2016; 19(1): 20773. 
487. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, 
Flepp M, Furrer H, Francioli P, Weber R. Clinical progression and virological failure on highly active 
antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet. 1999; 353(9156): 
863-8. 
488. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO 
criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008; 22(15): 1971-7. 
489. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, 
Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, 
Wang YC, Weiner M, Weis S. Rifapentine and isoniazid once a week versus rifampicin and isoniazid 
twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a 
randomised clinical trial. Lancet. 2002; 360(9332): 528-34. 
490. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, Kim DS, Shim TS. Risk factors for 1-year 
relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med. 2014; 108(4): 
654-9. 
491. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson 
RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, 
Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, 
Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and 
Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-
susceptible tuberculosis. Clin Infect Dis. 2016; 63(7): e147-e95. 
492. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, 
Lawrence KA, Gie RP, van Helden PD, Beyers N. Baseline sputum time to detection predicts month 
two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis. 2010; 14(5): 
560-70. 
References 
Page 294 
493. Visser ME, Stead MC, Walzl G, Warren R, Schomaker M, Grewal HM, Swart EC, Maartens G. 
Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, 
smoking, time to detection and W-Beijing genotype. PLoS One. 2012; 7(1): e29588. 
494. Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC, Jr., Diem 
L, Metchock B, Eisenach K, Dorman S, Goldberg S. Geographic differences in time to culture 
conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in 
Africa. PLoS One. 2011; 6(4): e18358. 
495. Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH. A 
comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials 
for new regimens. BMC Med. 2017; 15(1): 207. 
496. Chihota VN, Grant AD, Fielding K, Ndibongo B, van Zyl A, Muirhead D, Churchyard GJ. Liquid 
vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J 
Tuberc Lung Dis. 2010; 14(8): 1024-31. 
497. Salihu HM, Aliyu MH, Ratard R, Pierre-Louis BJ. Characteristics associated with reported 
sputum culture conversion in the era of re-emergent Mycobacterium tuberculosis in the State of 
North Carolina, 1993-1998. Int J Tuberc Lung Dis. 2003; 7(11): 1070-6. 
498. Aliyu MH, Salihu HM, Ratard R. HIV infection and sputum-culture conversion in patients 
diagnosed with Mycobacterium tuberculosis: a population-based study. Wien Klin Wochenschr. 
2003; 115(10): 340-6. 
499. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson 
DA, Behr MA, van Helden PD. Rate of reinfection tuberculosis after successful treatment is higher 
than rate of new tuberculosis. Am J Respir Crit Care Med. 2005; 171(12): 1430-5. 
500. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie 
SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011; 
52(9): e194-9. 
501. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. 
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. 
Antimicrob Agents Chemother. 2010; 54(3): 1068-74. 
502. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, 
Danusantoso H, Aarnoutse RE, van Crevel R. Exposure to rifampicin is strongly reduced in patients 
with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006; 43(7): 848-54. 
503. Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G. Recent 
bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on 
the global market. Int J Tuberc Lung Dis. 1999; 3(11 Suppl 3): S309-16; discussion S17-21. 
504. McIlleron H, Hundt H, Smythe W, Bekker A, Winckler J, van der Laan L, Smith P, Zar HJ, 
Hesseling AC, Maartens G, Wiesner L, van Rie A. Bioavailability of two licensed paediatric rifampicin 
suspensions: implications for quality control programmes. Int J Tuberc Lung Dis. 2016; 20(7): 915-9. 
  References 
 
  Page 295 
505. McIlleron H, Wash P, Burger A, Folb P, Smith P. Widespread distribution of a single drug 
rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis. 2002; 6(4): 
356-61. 
506. Torok ME, Aljayyoussi G, Waterhouse D, Chau T, Mai N, Phu NH, Hien TT, Hope W, Farrar JJ, 
Ward SA. Suboptimal exposure to anti-TB drugs in a TBM/HIV+ population is not related to anti-
retroviral therapy. Clin Pharmacol Ther. 2017. 
507. Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH. 
A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction 
for high rifampicin doses. Clin Pharmacol Ther. 2017. 
508. Rockwood N, Meintjes G, Chirehwa M, Wiesner L, McIlleron H, Wilkinson RJ, Denti P. HIV-1 
coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African 
tuberculosis outpatients. Antimicrob Agents Chemother. 2016; 60(10): 6050-9. 
509. Jing Y, Zhu LQ, Yang JW, Huang SP, Wang Q, Zhang J. Population pharmacokinetics of 
rifampicin in Chinese patients with pulmonary tuberculosis. J Clin Pharmacol. 2016; 56(5): 622-7. 
510. Chang MJ, Chae JW, Yun HY, Lee JI, Choi HD, Kim J, Park JS, Cho YJ, Yoon HI, Lee CT, Shin 
WG, Lee JH. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in 
tuberculosis patients. Tuberculosis (Edinb). 2015; 95(1): 54-9. 
511. Milan Segovia RC, Dominguez Ramirez AM, Jung Cook H, Magana Aquino M, Vigna Perez M, 
Brundage RC, Romano Moreno S. Population pharmacokinetics of rifampicin in Mexican patients 
with tuberculosis. J Clin Pharm Ther. 2013; 38(1): 56-61. 
512. Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. Population pharmacokinetic analysis 
of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents 
Chemother. 2015; 59(11): 6791-9. 
513. Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA. 
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. Antimicrob Agents 
Chemother. 2017; 61(6). 
514. Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P. 
Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant 
tuberculosis. Antimicrob Agents Chemother. 2017; 61(8). 
515. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002; 
62(15): 2169-83. 
516. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse 
RE. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents 
Chemother. 2013; 57(7): 3208-13. 
517. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, 
Maritz JS. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the 
pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007; 63(7): 633-9. 
References 
Page 296 
518. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium 
tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988; 32(7): 
1002-4. 
519. Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, McIlleron H. Quality 
assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J 
Tuberc Lung Dis. 2018; 22(5): 537-43. 
520. Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound 
drug concentrations for anti-infective agents. Clin Microbiol Rev. 2013; 26(2): 274-88. 
521. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE, 3rd, Stoeckli M. High-
sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs 
and granulomatous lesions. Anal Chem. 2011; 83(6): 2112-8. 
522. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary 
epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin 
Pharmacokinet. 2011; 50(11): 689-704. 
523. Ziglam HM. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar 
macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic 
bronchoscopy. Journal of Antimicrobial Chemotherapy. 2002; 50(6): 1011-5. 
524. Goutelle S, Bourguignon L, Jelliffe RW, Conte JE, Jr., Maire P. Mathematical modeling of 
pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. J Theor Biol. 2011; 
282(1): 80-92. 
525. Lalande L, Bourguignon L, Bihari S, Maire P, Neely M, Jelliffe R, Goutelle S. Population 
modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of 
isoniazid in lungs. Antimicrob Agents Chemother. 2015. 
526. Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis 
M, Alffenaar JC, Davies G, Sloan DJ. Linezolid pharmacokinetics in MDR-TB: a systematic review, 
meta-analysis and Monte Carlo simulation. J Antimicrob Chemother. 2018. 
527. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. Population 
pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb). 2002; 82(2-3): 
91-6. 
528. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van 
Soolingen D, Bakker-Woudenberg IA. Time-kill kinetics of anti-tuberculosis drugs, and emergence of 
resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother. 
2010; 65(12): 2582-9. 
529. Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, 
Cobelens FG, Wood R, Moore DA, Abubakar I. The transmission of Mycobacterium tuberculosis in 
high burden settings. Lancet Infect Dis. 2016; 16(2): 227-38. 
530. Mathema B, Andrews JR, Cohen T, Borgdorff MW, Behr M, Glynn JR, Rustomjee R, Silk BJ, 
Wood R. Drivers of tuberculosis transmission. J Infect Dis. 2017; 216(suppl_6): S644-S53. 
  References 
 
  Page 297 
531. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at 
the sites of pulmonary infection. Eur Respir J. 1990; 3(8): 886-90. 
532. Lakshminarayana SB, Huat TB, Ho PC, Manjunatha UH, Dartois V, Dick T, Rao SP. 
Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J 
Antimicrob Chemother. 2015; 70(3): 857-67. 
533. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 
1985; 66(3): 219-25. 
534. Zimmerman M, Lestner J, Prideaux B, O'Brien P, Freedman I, Chen C, Dietzold J, Daudelin I, 
Kaya F, Blanc L, Chen PY, Park S, Salgame P, Sarathy J, Dartois V. Ethambutol partitioning in 
tuberculous pulmonary lesions explains its clinical efficacy. Antimicrob Agents Chemother. 2017. 
535. Hartkoorn RC, Khoo S, Back DJ, Tjia JF, Waitt CJ, Chaponda M, Davies G, Ardrey A, Ashleigh 
S, Ward SA. A rapid and sensitive HPLC–MS method for the detection of plasma and cellular 
rifampicin. Journal of Chromatography B. 2007; 857(1): 76-82. 
536. Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-
MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in 
PBMCs. J Antimicrob Chemother. 2015; 70(9): 2572-5. 
537. Hutschala D, Skhirtladze K, Kinstner C, Zeitlinger M, Wisser W, Jaeger W, Hoeferl M, Muller 
M, Tschernko E. Effect of cardiopulmonary bypass on regional antibiotic penetration into lung tissue. 
Antimicrob Agents Chemother. 2013; 57(7): 2996-3002. 
538. Khoo SH, Hoggard PG, Williams I, Meaden ER, Newton P, Wilkins EG, Smith A, Tjia JF, Lloyd J, 
Jones K, Beeching N, Carey P, Peters B, Back DJ. Intracellular accumulation of human 
immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother. 2002; 46(10): 3228-35. 
539. Willcox M, Kervitsky A, Watters LC, King TE, Jr. Quantification of cells recovered by 
bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. Am Rev 
Respir Dis. 1988; 138(1): 74-80. 
540. Lavielle M, Aarons L. What do we mean by identifiability in mixed effects models? J 
Pharmacokinet Pharmacodyn. 2016; 43(1): 111-22. 
541. Grigg J, Kleinert S, Woods RL, Thomas CJ, Vervaart P, Wilkinson JL, Robertson CF. Alveolar 
epithelial lining fluid cellularity, protein and endothelin-1 in children with congenital heart disease. 
Eur Respir J. 1996; 9(7): 1381-8. 
542. Dargaville PA, South M, Vervaart P, McDougall PN. Validity of markers of dilution in small 
volume lung lavage. Am J Respir Crit Care Med. 1999; 160(3): 778-84. 
543. Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra 
UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, 
Schoeman JF, Wilkinson RJ, Thwaites GE. Standardized Methods for Enhanced Quality and 
Comparability of Tuberculous Meningitis Studies. Clin Infect Dis. 2017; 64(4): 501-9. 
References 
Page 298 
544. Alffenaar JW, van Altena R, Bokkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, van der 
Werf TS. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with 
tuberculous meningitis. Clin Infect Dis. 2009; 49(7): 1080-2. 
545. van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, Peter J, Whitelaw A, 
Sharma SK, Warren R, Bateman ED, Dheda K. Comparison of quantitative techniques including Xpert 
MTB/RIF to evaluate mycobacterial burden. PLoS One. 2011; 6(12): e28815. 
546. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, Dawson R, Whitelaw A, 
Hoelscher M, Sharma S, Pai M, Warren R, Dheda K. Evaluation of the Xpert MTB/RIF assay for the 
diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 
2011; 184(1): 132-40. 
547. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, Nicol M, Jones M, 
Persing DH, Hillemann D, Ruesch-Gerdes S, Leisegang F, Zamudio C, Rodrigues C, Boehme CC, Perkins 
MD, Alland D. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am 
J Respir Crit Care Med. 2011; 184(9): 1076-84. 
548. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, 
Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, 
Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin 
resistance. N Engl J Med. 2010; 363(11): 1005-15. 
549. Beal SL. Ways to fit a PK model with some data below the quantification limit. J 
Pharmacokinet Pharmacodyn. 2001; 28(5): 481-504. 
550. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data 
below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008; 35(4): 401-
21. 
551. Cepheid. Xpert® MTB/RIF Assay. Sunnyvale, CA, USA: Cepheid; 2015. 
552. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 
Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 2010; 48(7): 
2495-501. 
553. Cornfield DB, Beavis KG, Greene JA, Bojak M, Bondi J. Mycobacterial growth and bacterial 
contamination in the Mycobacteria Growth Indicator Tube and BACTEC 460 culture systems. J Clin 
Microbiol. 1997; 35(8): 2068-71. 
554. Pfyffer GE, Welscher HM, Kissling P, Cieslak C, Casal MJ, Gutierrez J, Rüsch-Gerdes S. 
Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture 
for recovery of acid-fast bacilli. J Clin Microbiol. 1997; 35(2): 364-8. 
555. Peres RL, Palaci M, Loureiro RB, Dietze R, Johnson JL, Maciel EL. Reduction of contamination 
of mycobacterial growth indicator tubes using increased PANTA concentration. Int J Tuberc Lung Dis. 
2011; 15(2): 281-3, i. 
556. Tortoli E, Cichero P, Piersimoni C, Simonetti MT, Gesu G, Nista D. Use of BACTEC MGIT 960 
for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol. 1999; 
37(11): 3578-82. 
  References 
 
  Page 299 
557. Leitritz L, Schubert S, Bücherl B, Masch A, Heesemann J, Roggenkamp A. Evaluation of 
BACTEC MGIT 960 and BACTEC 460TB systems for recovery of mycobacteria from clinical specimens 
of a university hospital with low incidence of tuberculosis. J Clin Microbiol. 2001; 39(10): 3764-7. 
558. Burdz TV, Wolfe J, Kabani A. Evaluation of sputum decontamination methods for 
Mycobacterium tuberculosis using viable colony counts and flow cytometry. Diagn Microbiol Infect 
Dis. 2003; 47(3): 503-9. 
559. Chatterjee M, Bhattacharya S, Karak K, Dastidar SG. Effects of different methods of 
decontamination for successful cultivation of Mycobacterium tuberculosis. Indian J Med Res. 2013; 
138(4): 541-8. 
560. Donald PR, van Helden PD. Antituberculosis chemotherapy. Basel: Karger; 2011. 
561. McCarter YS, Ratkiewicz IN, Robinson A. Cord formation in BACTEC medium is a reliable, 
rapid method for presumptive identification of Mycobacterium tuberculosis complex. J Clin 
Microbiol. 1998; 36(9): 2769-71. 
562. Middlebrook G, Dubos RJ, Pierce C. Virulence and morphological characteristics of 
mammalian tubercle bacilli. J Exp Med. 1947; 86(2): 175-84. 
563. Abou-Zeid C, Harboe M, Rook GA. Characterization of the secreted antigens of 
Mycobacterium bovis BCG: comparison of the 46-kilodalton dimeric protein with proteins MPB64 
and MPB70. Infect Immun. 1987; 55(12): 3213-4. 
564. Harboe M, Nagai S, Patarroyo ME, Torres ML, Ramirez C, Cruz N. Properties of proteins 
MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun. 1986; 52(1): 293-302. 
565. Nagai S, Wiker HG, Harboe M, Kinomoto M. Isolation and partial characterization of major 
protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun. 1991; 59(1): 372-
82. 
566. Abe C, Hirano K, Tomiyama T. Simple and rapid identification of the Mycobacterium 
tuberculosis complex by immunochromatographic assay using anti-MPB64 monoclonal antibodies. J 
Clin Microbiol. 1999; 37(11): 3693-7. 
567. Hasegawa N, Miura T, Ishii K, Yamaguchi K, Lindner TH, Merritt S, Matthews JD, Siddiqi SH. 
New simple and rapid test for culture confirmation of Mycobacterium tuberculosis complex: a 
multicenter study. J Clin Microbiol. 2002; 40(3): 908-12. 
568. Giampaglia CM, Martins MC, Chimara E, Oliveira RS, de Oliveira Vieira GB, Marsico AG, 
Mello FC, de Souza Fonseca L, Kritski A, da Silva Telles MA. Differentiation of Mycobacterium 
tuberculosis from other mycobacteria with rho-nitrobenzoic acid using MGIT960. Int J Tuberc Lung 
Dis. 2007; 11(7): 803-7. 
569. Tsukamura M, Tsukamura S. Differentiation of mycobacterium tuberculosis and 
mycobacterium bovis by p-nitrobenzoic acid susceptibility. Tubercle. 1964; 45(1): 64-5. 
570. de Kantor IN, Kim SJ, Frieden T, Laszlo A, Luelmo F, Norval P, Rieder H, Valenzuela P, Weyer 
K. Laboratory services in tuberculosis control. Part III: Culture. Geneva: World Health Organization; 
1998. 
References 
Page 300 
571. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on 
antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic 
variability. Antimicrob Agents Chemother. 2010; 54(4): 1484-91. 
572. Grandjean L, Martin L, Gilman RH, Valencia T, Herrera B, Quino W, Ramos E, Rivero M, 
Montoya R, Escombe AR, Coleman D, Mitchison D, Evans CA. Tuberculosis diagnosis and multidrug 
resistance testing by direct sputum culture in selective broth without decontamination or 
centrifugation. J Clin Microbiol. 2008; 46(7): 2339-44. 
573. Peres RL, Maciel EL, Morais CG, Ribeiro FC, Vinhas SA, Pinheiro C, Dietze R, Johnson JL, 
Eisenach K, Palaci M. Comparison of two concentrations of NALC-NaOH for decontamination of 
sputum for mycobacterial culture. Int J Tuberc Lung Dis. 2009; 13(12): 1572-5. 
574. Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, 
Muzanye G, Mugerwa RD, Sturm AW. Evaluation of time to detection of Mycobacterium tuberculosis 
in broth culture as a determinant for end points in treatment trials. J Clin Microbiol. 2010; 48(12): 
4370-6. 
575. O'Shea MK, Koh GC, Munang M, Smith G, Banerjee A, Dedicoat M. Time-to-detection in 
culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study. Clin Infect Dis. 
2014; 59(2): 177-85. 
576. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, 
Horter L, Boom WH, Johnson JL, Eisenach KD. Cavitary disease and quantitative sputum bacillary load 
in cases of pulmonary tuberculosis. J Clin Microbiol. 2007; 45(12): 4064-6. 
577. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965; 
92(5): 687-703. 
578. Zierski M, Bek E, Long MW, Snider DE, Jr. Short-course (6 month) cooperative tuberculosis 
study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980; 122(6): 
879-89. 
579. Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, Roholl P, Arend SM, Van 
Soolingen D. Correlation of virulence, lung pathology, bacterial load and delayed type 
hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a 
BALB/c mouse model. Clin Exp Immunol. 2004; 137(3): 460-8. 
580. Hr S, Mc L, Td M, He J. Isoniazid resistant tuberculosis- a cause for concern? Int J Tuberc 
Lung Dis. 2017; 21(2): 129-39. 
581. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, 
Moosa M-YS, Sterling TR, Pym AS. Isoniazid mono-resistant tuberculosis is associated with poor 
treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis. 2017; 21(6): 670-6. 
582. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, Lienhardt C. 
Standardized treatment of active tuberculosis in patients with previous treatment and/or with 
mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009; 6(9): 
e1000150. 
  References 
 
  Page 301 
583. Beynon F, Theron G, Respeito D, Mambuque E, Saavedra B, Bulo H, Sanz S, Dheda K, Garcia-
Basteiro AL. Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis 
bacillary burden in high HIV burden areas of Southern Africa. Sci Rep. 2018; 8(1): 5201. 
584. Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, 
Dodd LE, Via LE, Barry CE, 3rd, Walzl G, Alland D. Bacterial loads measured by the Xpert MTB/RIF 
assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One. 2016; 
11(8): e0160062. 
585. Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, 
Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P. Xpert MTB/RIF 
assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine 
exposure. J Clin Microbiol. 2016; 54(12): 3028-33. 
586. Devonshire AS, O’Sullivan DM, Honeyborne I, Jones G, Karczmarczyk M, Pavšič J, Gutteridge 
A, Milavec M, Mendoza P, Schimmel H, Van Heuverswyn F, Gorton R, Cirillo DM, Borroni E, Harris K, 
Barnard M, Heydenrych A, Ndusilo N, Wallis CL, Pillay K, Barry T, Reddington K, Richter E, Mozioğlu E, 
Akyürek S, Yalçınkaya B, Akgoz M, Žel J, Foy CA, McHugh TD, Huggett JF. The use of digital PCR to 
improve the application of quantitative molecular diagnostic methods for tuberculosis. BMC Infect 
Dis. 2016; 16: 366. 
587. World Health Organization. Xpert MTB/RIF implementation manual: technical and 
operational ‘how-to’; practical considerations. Geneva2014. 
588. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, Lennon-Dumenil AM, 
Seabra MC, Raposo G, Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing 
during crosspresentation by dendritic cells. Cell. 2006; 126(1): 205-18. 
589. Kugathasan K, Roediger EK, Small C-L, McCormick S, Yang P, Xing Z. CD11c+ antigen 
presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and 
capabilities to activate naïve and antigen-primed T cells. BMC Immunology. 2008; 9: 48-. 
590. Lennon-Dumenil AM, Bakker AH, Maehr R, Fiebiger E, Overkleeft HS, Rosemblatt M, Ploegh 
HL, Lagaudriere-Gesbert C. Analysis of protease activity in live antigen-presenting cells shows 
regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med. 2002; 
196(4): 529-40. 
591. Jambo KC, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ, Gordon SB, 
Heyderman RS, Russell DG, Mwandumba HC. Asymptomatic HIV-infected individuals on 
antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria. Am J Respir Crit 
Care Med. 2014; 190(8): 938-47. 
592. Marti-Lliteras P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, Agusti AG, Bengoechea 
JA, Garmendia J. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is 
impaired by exposure to cigarette smoke. Infect Immun. 2009; 77(10): 4232-42. 
593. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for 
interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993; 178(6): 
2249-54. 
References 
Page 302 
594. Green AM, Difazio R, Flynn JL. IFN-gamma from CD4 T cells is essential for host survival and 
enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol. 2013; 190(1): 
270-7. 
595. Carranza C, Juarez E, Torres M, Ellner JJ, Sada E, Schwander SK. Mycobacterium tuberculosis 
growth control by lung macrophages and CD8 cells from patient contacts. Am J Respir Crit Care Med. 
2006; 173(2): 238-45. 
596. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated 
tuberculosis in interferon gamma gene-disrupted mice. J Exp Med. 1993; 178(6): 2243-7. 
597. Mzinza DT, Sloan DJ, Jambo KC, Shani D, Kamdolozi M, Wilkinson KA, Wilkinson RJ, Davies 
GR, Heyderman RS, Mwandumba HC. Kinetics of Mycobacterium tuberculosis-specific IFN-γ 
responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary 
tuberculosis. Tuberculosis (Edinburgh, Scotland). 2015; 95(4): 463-9. 
598. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal 
activity by blocking the endogenous production of tumor necrosis factor alpha required as a 
costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A. 1992; 
89(18): 8676-80. 
599. Cunha FQ, Moncada S, Liew FY. Interleukin-10 (IL-10) inhibits the induction of nitric oxide 
synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun. 1992; 
182(3): 1155-9. 
600. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by gamma 
interferon, interleukin-4, and tumor necrosis factor. Infect Immun. 1990; 58(8): 2675-7. 
601. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis 
factor in the development of bactericidal granulomas during BCG infection. Cell. 1989; 56(5): 731-40. 
602. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, 
Bloom BR. Tumor necrosis factor-alpha is required in the protective immune response against 
Mycobacterium tuberculosis in mice. Immunity. 1995; 2(6): 561-72. 
603. Bean AGD, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural 
deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened 
susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by 
lymphotoxin. The Journal of Immunology. 1999; 162(6): 3504-11. 
604. Waitt CJ, Peter K. Banda N, White SA, Kampmann B, Kumwenda J, Heyderman RS, 
Pirmohamed M, Squire SB. Early deaths during tuberculosis treatment are associated with depressed 
innate responses, bacterial infection, and tuberculosis progression. J Infect Dis. 2011; 204(3): 358-62. 
605. Lee WL, Harrison RE, Grinstein S. Phagocytosis by neutrophils. Microbes Infect. 2003; 5(14): 
1299-306. 
606. Oh YK, Straubinger RM. Intracellular fate of Mycobacterium avium: use of dual-label 
spectrofluorometry to investigate the influence of bacterial viability and opsonization on 
phagosomal pH and phagosome-lysosome interaction. Infect Immun. 1996; 64(1): 319-25. 
  References 
 
  Page 303 
607. Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas V, 
Palfrey HC, Nelson DJ. CFTR regulates phagosome acidification in macrophages and alters 
bactericidal activity. Nat Cell Biol. 2006; 8(9): 933-44. 
608. Mc DW, Ormond L, Muschenheim C, Deuschle K, Mc CR, Jr., Tompsett R. Pyrazinamide-
isoniazid in tuberculosis. Am Rev Tuberc. 1954; 69(3): 319-33. 
609. Hong BY, Maulen NP, Adami AJ, Granados H, Balcells ME, Cervantes J. Microbiome changes 
during tuberculosis and antituberculous therapy. Clin Microbiol Rev. 2016; 29(4): 915-26. 
610. Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A, O'Garra A. 
Influenza A Virus impairs control of Mycobacterium tuberculosis coinfection through a type I 
interferon receptor–dependent pathway. J Infect Dis. 2014; 209(2): 270-4. 
611. Rayamajhi M, Humann J, Penheiter K, Andreasen K, Lenz LL. Induction of IFN-alphabeta 
enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma. J Exp Med. 2010; 
207(2): 327-37. 
612. Lin GM, Chang FY, Chou CH, Lin YP, Ku CH. Characteristics and outcome of patients with 
dual pulmonary tuberculosis and non-mycobacterial respiratory infections. J Clin Med Res. 2011; 
3(6): 309-18. 
613. Cui Z, Zhou Y, Li H, Zhang Y, Zhang S, Tang S, Guo X. Complex sputum microbial composition 
in patients with pulmonary tuberculosis. BMC Microbiol. 2012; 12: 276. 
614. Cheung MK, Lam WY, Fung WY, Law PT, Au CH, Nong W, Kam KM, Kwan HS, Tsui SK. Sputum 
microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing. PLoS One. 2013; 8(1): e54574. 
615. Podinovskaia M, VanderVen BC, Yates RM, Glennie S, Fullerton D, Mwandumba HC, Russell 
DG. Dynamic quantitative assays of phagosomal function. Curr Protoc Immunol. 2013; 102: Unit 14 
34. 
616. Garcia-Knight MA, Nduati E, Hassan AS, Gambo F, Odera D, Etyang TJ, Hajj NJ, Berkley JA, 
Urban BC, Rowland-Jones SL. Altered memory T-cell responses to Bacillus Calmette-Guerin and 
tetanus toxoid vaccination and altered cytokine responses to polyclonal stimulation in HIV-exposed 
uninfected Kenyan infants. PLoS One. 2015; 10(11): e0143043. 
617. Molecular Probes. pHrodo™ phagocytosis particle labeling kit for flow cytometry. Eugene, 
Oregon, USA: Molecular Probes, Inc.; 2007. 
618. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: 
From bench to bedside. Respirology (Carlton, Vic). 2010; 15(3): 433-50. 
619. Robinson DS, Ying S, Taylor IK, Wangoo A, Mitchell DM, Kay AB, Hamid Q, Shaw RJ. Evidence 
for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation 
in pulmonary tuberculosis. Am J Respir Crit Care Med. 1994; 149(4 Pt 1): 989-93. 
620. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, 
Van Helden PD, Walzl G, Dockrell HM. Distinct phases of blood gene expression pattern through 
tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis. 2013; 
207(1): 18-29. 
References 
Page 304 
621. Knox KS, Vinton C, Hage CA, Kohli LM, Twigg HL, 3rd, Klatt NR, Zwickl B, Waltz J, Goldman M, 
Douek DC, Brenchley JM. Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation 
of highly active antiretroviral therapy. J Virol. 2010; 84(18): 9010-8. 
622. Twigg HL, Soliman DM, Day RB, Knox KS, Anderson RJ, Wilkes DS, Schnizlein-Bick CT. 
Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency 
virus infection. Am J Respir Crit Care Med. 1999; 159(5 Pt 1): 1439-44. 
623. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: 93-129. 
624. Ladel CH, Szalay G, Riedel D, Kaufmann SH. Interleukin-12 secretion by Mycobacterium 
tuberculosis-infected macrophages. Infect Immun. 1997; 65(5): 1936-8. 
625. Michlewska S, Dransfield I, Megson IL, Rossi AG. Macrophage phagocytosis of apoptotic 
neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory 
agents: key role for TNF-alpha. Faseb j. 2009; 23(3): 844-54. 
626. Corradin SB, Buchmuller-Rouiller Y, Smith J, Suardet L, Mauel J. Transforming growth factor 
beta 1 regulation of macrophage activation depends on the triggering stimulus. J Leukoc Biol. 1993; 
54(5): 423-9. 
627. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, 
Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential 
role in the regulation of T cell growth. J Exp Med. 1986; 163(5): 1037-50. 
628. Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, Doo H, Geng J, Rego L, 
Lazzarini LC, Kritski AL, Johnson WD, Jr., McCaffrey TA, Silva JR. Down-modulation of lung immune 
responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta 
receptors I and II in active tuberculosis. Infect Immun. 2004; 72(5): 2628-34. 
629. Jambo KC, Tembo DL, Kamng'ona AW, Musicha P, Banda DH, Kankwatira AM, Malamba RD, 
Allain TJ, Heyderman RS, Russell DG, Mwandumba HC. HIV-associated disruption of lung cytokine 
networks is incompletely restored in asymptomatic HIV-infected Malawian adults on antiretroviral 
therapy. ERJ Open Res. 2017; 3(4). 
630. Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. 
Mucosal Immunol. 2011; 4(3): 288-93. 
631. Díaz A, Santucci N, Bongiovanni B, D'Attilio L, Massoni C, Lioi S, Radcliffe S, Dídoli G, 
Bottasso O, Bay ML. Increased frequency of CD4+ CD25+ FoxP3+ T regulatory cells in pulmonary 
tuberculosis patients undergoing specific treatment and its relationship with their immune-
endocrine profile. Journal of Immunology Research. 2015; 2015: 985302. 
632. Neff CP, Chain JL, MaWhinney S, Martin AK, Linderman DJ, Flores SC, Campbell TB, Palmer 
BE, Fontenot AP. Lymphocytic alveolitis is associated with the accumulation of functionally impaired 
HIV-specific T cells in the lung of antiretroviral therapy-naive subjects. Am J Respir Crit Care Med. 
2015; 191(4): 464-73. 
633. Namasivayam S, Maiga M, Yuan W, Thovarai V, Costa DL, Mittereder LR, Wipperman MF, 
Glickman MS, Dzutsev A, Trinchieri G, Sher A. Longitudinal profiling reveals a persistent intestinal 
dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome. 2017; 5: 71. 
  References 
 
  Page 305 
634. Wu J, Liu W, He L, Huang F, Chen J, Cui P, Shen Y, Zhao J, Wang W, Zhang Y, Zhu M, Zhang 
W, Zhang Y. Sputum microbiota associated with new, recurrent and treatment failure tuberculosis. 
PLoS One. 2013; 8(12): e83445. 
635. Arora AA, Krishnaswamy UM, Moideen RP, Padmaja MS. Tubercular and bacterial 
coinfection: A case series. Lung India : Official Organ of Indian Chest Society. 2015; 32(2): 172-4. 
636. Shimazaki T, Taniguchi T, Saludar NRD, Gustilo LM, Kato T, Furumoto A, Kato K, Saito N, Go 
WS, Tria ES, Salva EP, Dimaano EM, Parry C, Ariyoshi K, Villarama JB, Suzuki M. Bacterial co-infection 
and early mortality among pulmonary tuberculosis patients in Manila, The Philippines. Int J Tuberc 
Lung Dis. 2018; 22(1): 65-72. 
637. Dangor Z, Izu A, Moore DP, Nunes MC, Solomon F, Beylis N, von Gottberg A, McAnerney JM, 
Madhi SA. Temporal association in hospitalizations for tuberculosis, invasive pneumococcal disease 
and influenza virus illness in South African children. PLoS One. 2014; 9(3): e91464. 
638. Moore DP, Klugman KP, Madhi SA. Role of Streptococcus pneumoniae in hospitalization for 
acute community-acquired pneumonia associated with culture-confirmed Mycobacterium 
tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J. 2010; 
29(12): 1099-104. 
639. Walaza S, Tempia S, Dreyer A, Dawood H, Variava E, Martinson NA, Moyes J, Cohen AL, 
Wolter N, von Mollendorf C, von Gottberg A, Haffejee S, Treurnicht F, Hellferscee O, Ismail N, Cohen 
C. The burden and clinical presentation of pulmonary tuberculosis in adults with severe respiratory 
illness in a high Human Immunodeficiency Virus prevalence setting, 2012-2014. Open Forum Infect 
Dis. 2017; 4(3): ofx116. 
640. Guillon JM, Autran B, Denis M, Fouret P, Plata F, Mayaud CM, Akoun GM. Human 
Immunodeficiency Virus-related lymphocytic alveolitis. Chest. 1988; 94(6): 1264-70. 
641. Autran B, Mayaud CM, Raphael M, Plata F, Denis M, Bourguin A, Guillon JM, Debre P, Akoun 
G. Evidence for a cytotoxic T-lymphocyte alveolitis in human immunodeficiency virus-infected 
patients. AIDS. 1988; 2(3): 179-83. 
642. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, Roth MD. Regional 
differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in 
dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004; 50(6): 1909-17. 
643. Garcia JG, Wolven RG, Garcia PL, Keogh BA. Assessment of interlobar variation of 
bronchoalveolar lavage cellular differentials in interstitial lung diseases. Am Rev Respir Dis. 1986; 
133(3): 444-9. 
644. Peterson MW, Nugent KM, Jolles H, Monick M, Hunninghake GW. Uniformity of 
bronchoalveolar lavage in patients with pulmonary sarcoidosis. Am Rev Respir Dis. 1988; 137(1): 79-
84. 
645. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, Oni T, Warwick JM, 
Said-Hartley Q, Koegelenberg CF, Walzl G, Flynn JL, Young DB, Barry CE, O’Garra A, Wilkinson RJ. 
Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[(18)F]fluoro-D-glucose 
positron emission and computed tomography. Nat Med. 2016; 22(10): 1090-3. 
References 
Page 306 
646. Lee KS, Im JG. CT in adults with tuberculosis of the chest: characteristic findings and role in 
management. AJR Am J Roentgenol. 1995; 164(6): 1361-7. 
647. Ministry of Health Malawi. National Tuberculosis Control Programme Manual 6th Edition. 
2007. 
648. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of 
tuberculosis. BMC Public Health. 2008; 8(1): 15. 
649. Prasad A, Ross A, Rosenberg P, Dye C. A world of cities and the end of TB. Trans R Soc Trop 
Med Hyg. 2016; 110(3): 151-2. 
650. Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the 
Sustainable Development Goals. Trans R Soc Trop Med Hyg. 2016; 110(3): 148-50. 
651. Gilbertoni-Cruz A, Fowler P. Decrypting drug resistance in tuberculosis around the world 
with CRyPTIC. Phenotype. 2016; (24): 20-1. 
652. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher 
K, Wright L, van Helden PD, Walzl G, Gillespie SH. Molecular bacterial load assay, a culture-free 
biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary 
load during treatment. J Clin Microbiol. 2011; 49(11): 3905-11. 
653. Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, 
Rojas-Ponce G, McHugh TD, Heinrich N, Pan African Consortium for the Evaluation of Anti-
tuberculosis A. The molecular bacterial load assay replaces solid culture for measuring early 
bactericidal response to antituberculosis treatment. J Clin Microbiol. 2014; 52(8): 3064-7. 
654. Gillespie SH, Sabiiti W, Oravcova K. Mycobacterial Load Assay. In: Bishop-Lilly KA, editor. 
Diagnostic Bacteriology: Methods and Protocols. New York, NY: Springer New York; 2017. p. 89-105. 
655. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc Res 
Treat. 2011; 2011: 798764. 
 
 
  Appendices 
 
  Page 307 
10 Appendices 
Appendix A: Informed consent form 
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Appendix B: Bronchoscopy informed consent form 
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Appendix C: COMREC approval certificate 
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Appendix D: LSTM REC approval letter 
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Appendix E: Rifampicin plasma NONMEM control stream 
 
$PROBLEM RIFAMPICIN PLASMA 
 
$INPUT ID TIME PTIME DV DOSE AMT MGKG SS II MDV EVID CMT WT HT BMI AGE SEX HIV CRCL 
OCC DSET 
$DATA RIFAMPICIN.csv IGNORE=# 
 
$ESTIMATION METHOD=1 INTER MAXEVALS=9999 SIG=3 PRINT=1 POSTHOC NOABORT 
NOTHETABOUNDTEST NOOMEGABOUNDTEST NOSIGMABOUNDTEST 
 
$COVARIANCE UNCONDITIONAL 
 
$TABLE NOPRINT ONEHEADER ID TIME TVCL TVV CL V KA K AUC CMAX TMAX ETA1 ETA2 ETA3 ETA4 
ETA5 ETA6 ETA7 ETA8 ETA9 IPRED IRES IWRES CWRES Y FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 
FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 
Y DV PRED RES WRES IPRED IWRES MDV FILE=xptab 
$TABLE ID WT HT BMI AGE CRCL NOPRINT NOAPPEND ONEHEADER FILE=cotab 
$TABLE ID SEX HIV NOPRINT NOAPPEND ONEHEADER FILE=catab 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
BSVCL=ETA(1) ; BSV for CL 
BSVV=ETA(2) ; BSV for V 
BSVKA=ETA(3) ; BSV for Ka 
 
IF(OCC.EQ.1)THEN 
WSVCL=ETA(4) ; WSV for CL on visit 1 
WSVV=ETA(6) ; WSV for V on visit 1 
WSVKA=ETA(8) ; WSV for KA on visit 1 
ENDIF 
 
IF(OCC.EQ.2)THEN 
WSVCL=ETA(5) ; WSV for CL on visit 2 
WSVV=ETA(7) ; WSV for V on visit 2 
WSVKA=ETA(9) ; WSV for KA on visit 2 
ENDIF 
 
TVCL=THETA(1)*THETA(4)**SEX 
TVV=THETA(2)*THETA(5)**HIV 
TVKA=THETA(3)  
 
CL=TVCL*EXP(BSVCL+WSVCL)  
V=TVV*EXP(BSVV+WSVV) 
KA=TVKA*EXP(BSVKA+WSVKA) 
 
S2=V 
F1=1 
K=CL/V 
 
AUC=DOSE*F1/CL 
TMAX = LOG(KA/K)/(KA-K) 
CMAX=((KA*DOSE)/(V*(KA-K)))*(EXP(-K*TMAX)-EXP(-KA*TMAX)) 
 
$THETA 
(0, 15) ; CL 
(0, 25) ; V 
(0, 0.2) ; Ka 
(0,1) ; Covariate effect for sex 
(0,1.3) ; Covariate effect for HIV 
  
$OMEGA 
0.03 ; IIV CL 
0.4 ; IIV V 
0 FIX ; IIV Ka 
$OMEGA BLOCK(1) 0.1 ; IOV CL OCC 1 
$OMEGA BLOCK(1) SAME ; IOV CL OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV V OCC 1 
$OMEGA BLOCK(1) SAME ; IOV V OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV Ka OCC 1 
$OMEGA BLOCK(1) SAME ; IOV Ka OCC 2 
 
$SIGMA   
0.05 ; EPS(1) Proportional 
 
$ERROR          
IPRED=F 
W=F         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*EXP(EPS(1)) 
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Appendix F: Isoniazid plasma NONMEM control stream 
 
$PROBLEM ISONIAZID PLASMA 
 
$INPUT ID TIME PTIME DV DOSE AMT MGKG SS II MDV EVID CMT WT HT BMI AGE SEX HIV CRCL 
OCC DSET 
$DATA ISONIAZID.csv IGNORE=# 
 
$ESTIMATION METHOD=1 INTER MAXEVALS=9999 SIG=3 PRINT=1 POSTHOC NOABORT 
NOTHETABOUNDTEST NOOMEGABOUNDTEST NOSIGMABOUNDTEST 
 
$COVARIANCE UNCONDITIONAL 
 
$TABLE NOPRINT ONEHEADER ID TIME TVCL TVV CL V KA K AUC CMAX TMAX ETA1 ETA2 ETA3 ETA4 
ETA5 ETA6 ETA7 ETA8 ETA9 IPRED IRES IWRES CWRES Y FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 
FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 
Y DV PRED RES WRES IPRED IWRES MDV FILE=xptab 
$TABLE ID WT HT BMI AGE CRCL NOPRINT NOAPPEND ONEHEADER FILE=cotab 
$TABLE ID SEX HIV NOPRINT NOAPPEND ONEHEADER FILE=catab 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
BSVCL=ETA(1) ; BSV for CL 
BSVV=ETA(2) ; BSV for V 
BSVKA=ETA(3) ; BSV for Ka 
 
IF(OCC.EQ.1)THEN 
WSVCL=ETA(4) ; WSV for CL on visit 1 
WSVV=ETA(6) ; WSV for V on visit 1 
WSVKA=ETA(8) ; WSV for KA on visit 1 
ENDIF 
 
IF(OCC.EQ.2)THEN 
WSVCL=ETA(5) ; WSV for CL on visit 2 
WSVV=ETA(7) ; WSV for V on visit 2 
WSVKA=ETA(9) ; WSV for KA on visit 2 
ENDIF 
 
TVCL=THETA(1) 
TVV=THETA(2)+THETA(4)*(WT-51.05) ; V, WT, CENT LINEAR ADD 
TVKA=THETA(3)  
 
CL=TVCL*EXP(BSVCL+WSVCL)  
V=TVV*EXP(BSVV+WSVV) 
KA=TVKA*EXP(BSVKA+WSVKA) 
 
S2=V 
F1=1 
K=CL/V 
 
AUC=DOSE*F1/CL 
TMAX = LOG(KA/K)/(KA-K) 
CMAX=((KA*DOSE)/(V*(KA-K)))*(EXP(-K*TMAX)-EXP(-KA*TMAX)) 
 
$THETA 
(0, 14) ; CL 
(0, 75) ; V 
(0, 2.5) ; Ka 
(1.1) ; Covariate effect for weight 
 
$OMEGA 
0.3 ; IIV CL 
0.09 ; IIV V 
0 FIX ; IIV Ka 
$OMEGA BLOCK(1) 0 FIX ; IOV CL OCC 1 
$OMEGA BLOCK(1) SAME ; IOV CL OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV V OCC 1 
$OMEGA BLOCK(1) SAME ; IOV V OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV Ka OCC 1 
$OMEGA BLOCK(1) SAME ; IOV Ka OCC 2 
 
$SIGMA   
0.05 ; EPS(1) Proportional 
 
$ERROR          
IPRED=F 
W=F         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*EXP(EPS(1))   
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Appendix G: Pyrazinamide plasma NONMEM control stream 
 
$PROBLEM PYRAZINAMIDE PLASMA 
 
$INPUT ID TIME PTIME DV DOSE AMT MGKG SS II MDV EVID CMT WT HT BMI AGE SEX HIV CRCL 
OCC DSET 
$DATA PYRAZINAMIDE.csv IGNORE=# 
 
$ESTIMATION METHOD=1 INTER MAXEVALS=9999 SIG=3 PRINT=1 POSTHOC NOABORT 
NOTHETABOUNDTEST NOOMEGABOUNDTEST NOSIGMABOUNDTEST 
 
$COVARIANCE UNCONDITIONAL 
 
$TABLE NOPRINT ONEHEADER ID TIME TVCL TVV CL V KA K AUC TMAX CMAX ETA1 ETA2 ETA3 
IPRED IRES IWRES CWRES Y FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 Y DV PRED RES WRES IPRED 
IWRES MDV FILE=xptab 
$TABLE ID WT HT BMI AGE CRCL NOPRINT NOAPPEND ONEHEADER FILE=cotab 
$TABLE ID SEX HIV NOPRINT NOAPPEND ONEHEADER FILE=catab 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK  
TVCL=THETA(1)*(WT/51.05)**0.75 ; CL, WT, CENT ALLOMETRIC POWER 
TVV=THETA(2)*(WT/51.05)**0.75 ; V, WT, CENT ALLOMETRIC POWER 
TVKA = THETA(3)  
 
CL=TVCL * EXP(ETA(1)) 
V=TVV * EXP(ETA(2)) 
KA=TVKA *EXP(ETA(3)) 
 
K=CL/V 
S2=V 
F1=1 
 
IF (AMT.GT.0) AUC=AMT*F1/CL 
TMAX = LOG(KA/K)/(KA-K) 
CMAX=((KA*DOSE)/(V*(KA-K)))*(EXP(-K*TMAX)-EXP(-KA*TMAX)) 
 
$THETA   
(0,3.6) ; CL 
(0,42) ; V 
(0,1) ; Ka 
 
$OMEGA   
0.18  ; ETA(1) IIV CL 
0.02  ; ETA(2) IIV V 
0.4  ; ETA(3) IIV KA 
 
$SIGMA  0.05  ; EPS(1) Proportional 
 
$ERROR           
IPRED=F 
W=F         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*(1+EPS(1)) 
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Appendix H: Ethambutol plasma NONMEM control stream 
 
$PROBLEM ETHAMBUTOL PLASMA 
 
$INPUT ID TIME PTIME DV DOSE AMT MGKG SS II MDV EVID CMT WT HT BMI AGE SEX HIV CRCL 
OCC DSET 
$DATA ETHAMBUTOL.csv IGNORE=# 
 
$ESTIMATION METHOD=1 INTER MAXEVALS=9999 SIG=3 PRINT=1 POSTHOC NOABORT 
NOTHETABOUNDTEST NOOMEGABOUNDTEST NOSIGMABOUNDTEST 
 
$COVARIANCE UNCONDITIONAL 
 
$TABLE NOPRINT ONEHEADER ID TIME TVCL TVV CL V KA K AUC CMAX TMAX ETA1 ETA2 ETA3 
IPRED IRES IWRES CWRES Y FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA ETA1 ETA2 ETA3 Y DV PRED RES WRES IPRED 
IWRES MDV FILE=xptab 
$TABLE ID WT HT BMI AGE CRCL NOPRINT NOAPPEND ONEHEADER FILE=cotab 
$TABLE ID SEX HIV NOPRINT NOAPPEND ONEHEADER FILE=catab 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
TVCL=THETA(1)+THETA(4)*(CRCL-108.7) ; CL, CRCL, CENT LINEAR ADD 
TVV=THETA(2) 
TVKA = THETA(3)  
 
CL=TVCL * EXP(ETA(1)) 
V=TVV * EXP(ETA(2)) 
KA=TVKA *EXP(ETA(3)) 
 
K=CL/V 
S2=V 
F1=1 
 
IF (AMT.GT.0) AUC=AMT*F1/CL 
TMAX = LOG(KA/K)/(KA-K) 
CMAX=((KA*DOSE)/(V*(KA-K)))*(EXP(-K*TMAX)-EXP(-KA*TMAX)) 
 
$THETA   
(0,42) ; CL 
(0,400) ; V 
(0,0.3) ; Ka 
(0,0.1) ; Covariate effect for creatinine clearance 
 
$OMEGA BLOCK(2) 0.1 0.1, 0.1 
$OMEGA 0.4 
 
$SIGMA   
0.1 ; EPS(1) Proportional 
 
$ERROR          
IPRED=F 
W=F         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*(1+EPS(1))  
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Appendix I: Rifampicin intrapulmonary NONMEM control stream 
 
$PROBLEM RIFAMPICIN INTRAPULMONARY: 1-CMT, CONSTANT RATIO 
 
$INPUT ID TIME PTIME DV DOSE AMT MGKG SS II MDV EVID CMT CMTLUN WT HT BMI AGE SEX HIV 
CRCL OCC DSET 
$DATA RIFAMPICIN_IPPK_ELF_AND_AC_CMT.csv IGNORE=# 
 
$ESTIMATION METHOD=1 INTER MAXEVALS=9999 SIG=3 PRINT=1 POSTHOC NOABORT 
NOTHETABOUNDTEST NOOMEGABOUNDTEST NOSIGMABOUNDTEST 
 
$COVARIANCE UNCONDITIONAL 
 
$TABLE NOPRINT ONEHEADER ID TIME TVCL TVV CL V KA K RELF RAM AUC CMAX TMAX CMT CMTLUN 
ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 IPRED IRES IWRES CWRES Y FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA RELF RAM ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 
ETA8 ETA9 FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME CL V KA RELF RAM ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 
ETA8 ETA9 Y DV PRED RES WRES IPRED IWRES MDV FILE=xptab 
$TABLE ID WT HT BMI AGE CRCL NOPRINT NOAPPEND ONEHEADER FILE=cotab 
$TABLE ID SEX HIV NOPRINT NOAPPEND ONEHEADER FILE=catab 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
BSVCL=ETA(1) ; BSV for CL 
BSVV=ETA(2) ; BSV for V 
BSVKA=ETA(3) ; BSV for Ka 
 
IF(OCC.EQ.1)THEN 
WSVCL=ETA(4) ; WSV for CL on visit 1 
WSVV=ETA(6) ; WSV for V on visit 1 
WSVKA=ETA(8) ; WSV for KA on visit 1 
ENDIF 
 
IF(OCC.EQ.2)THEN 
WSVCL=ETA(5) ; WSV for CL on visit 2 
WSVV=ETA(7) ; WSV for V on visit 2 
WSVKA=ETA(9) ; WSV for KA on visit 2 
ENDIF 
 
TVCL=THETA(1)*THETA(4)**SEX 
TVV=THETA(2)*THETA(5)**HIV 
TVKA=THETA(3)  
 
CL=TVCL*EXP(BSVCL+WSVCL)  
V=TVV*EXP(BSVV+WSVV) 
KA=TVKA*EXP(BSVKA+WSVKA) 
 
S2=V 
F1=1 
K=CL/V 
 
RELF=THETA(6) ; ELF:PLASMA ratio 
RAM=THETA(7) ; AC:PLASMA ratio 
 
AUC=DOSE*F1/CL 
TMAX = LOG(KA/K)/(KA-K) 
CMAX=((KA*DOSE)/(V*(KA-K)))*(EXP(-K*TMAX)-EXP(-KA*TMAX)) 
 
$ERROR          
IF(CMTLUN.EQ.2) THEN 
IPRED=F 
W=F         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*EXP(THETA(8)*EPS(1)) ; exponential error model   
ENDIF  
 
IF(CMTLUN.EQ.3) THEN 
IPRED=F*RELF 
W=IPRED         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*RELF*EXP(THETA(9)*EPS(2)) ; exponential error model 
ENDIF  
 
IF(CMTLUN.EQ.4) THEN 
IPRED=F* 
W=IPRED         
IRES=DV-IPRED 
IWRES=IRES/W 
Y=F*RAM*EXP(THETA(10)*EPS(3)) ; exponential error model 
ENDIF  
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$THETA 
(0, 15) ; CL 
(0, 25) ; V 
(0, 0.2) ; Ka 
(0,1) ; Covariate effect for sex 
(0,1.3) ; Covariate effect for HIV 
(0,2.2) ; ELF:PLASMA ratio 
(0,2.7) ; AC:PLASMA ratio 
(0.4) ; plasma residual error as scaling factor 
(0.4) ; ELF residual error  
(0.4) ; AC residual error  
 
$OMEGA 
0.03 ; IIV CL 
0.4 ; IIV V 
0 FIX ; IIV Ka 
$OMEGA BLOCK(1) 0.1 ; IOV CL OCC 1 
$OMEGA BLOCK(1) SAME ; IOV CL OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV V OCC 1 
$OMEGA BLOCK(1) SAME ; IOV V OCC 2 
$OMEGA BLOCK(1) 0 FIX ; IOV Ka OCC 1 
$OMEGA BLOCK(1) SAME ; IOV Ka OCC 2 
 
$SIGMA   
1 FIX ; EPS(1) 
1 FIX ; EPS(2) 
1 FIX ; EPS(3) 
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Appendix J: Pharmacodynamics NONMEM control stream 
 
$PROB M3 METHOD LOG 1/TTP DATA 
 
$DATA INV_TTP_PLM.csv IGNORE=#  
$INPUT C ID TIME TTP DV=INVTTP LOGTTP MDV FLG CONT  
 
$ESTIM METHOD=COND INTER LAPLACIAN MAXEVAL=9999 NOTHETABOUNDTEST NOOMEGABOUNDTEST 
NOSIGMABOUNDTEST 
 
$COVARIANCE 
 
$TABLE NOPRINT ONEHEADER ID TIME Y DV PRED IPRED RES WRES CWRES RPA RPAM HPA HPAM ZPA 
EPA EPAM RPC RPCM HPC HPCM ZPC EPC EPCM FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME A ALPHA ETA1 ETA2 RPA RPAM HPA HPAM ZPA EPA EPAM RPC 
RPCM HPC HPCM ZPC EPC EPCM FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME A ALPHA ETA1 ETA2 Y DV PRED RES WRES IPRED CWRES MDV 
FILE=xptab 
 
$PRED 
TVA=THETA(1)    ;Typical value for intercept 
A=TVA*EXP(ETA(1))    ;IIV on intercept 
 
TVALPHA=THETA(2)   ;Typical value for slope 
ALPHA=(TVALPHA*EXP(ETA(2)))  ;IIV on slope 
  
F=(A*10**(ALPHA*TIME))     
SIG1=THETA(3)*F    ;SD using proportional residual error 
LOQ=0.0233    ;1/43days 
IPRED=F  
  
IF (FLG.EQ.0) THEN 
F_FLAG=0 
Y=F+(SIG1*ERR(1)) 
ELSE     
F_FLAG=1 
DUM=(LOQ-IPRED)/SIG1    
CUMD=PHI(DUM)    
Y=CUMD 
ENDIF 
 
$THETA  
(0.13)      ; fixed effects for intercept (A) 
(-0.01)      ; fixed effects for slope (alpha)  
(0.5)      ; SD / SIG1 
 
$OMEGA 0.2     ; random effect on intercept 
$OMEGA 0.4     ; random effect on slope 
 
$SIGMA 1 FIXED 
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Appendix K: PK-PD NONMEM control stream 
 
$PROB SPITT TTP DATA M3 METHOD ADDITIVE ERROR 
 
$INPUT C ID TIME TTP DV=INVTTP LOGTTP MDV FLG CONT CXR DSET REA  
 
$DATA TTP_PLM_ALL.csv IGNORE=# IGNORE(DSET.EQ.2) ; 
$ESTIM METHOD=COND INTER LAPLACIAN MAXEVAL=9999 NOTHETABOUNDTEST NOOMEGABOUNDTEST 
NOSIGMABOUNDTEST 
 
$TABLE NOPRINT ONEHEADER ID TIME Y DV PRED IPRED RES WRES CWRES CXR REA FILE=sdtab 
$TABLE NOPRINT ONEHEADER ID TIME A ALPHA ETA1 ETA2 CXR REA FILE=patab 
$TABLE NOPRINT ONEHEADER ID TIME A ALPHA ETA1 ETA2 Y DV PRED RES WRES IPRED CWRES MDV 
CXR REA FILE=xptab  
 
$COVARIANCE 
 
$PRED 
TVA=THETA(1)+(THETA(2)*(CXR/33.4)) ;Typical value for intercept with CXR covariate 
A=TVA*EXP(ETA(1))    ;IIV on intercept 
TVALPHA=THETA(3)+(THETA(4)*(REA/1.812)) 
     ;Typical value for slope with PK covariate 
ALPHA=(TVALPHA*EXP(ETA(2)))  ;IIV on slope 
F=(A*10**(ALPHA*TIME))     
 
SIG1=THETA(5)*F    ;SD using proportional residual error 
LOQ=0.0233    ;1/43days 
IPRED=F   
   
IF (FLG.EQ.0) THEN    
F_FLAG=0 
Y=F+(SIG1*ERR(1)) 
ELSE      
F_FLAG=1 
DUM=(LOQ-IPRED)/SIG1     
CUMD=PHI(DUM)      
Y=CUMD 
ENDIF 
 
$THETA 
(0.11)      ; fixed effects for intercept (A) 
(0.02)      ; fixed effects for CXR 
(-0.015)     ; fixed effects for slope (alpha)  
(-0.0001)    ; fixed effects for PK 
(0.534)     ; SD / SIG1 
 
$OMEGA 0.2     ; random effect on intercept 
$OMEGA 0.4     ; random effect on slope 
 
$SIGMA 1 FIXED 
